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ABSTRACT 
 
 
Primary Hyperoxaluria Type 1 (PH1) is a rare autosomal recessive disorder 
characterized by the deposition of insoluble calcium oxalate crystals at first in the 
kidneys and urinary tract and then in the whole body. PH1 is caused by the 
deficiency of human liver peroxisomal alanine:glyoxylate aminotransferase 
(AGT). AGT is a pyridoxal 5'-phosphate (PLP)-dependent enzyme, which 
converts glyoxylate to glycine, thus preventing glyoxylate oxidation to oxalate 
and calcium oxalate formation. Only two curative therapeutic approaches are 
currently available for PH1: the administration of pyridoxine (PN), a precursor of 
PLP, which is only effective in a minority of patients (25- 35%), and liver 
transplantation, a very invasive procedure. AGT is encoded by the AGXT gene, 
which is present in humans as two polymorphic forms: the major allele (encoding 
AGT-Ma) and the minor allele (encoding AGT-Mi). PH1 is a very heterogeneous 
disease with respect to the clinical manifestations, the response to treatment and 
the pathogenic mechanisms. In fact, more than 200 pathogenic mutations have 
been identified so far and the molecular mechanisms by which missense 
mutations cause AGT deficiency span from functional, to structural and to 
subcellular localization defects or to a combination of them. Several lines of 
evidence at both molecular and cellular level, indicate that many disease-causing 
missense mutations interfere with AGT dimer stability and/or aggregation 
propensity. However, neither the dimerization nor the aggregation process of 
AGT have been analyzed in detail. Therefore, we engineered a mutant form of 
AGT stable in solution in the monomeric form and studied its biochemical 
properties and dimerization kinetics. We found that monomeric AGT is able to 
bind PLP and that the coenzyme stabilizes the dimeric structure. Moreover, the 
identification of key dimerization hot-spots at the monomer-monomer interface 
allowed us to unravel the mechanisms at the basis of the aberrant mitochondrial 
mistargeting of two of the most common PH1-causing variants. We also 
elucidated the molecular and cellular consequences of the pathogenic mutations 
R36H, G42E, I56N, G63R and G216R, involving residues located at the dimer 
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interface, and tested their in-vitro responsiveness to the treatment with PN. The 
latter results allowed us to suggest a possible correlation between the structural 
defect of a variant and its degree of responsiveness to PN. Finally, by combining 
bioinformatic and biochemical approaches, we analyzed in detail the tendency of 
AGT to undergo an electrostatically-driven aggregation. We found that the 
polymorphic changes typical of the minor allele have opposite effect on the 
aggregation propensity of the protein, and we predicted the possible effect/s of 
pathogenic mutations of residues located on the AGT surface. 
Overall, the results obtained allow not only to better understand PH1 
pathogenesis, but also to predict the response of the patients to the available 
therapies as well as to pave the way for the development of new therapeutic 
strategies. 
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INTRODUCTION 
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1.1 Pathogenesis of Primary Hyperoxaluria Type I 
 
Primary Hyperoxaluria Type I (PH1) is a human metabolic disease with an 
autosomal recessive pattern of inheritance. The principal hallmark of PH1 is the 
formation of calcium oxalate stones that deposit at first in the kidneys and then in 
the whole body (1). The disease has an estimated prevalence of 1 to 3 per million 
populations and an overall incidence of approximately 1:120,000 live births in 
Europe and North America (2, 3). However, the incidence is usually higher in 
geographically isolated countries such as Canary Islands and in populations where 
consanguineous marriages are common. The disease accounts for less than 1% of 
paediatric patients showing end-stage renal disease (ESRD) in Europe, but this 
percentage increases to more than 10% in Kuwait and Tunisia (4). PH1 is the 
most common and severe form of primary hyperoxaluria, a group of genetic 
disorders characterized by the abnormal production and urinary excretion of 
endogenous oxalate (5, 6). PH1 accounts for approximately 80% of the cases of 
PH and is caused by the deficit of the hepatic peroxisomal enzyme, 
alanine:glyoxylate aminotransferase (AGT) (5). AGT is a pyridoxal 5'- phosphate 
(PLP)-dependent enzyme that catalyzes an essentially irreversible transamination 
reaction in which the amino group of L-alanine is transferred to glyoxylate, 
leading to the formation of pyruvate and glycine. In the absence of functional 
AGT, glyoxylate accumulates into peroxisomes and is transported to the cytosol 
where it is oxidized to oxalate by lactate dehydrogenase (Fig. 1).  
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Fig. 1. Metabolic consequences of AGT deficiency. Sites and mechanisms of oxalate formation 
are shown. 
 
Oxalate is an end-product of human metabolism that should be excreted by urine. 
In PH1 patients, very high amounts of oxalate are formed and accumulate in the 
urinary tract. This generates calcium oxalate (CaOx), a poorly soluble salt 
forming crystals when the concentration reaches the saturation limit (7). In the 
early and intermediate stages of PH1, CaOx crystals are deposited mainly in the 
urinary tract as stones (urolithiasis) or more diffused in the renal parenchyma 
(nephrocalcinosis). The progressive accumulation of CaOx in the kidneys 
eventually leads to renal failure, after which the problem of increased oxalate 
synthesis by the liver is compounded by the failure to remove it from the body. 
The resulting increased burden of oxalate allows CaOx to deposit into many 
organs and tissues, a potentially fatal condition named systemic oxalosis (Table 
1).  
 
Table 1. Symptoms of systemic oxalosis in PH1. 
TISSUE CLINICAL SYMPTOM 
Kidney and urinary tract Urolithiasis, nephrocalcinosis, renal failure 
Bone Bone pain, multiple fractures and osteosclerosis 
Eye Retinopathy and optic atrophy 
Heart Heart block, myocarditis and cardioembolic stroke 
Nerves Peripheral neuropathy 
Deep vasculature Vasospasm 
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1.2 AGT structure and function 
AGT is present in human hepatocytes as an homodimeric protein, in which each 
subunit is composed by 392 amino acids. The crystal structure of AGT (8) reveals 
that it belongs to the Fold Type I class of PLP-dependent enzymes (Fig. 2, panel 
A). Each subunit comprises: a N-terminal extension (residues 1-21) wrapping 
over the surface of the neighboring subunit, a large domain (residues 22-282) 
containing the dimerization interface and most of the active site and a C-terminal 
domain (residues 283-392) containing the peroxisomal targeting information. As 
in all PLP-dependent enzymes, the coenzyme is covalently bound to the "-amino 
group of a lysine residue (Lys209 in AGT) by means of a Schiff base linkage, 
forming a complex called internal aldimine. Other weak interactions at the active 
site stabilize the AGT-PLP complex including: (i) a salt bridge between the 
pyridine nitrogen of PLP and Asp183, (ii) a base stacking interaction between 
Trp108 and the pyridine ring of PLP and (iii) hydrogen bonds between the 
hydroxyl group of PLP and Ser158 as well as between the phosphate group of 
PLP and the residues Gly82, His83, Tyr260 and Thr263 (Fig. 2, panel B) (8). The 
active site is located in a cleft at the monomer-monomer interface and involves 
residues belonging to both subunits, thus suggesting that the catalytic activity is 
strictly related to the acquisition of the dimeric structure. The importance of the 
quaternary structure is also indicated by the fact that 8550 Å2 of each monomer 
surface are buried upon dimerization (9). By looking to the surface of the protein 
it can be noticed an asymmetric distribution of charged residues, a peculiar feature 
that can promote self-association processes mediated by electrostatic forces.  
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Fig. 2. Representation of AGT structure. Panel A: dimeric AGT. One subunit is colored grey; 
on the other subunit are indicated the N-terminal extension (blue), the large domain (orange) and 
the C-terminal domain (red). Panel B: detail of the active site. PLP is shown as green sticks. 
Residues interacting with the coenzyme are shown as grey sticks (if belong to the same subunit of 
the coenzyme) or orange sticks (if belong to the neighboring subunit). Oxygen, nitrogen and 
phosphorous atoms are colored red, blue and fuchsia, respectively. 
 
AGT catalyzes the reversible transamination of L-alanine and glyoxylate to 
pyruvate and glycine by a classical ping-pong mechanism (Scheme 1). In the first 
half-reaction, after the binding of the substrate to the catalytic site of the enzyme 
in the internal aldimine form (AGT-PLP) and the formation of the Michaelis 
complex, the "-amino group of Lys209 is replaced by the #-amino group of L-
alanine, thus generating the external aldimine. The extraction of the C#-proton 
from the external aldimine yields a quinonoid intermediate, which is reprotonated 
at the C4’ of the coenzyme to give the ketimine intermediate. The latter is then 
hydrolyzed to pyridoxamine 5’-phosphate (PMP) and pyruvate. In the second half 
transamination, following the same steps of the first half-reaction but in reverse 
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order, glyoxylate reacts with the AGT-PMP complex and is converted to glycine, 
thus regenerating AGT-PLP (10). 
 
 
Scheme 1. Mechanism of the transaminase reaction catalyzed by AGT. 
 
Kinetic studies have indicated that AGT is highly specific for the glyoxylate-to 
glycine conversion, in agreement with the proposed physiological role of the 
enzyme in glyoxylate detoxification. In fact, the equilibrium constant of the 
overall transamination is about 9400 and the kcat for the transamination reaction of 
the alanine/glyoxylate pair is $150-fold higher with respect to that of the 
glycine/pyruvate pair (10). Moreover, it has been shown that the enzyme has a 
higher affinity for PMP than for PLP, and that PMP remains tightly bound to the 
apoprotein during the catalytic cycle, thus making the enzyme more reactive 
toward oxoacids (10). The spectral changes occurring in AGT during the two half-
transamination reactions have indicated that some conformational changes at the 
active site occurs. Through computational studies, it has been suggested that slight 
rearrangements of aromatic residues at the active site and a tilting of the 
coenzyme could take place and these structural re-orientations could be 
responsible for the tight PMP binding during catalysis (10). 
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1.3 AGT subcellular localization 
During evolution the targeting of AGT has been under the influence of strong 
dietary selection and for this reason the localization of the protein inside the cell 
can vary from one species to another (11). AGT tends to be mitochondrial in 
carnivores, peroxisomal in herbivores and both peroxisomal and mitochondrial in 
omnivores. For example, in humans, rabbit and guinea pig, AGT is exclusively 
peroxisomal whereas in many species it could be exclusively mitochondrial 
(domestic cat) or both peroxisomal and mitochondrial (rat and marmoset) (12). As 
it occurs for the large majority of peroxisomal proteins, AGT is synthetized in the 
cytosol of human hepatocytes and then transported inside peroxisomes by the 
Pex5p carrier protein (13). The interaction between AGT and the carrier occurs 
through a non-canonical peroxisomal targeting sequence (PTS1), i.e. a C-terminal 
KKL sequence instead of the SKL sequence normally found in most peroxisomal 
proteins (14). The crystal structure of AGT in complex with the PTS1-binding 
domain of the peroxisomal carrier Pex5p (15) has  shown that the stoichiometry of 
the complex is Pex5p-AGT-AGT-Pex5p and that the protein-receptor interface is 
composed by three regions: (i) the C-terminal PTS1 (residues 389-392) (ii) an 
extended PTS1, that includes the C-terminal part of the #-helix 13 (residues 381-
388) and the loop connecting the !-strand 9 and the #-helix 12 (residues 327-
330), and (iii) a region topologically separated from PTS1 formed by residues 
303-307. Moreover, Mesa-Torres et al (16) calculated the thermodynamic binding 
parameters for the interaction of Pex5p-pdb with AGT by means of bioinformatics 
and biophysical studies. They found that the interaction is quite weak (KD = 1.4 ± 
0.2 µM) and that the mutation of residues Ala328, Tyr330 and Lys390 can further 
reduce the binding affinity of AGT for Pex5p (16).  
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1.4 The major and minor allelic form of AGT 
AGT is coded by the AGXT gene, located on chromosome 2q37.3, which is 
present in human population as two polymorphic variants, named the “major 
allele” and the less common “minor allele”. The frequency of the minor allele 
varies among different populations, ranging from 2% in the Japanese population, 
to the 20% of Europeans and North Americans to 28% in the Saami population 
(17, 18). The minor allele differs from the major one for 74-bp duplication in 
intron 1 and two point mutations (32C!T and 1020A!G) leading to the 
Pro11Leu and Ile340Met amino acid substitutions (19). Although the presence of 
the minor allele polymorphism is not pathogenic per se, it makes AGT more 
susceptible to the effect of several missense mutations, which are predicted to be 
non-pathogenic when associated with the major allele. For this reason, many 
investigations have been carried out to understand the differences between the two 
allelic forms of AGT at cellular and molecular level. In human liver, the protein!
encoded by the minor allele (AGT-Mi) has a specific activity of about 70% as 
compared with that encoded by the major allele (AGT-Ma) (20, 21). Moreover, 
while AGT-Ma is entirely located in peroxisomes, AGT-Mi is about 95% 
peroxisomal and 5% mitochondrial (20). It has been demonstrated that the partial 
mitochondrial localization of AGT-Mi depends on the polymorphic mutation 
P11L, which generates a weak putative mitochondrial targeting sequence (MTS) 
at the N- terminus of the protein. Despite the presence of a putative MTS, a large 
part of AGT-Mi is not imported to mitochondria, probably because the protein 
quickly dimerizes, thus avoiding the interaction with the mitochondrial import 
machinery that only acts on unfolded or partly-unfolded monomeric species (22).  
Studies performed on purified recombinant AGT-Ma and AGT-Mi have indicated 
that the P11L/I340M mutations do not affect either the UV-visible absorbance, 
dichroic and fluorescence features of AGT or the equilibrium dissociation 
constant for PLP (KD(PLP)) value. This suggests the absence of gross 
conformational changes between the two allelic forms that share a similar active 
site architecture (2, 23). Nevertheless, AGT-Mi shows an approximately 30% 
decreased kcat value for the overall transamination of the L-alanine/glyoxylate 
pair, in agreement with the reduced specific activity observed in human 
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hepatocytes. Furthermore, yeast complementation assays (24) along with pulse-
chase and cross-linking experiments performed on cell-free 
transcription/translation products (25) have shown that AGT-Mi is less stable in 
vivo and is more susceptible to proteolytic degradation and aggregation in 
comparison with AGT-Ma (26). These data have been also confirmed by thermal 
and chemical unfolding studies, which have provided evidence for a less stable 
dimeric structure and a decreased overall stability of both holo- and apoAGT-Mi 
as compared with the corresponding forms of AGT-Ma. The structural 
destabilization of AGT-Mi has been exclusivey attributed to the P11L mutation 
(26). In fact, it has been suggested that the substitution of Pro11 with a leucine 
residue could alter the original position and the interaction of the N-terminal arm 
of one subunit of AGT with the large domain of the opposite subunit, generating a 
less stable dimeric form of AGT (Fig. 3). Moreover, the perturbation of the N-
terminal arm could also be transmitted to the AGT active site through a loop 
(residues 24-32), which contributes to the PLP binding site. Overall, the analyses 
on the differences between AGT-Ma and AGT-Mi, have allowed not only to 
better understand the structural features of AGT, but have also represented an 
important starting point to investigate the effect of pathogenic mutations 
associated with the major or the minor allele. 
 
 
Fig. 3. Molecular representation of Pro11 and Ile340 residues in the AGT structure. The two 
monomers of AGT are colored white and orange.  The residues Pro11 and Ile340 are represented 
as blue sticks. 
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1.5 Molecular effects of pathogenic mutations in AGT 
PH1 is a loss-of-function disorder, because the symptoms are only related to the 
absence of functional AGT inside peroxisomes. From a genetic point of view, it 
can be considered a very heterogeneous disease, counting over 200 different 
pathogenic mutations (Fig. 4) on the AGXT gene, including nonsense, frameshift 
and missense mutations (27). While nonsense and frameshift are null mutations 
that lead to the synthesis of a truncated and hence non-active protein, missense 
mutations lead to single amino acid substitutions causing the synthesis of an 
aberrant gene product. Missense mutations are the most frequent ones and can co-
segregate with the major allele, the minor allele or both alleles (27, 28). When a 
mutation is co-inherited with the minor allele polymorphism, the polymorphic 
changes can exacerbate the effect of the disease-causing mutation. In some cases, 
the synergism with polymorphic amino acid substitutions is so crucial that 
pathogenic mutation do not lead to PH1 if inherited on the background of the 
major allele (29). 
In the last years, a lot of attention has been focused on the elucidation of the 
molecular and cellular effects of missense pathogenic mutations on AGT.  
 
 
Fig. 4. AGT mutations map. The known pathogenic amino acid changes associated with PH1 are 
ordered on the basis of the position of the mutated residue. The underlined amino acid 
substitutions represent the polymorphic changes typical of the Caucasian minor allele.!
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These analyses have been directed to confirm the pathogenicity of each mutation, 
to assess its severity and to understand how it exerts a damaging effect, with the 
final aim of establishing genotype–phenotype correlations. Different types of in 
vitro expression systems and various forms of downstream analyses of the 
expressed protein have been used to shed light on the defect underlying the 
pathogenicity of AGT variants associated with PH1. Each approach has been used 
to explore a different facet of a mutation effect. Expression in mammalian cells is 
considered as the closest model of in vivo conditions and gives information on the 
expression level, intracellular stability and targeting of the protein. On the other 
hand, the purification and characterization of the variants expressed in E. coli is 
suitable to dissect and quantify the effect of a mutation on the functional 
properties of AGT as well as on its secondary, tertiary and quaternary structure 
(26, 30, 31). In addition, bioinformatic analyses allow to predict the effect of a 
mutation at structural level and to explain the results obtained on purified 
proteins.  
In PH1, the combination of the approaches has shown the extreme variability of 
enzymatic phenotypes leading to AGT deficiency (Fig. 5) (26, 32), due to the 
effects of mutations on either the functional and/or the structural properties of 
AGT. 20% of the missense variants do not display any alteration of the expression 
level, but show a reduced catalytic efficiency for the transamination reaction due 
to a reduced kcat and/or to an increased Km for the substrate, or to an altered 
PLP/PMP binding mode and/or affinity (Fig. 5) (10, 33). They typically involve 
mutations of residues that either directly interact with PLP or are located in the 
proximity of the active site, such as Ser81, Gly82, His83, Trp108, Phe152, 
Ser158, Asp183 and Ser218. However, a remote conformational change of the 
active site can be also occur upon mutation of residues located far from the active 
site such as Ser187, Ile244 and Gly350 (32, 34). On the other hand, the reduction 
of the AGT expression level is a common defect shared by several variants. It has 
been demonstrated that in many cases PH1 can be considered a misfolding 
disease, because the effect of most amino acid substitutions is a conformational 
change that alters the folding pathway of the protein leading to various 
downstream effects such as: 
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- a reduced stability of the dimeric unit, as demonstrated for the G41R, G170R 
and F152I mutations on the minor allele, and for the G41R and G41V on the 
major allele (23, 31) by studies on the variants in the purified form (23, 35). 
- a higher susceptibility to proteolytic degradation, as in the case of the G41R and 
I244T! mutations associated with the minor allele as well as of the G41R and 
G41V mutations associated with the major allele. Analyses on both the 
pathogenic variants in the purified form and in cell-free transcription-translation 
systems have shown that the mutation of Gly41 increases the sensibility to 
degradation of AGT, while the I244T mutation strongly sensitizes AGT to trypsin 
treatment (31).!
- an increased aggregation propensity, as observed for the Gly41 and Gly161 
variants in the purified form by dynamic light scattering (DLS) and for the F152I-
Mi variant by size-exclusion chromatography (SEC) (31, 35). While the 
aggregation of the F152I-Mi variant depends on protein monomerization, the 
aggregation of the Gly161 and Gly41 variants is driven by electrostatic 
interactions between dimers (31, 36).!
- the mitochondrial mistargeting, a pathogenic mechanism peculiar of PH1 in 
which the protein is aberrantly targeted to mitochondria, where it is not able to 
perform the detoxification of peroxisomal glyoxylate. The mistargeting is due to 
mutations inherited on the background of the minor allele, including the most 
common G170R, I244T, F152I, and the G41R (32, 37, 38), and is considered the 
clearest example of the synergic effect of polymorphic and pathogenic mutations. 
In these variants the pathogenic mutation strengthens the weak MTS generated by 
the P11L polymorphism by populating monomeric partly-folded or unfolded 
intermediates able to either directly interact with the mitochondrial import 
receptor or strongly bind molecular chaperones and be presented to the 
mitochondrial import machinery (32, 37). 
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Fig. 5. Schematic representation of the molecular (A) and cellular (B) effects of pathogenic 
amino acid substitutions in AGT. 
 
Overall, the determination of the effects of many PH1-causing mutations at 
molecular level has been of primary importance not only to clarify the relationship 
between the genotype, the enzymatic phenotype and the clinical symptoms, but 
also to understand the basis of the therapeutic response of the patients to the 
available treatments as well as to pave the way for an improved clinical 
management by the designing of new therapeutic approaches. Notably, it is 
becoming increasingly evident that many mutations affect mainly or exclusively 
the apo-form of AGT (as found for the G170R, F152I, G161R, G161C, G161S, 
I244T and A295T variants) (32, 33, 35, 36, 39, 40), thus highlighting the fact that 
the pathogenic mechanisms leading to AGT deficiency range probably wider than 
previously thought and that the study of each variant in both the holo- and apo-
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forms is a necessary step for the identification of the molecular defect.  
 
1.6 Treatment strategies 
PH1 is a very difficult-to-treat disease that can remain unrecognized for years, due 
to a similar initial clinical presentation with idiopathic kidney stone disease (29). 
The time of diagnosis, which is usually confirmed by genetic testing, represents a 
key factor influencing treatment efficacy. In fact, an early diagnosis allows a 
proper treatment to be initiated as soon as possible, thus reducing the morbidity 
and increasing life expectancy of the patients (7). The therapeutic options 
currently available for PH1 patients are quite poor. Classical treatments are aimed 
at preventing or delaying kidney failure, or at restoring kidney function (29). They 
include (i) a high fluid intake to allow the hyperhydration of the patients thus 
preventing CaOx crystallization, (ii) the administration of crystallization 
inhibitors (such as magnesium and potassium citrate), (iii) the physical destruction 
of CaOx stones by litiotripsy, and (iv) dialysis and/or kidney transplantation 
procedures, to treat renal failure and the associated uremia (41).  
Unfortunately, none of these approaches represents a real cure, since they focus 
on symptoms mitigation. Only two therapeutic approaches directed to the causes 
of the disease are available so far: the administration of pharmacological doses of 
Vitamin B6, and liver transplantation. Vitamin B6 is currently administered in 
form of pyridoxine (PN), which can be converted in the body to PLP (42), the 
essential cofactor of AGT. Clinical data indicate that only a minority of the 
patients is responsive to pyridoxine therapy (37, 43-46). The only curative 
approach available for patients unresponsive to pyridoxine is liver transplantation, 
a procedure aiming at replacing the entire enzymatic pool of AGT in the liver 
(41). Liver transplantation is usually performed in combination or in sequence 
with kidney transplantation, to prevent any oxalate accumulation while ensuring 
to the patients the ability to remove it from the body. However, this strategy is a 
very invasive intervention and accompanied by several side effects (such as organ 
rejection and the long-life administration of immunosuppressant drugs). For these 
reasons, many efforts have been devoted in the last years to develop new 
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strategies more effective and less invasive than the available treatments, able to 
provide long-term benefits to PH1 patients. Approaches currently under 
investigation include strategies to (i) improve the AGT folding efficiency, using 
pharmacological chaperones as B6-vitamers (see below) or substrate analogs as 
aminooxyacetic acid (AOA) (47), (ii) administer a functional enzyme to rescue 
the glyoxylate detoxification ability of the liver (48), (iii) reduce the amount of 
exogenous oxalate absorbed at intestinal level (e.g using oxalate degrading-
enzymes) (49, 50), (iv) restore AGT expression by gene therapy or cell therapy 
(51) (v) reduce oxalate production by substrate reduction therapies toward 
glycolate oxidase or proline dehydrogenase. 
 
1.7 The chaperone role of PLP on folding-defective AGT variants 
The administration of Vitamin B6 is the first-line approach for any PH1 patient 
upon diagnosis (1). Vitamin B6 includes a group of six water soluble vitamers: 
pyridoxine (PN), pyridoxamine (PM), pyridoxal (PL) and their phosphorylated 
forms (PNP, PMP and PLP) (Fig. 6).  
 
Fig. 6. Structures of B6 vitamers. The structures of PN, PM, PL and their relative 
phosphorylated forms (PNP, PMP and PLP) are shown. 
 
Vitamin B6 is usually utilized in therapy as PN, which is converted to PLP inside 
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the cell and has proven to be effective for several disorders due to the deficit of 
PLP-enzymes, although the percentage of responsive patients is variable. In PH1, 
only 25-35% of the patients are responsive, as demonstrated by a significant 
reduction of the urinary oxalate levels upon a 3-months treatment with PN (10 
mg/kg/day) (52, 53). Responsiveness seems to be associated with three of the 
most common missense variants, the G170R-Mi, F152I-Mi and I244T-Mi, which 
are aberrantly targeted to mitochondria and/or show an increased susceptibility to 
proteolytic degradation and aggregation (32, 37). In order to shed light on the 
molecular mechanism underling PN efficacy, the effects of vitamin B6 have been 
widely investigated at both molecular and cellular level. It has been proposed that, 
besides its prosthetic role, PLP might improve the efficiency of the folding 
pathway of AGT by shifting the equilibrium from the unstable apo-form to the 
more stable holo-form of misfolded variants. As shown in Fig. 7, PLP can either 
bind a partly-folded or fully-folded monomeric form of AGT. This would 
generate a PLP-bound monomer that then dimerizes (pathway A). As an 
alternative, the folded apomonomer can dimerize and subsequently bind PLP 
(pathway B). Analyses of the role of the coenzyme on AGT folding and 
dimerization are still lacking. 
 
 
Fig. 7. Folding pathway of AGT and chaperone role of PLP. PLP could bind different folding 
intermediates shifting the equilibrium toward the more stable holo-form of the protein. U = 
unfolded monomer; M* = partially folded monomer; M = folded apomonomer; MPLP = monomer-
bound PLP; D = apodimer; DPLP = PLP-bound dimer. 
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Nevertheless, recent studies have provided evidence that the coenzyme can exert a 
chaperone role (54). In fact, the presence of PN in the culture media of CHO-GO 
cells expressing F152I-Mi, G170R-Mi or I244T-Mi variants (23, 36, 37) not only 
improves their specific activity, but also increases the total expression level and 
promotes their correct subcellular localization, thus enhancing the capability to 
detoxify glyoxylate. These data suggest that PLP increases the productive folding 
of the proteins (Fig. 7) and prevents their aggregation and degradation, leading to 
higher amounts of active dimers imported inside peroxisomes (54).  
Furthermore, recent studies performed in my research group (55), have shown that 
PM and PL are more effective than PN in rescuing the two PN-responsive variants 
F152I-Mi and G170R-Mi when expressed in a cellular model of PH1. Indeed, the 
administration of PN leads to the intracellular accumulation of PNP, which is able 
to compete with PLP for the binding to apoAGT generating an inactive AGT-PNP 
complex (55). On the other hand, PM or PL supplementation causes the 
intracellular accumulation of PLP and PMP, the two active forms of the coenzyme 
exerting both a chaperone and a prosthetic role, without any accumulation of 
PNP. Although experiments in a mouse model of PH1 have to be performed, these 
results support the potential use of PM and PL as a novel coenzyme 
administration therapy for patients bearing PH1-causing mutations that affect 
protein folding.  
  
  
!! 27!
 
 
!
!
!
!
2 
AIM OF THE RESEARCH 
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Primary Hyperoxaluria Type I (PH1) is a rare disease caused by mutations in the 
gene encoding alanine:glyoxylate aminotransferase (AGT), an enzyme that 
utilizes pyridoxal 5’-phosphate (PLP) as coenzyme to catalyze the transamination 
of L-alanine and glyoxylate to pyruvate and glycine. AGT deficiency allows 
glyoxylate accumulation and oxidation to the metabolic end-product oxalate. The 
high amounts of oxalate formed in PH1 patients cause the formation and 
deposition of calcium oxalate crystals at first in the urinary tract and then in the 
whole body. The only two curative treatments currently available for PH1 are the 
administration of Vitamin B6 in form of pyridoxine, which is effective only in a 
minority of the patients, and liver transplantation, which is a very invasive and 
problematic procedure. PH1 is a very heterogeneous disease with respect to the 
clinical manifestations, the response to treatment and the pathogenic mechanisms. 
In fact, more than 200 pathogenic mutations have been identified so far and the 
molecular mechanisms by which missense mutations cause AGT deficiency span 
from functional, to structural and to subcellular localization defects or to a 
combination of them. Additionally, some pathogenic mutations functionally 
synergize with polymorphic mutations typical of a minor allelic form of the 
protein. Several lines of evidence at both molecular and cellular level, indicate 
that PH1 can be considered a misfolding disease. In fact, most disease-causing 
missense mutations interfere with AGT folding leading to a variety of 
downstream effects that finally result in a reduced expression level. In particular, 
it has been supposed that the majority of them reduce the stability of the dimeric 
structure of the protein. However, the biochemical features of monomeric AGT as 
well as the equilibrium and kinetics of the dimerization process are unknown. 
Moreover, although it is well known that AGT is endowed with a significant 
tendency to aggregation, neither the molecular mechanisms underlying the 
aggregation process nor the possible effect of the polymorphic changes typical of 
the minor allele have been clarified in detail. 
Based on the above considerations, the main objectives of my PhD project have 
been: 
!! 29!
-engineer a mutant form of AGT stable in solution in the monomeric form, study 
its biochemical properties and dimerization process, as well as define the effect of 
the coenzyme on the stability of the dimeric structure.  
-elucidate the molecular and cellular consequences of pathogenic mutations 
involving residues located at the dimer interface such as the R36H, G42E, I56N, 
G63R and G216R, and test their responsiveness to the treatment with pyridoxine. 
 -investigate the molecular mechanism of the aggregation process of the two 
polymorphic forms of AGT by means of bioinformatic and biochemical studies as 
the base to predict the possible effect/s of pathogenic mutations of residues 
located on the AGT surface. 
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3 
MATERIALS AND METHODS 
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3.1 Materials 
 
PLP, pyridoxine, L-alanine, sodium glyoxylate, rabbit muscle L-lactic 
dehydrogenase, isopropyl-!-D-thiogalactoside (IPTG), EDTA and imidazole were 
all purchased from Sigma. ANS was purchased from Molecular Probes. The 
Ham’s F12 Glutamax medium w/o pyridoxine and G-418 were purchased from 
Invitrogen. All other chemicals were of the highest purity available. The rabbit 
polyclonal anti-AGT human and guinea-pig anti–peroxisomal proteins antibodies 
were kindly provided by Prof. C.J. Danpure of University College London (UK); 
the anti-rabbit HRP antibody was purchased from GE Healthcare. 
Oligonucleotides for site directed mutagenesis were purchased from MWG 
Biotech AG (Anzinger, Germany). 
 
3.2 Bioinformatic studies 
3.2.1 Alanine scanning mutagenesis, molecular modeling and hydrophobic 
patch analysis 
 
In silico analyses for the engineering of monomeric AGT-Mi as well as the 
alanine scanning mutagenesis were performed by using the software Molecular 
Operating Environment (MOE 2015.1001 and MOE 2016.08) (56) of the 
Chemical Computing Group using the available crystal structure of human AGT 
(pdb id: 1H0C) (8). Each residue present on the dimerization interface involved in 
either intrachain or interchain contacts was subjected to alanine scanning 
mutagenesis using the Unary Quadratic Optimization (UQO) under the LowMode 
ensemble, which uses the LowModeMD (57) to search the conformational space 
of the mutants. The conformations that satisfied the required energetic and 
geometric criteria were saved to the output database. Atoms located at a distance 
greater than 4.5 Å from the mutation site were marked as inert, iterations were 
limited to 50, and conformations were limited to ten for each mutated complex. 
The dStability values (kcal/mol) were calculated using the “Protein design” tool 
of MOE 2015.1001 (56). The analysis of the interfacial hydrophobic patches and 
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the inspection of the AGT structure and of the interface contacts were performed 
by using the “Patch analyzer” tool of MOE 2015.1001 (56). 
 
3.2.2 Molecular and essential dynamics 
 
These analyses were performed in collaboration with Dr. Giorgetti of Department 
of Biotechnology of the University of Verona. Molecular dynamics (MD) 
simulations were carried out by using the software GROMACS 4.5.5 (68) 
GROMOS 53A6 united atom force field (69) and the explicit simple point charge 
(spc/e) water model (70) were used for the simulations. The dimeric structure of 
human AGT was obtained by means of the PISA web server starting from the 
available coordinate file of the monomer (PDB id: 1H0C). In the original 
structure, loop residues 120-123 are missing, so the latter were modelled by a loop 
modelling script of the Modeller software (71). We modelled AGT-Mi by 
introducing the P11L and I340M mutations in the AGT protein using the Chimera 
software (64). The latter was also used to introduce the F152I and I244T 
mutations on AGT-Mi. The molecular topology and atoms parameters for PLP 
covalently bound to lysine 209 were taken from ATB (72). The systems were 
simulated in a triclinic water box, and the minimum distance between any atom of 
the protein and the box wall was set up to 1.0 nm. The systems were neutralized 
by adding Na+ and Cl− ions using the genion program of the GROMACS 4.5.5 
package (68). Each system was energy minimized in four phases. In the first two 
phases, 800 steps of steepest descent algorithm followed by 3000 steps of 
conjugate gradient were performed to gently relax the water molecule around the 
protein, which was constrained imposing harmonic position restraints of 
1000 kJ mol−1 nm−2. In the third and in fourth phases, the protocol was repeated 
without using any constraint. Subsequently the minimizations steps, the systems 
were equilibrated in four steps. In the first stage, the systems were slowly heated 
up from 0 K to 300 K in 1 ns at 1 atm, followed by two stages of equibration in 
isothermal-isobaric (NPT) conditions for 600 ps, in which positional constraints 
were applied on the solute atoms (force constant of 1000 J mol−1 nm−2). In the last 
stage, a 400 ps unrestrained MD simulation was performed at 300 K and 1 atm to 
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assess the stability of the systems. The temperature and pressure were regulated 
by a Berendsen thermostat and barostat, respectively (73). The LINCS algorithm 
(74) was used to constrain all bonds involving hydrogen atoms and the time step 
was set to 2 fs Periodic boundary conditions (PBC) were applied. The particle 
mesh Ewald method (PME) (75) with a cut-off length of 1 nm was used to treat 
long-range electrostatic interactions, and the same cut-off length was adopted for 
van der Waals interactions. Finally, all monomer systems were simulated for 170 
ns while dimer systems were simulated for 200 ns. For the dimer systems, we 
decided to carry out longer MD simulations (ca. 200 ns) because the equilibrium 
state of the two dimer systems was reached at ca. 110 ns. To sum up, the AGT-Mi 
protein was simulated, in all its mutated forms, totalizing ca. 740 ns of simulation 
time. For the production runs, a Nosè-Hoover thermostat (76) at 300 K and an 
Andersen-Parrinello-Rahman barostat (77), at 1 atm were used. The trajectories 
were analyzed using the standard GROMACS tools. The root mean square 
deviations (RMSD) and the root mean square fluctuations (RMSF) were 
performed through GROMACS inbuilt tools. RMSD plots for the AGT-Mi and 
F152I-Mi mutant were calculated without considering 4-23 region, which it is 
extremely flexible in the monomeric form and introduces artifacts to RMSD 
analysis. Cutoff of 4 Å between N—O atom pairs as a definition of salt bridge 
formation between Arg118 and Asp243 was used (78). All the graphical displays 
were generated using XMgrace program. The molecular graphics shown in this 
work were created using UCSF Chimera (64). 
Essential dynamics (ED) was performed for AGT-Mi and F152I-Mi MD 
simulations according to principal component analysis (PCA). ED is a standard 
technique able to highlight the dominant motions of the investigated systems (79). 
The principal components (PCs), also called eigenvectors, were calculated by 
using ED and represent the protein's collective motions. Here, the first 
eigenvector, that accounts for ca. 50% of the total motions accomplished by the 
system, was used to understand the dynamical differences between the AGT-Mi 
and the F152I-Mi systems. Therefore, RMSF along the first eigenvector for the 
AGT-Mi and F152I-Mi were calculated (data not shown). Covariance matrix was 
calculated using Cα atoms and the matrix was diagonalized. The PCs were 
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extracted from the covariance matrix. PCA was performed in three steps: i) the 
covariance matrix was calculated using the Cα atoms; ii) the matrix was 
diagonalized and iii) a set of eigenvectors and eigenvalues were extracted from 
the covariance matrix. The eigenvectors correspond to a direction in the 
multidimensional space while the eigenvalues express the amplitude of the motion 
of each eigenvectors. PCA was carried out by using the standard GROMACS tool 
i.e. g_covar and g_anaeig. 
 
3.2.3 Rigid-body docking simulations 
 
Since rigid-body docking simulations are based on the analysis of the monomer-
monomer interface, and considering that the crystal structure of AGT-Ma the 
protein is in the monomeric form, we decided to use the structure of AGT in 
complex with the TPR domain of human Pex5p, which is in the dimeric form (pdb 
id: 3R9A) (15) as a template for AGT-Ma. Thus, we first performed an in-silico 
mutagenesis on both AGT monomers to obtain the three dimensional structure of 
mutants. We used the software Pymol (58), and we selected the most probable 
rotamers when multiple side chain rotamers were available. 
Protein-protein docking simulations were carried out by means of the rigid-body 
docking algorithm ZDOCK2.3 using one of the monomers as a fixed molecule 
(target) and the other monomer as a probe (ligand) for roto-translational space 
sampling. The Fast Fourier Transform-based algorithm performs a search to 
optimizes the molecular complementarity between target and ligand and provides 
a score (ZD-s) for each docking solution, which can be summarized as a 
combination of three components: 
 
ZD-s = # Ssc + ! Sel + % Sdes = ZDsc + ZDel + ZDdes     
 
where sc, el and des indicate the shape complementary, electrostatic and 
desolvation terms, respectively, and # = 0.01, ! = 0.06 and % = 1 are scaling 
factors of the energy terms (S) proposed by the ZDOCK developers (59). 
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Docking simulations were run to test whether mutated monomers are predicted to 
assemble in a wild type-like quaternary structure or if the mutation prevents the 
formation of a native conformation. According to a computational protocol 
previously developed (60), three independent and parallel docking runs were run 
for AGT-Ma and the pathogenic variants by randomizing the initial coordinates of 
the ligand, thus obtaining 12,000 solutions for each protein complex ranked 
according to the ZD-s. Thereafter, native-like structures were selected, consisting 
in all the docked complexes characterized by an alpha carbon root-mean square 
deviation (C#-RMSD) lower than 1.0 Å from the native complex. For each 
docking simulation, the selected complexes resulting from the three independent 
runs were averaged in the resulting ZDavg. The ZDavg was then used to calculate 
the predicted relative binding affinity &&G°pred by making use of a linear 
correlation equation which successfully predict the binding affinity of a variety of 
soluble and membrane protein systems (61). For each docked complex, the 
obtained &&G°pred value was directly compared with the relative dissociation 
constants at equilibrium (ln (KD(mut)/KD(AGT-Ma))), where the term “mut” indicates 
each pathogenic variant tested, whose values were taken from the in vitro studies 
presented on this thesis. 
 
3.2.4 Calculation of electrostatic potential maps, 2D maps and predicted pKa 
 
The electrostatic potential maps of AGT-Ma and mutants were calculated by 
using the APBS (Adaptive Poisson-Boltzmann Solver) 1.3 tool (62), using the 
non-linear Poisson-Boltzamm equation and modulating the ionic strength and 
temperature. The graphic interface of the tool is integrated in UCSF Chimera 
version 1.1 (63, 64). The calculation were performed on Opal web server (65). 
The structures preparation and the protonation state of residues at different pH 
values were carried out using the PDB2PQR (66) (using CHARMM as forcefield) 
and PROPKA 3.0 (67) tools respectively, on Opal web service. The 2Dmaps were 
calculated with the tool “Patch Analyzer” of MOE 2016.08 (56). In the latter case, 
structure preparation and protonation were performed directly on MOE 2016.08. 
The calculation of the predicted pKa of the AGT residues was obtained by using 
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the tool “Residue pKa” of MOE 2015.1001.  
 
3.3 Site-directed Mutagenesis 
 
The expression vectors for the polymorphic, pathogenic and artificial variants of 
AGT were constructed starting from the pAGT-His construct, which contains the 
complete open reading frame of AGT together with a C-terminal histidine-tag 
(AVDHHHHHH), cloned in a pTrcHis2A plasmid (Invitrogen). This vector 
allows to express recombinant AGT in E. coli under the lactose operon controller 
by adding IPTG to the culture broth. Moreover, the presence of a C-terminal 6- 
Histidine tag allows a one step purification of the protein by Immobilized Metal 
Affinity Chromatography. For cell biology studies, the cDNA encoding human 
AGT was cloned in the mammalian expression vector pcDNA3.1/V5-His-TOPO, 
by means of the TOPO cloning kit (Invitrogen). This expression vector contains 
the human cytomegalovirus enhancer-promoter sequences upstream of the 
multicloning site, the transcription-termination sequence of the bovine growth 
hormone gene (bGH) downstream of the multicloning site and the gene for 
neomycine resistance. The constructs for the expression of AGT P11L and I340M 
were already available in our laboratory.  The mutations R36H, G42E, I56N, 
G63R, R118A, G216R, F238S and F240S were introduced on the desired vector 
by the QuikChange site-directed mutagenesis kit (Stratagene), which employs 
double-stranded DNA as a template, two complementary oligonucleotide primers 
containing the desired mutation, and DpnI endonuclease to digest the parental 
DNA template. The oligonucleotides used for mutagenesis are reported in Table 
2.  
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Table 2. Sequence of primers used for the site-directed mutagenesis. Mutated codons are 
underlined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 Expression and purification of the AGT variants 
 
E. coli BL21 or JM109 cells transformed with the constructs encoding the AGT 
variants were grown in 750 ml of Luria broth at 37°C to an absorbance at 600 nm 
of 0.4-0.6. Expression was induced with 0.1 mM IPTG for 15 h at 30°C. Cells 
were harvested and resuspended in 20 mM sodium phosphate buffer, pH 7.4 
containing 0.5 M NaCl, 20 mM imidazole and 100 µM PLP. Lysozyme was added 
to a concentration of 0.2 mg/ml and the culture was incubated for 15 min at room 
temperature. After a freeze-thaw, leupetin (0.5 µg/ml) and pepstatin (0.7 µg/ml) 
were added and the suspension was centrifuged at 30,000 g for 30 min at 4°C. The 
lysate was loaded on a HisPrep FF 16/10 (GE Healthcare) equilibrated with 20 
mM sodium phosphate buffer pH 7.4 containing 0.5 M NaCl and 20 mM 
imidazole. A linear gradient was then inserted (0-100% in 200 ml) with the same 
buffer containing 500 mM imidazole. Soluble AGT elutes from the Ni2+ resin 
between 300 and 400 mM imidazole. After addition of 100 µM PLP, the protein 
solution was concentrated; imidazole and unbound coenzyme were removed by 
Mutation Primer sequence (5’-3’) 
R118A GGACATCGGGGAGGCCATAGGAGCCCGA 
F238S CAAGACGAAGCCCTCCTCCTTCTACCTGG 
F240S GAAGCCCTTCTCCTCCTACCTGGACATCAAG 
F238S-F240S AAGACGAAGCCCTCCTCCTCCTACCTGGACAT 
R36H CAACCTGCCTCCTCACATCATGGCAG 
G42E ATCATGGCAGCCGGGGAACTGCAGATGAT 
I56N GATATGTACCAGACCATGGACGAGATC 
G63R GAGATCAAGGAACGCATCCAGTACGTG 
G216R GAACGCCCCTCCAAGGACCTCGCTC 
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extensive washing with 100 mM potassium phosphate (KP) buffer, pH 7.4, using 
Amicon Ultra 10 concentrators (Amicon). AGT can be stored at -20 °C without 
loss of activity for more than 6 months. Protein concentration was determined by 
using the apparent molar absorption coefficient of 95400 M-1 cm-1 at 280 nm (80). 
The PLP content was determined by releasing the coenzyme in 0.1 M NaOH and 
by using the apparent molar absorption coefficient of 6600 M-1 cm-1 at 388 nm.  
 
3.5 Preparation of apoenzyme 
 
AGT variants in the apo-form were prepared by incubating each species (10–20 
µM) in the holo-form with 500 mM L-alanine for 20 min at 25 °C, in a final 
volume of 2 ml. The reaction mixture was concentrated to 0.2 ml by a Amicon 
Ultra 4 device (Millipore), washed twice with 2 ml of KP 1 M pH 6 and then 4–5 
times with KP 0.1 M, pH 7.4. 
 
3.6 Determination of the equilibrium dissociation constants for 
PLP (KD(PLP)) 
 
The equilibrium dissociation constant for PLP (KD(PLP)) of R36H-Ma, G42E-Ma, 
I56N-Ma, G63R-Ma, R118A-Mi, F238S-Mi, F240S-Mi, and F238S/F240S-Mi 
variants was determined by measuring the quenching of the intrinsic fluorescence 
of the apo-enzymes (protein concentration 0.1-0.3 µM) incubated 24 h in the 
presence of PLP at a concentration range of 0.01–10 µM. In the case of G216R-
Ma and R118A-F238S-F240S-Mi variants, the KD(PLP) was determined by 
measuring the CD signal at 424 or 430 nm (depending on the maximum of the 
dichroic band of each variant) of 10 µM and 2 µM apo-form, respectively, 
incubated 24 h in the presence of PLP at concentrations ranging from 1 to 300 
µM. The experiments were performed in 100 and 50 mM KP, pH 7.4, at 25°C, 
respectively. 
The KD(PLP) values for the mutant-coenzyme complexes were obtained by fitting 
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the data to the following equation: 
! = !#$% &[E]t + [PLP]t
&
+ ./(121) − & [E]t + [PLP]t
&
+ ./(121)5 − 4[E]t[PLP]t
&
2[E]t &&&&&&&&&&&&&&&(1) 
where [E]t and [PLP]t  represent the total concentrations of the mutant and PLP, Y 
refers to either the intrinsic fluorescence quenching or the 424-430 nm dichroic 
signal changes at a PLP concentration, and Ymax refers to the aforementioned 
changes when all enzyme molecules are complexed with coenzyme.  
 
3.7 Determination of the kinetic parameters 
The kinetic parameters for the overall transamination reaction for the pair 
alanine/glyoxylate of the AGT variants (0.1–20 µM) were determined in the 
presence of saturating PLP concentrations by varying the substrate concentration 
at a fixed saturating co-substrate concentration. At different times, the reactions 
were stopped by adding TCA 10% (v/v). The produced pyruvate was measured by 
a spectrophotometric assay using the coupled lactate dehydrogenase system (10). 
Data of initial velocity (v) as a function of substrate concentration were fitted to 
the Michaelis-Menten equation:  
9:; = & <=$>[?]Km + [S]&&&&&&&&(2) 
where Et is the total enzyme concentration, S is the substrate concentration, kcat is 
the turnover number, and Km is the Michaelis-Menten constant.The AGT 
enzymatic activity of CHO-GO cell clones was determined by incubating the 
cellular lysate with 0.5 M L-alanine and 10 mM glyoxylate for 10 or 30 min in KP 
100 mM, pH 7.4. The reactions were stopped by adding TCA 10% (v/v) and 
pyruvate production was measured using the spectrophotometric assay coupled 
with lactate dehydrogenase already described (10).  
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3.8 Size exclusion chromatography 
SEC analyses were performed on an Akta FPLC system (GE Healthcare) using 
the Unicorn 5.01 (GE Healthcare) software and a Superdex 200 10/300 GL 
column at room temperature. The injection volume was 100 µl, the flow rate 
0.5 ml/min, and the detection at 280 nm. The mobile phase was 50 mM potassium 
phosphate buffer, pH 7.4, containing 100 µM PLP in the case of R118A-Mi, 
F238S-Mi, F240S-Mi, R118A-F238S-Mi, R118A-F240S-Mi, F238S-F240S-Mi 
and R118A-F238S-F240S-Mi. For the R36H-Ma, I56N-Ma, G63R-Ma and 
G216R-Ma variants the mobile phase was 60 mM potassium phosphate buffer, pH 
7.4 to mimic the physiological conditions. To determine the dimer-monomer 
equilibrium dissociation constant (Kd(dim-mon)), a stock solution of enzyme in the 
apo- or holo-form was dissolved in 50 or 60 mM potassium phosphate buffer at 
pH 7.4 at different concentrations, and after overnight incubation at 25 °C (a 
sufficient time to reach the equilibrium between monomer and dimer) subjected to 
SEC. The concentration of monomer and dimer was determined by integrating the 
area under the curve and expressed as percent of total area of all protein-related 
peaks. 
According to Manning et al. (81)  the Kd(dim-mon) value was determined by the 
following equation: 
 %D = & 8 : + .F(FG#H#IJ) − .F(FG#H#IJ)5 + 16&.F(FG#H#IJ) : LM /0.08[:]    (3) 
 
where %D is the percentage of dimer to total enzyme, and [E] represents the total 
enzyme concentration in dimer equivalents. A plot of log [%D/0.04(100-%D)2] 
with respect to log[E] yields a straight line of slope 1. When log[%D/0.04(%D-
100)2] =1, Kd(dim-mon) = [E]. 
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3.9 Kinetics of the dimerization process of AGT R118A-F238S-
F240S-Mi 
The time course of AGT R118A-F238S-F240S-Mi dimerization:  
                                                         2M → D  
induced by exogenous PLP was fitted to a simple second-order kinetics: 
 D = & [/]QR[S]TUVV>WX[S]TUVV>              (4) 
where [D] and [D]eq represent the dimer concentrations at time t and at 
equilibrium, respectively, [E] the enzyme concentration expressed as dimer, and 
kass the association rate constant. The equation was derived under the assumption 
that the reaction of dimerization is irreversible. Although this is never true, at 
conditions where kass is >> kdiss this assumption is valid and will not significantly 
alter the determined kass. Eq. 4 has also been used to fit the data of regain of 
enzyme activity and change in CD signal at 424 nm as a function of time. 
On the other hand, to determine the kass of the reversible association of the apo-
form, the kobs of dimerization was calculated at different protein concentrations by 
the linear fit of the decrement of monomer concentration (1/[M]) versus time. kobs 
values as a function of protein concentration were fit to a line whose slope gives 
the kass value. 
 
3.10 Spectroscopic measurements 
Absorption measurements were made with a Jasco V-550 spectrophotometer with 
1 cm path length quartz cuvettes at a protein concentration of 1-10 µM in 50 or 
100 mM KP pH 7.4. Intrinsic fluorescence emission spectra were recorded on a 
Jasco FP-750 spectrofluorimeter equipped with a thermostatically controlled cell 
holder by using a 1 cm path length quartz cuvette. Protein emission spectra were 
taken from 300 to 550 nm (excitation at 280 nm) with both the excitation and the 
emission slits set to 5 nm. The protein concentration was 1 or 5 µM. Spectra of 
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blanks, i.e. of samples containing all components except the enzyme, were taken 
immediately before the measurements of samples containing protein.Visible and 
far-UV CD spectra were recorded on a Jasco J-710 spectropolarimeter equipped 
with a Peltier temperature controlled compartment, by using 1 cm and 1 mm path 
length cells, respectively. The enzyme concentration was 1-15 µM. Routinely, 
three spectra were recorded at a scan speed of 50 nm/min-1 with a bandwidth of 2 
nm and averaged automatically, except where indicated. The thermal unfolding of 
variants was monitored by CD at 222 nm at a concentration of 1 µM or 10 µM in 
KP 100 mM, pH 7.4 with temperature increasing of 0.5 °C/min from 25 to 90 °C 
whereas for the monomeric R118A-Mi/F238S-Mi/F240S-Mi the buffer was KP 
50 mM, pH 7.4.  
 
3.11 Dynamic light scattering (DLS) 
DLS measurements were made on a Zetasizer Nano S device from Malvern 
Instruments. The temperature of sample cell was controlled by a Peltier 
thermostating system within ± 0.1 °C and 12.5 × 45 mm disposable cells with 
stopper were used. To study the aggregation propensity of the R36H-Ma, G42E-
Ma, I56N-Ma, G63R-Ma and G216R-Ma variants under physiological conditions, 
each species was diluted to a final concentration of 4 µM in KP 60 mM pH 7.4 at 
37 °C. The aggregation kinetics of AGT-Ma, AGT-Mi, AGT P11L and AGT 
I340M was determined at an enzyme concentration of 10 µM in KP at different 
pHs and ionic strengths, at 37°C. The buffer was filtered immediately before use 
to eliminate any impurities. 
 
3.12 Aggregation kinetics: the minimalistic/”Ockham’s razor” 
Finke-Watzky (F-W) two-step model 
 
The minimalistic/‘‘Ockham’s razor’’ Finke–Watzky (F–W) two-step model was 
routinely used to analyze protein aggregation kinetic data (82, 83). This model is 
characterized by nucleation and autocatalytic growth, yielding quantitative 
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(average) rate constants for nucleation (k1) and growth (k2), respectively.  
Y TL Z 
Y + Z TM 2Z 
where A is the monomeric protein and B is the polymeric protein i.e. in oligomers 
that are past the nucleation stages. The F–W 2-step model is an oversimplified, 
phenomenological kinetic model that consists of hundreds, if not thousands, of 
steps in most cases. The resultant k1 and k2 values are therefore averages of the 
true underlying steps. The classic F–W 2-step mechanism assumes an initial zero 
concentration of aggregate, and so the rate equation becomes:  
− F [F> = & <W Y + <5[Y][Z]                        (5) 
By mass balance, 
[Y]\ = [Y]> + [Z]>                               (6) 
Combining these two equation (5 and 6), integrating and solving for [A]t: 
[Y]> = ]L]MX&[[]^WX& ]L]M[_]^ `ab TLX&TM[[]^ >                   (7) 
where [A]0 represent the initial monomeric concentrations and [A]t represents the 
loss of [A] with time. 
 
3.13 Calculation of pKspec 
 
The pKspec was calculated with the following equation (84): 
 &&&&&&&&&! = & cdH&ceWX&W\fgVfQhijd + !k             (8) 
 
where YH and YL are the rate constant values of k1 and k2 at high and low pH. 
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3.14 Limited proteolysis 
 
The holo- and apo-forms of AGT-Ma and of the variants R36H-Ma and G42E-Ma 
(10 µM) were treated with proteinase K in 100 mM potassium phosphate buffer, 
pH 7.4, at 25°C. At various times, 15 µL of each reaction mixture were withdrawn 
and the protease activity was stopped by adding PMSF to a final concentration of 
2 mM. Each aliquot was then subjected to SDS-PAGE and the gel stained with 
Comassie blue. The relative intensities of the bands were obtained by analyzing 
the digital image of each gel using the software ImageJ (85). 
 
3.15 Cell culture and lysis 
 
CHO-GO cells were cultured at 37°C under O2/CO2 (19:1) atmosphere in Ham’s 
F12 Glutamax medium (Invitrogen) supplemented with fetal bovine serum (10%, 
v/v), penicillin (100 units/ml) and streptomycin (100 µg/ml). When the cells were 
70–80% confluent they were trypsinized, counted and re-seeded into 6-well plates 
or 60 mm dishes at a density of 0.3-0.6 x 106 cells/well respectively. After over 
night incubation at 37°C, cells were transfected with TurbofectTM Transfection 
Reagent (Fermentas) according to the manufacturer’s instructions. After 4 hours 
from transfection cells were washed in phosphate buffered saline (PBS) and the 
medium was changed with a custom-made Ham’s F12 medium without 
pyridoxine (PN) supplemented with fetal bovine serum (10%, v/v), penicillin (100 
units/ml) and streptomycin (100 µg/ml) (low-B6 medium). To generate stably-
transformed cell clones, the selection agent G-418 at 1 mg/ml concentration was 
added to the medium and cells where left growing for at least 4 weeks. Where 
indicated, 10 µM pyridoxine (PN) was added to the medium. Cells were harvested 
after 24 hours and lysed in phosphate buffered saline (PBS), pH 7.2, plus protease 
inhibitor cocktail (Complete Mini, Roche), by five freeze/thaw cycles followed by 
treatment with DNAse (1 unit) at RT for 45 min. The whole cell extract was 
separated by centrifugation (29200 g, 10 min, 4°C) to obtain the soluble fraction. 
The pellets were then resuspended in an equal volume of denaturing gel loading 
buffer to obtain the insoluble fraction. The total protein concentration in the cell 
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lysate and/or in the soluble fraction, was measured using the Bradford protein 
assay. 
 
3.16 Western blot analysis 
 
10 µg of cell lysate were loaded per lane on a Mini Protean TGXTM pre-cast gel 
(Biorad) along with Precision plus protein KaleidoscopeTM (Bio-Rad) as 
molecular mass markers. Following transfer on a nitrocellulose membrane by the 
iBlot device (Invitrogen) the membrane was blocked in 5% bovine serum albumin 
(BSA) for 1 h at 37°C. For AGT detection the membrane was incubated with 
polyclonal rabbit anti AGT serum (dilution 1:2000), washed three times in TBST 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) and then incubated 
with peroxidase-conjugated anti rabbit IgG (dilution 1:1000). Blotted proteins 
were detected and quantified with ECL® (Millipore), using the ChemiDoc XRS 
Imaging System (Bio-Rad, Hercules, CA).   
 
3.17 Immunofluorescence microscopy (IFM) 
CHO-GO cells expressing AGT-Ma and the R36H, G42E, I56N, G63R and 
G216R variants were grown in the absence or presence of 10 µM PN. 
Approximately 3 × 105 cells were seeded into each well of a 24-well plate, 
containing a 13-mm glass coverslip, and grown for 24 h in complete Ham's F12 
medium at 37 °C under O2/CO2 (19:1). Cells were fixed in 4% (w/v) 
paraformaldehyde permeabilized with 0.3% Triton X-100 in PBS and then 
blocked in 3% bovine serum albumin (BSA) in PBS. For the immunolabeling, 
rabbit polyclonal anti-human AGT and anti-peroxisomal protein from guinea-pig 
were used as primary antibodies, and Alexa Fluor conjugated antibodies (Life 
technologies) were used as secondary antibodies. Nuclei were stained with DAPI 
and the coverslips were mounted over slides in AF1 medium (Dako). Images were 
captured using a confocal laser-scanning fluorescence microscope Leica SP5 
(Leica Microsystem, Manheim, Germany) at 63×
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using ImageJ (http://rsb.info.nih.gov/ij/). For figure preparation images were 
processed using Adobe Photoshop.  
 
3.18 Statistical analysis 
Experiments have been performed at least in triplicate and in any case the 
standard error mean (SEM) was less than 10%. Statistical analyses were 
performed by Origin® 7 (Origin Lab) or GraphPad Prism Version 6.0 (GraphPad 
software, San Diego, CA, USA).  
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4 
ENGINEERING OF A SOLUBLE MONOMERIC 
FORM OF AGT AND STUDY OF THE 
DIMERIZATION PROCESS 
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Background information 
Human AGT is functionally active as a homodimer in liver peroxisomes (5). The 
protein displays a large monomer-monomer interface (Fig. 8) as compared with 
other PLP-dependent enzymes. Molecular and cellular analyses have suggested 
that the dimerization process could be crucial for the correct folding and 
intracellular targeting of the enzyme. In line with this view, many pathogenic 
mutations leading to PH1 involve residues located at or near the dimerization 
interface, whose mutation strongly reduces the thermodynamic and kinetic 
stability of the protein, decreases its intracellular half-life, increases its 
aggregation propensity, and, when associated with the minor allele 
polymorphism, leads to the aberrant targeting to mitochondria (26, 32, 45, 86). It 
is also well known that patients expressing pathogenic variants of AGT showing a 
reduced dimer stability respond to the administration of Vitamin B6 in form of 
PN. PN treatment raises the intracellular concentration of PLP (32, 54), which is 
supposed to promote dimer formation thus increasing variants stability (54). 
However, neither the structural elements that govern the self-association of the 
AGT subunits, nor the effect of the coenzyme have been elucidated at molecular 
level. To fill this gap, we engineered, purified and characterized a soluble 
monomeric form of AGT. As a first approach, we decided to start from the minor 
allelic form of the protein. This choice was dictated by the fact that (i) the P11L 
polymorphic mutation is known to destabilize the interfacial contacts between the 
N-terminal arm of one subunit and the large domain of the neighboring subunit, 
and (ii) many pathogenic variants showing reduced dimer stability are associated 
with the minor allele. We then studied the kinetics of the dimerization process in 
the absence or presence of the PLP coenzyme. These data provided the basis to 
understand the responsiveness to PN administration of two of the most common 
PH1 mutations, F152I and I244T, associated with the minor allele.  
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Fig. 8. Representation of the AGT dimer interface. Panel A: structure of AGT highlighting the 
interface residues as sticks. Panel B: surface representation of the AGT interface residues. The two 
monomers are coloured red and white. 
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RESULTS AND DISCUSSION 
4.1 Identification of the AGT interface hotspots 
The crystal structure of AGT reveals that 48% of the total solvent accessible area 
(ASA) of the protein is buried upon dimerization. Such surface comprises 110 
residues per subunit, many of which are directly involved in inter-chain contacts. 
In particular, 15 hydrophobic patches, 40 interchain hydrogen bonds and two salt 
bridges contribute to the monomer-monomer interaction. Considering the high 
number and the different type of interchain contacts as well as their wide 
distribution, the identification of possible dimerization hot spot/s could be 
difficult. Thus, to identify residues or clusters of residues that mainly contribute to 
the binding free energy at the dimerization interface, we performed an in silico 
alanine-scanning mutagenesis analysis on the AGT interfacial residues using the 
Molecular Operating Environment software by Chemical Computing Group (56). 
We first constructed the model of monomeric and dimeric AGT-Mi by in silico 
mutagenesis introducing the polymorphic mutations P11L and I340M followed by 
an energetic minimization of the structure, as reported in the “Material and 
Methods” section 4.2. Then, in order to find out residues whose substitution 
destabilizes the quaternary structure without any significant impact on the tertiary 
structure of each monomer, we performed the alanine-scanning mutagenesis 
analysis on both dimeric and monomeric AGT-Mi.  
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Fig. 9. Plot of the alanine scanning mutagenesis results either on the monomer (red bars) and 
dimer (black bars) of AGT expressed as dStability (kcal/mol) of each interfacial residue. The 
dStability (kcal/mol) represents the relative thermostability of each mutant with respect to AGT-
Mi. Only residues with a positive value of dStability '2 kcal/mol are shown. 
As shown in Fig. 9, the dStability values, representing the predicted relative 
thermostability of each mutant with respect to AGT-Mi, indicate that among the 
15 residues predicted to play a role in stabilizing the dimeric structure (black 
bars), only Arg118, Phe238 and Phe240 do not significantly change the intrinsic 
stability of monomeric AGT (red bars). These residues are not directly involved in 
the binding of the coenzyme and/or of the substrate, thus suggesting that their 
would not affect the AGT functional properties. Arg118 forms with Asp243 of the 
neighbouring chain the unique salt bridge present at the AGT-Mi interface (Fig. 
10, panel A). Thus, its substitution with an alanine residue could weaken the 
dimer interface without substantially affecting the monomer structure. Phe238 is 
engaged in hydrophobic base stacking interactions with the same residue of the 
other subunit, while Phe240 interacts with Trp246 of the same subunit as well as 
with Ile115, and possibly His83, of the adjacent monomer (Fig. 10, panel A). The 
predicted role of Phe238 and Phe240 in AGT dimerization was also investigated 
by the Protein Patch Analyzer tool of MOE 2015.01. The hydrophobic patches on 
the dimerization interface of AGT-Mi were ordered from 1 to 15 in the output list 
on the basis of a decreasing solvent-accessible surface area of the patch (Å2) (Fig. 
10, panel B). The main hydrophobic interactions at the dimer interface are formed 
by patches enumerated as 1, 10, 13 and 14. It can be observed that both Phe238 
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(patch 13) and Phe240 (patch 1) are predicted to critically contribute to the 
hydrophobicity of the interface because both residues show a high ASA value 
when they become exposed to the solvent upon monomerization (Fig. 10, panel 
B). We decided to substitute the two phenilalanine residues with serine residues, 
in order to weaken the dimer interface and concomitantly enhance the solubility of 
the monomer. 
 
 
Fig. 10. The main interface hot spots and hydrophobic patches along the AGT dimerization 
interface. Panel A: detail of the main interface hotspots. The labelled residues are shown as 
yellow or cyan sticks on the basis of the colour of the belonging subunit. PLP is shown as green 
sticks. Panel B: interfacial hydrophobic patches of an AGT monomer shown as green areas on the 
grey background of AGT. The size and the energy cut-offs of each patch are 75 Å2 and 0.25 
kcal/mol, respectively. 
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PLP
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4.2 Role of the residues Arg118, Phe238 and Phe240 on AGT 
dimerization 
Based on the results obtained by the computational analysis, we constructed, 
expressed, purified and characterized the mutants R118A-Mi, F238S-Mi, and 
F240S-Mi. The variants display spectral properties in the visible region analogous 
to those of AGT-Mi, although the R118A and the F238S mutations reduce the 
intensity of the 340-nm absorbance band, while the F240M mutation causes a 5-
nm blue shift of the 424 nm dichroic band (Fig. 11).  
 
 
Fig. 11. CD and absorbance spectra of AGT-Mi and single variants. CD and absorbance 
(inset) spectra of AGT-Mi (—), R118A-Mi (·····), F238S-Mi (---) and F240S-Mi (– – –) were 
obtained at 10 µM enzyme concentration in 50 mM potassium phosphate buffer, pH 7.4 
 
These data indicate that the variants show a PLP binding mode similar to that of 
AGT-Mi. Moreover, as shown in Table 3, the three mutations do not significantly 
alter the KD(PLP) value of AGT-Mi as well as the steady-state kinetic parameters 
for the overall transamination of the alanine-glyoxylate pair. F238S-Mi shows a 
kcat value comparable to that of AGT-Mi, while R118A-Mi and F240S-Mi display 
kcat values reduced by approximately 50 % with respect to AGT-Mi. Thus, none of 
these residues is essential for catalytic activity. However, it can be suggested that 
the mutation of Arg118 and Phe240 could alter the proper juxtaposition of the two 
subunits, thus negatively influencing the catalytic power.  In this regard, it should 
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be mentioned that a stretch of amino acids of the N-terminus called “active site 
loop” (residues 24-32) is present at the entrance of the AGT active site (8). 
Previous results indicate that interfacial mutations interfering with the interaction 
between the N-terminal arm and the neighboring subunit can alter the position of 
the active site loop and negatively influence the catalytic efficiency of the enzyme 
(31). Although more detailed information on the structural features of the variants 
would be necessary, it can be speculated that a similar phenomenon could be also 
caused by the R118A and F240S mutations, thus explaining their effect on 
catalysis.  
 
Table 3. Steady-state kinetic parameters and KD(PLP) of AGT-Mi and variants obtained in 50 
mM potassium phosphate buffer, pH 7.4 in the presence of 100 µM PLP. 
Enzyme Substrate 
 
Cosubstrate kcat     
(s-1) 
Km        
(mM) 
kcat/Km 
(mM-1s-1) 
KD(PLP) 
(µM) 
AGT-Mi L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
35 ± 1 
39 ± 3 
 
51 ± 7 
0.20 ± 0.05 
0.68 ± 0.09 
195 ± 43 
0.10 ± 0.01 
AGT R118A-Mi* L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
21 ± 1 
19 ± 1 
 
77 ± 10 
0.18 ± 0.02 
0.27 ± 0.04 
106 ±12 
0.20 ± 0.04 
AGT F238S-Mi L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
36 ± 1 
35 ± 1 
 
46 ± 1 
0.71 ± 0.06 
0.78 ± 0.03 
49 ± 4 
0.25 ± 0.02 
AGT F240S-Mi L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
22 ± 1 
20 ± 1 
84 ± 7 
0.28 ± 0.04 
0.26 ± 0.02 
71 ± 15 
 
0.19 ± 0.03 
*data obtained in presence of 10% glycerol. 
 
The impact of each single mutation on the AGT-Mi dimeric structure was 
investigated by SEC analyses of each variant in the holo- and apo-form at 
different enzyme concentrations (Table 4). HoloR118A-Mi elutes as a peak whose 
elution volume corresponds to that of a dimer and whose total area does not 
change up to 0.3 µM, while the apo-form elutes as three peaks whose elution 
volumes correspond to a dimer, a monomer and aggregates at high molecular 
weight. The integrated area of the dimer decreases and concomitantly that of the 
monomer and aggregates increases as the enzyme concentration decreases from 
10 to 1.25 µM. These data strongly indicate that the apomonomer form is prone to 
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aggregation, as supported by DLS measurements. In fact, at 5 µM concentration, 
apoR118A-Mi exhibits a rapid increase in count rate typical of a fast aggregation 
process, leveling off after approximately 12 min (data not shown). If SEC 
experiments are carried out in the presence of 10% glycerol to avoid aggregation, 
the proportion of the apomonomer increases at the expense of the dimer as the 
overall enzyme concentration is lowered from 18 to 1 µM. This indicates a slow 
equilibrium process. A plot of the percent dimer as a function of apoR118A-Mi 
concentration gives a hyperbolic curve whose linear transformation yields a 
Kd(dim-mon) value of 9.3 ± 0.1 µM (Table 4), a value at least 30-fold higher than that 
of apoAGT-Mi. Since both the apo- and holo-forms of the variants F238S-Mi and 
F240S-Mi maintain the dimeric structure up to 0.3 µM, it is not possible to 
establish if Phe238 or Phe240 play a role in the dimer formation of AGT-Mi.  
Table 4. Kd(dim-mon) values of AGT-Mi and variants. 
Enzymes Apo Kd(dim-mon)  
(µM) 
Holo Kd(dim-mon)  
(µM) 
AGT-Mi < 0.3 < 0.3 
R118A-Mi 9.3 ± 0.1* < 0.3 
F238S-Mi < 0.3 < 0.3 
F240S-Mi < 0.3 < 0.3 
F238S-Mi/F240S-Mi <0.3 <0.3 
R118A-Mi/F238S-Mi 7.4 ± 0.4 <0.3 
R118A-Mi/F240S-Mi 24 ± 1 2.4 ± 0.9 
R118A-Mi/F238S-Mi/F240S-Mi 80 ± 1 9.4 ± 0.5 
             *data obtained in presence of 10% glycerol. 
 
To promote AGT-Mi monomerization, double mutants were subsequently created 
in the following combinations: F238S-Mi/F240S-Mi, R118A-Mi/F238S-Mi, and 
R118A-Mi/F240S-Mi. Both the apo- and holo-form of F238S-Mi/F240S-Mi still 
existed predominantly in the dimeric form up to 0.3 µM, thus preventing the 
quantification of the effect of the combinations of the two mutations on the Kd(dim-
mon) value of AGT-Mi. On the other hand, the combination of each of the 
mutations with the R118A substitution gave different results. In fact, the double 
mutant R118A-Mi/F238S-Mi in the holo-form eluted from gel filtration as a 
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dimer up to 0.3 µM, while the apo-form had a Kd(dim-mon) value of 7.4 ± 0.4 µM 
(Table 4). The R118A-Mi/F240S-Mi double mutant demonstrated a significant 
shift from dimer to monomer both in the apo- (Kd(dim-mon) = 24 ± 1 µM) and holo-
form (Kd(dim-mon) = 2.4 ± 0.9 µM) (Table 4). It should be noted that the Kd(dim-mon) 
values of the double mutants are obtained in the absence of glycerol, thus 
suggesting that the combination of the mutations F238S and F240S with the 
R118A mutation prevents apomonomer aggregation. All together, these data 
highlight that (i) the interacting forces between Arg118 and Asp243 of the 
neightboring monomer may drive dimer formation in apoAGT-Mi, (ii) Arg118 
and Phe240 synergize in promoting the formation of the dimer of AGT-Mi, and 
(iii) substitution of both Phe238 and Phe240 with Ser could be relevant in 
increasing monomer solubility by reducing the hydrophobicity of the dimer 
interface. Therefore, we decided to construct, express, purify, and characterize the 
triple mutant R118A-Mi/F238S-Mi/F240S-Mi. The triple mutant displays a slow 
dimer-monomer equilibrium process in both the apo- and holo-form, and Kd(dim-
mon) values of 80 ± 1 µM and 9.4 ± 0.5 µM, respectively (Table 4). These results 
highlight that the salt bridge between Arg118 and Asp234 plays a pivotal role in 
stabilizing the AGT monomer-monomer interface, thus indicating that it 
represents at hot-spot for protein dimerization. On the other hand, both Phe238 
and Phe240 take part to main hydrophobic interactions, which significantly 
influence the dimerization equilibrium only in the presence of the R118A 
mutation but represent a key factor in determining monomer stability in solution. 
The triple mutant R118A-Mi/F238S-Mi/F240S-Mi is stable in solution as a 
monomer in both the apo- and holo-form. Thus, it represents an excellent model 
to study the biochemical properties of AGT in the monomeric form as well as the 
kinetics of the dimerization process.  
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4.3 Spectroscopic features of the engineered monomeric AGT 
 
The far-UV CD spectrum of the apomonomer R118A-Mi/F238S-Mi/F240S-Mi 
was comparable to that of apoAGT-Mi in the dimeric form, and the deconvolution 
revealed that they have an identical composition of the overall secondary 
structure. On the other hand, the comparison of near-UV CD spectra and intrinsic 
fluorescence spectra (both reflecting the microenvironment of aromatic side 
chains) as well as ANS fluorescence spectra and thermal stability data of the 
apomonomer and apoAGT-Mi provided evidence that a different conformation 
exists between the two forms. In fact, as shown in Fig. 12, the apomonomer 
exhibited an increase of the dichroic signals in the near-UV region and a decrease 
of the intrinsic fluorescence emission intensity along with a 4-nm red-shift of the 
maximum intensity, as well as a ~8-fold increase in ANS emission fluorescence 
intensity with a 4-nm red shift of the emission maximum. Additionally, unlike 
apoAGT-Mi which displayed a two-steps thermal transition curve with apparent 
mid-denaturations at 53.8 ± 0.1 °C and 66.1 ± 0.1 °C (33), the unfolding of the 
triple mutant in the apo-form occurred through a single step with an apparent Tm 
value of 47.5 ± 0.3 °C. These data indicate that the monomer is characterized by a 
different tertiary structure, and by an increased exposure of hydrophobic surfaces, 
leading to a higher sensitivity to thermal stress. Similar features were also 
observed for the apomonomer of the double mutant R118A-Mi/F240S-Mi. 
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Fig. 12. Spectroscopic features of apomonomer R118A-Mi/F238S-Mi/F240S-Mi (red line) in 
comparison with the apodimer AGT-Mi (black line). Panel A: near-UV CD spectra at 5 µM 
concentration; Panel B: intrinsic fluorescence emission spectra at 1 µM concentration. Inset of 
panel B: ANS emission fluorescence spectra at 1 µM concentration. All measurements were 
obtained in 50 mM KP buffer, pH 7.4. 
 
We then monitored the ability of the apomonomer (2 µM) to bind PLP by 
following the time-dependent changes in the dichroic signal at 424 nm, due to the 
formation of the internal aldimine complex in the presence of 100 µM PLP, i.e. 
under conditions in which the triple mutant is monomeric either in the apo-form 
and holo-form. The kinetics of PLP binding was monophasic and the process 
occurred with a rate constant of 2.44 ± 0.08 min-1. At the end of the process, the 
loading of the solution on a SEC column confirmed that all the protein remained 
in the monomeric form upon PLP binding. The prolonged incubation (> 3 h) of 
the monomer at a concentration of 0.1 or 0.2 µM with L-alanine and glyoxylate 
did not lead to any pyruvate formation, thus indicating that it does not show any 
significant catalytic activity. When compared with holoAGT-Mi in the dimeric 
form, the holomonomer also revealed (i) a decrease of the dichroic band in the 
near-UV region, (ii) a 20-fold increase in the ANS emission intensity with a 9 nm 
red shifted maximum, and (iii) a mid-point denaturation reduced by 23 degrees 
(50.1 ± 0.1 °C) (see below). In the visible region, the PLP- bound monomer 
showed a positive dichroic band at 424 nm whose magnitude was about half that 
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of holoAGT-Mi indicating a different PLP binding mode (data not shown). This is 
also confirmed by the fluorescence emission spectra of the NaBH4-reduced 
holomonomer upon excitation at 325 nm, which displayed a 6-nm red shifted 
maximum and 2-fold increased intensity in comparison with that of the reduced 
holoAGT-Mi (Fig. 13). Moreover, while the intrinsic fluorescence emission 
spectrum of the reduced holodimer showed a single maximum at 341 nm, the 
holomonomer fluoresced not only at 342 nm but also at 393 nm, possibly due to 
the occurrence of an energy transfer from tryptophan(s) to the reduced coenzyme 
(inset of Fig. 13).  
 
Fig. 13. Fluorescence properties of NaBH4-reduced R118A-Mi/F238S-Mi/F240S-Mi (red line) 
and dimeric AGT-Mi (black line). Emission fluorescence spectra upon excitation at 325 nm. The 
inset show the fluorescence emission upon excitation at 280 nm. Spectra were registered at 1 µM 
concentration. 
 
When the apomonomer was treated with PLP concentrations ranging from 1 to 40 
µM, the trend of the dichroic signal values at 424 nm as a function of PLP 
concentration gave a KD(PLP) value of 4.4 ± 0.5 µM per subunit. This value is 
about 17-fold higher than the KD(PLP) value of AGT-Mi (36). Taken together, these 
data indicate that the holo and apomonomer display a conformation similar to 
each other but different from the corresponding ones of the dimeric forms of 
AGT-Mi (Fig. 13 and Fig. 14), as revealed by spectroscopic properties and 
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apparent Tm values. Monomeric AGT is able to bind PLP, although with an 
affinity lower than holoAGT-Mi. The PLP-bound monomer is catalytically 
inactive and exhibits local structural alterations of the coenzyme 
microenvironment leading to a more pronounced exposure to the solvent of the 
PLP binding site as well as an altered spatial geometry of the functional groups in 
the PLP microenvironment, with respect to the holodimer.  
 
 
Fig. 14. Spectroscopic feature of apo and holomonomer R118A-Mi/F238S-Mi/F240S-Mi in 
comparison with apo and holodimer AGT-Mi. ANS emission fluorescence spectra at 1 µM 
concentration. In the inset: near-UV CD spectra at 1 µM concentration. Color code: cyan and red 
correspond to holo and apodimer of AGT-Mi, respectively, while blue and green correspond to the 
holo and apomonomer of R118A-Mi/F238S-Mi/F240S-Mi. 
 
Although the vast majority of PLP-enzymes are present as dimers, only few 
studies until now have addressed the role of the quaternary structure on the 
enzyme structural and functional properties. In analogy with what already known 
for ornithine decarboxylase (87), bacterial diaminopimelate decarboxylase (88) 
and Treponema denticola cystalysin (89), we found that monomeric AGT does 
not display transaminase activity and shows an altered active site 
microenvironment. This is not surprising, since residues belonging to both 
subunits form the protein active site. Residues of the neighboring subunit are 
involved in key interactions with the coenzyme, such as the hydrogen bonds 
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coordinated by Tyr260 and Thr263 with the phosphate group of PLP (8). 
Moreover, by engineering a monomeric form of the protein stable in solution, we 
could show that dimerization in AGT seems to be important for both the stability 
and the achievement of the final tertiary structure. This is in line with the finding 
that pathogenic mutations involving interfacial residues often lead to an increased 
propensity of the protein to unfolding, aggregation and degradation (90).   
 
4.4 Kinetics of the dimerization process and role of PLP 
To investigate the kinetics of the dimerization process and the effect of the 
coenzyme, we monitored PLP binding as a function of time at 5 µM R118A-
Mi/F238S-Mi/F240S-Mi concentration, i.e under conditions in which the triple 
mutant is monomeric in the apo-form and mostly dimeric in the holo-form. We 
observed that the magnitude of the dichroic signal at 424 nm increased in a 
biphasic way. The fast phase, obtained by fitting the data to a single exponential 
process, occurred with a rate constant of 2.4 ± 0.2 min-1, while the slow phase, 
fitted to Eq. (4) (“Materials and Methods”, section 3.9), was characterized by a 
rate constant of 0.020 ± 0.002 µM-1min-1 (Fig. 15). Aliquots withdrawn from the 
reaction mixture at various times were subjected to SEC and activity analyses. As 
shown in the inset of Fig. 15, the dimeric species increased with time at the 
expense of the monomeric one in a slow equilibrium process. The percentage of 
the dimeric form as a function of time fitted Eq. (4), yielded a rate constant value 
of dimerization of 0.019 ± 0.002 µM-1 min-1. On the basis of this value and that of 
Kd(dim-mon) of the triple mutant in the holo-form, we could estimate a kdiss value of 
0.18 ± 0.004 min-1. As shown in Fig. 15, the regain of transaminase activity as a 
function of time occurred with a rate constant of 0.021 ± 0.002 µM-1 min-1, a value 
in excellent agreement with those of dimerization and of the slow phase of PLP 
binding. Thus, it is possible to suggest that the biphasic process is characterized 
by a fast phase representing the internal aldimine formation between the 
apomonomer and the coenzyme, followed by a slow phase representing 
dimerization and regain of transaminase activity. To obtain a realistic estimation 
of the catalytic activity of the triple mutant in the holodimeric form, we incubated 
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the apomonomer at concentrations ranging from 1.4 to 19 µM with 100 µM PLP, 
and we assayed the reaction mixtures both for transaminase activity and amount 
of formed dimer. By plotting the catalytic activity as a function of the percentage 
of dimer we noticed a linear relationship between the two variables (data not 
shown) and we calculated that 1 nmol of the triple mutant in the holodimeric form 
reacting with L-alanine and glyoxylate produces pyruvate with an initial rate of 
4.8 nmol pyruvate/sec. Assuming that this value is close to the kcat of the half-
transamination, this rate is about 9-fold lower than the kcat value of AGT-Mi.   
 
Fig. 15. Second-order kinetic plots for data of dimerization ((), increase of magnitude of the 
CD signal at 424 nm (●), and catalytic activity (▲) according to Eq. (4). Inset: SEC profiles of 
the apomonomer after addition of 100 µM PLP at the indicated times. 
 
We also investigated the kinetics of the dimerization of the triple mutant in the 
apo-form by SEC experiments. We found a value of kass equal to 7.9 ± 0.6 x 10-6 
µM-1 min-1 and, on the basis of the Kd(dim-mon), we estimated a kdiss value of 6.4 ± 
0.4 x 10-4 min-1. Thus, the apomomer is able to dimerize even if with rates of 
association and dissociation about 2700- and 280-fold lower respectively, than the 
corresponding ones of the PLP-bound monomer. 
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Overall these data show that PLP binding shifts the equilibrium toward the 
dimeric form of AGT mainly by accelerating the dimerization process. This 
implies that, in line with previous evidences, the coenzyme does not only play a 
prostethic role for the enzyme, but also a chaperone role by promoting the 
achievement of the native structure. A similar behavior has been also suggested 
for other B6 enzymes such as Treponema denticola cystalysin, Dopa 
decarboxylase (DDC) and delta-Aminolevulinate Synthase (ALA Synthase) (54). 
 
4.5 In silico analyses to explain the pathogenicity of the F152I-Mi 
and I244T-Mi variants 
 
Studies performed on both purified proteins and cellular systems have suggested 
that some of the most common pathogenic mutations could reduce the stability of 
the dimeric structure of AGT leading to various effects (32). Based on the results 
reported above indicating that Arg118 is a hot-spot interfacial residue playing a 
relevant role in the dimerization of AGT-Mi, we wonder if some PH1-causing 
mutations could play their effects by directly or indirectly interfering with 
Arg118. Taking into consideration in the crystal structure of AGT an ideal sphere 
of 15 Å radius whose center is the C# of Arg118, we noticed the presence of 
several residues of the large domain whose mutation is associated with PH1. 
Among them, we focused our attention on Phe152 and Ile244, because the 
mutations F152I and I244T are two of the most common and studied. Molecular 
and cellular analyses have suggested that both the Phe152-to-Ile and the Ile244-
to-Thr substitutions could synergize with the P11L polymorphism and destabilize 
the AGT dimer leading to a various effect including in particular the 
mitochondrial mistargeting of the protein.  To analyze the effects of the F152I and 
I244T mutations on AGT-Mi we carried out MD simulations on the modeled 
structures of AGT-Mi, I244T-Mi and F152I-Mi in the dimeric form in 
collaboration with the group of Dr. Giorgetti of the Department of Biotechnology 
of the University of Verona. By visual inspection, we observed that the salt bridge 
formed by Arg118 and Asp243 was maintained for about 87.3% of the time in 
AGT-Mi, while it remained stable for only 17.5% of the time in the I244T-Mi 
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mutant. Thus, we hypothesized that the I244T mutation could have a direct 
influence on the formation of a key interface contact. Indeed, we observed that the 
breaking of the Arg118-Asp243 salt bridge coincided with the formation of a 
hydrogen bond between Thr244 and Asp92, which forced a backbone 
conformational change (Fig. 16).  
 
 
Fig. 16. Perturbation of the microenvironment of Arg118. Panel A: Arg118-Asp243 salt 
bridge, together without Asn92-Thr244 hydrogen bond interaction. Panel B: breaking of Arg118-
Asp243 salt bridge, together with Asn92-Thr244 hydrogen bond interaction; the two monomeric 
subunits are displayed in aquamarine and brownish. Depicted hydrogen atoms were added within 
the setup of the simulations. 
 
This was not possible in AGT-Mi because the isoleucine at position 244, which 
cannot form H-bonds with neighboring residues, guaranteed the stability of the 
Arg118-Asp243 salt-bridge. Conversely, we did not observe any significant 
difference between the interface contacts of dimeric AGT-Mi and F152I-Mi. 
Thus, we conducted MD simulations for 170 ns on the monomeric structure of 
both AGT-Mi and F152I-Mi. However, neither these analyses nor visual 
inspection revealed significant changes at the dimer interface regions between the 
two proteins. Thus, we decided to calculate the ED on the MD simulations. The 
ED technique allows not only to highlight the dominant motions of the system, 
which are often meaningful and correlated with protein function, but also to 
reduce the complexity of the data. Fluctuations analysis by ED revealed that the 
F152I mutation could influence the dynamics of several amino acid stretches of 
AGT-Mi, i.e., 95-97, 118-121, 141-145, 171-176 and 281-290, with peaks for 
residues 97, 118, 143, 175 and 281. These results suggest that the latter residues 
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have a different behavior in terms of flexibility in F152I-Mi as compared with 
AGT-Mi. In particular, one of the stretches exhibiting a different behavior in the 
mutated system was formed by residues 118-121, located at the dimerization 
interface (data not shown). On these bases, we can suggest that the F152I 
mutation could affect dimer formation by increasing the flexibility of the region 
118-121, thus possibly reducing the complementarity between the two monomers.  
 
4.6 Proposed folding and dimerization pathway of AGT-Mi and 
I244T-Mi and F152T-Mi variants 
 
The aberrant targeting to mithocondria is a pathogenic mechanism leading to PH1 
that deserves particular attention (46). The import into peroxisomes mainly acts 
on the fully-folded dimeric state of AGT (26), while that in mitochondria requires 
a monomeric state of the enzyme provided with a mitochondrial targeting 
sequence resulting from the P11L polymorphism. It follows that the dimerization 
and the correct subcellular localization of AGT are correlated events for this PLP-
enzyme. It has been suggested that the combined effect of some mutations with 
P11L could result in a destabilization of the dimeric structure of AGT-Mi, thus 
allowing the population of monomeric folding intermediates that are compatible 
with the mitochondrial import. However, no structural explanations for these 
effects have been provided until now. In this study we engineered for the first 
time a mutant form of AGT stable in solution as apomonomer and holomonomer. 
We used this form to analyze how the quaternary structure influences the spectral 
features of the protein. Moreover, we demonstrated that the coenzyme PLP is able 
to bind monomeric AGT and promotes protein dimerization. This confirm 
previous hypothesis on the chaperone role of PLP for AGT (54). Moreover, the 
analysis of the AGT dimerization process as well as the MD experiments reported 
above can allow to understand how the F152I and I244T mutations can lead to 
folding defects as well as explain their functional synergism with the polymorphic 
mutation P11L.  
A possible pathway of AGT folding has been already proposed (8) in which the 
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unfolded monomer is converted to a partly unfolded monomer, and then to a 
folded monomer which finally dimerizes (8). Based on the finding that AGT is 
endowed with a large core dimer interface and that a truncated form of the protein 
devoid of the first 21-N-terminal residues is able to dimerize (91), it can be 
advanced the proposal that dimerization could start by means of core dimer 
interfacial interaction and not by the N-terminal extension (Fig. 17, pathway 1). 
 
 
 
Fig 17. Proposed folding and dimerization pathway of AGT-Mi (1) and of the I244T-Mi and 
F152T-Mi variants (2). The green dots indicate the P11L polymorphism. The yellow dots 
represent the PLP coenzyme. 
 
Following this view, the N-terminal extensions, containing the P11L 
polymorphism generating a putative MTS, should be exposed and flexible and not 
tightly bound to the surface of the neighboring subunit. Since MD simulations 
predict that the mutations I244T and F152I interfere with dimerization, the 
formation of the dimeric structure of the variants I244T-Mi and F152I-Mi should 
be greatly impaired, while the formation of the partly unfolded and unfolded 
monomeric forms should prevail. Thus, the partially unfolded monomers of the 
variants I244T-Mi and F152-Mi containing the P11L polymorphism, could be 
imported into mitochondria, possibly with a rate higher than that of their 
conversion to the corresponding folded monomers (Fig. 17, pathway 2). 
Nevertheless, here we have demonstrated that the dimerization of the 
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apomonomer of the triple mutant occurs with kass and kdiss remarkably lower that 
the corresponding ones of the PLP-bound monomer. These findings indicate that 
high levels of PLP could shift the equilibrium from the PLP-bound monomer of 
the variants F152I-Mi and I244T-Mi to the dimeric form, thus preventing their 
mislocalization. This could explain why the F152I-Mi or I244T-Mi variants have 
been found to be responsive to pyridoxine administration, a therapeutic strategy 
that increases the intracellular level of PLP (37).  
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CONCLUSIONS 
In this work, by combining in silico analyses with biochemical studies on purified 
proteins, we were able to: (i) identify the interfacial residues, Arg118, Phe238, 
and Phe240, which are not essential for catalytic activity of AGT-Mi but have a 
relevant impact on its dimerization process, (ii) engineer and characterize a folded 
apomonomer and holomonomer, both able to dimerize (iii) demonstrate that 
dimerization is critical for catalytic activity, and (iv) outline the possible structural 
basis of the functional synergism between the mutations I244T or F152I and the 
mutation P11L responsible for the aberrant targeting to mitochondria of the 
variants I244T-Mi and F152I-Mi associated with PH1. These results are 
significant not only for the AGT folding and dimerization processes as well as for 
the effect of mutations interfering with dimer stability, but they can also provide 
useful insights to understand the behavior of other PLP enzymes for which the 
coenzyme can play a similar role. 
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5 
MOLECULAR AND CELLULAR EFFECTS OF 
PATHOGENIC INTERFACIAL MUTATIONS IN 
ALANINE:GLYOXYLATE AMINOTRANSFERASE 
AND RESPONSE TO VITAMIN B6 
ADMINISTRATION 
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Background information 
 
 
Dimerization is considered a crucial event for AGT, because it is supposed to 
influence the overall stability of the protein and its intracellular fate, including in 
particular the correct peroxisomal localization (32). The binding of the PLP 
coenzyme favors the attainment of the dimeric structure, as previously claimed by 
various authors (9, 37, 45, 54, 55) and demonstrated in the previous chapter of 
this thesis. This would imply that PH1 patients bearing missense mutations that 
cause a destabilization of the AGT dimeric structure could be responsive to 
Vitamin B6 administration. Clinical data have demonstrated that this is true for 
two of the most common mutations, the G170R and the F512I associated with the 
minor allele (43). Both amino acid substitutions interfere with AGT dimerization 
leading to the increase of population of monomeric folding intermediates that 
undergo aggregation and/or intracellular degradation and/or mitochondrial 
mistargeting (32).  
Among the 79 missense mutations known to be associated with PH1, 26 involve 
residues directly located at the monomer-monomer interface. The effects of many 
of them have not been analyzed in detail, as well as their possible response to 
Vitamin B6. On these bases, we carried out an in silico analysis to rank the 
interface destabilization caused by each amino acid substitution. Then, we 
analyzed the molecular and cellular effects of a selected group of mutations and 
we tried to correlate the defect of each variant with the in vitro responsiveness to 
PN administration. We limited the study to missense mutations associated with 
the major allele because the polymorphic P11L mutation typical of the minor 
allele (i) is known to influence AGT dimerization and can functionally synergize 
with pathogenic interfacial mutations (32, 92), and (ii) generates a putative 
targeting sequence for mitochondria (37), thus possibly making more difficult the 
interpretation of the results obtained in the cellular system.  
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RESULTS  
 
5.1 Computational screening of the effects of pathogenic amino 
acid substitutions on AGT-Ma dimerization 
 
We applied a rigid body docking-based screening to predict the effects of AGT 
pathogenic mutations involving residues located at the dimerization interface on 
the monomer-monomer binding affinity (8). The method was applied to 12 
dimeric variants prepared in silico, corresponding to mutations associated with 
either the major allele or an unknown locus. The results of docking simulations of 
AGT-Ma and pathogenic variants are reported in Table 5 and show that on 
average 11 native-like solutions out of 12,000 total solutions from the three 
independent sets of docking runs were found. Moreover, in all cases, the native-
like conformations are comprised within the first ten solutions of each run. This 
guarantees the efficacy of the method. The final output of the analysis is the ZD 
score of each single run. The arithmetic mean between the three ZD score gives 
the ZD average (ZDavr) from which we obtained the predicted &&G° (&&G°pred) 
(“Materials and Methods”, section 3.2.3), that represents the difference in the 
predicted &G° of dimerization between each variant and AGT-Ma, thus providing 
a possible quantification of the stabilizing or destabilizing effect of each amino 
acid substitution on the monomer-monomer interaction. 
Besides the L25R variant, for which no significant difference in dimer stability 
was predicted as compared with AGT-Ma, and the S275R-Ma, predicted to have 
an increased stability of the dimeric structure (Table 5), all the other variants show 
a negative value of &&G°pred, indicating a probable destabilization of the dimeric 
structure, though to a different extent.  
Predictions generated by docking-based simulations were then combined with 
information derived from the inspection of the AGT structure and from previous 
knowledge of the structural properties of the protein. Three of the mutations 
(D243H, R111Q, R233L) involve residues that directly or indirectly interact with 
dimerization hot-spots already identified in previous studies (this thesis). Asp243 
and Arg118 form a ionic bridge that is the only one present on the dimerization 
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interface, thus explaining the significant destabilization of the dimeric structure 
predicted by docking analyses (&&G°pred= -2.30 kcal/mol) (Table 5). Arg111 
interacts with the main chain of the residues His261 and Tyr260. Its replacement 
by a glutamine residue could destabilize the orientation of His261 that forms a 
hydrogen bond with the main chain of Phe240, an important dimerization hotspot 
already described (this thesis). Finally, the replacement of Arg233 with a leucine 
residue interrupts the hydrogen bond between Arg233 and the main chain of 
Lys236 and destabilizes the orientation of the loop composed by residues Phe238, 
Phe240 and Asp243 involved in the formation of an interface hotspot. 
 
Table 5. Results of docking simulations for AGT-Ma and pathogenic variants. 
 
Enzyme Allele #native-like 
solutions 
ZDavg ZD(mut)-
ZD(AGT-Ma)  
&&G°pred 
(kcal/mol) 
AGT Ma 12 195.6 ± 7.0 / / 
L25R Unknown 11 195.3 ± 6.4  -0.3 -0.11 
R36H Ma 10 191.8 ± 5.7 -3.8 -1.48 
G42E Ma 12 192.2 ± 6.3 -3.4 -1.32 
I56N Ma 9 193.3 ± 5.5 -2.3 -0.89 
G63R Ma 9 186.6 ± 6.5 -9.0 -3.51 
R111Q Unknown 11 192.6 ± 6.2 -3.0 -1.17 
G216R Ma 10 170.9 ± 6.2 -24.7 -9.62 
R233L Unknown 12 192.3 ± 6.4 -3.3 -1.28 
D243H Unknown 12 189.7 ± 6.2 -5.9 -2.30 
H261Q Unknown 13 191.8 ± 6.7 -3.9 -1.52 
S275R Ma 10 204.6 ± 6.6 +9.0 +3.51 
 
 
Based on the above considerations, in the present study we focused our attention 
on the mutations R36H, G42E, I56N, G63R and G216R (Fig. 18) because they are 
all supposed to have a destabilizing effect on the dimeric structure (Table 5) 
although involve residues far from the AGT interface hot-spots. Within the pool 
of selected mutants, it is of note the predicted destabilization of the dimeric 
structure induced by the mutations G63R and G216R, leads to a decrease in 
affinity of 3.5 and 9.6 kcal/mol respectively (Table 5), thus suggesting an 
important role of these residues in the stability of the dimeric structure.  
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Fig. 18. Tridimensional representation of the mutation sites. Ribbons representation of the 
crystal structure of human AGT (PDB :1H0C). Monomers are colored grey and orange. PLP is 
colored green. A) Overall dimeric structure of holoAGT with all the mutation sites, represented as 
grey sticks. B, C, D, E and F) Residues subjected to pathogenic mutations (grey or orange sticks) 
and their main contact residues belonging to both subunits, colored as the belonging monomer. 
 
As reported in Fig. 18, all the mutation sites are located in the large domain of 
AGT. Arg36, Gly42, Ile56 and Gly63 interact with residues located at the N-
terminal domain of the adjacent subunit while Gly216 is located in the proximity 
of the active site and it interacts with Gly216 of the other subunit and Ser81, an 
important residue involved in the binding of the PLP phosphate group (chapter 1.2 
of this thesis). 
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5.2 Intracellular behavior of the R36H, G42E, I56N, G63R and 
G216R variants 
 
We introduced the R36H, G42E, I56N, G63R and G216R mutations in the AGT 
cDNA cloned in a pcDNA 3.1 vector suitable for the expression in mammalian 
cells. Then, we transfected Chinese Hamster Ovary (CHO) cells expressing 
glycolate oxidase (GO) (CHO-GO), a well-recognized disease model for PH1 (32, 
55), with the resulting constructs. We selected cells stably expressing each species 
and we adapted them for growing in a custom-made medium containing a 
Vitamin B6 concentration mimicking that present under physiological conditions 
(low B6) (“Material and Methods”, section 3.15). Thereafter, we compared the 
AGT expression level and specific activity of the cells before and after treatment 
with 10 µM PN, a condition mimicking that of treated patients (52).  
The results shown in Fig. 19 panels A and B indicate that all the mutations caused 
a structural defect in AGT.  
 
 
 
Fig. 19. Effect of PN on the expression level of AGT-Ma and variants. CHO-GO cells 
expressing the indicated enzymatic species were grown in the presence or absence of 10 µM PN. 
Cells were harvested and lysed, 2 µg of soluble lysate were subjected to SDS-PAGE, 
immunoblotted with anti-AGT from rabbit (1:6000) and detected by chemiluminescence. Bar 
graphs represent the mean + SEM. Panel A: histograms representative of the immunoblot band 
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volume. The color code is the following: soluble fraction colored orange while the insoluble 
fraction colored in blue. Panel B: immunoblot of the soluble fraction; lanes are coded as follows: 
cells grown in low-B6 (L) and cells grown in presence of 10 µM PN (PN). 
 
In fact, as compared with AGT-Ma, the amount of soluble protein was 24, 21, 39, 
9, and 11%, for R36H, G42E, I56N, G63R and G216R, respectively. Conversely, 
the relative amount of protein present in the insoluble fraction increased of 30% 
for AGT-Ma to 76, 79, 61, 91, and 89% of R36H, G42E, I56N, G63R and G216R, 
respectively, thus possibly suggesting an increased aggregation propensity. We 
also observed that R36H and G42E variants were prone to proteolytic 
degradation, as shown by the presence of a faster migrating band in western-blot 
(Fig. 19, panel B), thus indicating that the two mutations could increase the 
flexibility of exposed regions of the protein that become susceptible to the 
cleavage by proteases (31). As compared with wild-type AGT, the specific 
activity of R36H, G42E, I56N and G63R was 10, 12, 9 and 3%, respectively. No 
transaminase activity was detected for the G216R variant, even at high protein 
concentration and incubation time, thus suggesting that the Gly216-to-Arg 
substitution could also alter the AGT functional properties. The presence of PN in 
the culture medium did not change the levels of AGT-Ma in the soluble fraction, 
but increased by 3.2-, 3.7-, 4.8-, 13.2- and 1.4-fold that of R36H, G42E, I56N, 
G63R and G216R, respectively. This effect was also accompanied by a reduction 
of the relative amount of protein present in the insoluble fraction. Notably, no 
significant changes in the expression level of G216R were observed, even after 
treatment of the cells with PN at millimolar concentrations, taking into account 
the high value of KD(PLP) of the variant (see below). PN treatment also 
counteracted the proteolytic cleavage of the R36H and G42E variants, as indicated 
by the presence of a single band in western-blot. The specific activity of AGT-Ma 
decreased by 75% in the presence of PN, in agreement with previous reports (55), 
due to the intracellular accumulation of PNP that competes with PLP and 
generates an inactive AGT-PNP complex. On the other hand, PN treatment 
increased the specific activity of R36H, G42E, I56N and G63R by 1.7-, 2.5-, 2.5-, 
and 2.6-fold, respectively (Fig. 20).  
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Fig. 20. Effect of PN on the specific activity of AGT-Ma and variants. CHO-GO cells 
expressing the indicated AGT species were grown in the absence or presence of 10 µM PN. The 
AGT transaminase activity was detected by incubating the soluble lysate with 0.5 M L-alanine, 10 
mM glyoxylate and 200 µM PLP at 25°C in 100 mM KP buffer, pH 7.4. Bars are colored as 
follows: cells grown in low-B6 in black and cells grown with 10 µM PN in red. 
 
We also investigated the influence of the pathogenic interfacial mutations under 
study on the subcellular localization of AGT. In the absence of PN added to the 
culture medium, all the variants displayed a peroxisomal localization, as shown by 
the colocalization between the signal of AGT and that of the peroxisomal marker 
(Fig. 21).  
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Fig. 21. Subcellular localization of AGT-Ma and pathogenic variants grown in low-B6 
medium. CHO-GO cells expressing each species were fixed and colored as follows: anti-AGT 
(red) and anti-peroxisomal GO (green). Nuclei were stained with Dapi (blue). Merge and single-
channel images come from a single z-plane. Scale bar: 10 µm. 
 
The partial cytosolic localization of R36H, G42E and G63R suggested that their 
structural alteration could somehow influence the peroxisomal import of the 
protein. The treatment with PN redirected all the variants to peroxisomes, as 
shown by the complete correspondence between the pattern of AGT and that of 
the peroxisomal marker (Fig. 22).  
 
 
Fig. 22. Subcellular localization of the pathogenic variants R36H, G42E and G63R upon 
treatment with 10 µM PN. CHO-GO cells expressing the pathogenic variants were fixed and 
colored as follows: anti-AGT (red) and anti-peroxisomal GO (green). Nuclei were stained with 
Dapi (blue). Merge and single-channel images come from a single z-plane. Scale bar: 10 µm. 
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All together, these data lead to conclude that (i) all the analyzed mutations should 
cause a structural defect, which probably increases the aggregation propensity of 
AGT in the cell and, in some cases, makes the protein more susceptible to 
proteolytic degradation and/or affects its peroxisomal import; (ii) PN treatment is 
able to partly rescue for the effects of interfacial mutations, although to a different 
extent. 
 
 
5.3 Characterization of the R36H, G42E, I56N, G63R and G216R 
variants in the purified form 
 
In order to define how each interfacial mutation affects the biochemical properties 
of AGT, the R36H, G42E, I56N, G63R and G216R variants were expressed in E. 
coli, purified and characterized. SDS-PAGE analyses revealed that the proteins 
were homogeneous as indicated by a single band with a mobility identical to that 
of AGT-Ma. The far-UV dichroic spectrum of each variant was identical to that of 
AGT-Ma indicating no gross structural alterations of the secondary structure of 
the protein. Therefore, we investigated how each mutation affects (i) the 
functional properties of AGT, including the PLP binding mode and affinity as 
well as the kinetic parameters for the overall transamination reaction, and (ii) the 
structural properties of the protein in the holo- and apo-form, including the 
tertiary and quaternary structure, the aggregation propensity and the susceptibility 
to proteolytic cleavage. 
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5.3.1 Functional properties of the R36H, G42E, I56N, G63R and 
G216R variants  
 
The values of the equilibrium dissociation constant for PLP (KD(PLP)) of each 
species show a slightly altered of the PLP binding affinity, the only exception 
being the G216R-Ma that displays a KD(PLP) value $400-fold higher than that of 
AGT-Ma.  
 
 
Table 6. Equilibrium dissociation constants for PLP (KD(PLP)) and optical activity of AGT-
Ma and variants. 
 
Enzymatic species KD(PLP) (µM) Optical activity 
AGT-Ma 0.27 ± 0.03a 97 mdeg/Abs 420 nmb 
R36H 0.36 ± 0.04 95 mdeg/Abs 417 nm 
G42E 0.40 ± 0.04 104 mdeg/Abs 424 nm 
I56N 0.74 ± 0.10 102 mdeg/Abs 422 nm 
G63R 0.85 ± 0.13 93 mdeg/Abs 422 nm 
G216R 110 ± 14 n.d. 
                  n.d., not determined 
                            aFrom reference (10) 
                 bFrom reference (33) 
 
 
  
Coenzyme binding to AGT gives typical absorbance bands at 430 and 340 nm 
associated with a positive and negative dichroic signal, respectively, at the same 
wavelength (10). We calculated the optical activity from the UV-visible 
absorbance and CD spectra of the R36H, G42E, I56N, G63R variants at 10 µM 
concentration in the presence of saturating PLP (Table 6). We did not notice 
significant changes of the coenzyme binding mode. The high value of KD(PLP) of 
the G216R variant did not allow to register the absorbance and CD spectrum at 
saturating PLP concentration. 
The steady-state kinetic parameters for the overall transamination of the alanine-
glyoxylate pair of the variants are reported in Table 7. The R36H, G42E, I56N, 
G63R variants do not show a strong alteration of catalytic efficiency value. 
However, we noticed an approximately 70% reduction of the kcat value for the 
R36H. Moreover, the kcat/Km value of G216R obtained in presence of saturating 
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PLP was decreased by )254-fold with respect to AGT-Ma, mainly driven by the 
decrease in the kcat value.  
Therefore, the G216R is the only interfacial mutation causing a significant 
functional defect in AGT among those analyzed, while the other variants should 
mainly display a structural defect. 
 
 
 
Table 7. Steady-state kinetic parameters of AGT-Ma and the pathogenic variants for the 
overall transamination reaction. 
 
aFrom reference (10) 
 
 
 
 
 
 
 
 
 
 
 
 
Enzyme Substrate Cosubstrate kcat  
(s-1) 
Km L-
Alanine  
(mM) 
Km Glyoxylate 
(mM) 
kcat/ Km  
(s-1mM-1) 
 
AGT-Ma L-Alanine 
Glyoxylate 
Glyoxylate 
L-Alanine 
a45 ± 2 
a45 ± 3 
a31 ± 4 
 
 
a0.23 ± 0.05 
a1.40 ± 0.20 
a196 ± 44  
R36H L-Alanine 
Glyoxylate 
Glyoxylate 
L-Alanine 
12 ± 1 
13 ± 1 
20 ± 3 
 
 
0.23 ± 0.03 
0.41 ± 0.06 
56 ± 5 
G42E L-Alanine 
Glyoxylate 
Glyoxylate 
L-Alanine 
40 ± 1 
42 ± 2 
86 ± 6 
 
 
0.48 ± 0.08 
0.46 ± 0.04 
89 ± 15 
I56N L-Alanine 
Glyoxylate 
Glyoxylate 
L-Alanine 
30 ± 1 
29 ± 1 
59 ± 3 
 
 
0.37 ± 0.01 
0.50 ± 0.04 
78 ± 8 
G63R L-Alanine 
Glyoxylate 
Glyoxylate 
L-Alanine 
28 ± 1 
32 ± 2 
36 ± 3 
 
 
0.50 ± 0.10 
0.77 ± 0.07 
64 ± 13 
G216R L-Alanine 
Glyoxylate 
Glyoxylate 
L-Alanine 
0.160 ± 0.007 
0.171 ± 0.003 
60 ± 10 
 
 
0.22 ± 0.03 
0.0026 ± 0.0004 
0.77 ± 0.15 
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5.3.2 Structural properties of the R36H, G42E, I56N, G63R and 
G216R variants in the purified form 
 
-Tertiary structure. The near-UV CD and ANS emission fluorescence spectra 
shown in Fig. 23 panels A and C, indicate that the variants in the holo-form do not 
show significant variations as compared with holoAGT-Ma. We observed a small 
increase of the ANS fluorescence only for the holoR36H and holoG63R. In 
contrast, all variants in the apo-form we show a remarkable reduction of the 
dichroic signal at 280 nm in comparison with AGT-Ma, although to a different 
extent (Figure 23, Panel B) In addition, the ANS emission fluorescence spectra of 
the apo variants (Figure 23, Panel D) revealed an enhanced emission intensity 
(from 3.5- to 15-fold) and a blue shift of the emission maximum (from 10 to 18 
nm). These data indicate that all the mutations cause structural changes mainly on 
the apo-form of AGT, consisting in a different microenvironment of aromatic 
residues as well as in an increased exposure of hydrophobic surfaces. Notably, the 
alterations of the tertiary structure seem to be especially marked for the apo 
variants R36H, G63R and G216R. 
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Fig. 23. Circular dichroism and ANS emission fluorescence spectra of the variants in the 
holo- and apo-form. Panels A and B: near-UV CD spectra of the variants in the holo- (A) and 
apo-form (B). Panels C and D: ANS emission fluorescence spectra (λexc 365 nm) of the variants in 
the holo- (C) and apo-form (D). For each panel, the spectrum of AGT-Ma is shown for 
comparison. The color code is: red, AGT-Ma; yellow, I56N; cyan, G42E; blue, R36H; purple 
G63R; green, apoG216R. Protein concentration was 10 µM for the CD-spectra while for the ANS-
binding experiments was 1 µM in KP buffer 0.1 M, pH 7.4. 
 
 
-Quaternary structure. All the mutations under study involve residues located at 
the monomer-monomer interface and, as predicted by the rigid-body docking 
simulations reported above (paragraph 5.1), they should destabilize the dimeric 
structure of AGT. We investigated the impact of each mutation on the quaternary 
structure of both apo and holoAGT by SEC. The results obtained are reported in 
Table 8. The holo- and apo-form of AGT-Ma as well as the holo-forms of the 
R36H, G42E, I56N, and G63R variants eluted as a single peak with a retention 
volume corresponding to a dimer from 5 to 0.3 µM concentration (the latter value 
being the detection limit). On the other hand, holoG216R and all the variants in 
the apo-form, except G42E, displayed a destabilized dimeric structure. ApoR36H, 
apoI56N, apoG216R and holoG216R exhibited an elution profile consisting in 
two peaks whose elution volume correspond to a dimer and a monomer. The 
proportion of the dimer decreased while that of the monomer increased as the 
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enzyme concentration was lowered from 15 to 0.3 µM, thus indicating a slow 
equilibrium process. In the same concentration range, apoG63R eluted as a single 
peak whose position varied between the dimeric and monomeric forms of the 
protein, thus indicating a rapid equilibrium process. From the % of dimer at each 
enzyme concentration we calculated the Kd(dim-mon) value of each species (Table 
8).  
 
Table 8. Kd(dim-mon) of AGT-Ma and the pathogenic variants. 
 
 
Enzymatic species 
Kd(dim-mon) (µM) 
Apo-form Holo-form 
AGT-Ma < 0.3 < 0.3 
R36H 1.4 ± 0.2 < 0.3 
G42E < 0.3 < 0.3 
I56N 1.2 ± 0.3 < 0.3 
G63R 1.6 ± 0.3 < 0.3 
G216R 4.8 ± 0.5 0.9 ± 0.2 
 
 
Taken together, these data clearly indicate that the R36H, I56N, G63R and G216R 
mutations destabilize the dimeric structure of AGT. The effect is mainly related to 
the apo-form of the protein, except for the G216R variant, for which we observed 
a strong impact on both the holo- and the apo-form. This is in line with 
spectroscopic data indicating a structural effect of the mutations mainly on the 
apo-form of the protein, and further confirms the stabilizing effect of PLP on the 
AGT quaternary structure demonstrated by the study of the dimerization process 
(chapter 4.4 of this thesis). At present, it is not possible to establish if the G42E 
mutation affects the quaternary structure of AGT, since the Kd(dim-mon) values of 
the variant are below the detection limit of the technique, as already observed for 
AGT-Ma.  
With the aim of defining if there was any correlation between the results obtained 
in solution and those obtained by docking simulations, we performed a combined 
analysis of the &&G°pred values predicted in silico and the Kd (dim-mon) determined in 
vitro for the variants under study (Fig. 24). We noticed a striking linear 
correlation (R2= 0.98), which suggests interesting implications related to the AGT 
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folding/dimerization mechanism. Indeed, the general assumption underlying rigid-
body protein-protein docking is that neither the target, nor the ligand protein 
undergo major conformational changes upon binding. As shown previously (61), 
under these circumstances, a rigid-body docking algorithm (that describes with 
sufficient accuracy all the energetic terms virtually making up the Gibbs free 
energy, except those related  to conformational and entropy changes) may be used 
to predict the effect of point mutations on the binding affinity, provided that an 
exhaustive sampling of the roto-translational space of the ligand with respect to 
the target is performed (60). Therefore, the strong correlation observed for the 
AGT variants simulated in the present study (Fig. 24) suggests that dimerization 
could occur in a rigid body-like fashion, i.e. without involvement of major 
conformational changes in each of the monomers, and that the monomer folding 
and dimerization processes might constitute two separate steps in the AGT folding 
pathway.  
 
 
 
Fig. 24. Plot of the relative affinities predicted by docking simulations (&&G°pred) versus the 
ln (Kd(mut)/Kd(AGT-Ma)) obtained in vitro for the AGT pathogenic variants. The linear fitting of 
the data is shown. R2 is equal to 0.98. 
 
 
-Aggregation propensity. One of the effects caused by the R36H, G42E, I56N, 
G63R and G216R interfacial mutations at cellular level is the increased amount of 
AGT found in the insoluble fraction of the lysate, which suggests an increased 
aggregation propensity of the variants. Therefore, we analyzed the aggregative 
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behavior of each variant under physiological conditions (37°C, pH 7.4 at I = 150 
mM). Fig. 25 shows the change in the total count rate in DLS (a parameter that 
depends on the size of the particles in solution) as a function of time for the apo 
and holovariants. In the case of G216R, only the apo-form is shown, due to the 
high KD(PLP) value. In agreement with previous evidences (31), no changes of the 
count rate were observed for apo and holoAGT-Ma. The holo-forms of the R36H, 
G42E and I56N variants showed a very low increase in count rate, while 
holoG63R underwent a significant aggregation process, with count rate leveling 
off after approximately 30 min. Notably, all variants in the apo-form were highly 
prone to aggregation, with count rate levelling off after 15-70 minutes depending 
on the species. On the basis of the aggregation rate and extent, the apovariants can 
be ranked in the order: G63R>G216R>I56N>R36H>G42E. The aggregation 
extent of the apovariants increased as the protein concentration increased (from 5 
to 25 µM) and decreased as the ionic strength increased (from 0.1 to 1 M), thus 
suggesting that the aggregating species is probably a dimer and that aggregation is 
mediated by electrostatic forces. Based on previous results obtained on AGT 
variants bearing mutations at Gly41 (31) as well as on those reported in chapter 6 
of this thesis, it can be speculated that the conformational change induced by each 
interfacial mutation could alter the electrostatic potential of the AGT surface, thus 
enhancing the intrinsic propensity of the protein to electrostatic aggregation. The 
finding that holoenzymes are less susceptible to aggregation with respect to 
apoenzymes suggests that bound PLP is able to prevent or limit the 
conformational change caused by the mutations and shifts the equilibrium from 
the apo- to the more stable holo-form. This can contribute to explain why PN 
administration to cells expressing the variants increases the amount of protein in 
the soluble fraction of the lysate.  
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Fig. 25. Time-dependence of the total count rate (measured as kilo counts per second) of 
AGT-Ma and variants in the holo- (A) and apo-form (B). Measurements were performed at 10 
µM enzyme concentration at 37°C, pH 7.4 and I = 150 mM. The color code is the following for 
both apo and holoenzymes: red, AGT-Ma; yellow, I56N; blue, R36H; cyan, G42E; purple, G63R; 
green, apoG216R. 
 
 
-Susceptibility to proteolytic cleavage- Based on the data obtained in CHO-GO 
cells indicating that the pathogenic variants R36H and G42E were prone to 
proteolytic degradation, we analyzed the behavior of the two variants by limited 
proteolysis experiments. AGT-Ma and the pathogenic variants in the apo- and 
holo-form were incubated with proteinase K at an AGT/protease weight ratio of 
50/1 and subjected to SDS-PAGE analysis, as described in the “Materials and 
Methods” section 3.14. No proteolytic events were detectable for the apo- and 
holo-forms of AGT-Ma up to 2 hours as well as for the R36H and G42E variants 
in the holo-form. On the other hand, apoR36H and apoG42E underwent a very 
fast cleavage, as shown by the progressive disappearance of the band 
corresponding to the intact monomer and the concomitant appearance of a faster 
migrating band at ≈ 40 kDa. By determining the percentage of dimer as a function 
of time, we calculated a cleavage rate of 0.10 ±  0.02 min-1 and 0.07 ± 0.01 min-1 
for the R36H and G42E, respectively (Fig. 26). Moreover, western blot analyses 
of the proteolysis mixture revealed that the cleaved protein is not detectable by an 
antibody specific for the AGT N-terminus.  
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Fig. 26. Proteolytic cleavage of the apoR36H and apoG42E variants. Kinetics of proteolysis of 
apoR36H and apoG42E at 10 µM incubated at 25 °C in 100 mM KP, pH 7.4, at a 500:1 (w/w) 
mutant:proteinase K ratio. At the times indicated, aliquots were removed, treated with 2 mM 
PMSF and subjected to 12% SDS-PAGE. The band intensities were analyzed using the ImageJ 
software (Rasband, WS). The rate of proteolysis was determined by plotting the percentage of 
native apoR36H (black dots) and apoG42E (red dots) vs time and by fitting the data to a first-order 
equation. 
 
This indicates that, as already reported for other AGT pathogenic variants (92), 
the cleavage occurs within the N-terminal domain, which probably becomes more 
flexible and/or exposed to the solvent as a consequence of the mutations. These 
data well agree with the partial proteolytic degradation of the variants observed in 
the cellular system. Moreover, the fact that only the apo-forms are susceptible to 
proteolysis explains why no cleavage occurs in the cell upon PN administration 
when the equilibrium is shifted toward the holoenzymes (32).  
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DISCUSSION 
 
One of the open questions related to inherited disorders caused by enzymatic 
deficits is the relationship between the genotype of the patients and the metabolic 
phenotype, including in particular the responsiveness to the available treatments. 
This is particularly true for genetically heterogeneous diseases, such as 
phenylketonuria, where hundreds of disease-causing mutations are known, but the 
effects of many of them have not been extensively clarified (93). In the case of 
PH1, the genetic heterogeneity is compounded by the high frequency of missense 
mutations and by the variety of different mechanisms by which they can lead to 
the deficit of AGT (32). In fact, while null mutations are expected to completely 
abolish the enzyme expression and activity, the cellular and molecular 
consequences of single amino acid substitutions are not directly evident. 
Furthermore, although the solved crystal structure of holo-AGT has greatly 
supported the interpretation of in vitro results, it is becoming clear that many 
pathogenic mutations mainly affect the apo-form of the protein, whose structural 
features are probably different with respect to those of holoAGT, as suggested by 
spectroscopic data (35). It follows that the establishment of solid 
genotype/phenotype correlations should pass through the analysis of the 
consequences of each mutation at protein and cell level. Nevertheless, the 
administration of Vitamin B6 in form of PN is the only pharmacological approach 
currently available for PH1. Patients bearing the common mutations G170R and 
F152I on the minor allele are generally responsive, but no clear evidences have 
been provided for the other mutations. Since various studies support a role of PLP 
in the stabilization of the AGT dimeric structure (26, 37, 54), and considering the 
predicted importance of dimerization for the correct folding and localization of 
the protein (9, 92), we focused our attention on AGT variants bearing mutations 
involving residues located at the monomer-monomer interface. The main aims of 
our study were (i) to unravel the molecular and cellular defect(s) of each variant, 
and (ii) to look for possible correlations between the biochemical features of the 
variants and their degree of responsiveness to PN administration in vitro. 
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-Molecular and cellular effects of pathogenic interfacial mutations in AGT. Based 
on a preliminary in silico simulation of the possible interfacial destabilization 
caused by known pathogenic mutations involving interfacial residues, we decided 
to analyze in detail the molecular and cellular effects of the mutations R36H, 
G42E, I56N, G63R and G216R, all associated with the major allele. We found 
that they do not merely interfere with the dimerization process, but also affect the 
structural and/or functional properties of the protein. A global analysis of the 
results obtained allows us to conclude that: 
-the G216R variant is the only one showing remarkable functional (reduced PLP 
binding affinity and catalytic activity) and structural (altered tertiary and 
quaternary structure, aggregation propensity) defects. The latter features explain 
the very low levels of soluble protein in the cell as well as the undetectable 
transaminase activity. The inspection of the AGT crystal structure (8) reveals that 
the Gly216-to-Arg substitution could generate a high steric hindrance in the active 
site pocket, thus possibly explaining the effects on PLP binding and catalysis. In 
fact, the Arg side chain would probably interfere with the orientation of Ser81 and 
Gly82 that are involved in the PLP binding (chapter 1.2 of this thesis). 
-among the variants displaying only structural defects, the G63R shows the 
greatest changes consisting in an altered tertiary structure, a reduced apodimer 
stability, and an enhanced aggregation propensity mainly related to the apo-form. 
It can be speculated that the insertion of an Arg residue at position 63 could 
induce a significant conformational change of apoAGT, possibly due to a 
destabilization of the hydrophobic pocket composed by Leu14, Ile60, Val77, 
Leu269 and Leu276 that could stabilize both the dimeric structure and the native 
monomer conformation of AGT. 
-the R36H, G42E and I56N mutations seem to give rise to milder structural 
defects on AGT consisting in an alteration of the tertiary structure and an 
increased aggregation propensity. Both the R36H and the G42E variants are 
susceptible to proteolytic degradation both in the cell and in the purified form. 
Unexpectedly, while the R36H mutation destabilizes the AGT dimer, the G42E 
variant does not show any change of the Kd (dim-mon). Molecular modeling studies 
on dimeric AGT reveal that a Glu residue at position 42 is not predicted to 
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generate steric hindrance between the subunits. Furthermore, the mutation does 
not alter intra- and inter-chain contacts. On the other hand, the presence of an His 
residue at position 36 interfere with the formation of ionic bridge between Arg36 
and the Glu274 of the same subunit but in proximity of the monomer-monomer 
interface (see Fig. 18 panel C of the chapter 4.1) probably destabilizing the region 
explaining the dimer destabilization. The I56N mutation destabilizes the apoAGT 
quaternary structure and makes it particularly prone to aggregate under 
physiological conditions. The latter effect is almost undetectable in holoI56N, 
thus indicating that the binding of PLP is able to rescue for the conformational 
change caused by the mutation. The substitution of Ile56 to Asn interferes with 
inter-chain hydrophobic attractions between Ile56 and Leu18 and Ile20 of the 
other subunit, thus probably explaining dimer destabilization. 
 
-Correlation between the molecular properties of the variants and the in vitro 
responsiveness to PN. We observed that all the analyzed mutations cause a 
structural defect mainly related to the apo-form of the variants, as already reported 
for other pathogenic forms of AGT. Considering the demonstrated role of the 
coenzyme in promoting AGT dimerization, we hypothesized that it could be 
effective in the rescue of interfacial mutations. Indeed, except for G216R, we 
found that the presence of PN in the culture medium of cells expressing the 
analyzed variants is able to increase their expression level and specific activity, 
although to a different extent.  Thus, we wonder if there is any relationship 
between the molecular features of the apovariants and their responsiveness upon 
PN administration. We used the increase in the Kd(dim-mon), the increase in the ANS 
emission fluorescence and the decrease of the CD signal at 280 nm with respect to 
AGT-Ma, as parameters indicative of the structural alterations of the apovariants. 
To quantify the response to PN, we used two different parameters: the increase of 
the amount of soluble protein and the increase of specific activity. The first 
reports the levels of protein without any indication of its functionality. The second 
reports the levels of functional enzyme, but could be influenced by the inhibitory 
effect of PN (55). 
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Fig. 27. Correlation analyses between the structural alteration of the apovariants and the 
expression level (A) and the specific activity (B) upon PN treatment. A) Plot of the ratio 
between the ANS emission fluorescence of the apovariants and that of apoAGT-Ma (black dots), 
the ratio between the Kd(dim-mon) of the apovariants and that of apoAGT-Ma (green dots) and the 
magnitude of the near-UV CD signal at 262 nm (red dots) as a function of the increase in the 
expression level (A) and specific activity (B) of the variants upon PN treatment. 
 
 
The resulting correlation analyses shown in Fig. 27, panel A and B, suggest that 
the degree of structural alteration of the apo-form of the variants could inversely 
correlate with the response to PN treatment. In particular, a remarkable difference 
can be observed between G216R and the other species, in agreement with the 
strong structural and functional alterations typical of this variant and with its 
complete absence of response to PN. Among the responsive variants, G63R and 
R36H have more evident structural alterations and a lower level of responsiveness 
with respect to G42E and I56N. This would imply that lower is the structural 
alteration of an enzyme, higher is the expected chaperone effect of the coenzyme. 
Although these results should be interpreted with caution considering the small 
number of analyzed variants, they would indicate that the response to PN 
administration could be higher for mutations causing milder effects on AGT. 
Nonetheless, our preliminary data suggest that it could be possible to identify a 
relation between the biochemical features of AGT variants and the degree of 
responsiveness to PN administration in a cellular model of PH1. The integration 
of our correlation analysis with data obtained from PH1 patients, could be 
considered an excellent starting point to predict PN responsiveness at clinical 
level. Further analyses are currently ongoing to widen the number of analyzed 
mutation, as well as to test the effect of B6 vitamers that not lead to inhibitory 
effect (pyridoxamine and pyridoxal). 
!! 92!
 
-Possible implications of the results for AGT folding. The analysis of the 
significance of the data obtained from the AGT perspective allows to draw some 
interesting hypotheses. In particular, the finding that a high degree of structural 
alteration reduces the chaperone effect of the coenzyme, could support the view 
that PLP binding is a late event during AGT folding. This would mean that PLP 
binds partly-folded or quasi-folded monomers. Moreover, the strict correlation 
between the rigid-body protein-protein docking results and the degree of 
destabilization of the dimeric structure measured in vitro (Fig. 24) suggests that 
AGT dimerization could occur upon the interaction of monomers in a folded or 
quasi-folded conformation. However, it should be taken into account that in silico 
data are obtained based on the structure of the holo-form, while in vitro 
experiments are related to the apo-form of the protein. Nonetheless, these 
considerations support the view that AGT folding passes through the first collapse 
of the unfolded chain into a partly-folded monomer, which should then acquire a 
native or quasi-native conformation to bind the PLP coenzyme and form the final 
dimeric and functional structure. Although this would be in agreement the AGT 
folding pathway previously proposed on the basis of denaturation studies 
performed with the purified protein (23), a more detailed analysis of the role of 
coenzyme binding and dimerization for the intracellular fate of the protein will be 
necessary.  
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6 
AGGREGATION PROPENSITY OF HUMAN 
AGT: THE OPPOSITE EFFECT OF THE 
POLYMORPHIC MUTATIONS P11L AND 
I340M 
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Background information 
 
The propensity to aggregation is an inevitable issue for many proteins. This 
phenomenon has important implications for pharmaceutical industries, in 
particular for the formulation and manufacturing of therapeutic proteins (94). 
Moreover, the abnormal formation of protein aggregates has been identified as 
one of the leading causes of several diseases. Aggregation can occur through 
different pathways, including the formation of partly-folded intermediates 
exposing sticky patches, or the self-association of native-like states under 
conditions that favour protein-protein interactions. In most cases, protein 
aggregation is nucleation-controlled, because it depends on the formation of a 
critical nucleus (a lag phase in which no large particles are detected) followed by 
the rapid growth of insoluble aggregates until a plateau phase when all the protein 
is in the aggregated state (95). Research efforts devoted to the understanding of 
protein aggregation have been mainly focused on the identification of critical 
factors that influence the aggregation extent as well as of the forces governing 
protein-protein interactions (96). Among them, the interaction of protein folding 
intermediates exposing hydrophobic patches is a well-known mechanism (97). 
However, theoretical (98) and experimental (99) evidences suggest that also 
electrostatic forces can play an important role in inducing or enhancing protein 
aggregation. The process of electrostatic aggregation is based on the attraction 
between complementary charged domains of a protein surface and it usually 
decreases at high ionic strength, due to screening effects (99). One of the key 
factors governing electrostatic aggregation is protein charge anisotropy, i.e. the 
asymmetric distribution of charged residues on the exterior of a particular protein. 
Although in many cases the aggregation occurs at a pH close to the isoelectric 
point, it has been reported that a difference can exist between pI and the pH of 
maximum aggregation (99). Some data suggest that electrostatic interactions can 
also contribute to the stabilization of protein-protein complexes, by influencing 
the binding rate and/or equilibrium (100).  
The propensity to self-association is also a problem for AGT. Data obtained in 
prokaryotic and eukaryotic models as well as by analyses on variants in the 
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purified form, indicate that many mutations reduce the folding efficiency of AGT 
by promoting its aggregation (31, 35). In some cases the aggregation is due to a 
low dimer stability, which allows the formation of monomers exposing 
hydrophobic surfaces and prone to self-association (9, 36). In other cases 
however, an aggregation driven by electrostatic interactions between folded 
dimers showing an increased surface charge anisotropy has been reported (31). 
Interestingly, some differences between the two polymorphic forms of AGT have 
been reported. In fact, although AGT-Mi is not disease-associated, it shows an 
increased aggregation propensity and a reduced stability with respect to AGT-Ma, 
both in vitro and in the cell (23). Between the two amino acid substitutions typical 
of AGT-Mi, the P11L mutation seems to be the main actor in reducing the 
stability of the protein, while the I340M mutation has been supposed to mitigate 
the effects of the Pro11 substitution (30).  
Since the aggregation tendency of AGT has not been investigated in detail, during 
my PhD I studied the aggregation propensity of dimeric AGT in the recombinant 
purified form by means of bioinformatic and biochemical studies, with particular 
emphasis on the role of electrostatic interactions between exposed surfaces of 
opposite charge as well as on the effect of the polymorphic substitutions P11L and 
I340M.  
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RESULTS AND DISCUSSION 
6.1 In silico analysis of the AGT surface: molecular map of the 
electrostatic potential 
Based on the known 3D structure of AGT-Ma in the holo-form (Pdb id:3RBF), 
we evaluated the distribution of hydrophobic surfaces as well as the electrostatic 
map, in order to understand the physical/chemical features of the protein that 
could govern its aggregation process. As reported in Fig. 28, AGT-Ma shows only 
few hydrophobic patches on its surface, mainly located along the dimerization 
interface (8), in line with the finding that the native monomeric form of AGT 
tends to aggregate probably driven by hydrophobic attractions (9, 23). 
 
Fig. 28. Distribution of the hydrophobic patches around AGT-Ma. Panel A: hydrophobic 
patches of dimeric AGT shown as green areas on the grey background of AGT. The area and the 
energy cut-offs of each patch are 100 Å2 and 0.25 kcal/mol, respectively. Panel B: representation 
of  the hydrophobic patches around AGT as 2D maps. Patches are enumerated in decreasing order 
based on their area. The red and blue lines indicate the equatorial and central meridians projection 
axes, respectively. 
Interestingly, the electrostatic map of AGT-Ma reveals an asymmetric distribution 
of negative and positive charges on the dimeric surface. In particular, as shown in 
Fig. 29 panels A and C, four main negative patches are present in one face of the 
dimer, mainly formed by residues Asp331, Asp334, Asp341 and Asp344 (patch 1 
and 2, size 351 Å2) Glu281, Glu371, Asp374 and Glu378 (patch 3 and 4, size 175 
Å2). On the other hand, as shown in Fig. 29 panels B and D, four main positive 
patches are present on the other side composed by Arg289, Arg292, His299, 
Arg301, Lys312, Arg333, Lys357, His386, Lys389 and Lys390 (patches 5 and 6, 
size 522 Å2) and by Arg122, His124, His146, His174, Arg175, Arg197, Lys225, 
Lys227, Arg233, Lys234 and Lys236 (patches 7 and 8, size 568 Å2). We 
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compared the electrostatic map of AGT with those of other PLP-dependent 
aminotransferases belonging to the Fold type I family such as human cytosolic 
aspartate aminotransferase (PDB: 3WZF, to be published), human ornithine 
aminotransferase (101) and human tyrosine aminotransferase (PDB: 3DYD, to be 
published) as well as of proteins sharing a sequence similarity ≥ 30% with AGT. 
We found that all the latter proteins (except alanine: glyoxylate aminotransferase 
from Aedes aegypti that displays some positive patches), show an unvarying 
negative potential on their surface (data not shown). These analyses led us to 
hypothesize that the aggregation propensity of AGT could depend on the peculiar 
distribution of charges on its surface. Following this view, parameters such a pH 
and ionic strength should critically influence its aggregation rate and/or extent. 
Moreover, mutations of surface residues could change the charge distribution and 
negatively or positively influence the self-association process. 
 
 
 
 
 
 
 
 
!! 98!
 
Fig. 29. Charged patches and electrostatic potential around AGT. Panel A and B: positive 
(blue) and negative (red) patches of dimeric AGT on a grey background. The size and the energy 
cut-offs of each patch are > 100 Å2 and 50 kcal/mol, respectively. Patches characterized by an high 
potential are rendered in a dark color and indicated by numbers and arrows. Panel C and D: 
electrostatic potential contours showed as mesh (-0.5 (red) and +0.5 (blue) kT/e) around AGT 
obtained by using the PDB2PQR tool for structure preparation, PROPKA 3.0 for the protonation 
state of the residues of AGT at different pH values and APBS tool to generate the electrostatic 
potential map. Each tool was run on an Opal web-service. The visualization of the potential 
electrostatic map was performed by using UCSF CHIMERA 1.11 program at I = 0.06 M, at pH 
7.4, at 37 °C. 
 
6.2 Effect of pH and ionic strength on the aggregation propensity 
of AGT-Ma  
To have insights into the forces involved in the aggregation process of AGT-Ma, 
we evaluated the aggregation propensity of the protein by dynamic light scattering 
(DLS) experiments performed at various pH and ionic strength. All the analyses 
were performed at the physiological temperature of 37°C and at a protein 
concentration of 10 µM, to guarantee that no monomerization occurred (23). We 
monitored the increase in mean count rate, a parameter that represents the average 
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scattering intensity during the measurement and is related to the amount and the 
size of the species present in solution (102). To determine the aggregation rate, 
data on the time-dependent increase in count rate were fitted using the analytic 
equation (7) proposed by Morris et al (83) (see “Material and Methods”, section 
3.12). This equation is related to the minimalistic/”Ockham’s razor” Finke-
Watzky (F-W) two-step model, which has been used to analyse the aggregation 
data of a wide set of protein (83), giving averaged rate constants for nucleation 
(k1) and autocatalytic growth (k2). Moreover, we analysed the species present in 
the aggregating solution and accounting for the scattering signal, taking into 
account that the DLS signal is proportional to the sixth power of a particle 
diameter, hence the presence of the signal related to the dimer indicates that it 
should be by far the most abundant species in solution. 
Many proteins tend to have decreased solubility near the isoelectric point, often 
referred to as isoelectric precipitation, where the low net charge of the protein 
corresponds to the loss of aggregation inhibiting repulsion. AGT has a predicted 
isoelectric point (pI) of 8.59. We incubated the apo- and holo-form of the protein 
at 37°C the KP buffer 0.1 M in the pH range 5.5-8.0, to avoid protein unfolding 
due to strong acid or alkaline conditions. HoloAGT-Ma does not show any 
significant increase in count rate from pH 8 down to 6.5, while slight aggregation 
propensity can be seen at pH 5.5 and 6 (Fig. 30, panel A). 
 
!! 100!
 
Fig. 30. Aggregation profiles of holoAGT-Ma (A) and apoAGT-Ma (B) and plot of rate 
constants values of k1 and k2 of apoAGT-Ma (C). Panel A: time dependence of total count rate 
(measured as kilo counts per second) of holoAGT-Ma. Panel B: time dependence of total count 
rate (measured as kilo counts per second) of apoAGT-Ma. Panel C: plot of the k1 (black dots) and 
k2 (blue dots) rate constants (obtained using Eq. 7) as a function of pH. The lines represent the 
fitting of each set of data to Eq. 8. Measurements were performed at 10 µM enzyme concentration, 
0.1 M ionic strength in potassium phosphate buffer, at 37°C. The color code of the panel A and B 
is the following: blue, pH 5.5; black, pH 6.0; green, pH 6.5; purple, pH 7.0; red, pH 7.5 and cyan 
pH 8.0. 
 
At pH 5.5, the values of k1 and k2 were equal to 1.7 * 10-2 ± 2.0 * 10-4 min-1 and 7.3 
* 10-4 ± 5.0 * 10-5 min-1 µM-1, respectively. On the other hand, apoAGT-Ma 
showed an increase in count rate along the whole pH range, with extent and rate 
of aggregation higher than the corresponding of holoAGT-Ma (Fig. 30, panel B). 
The estimated values of k1 and k2 increase as the pH is lowered from 8 to 5.5, 
giving values of pkspec of 6.03 ± 0.13, and 6.18 ± 0.09, respectively (Fig. 30, panel 
C). Thus, holo- and apoAGT-Ma do not undergo an isoelectric precipitation, 
because the aggregation extent is higher at pHs where the protein net charge 
shows the highest values. It should be mentioned that the aggregation process 
leads to the formation of aggregates of size spanning from 400 to 800 nm (data 
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not shown), with a rate that fits very well that of the increase in count rate. 
However, the signal of the dimer is always visible in the whole pH range. Thus, 
although aggregates are the main responsible for the scattering signal, the dimer 
still remains the more represented species in solution and it is probably the form 
of the protein that primes aggregate formation. The fact that the dimer is the 
aggregating species is also shown by the linear increase of the aggregation rate 
constants at increasing AGT concentrations (Fig. 31). 
 
 
 
Fig. 31. Aggregation profiles of apoAGT-Ma at different protein concentrations. Time 
dependence of total count rate (measured as kilo counts per second) of apoAGT-Ma. 
Measurements were performed at 2 µM (black), 5 µM (green), 10 µM (blue), 15 µM (red) and 20 
µM (purple dots) protein concentration, 0.1 M KP buffer, at pH 5.5, at 37 °C. 
 
We then monitored the aggregation process of apoAGT-Ma at pH 5.5 at ionic 
strengths varying from 0.05 to 1 M, to include values below and above the 
physiological one (0.15 M corresponding to 0.06 M potassium phosphate).  As 
reported in Fig. 32, the aggregation propensity of apoAGT-Ma increases at 
decreasing ionic strength of the buffer. In particular, the aggregation is completely 
prevented at values equal or higher than 0.2 M, and occurs with k1 values of 3.1 * 
10-2  ± 3.0 * 10-3 min-1 and 2.2 * 10-2 ± 2.0 * 10-3 min-1, and k2 values of 2.9 * 10-3 ± 
3.0 * 10-4 min-1 µM-1 and 2.0 * 10-3 ± 2.0 * 10-4 min-1 µM-1, at values of 0.05 M and 
0.1 M, respectively. These data indicate that aggregation is not due to 
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hydrophobic attractions, which would have been enhanced by increased salt 
concentrations. Rather, it depends on electrostatic interactions, which are reduced 
or suppressed at high ionic strength due to screening effects (99). 
 
Fig. 32. Aggregation of apoAGT-Ma at different ionic strength. Time dependence of total 
count rate (measured as kilo counts per second) of 10 µM apoAGT-Ma at 37°C in KP buffer pH 
5.5 at the indicated ionic strength. 
 
We asked if aggregation was accompanied by an unfolding process by monitoring 
the dichroic signal at 222 nm, indicative of the secondary structure content, of 10 
µM apoAGT-Ma in 0.05 M potassium phosphate buffer pH 5.5, 37°C, i.e. under 
conditions in which a strong aggregation phenomenon is observed. Since we did 
not observe any loss of secondary structure with time during aggregation up to 
300 minutes, we concluded that the process is not dependent on a partial 
unfolding, but occurs starting from a native or native-like form of the protein. 
Furthermore, by exploiting the different behavior of the protein in the apo- and 
holo-form, we found that aggregation is not reversible. In fact, the addition of 100 
µM PLP (a saturating concentration) to an aggregating mixture of 10 µM 
apoAGT-Ma at pH 5.5 at 0.05 M ionic strength was able to stop but not to revert 
the self-association process. Finally, considering that AGT shows three cysteine 
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residues per subunit exposed to the solvent (48), we compared the rate constants 
of aggregation in presence and absence of 0.01 M !-mercaptoethanol. The 
absence of any effect of the reducing agent on the aggregation rate revealed that 
the process does not depend on the formation of disulphide bonds. 
 
 Altogether, these data allow us to conclude that AGT-Ma aggregation is not an 
isoelectric precipitation phenomenon, because it is not influenced by the net 
charge of the protein, and is not due to the formation of disulphide bonds. Rather, 
it depends on the electrostatic interaction between patches of opposite charge 
present on the native dimeric species as a consequence of the charge anisotropy of 
the protein surface. A similar aggregation mechanism has been already reported 
for !-Lactoglobulin at low ionic strength, which shows a strong aggregation 
phenomenon at pHs below the pI (99). In addition, the comparison between the 
aggregation rates of the holo- and apo-form of AGT-Ma suggests that PLP 
binding has a stabilizing effect on the protein. Although the crystal structure of 
apoAGT has not been solved, biochemical analyses indicate that it could have a 
tertiary structure slightly different from that of holoAGT, as suggested by the 
dichroic features in the near-UV region (10, 33), as well as an higher flexibility of 
the polypeptide chain making it more susceptible to unfolding and proteolytic 
degradation (31, 92). We can suggest that PLP binding could increase the rigidity 
of dimeric form of AGT and reduce the exposure of charged residues possibly 
involved in the aggregation process. Thus, besides its role in promoting AGT 
dimerization (this thesis) the coenzyme seems to have a wider chaperone role by 
counteracting the self-association of the protein in the dimeric form. 
In order to provide a possible structural explanation to the behavior of AGT-Ma, 
we evaluated the changes in the electrostatic map of the protein as function of pH, 
with particular attention on the identification of residues forming oppositely 
charged patches and to their predicted pKa value (Fig. 33). At pH 5.5, it can be 
observed a strongly asymmetric charge distribution and the presence of several 
negative and positive areas on the AGT surface (Fig. 33, panel A). The negative 
patches are mainly formed by exposed glutamate and aspartate residues, while the 
positive ones are mainly formed by exposed histidine, arginine and lysine 
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residues. Upon increasing the pH from 5.5 to 8, the surface area and the potential 
of the negative patches remain almost unchanged, while those of the positive 
patches decrease (Fig. 33, panel B).  
 
 
Fig. 33. Comparison between 2D maps (Panel A) and electrostatic potential map (Panel B) of 
AGT-Ma at the indicated pH values, at 37°C. Panel A: 2D maps calculated using the Patch 
Analyzer tool of MOE 2016.08. The positive and negative patches are colored blue and red, 
respectively. The residues mainly involved in the formation of each patch are shown. Panel B: 
electrostatic potential contours (-1.5 (red) and +1.5 (blue) kT/e) around AGT at different pH 
values. 
 
 
This effect is mainly due to the side chains of five exposed histidine residues 
(124, 146, 174, 342 and 386), which pass from the protonated to the neutral form 
between pH 6.0 and 7.0. This is confirmed by their predicted pKa values, 
calculated with the tool “Residue pKa” of MOE 2016.08, that are in good 
agreement with the pKspec obtained from the plot of the aggregation rate constants 
vs pH (Fig. 30). Thus, it can be speculated that patches formed by histidine 
residues could be the main actors in determining the electrostatically-driven 
aggregation of AGT, although site-directed mutagenesis experiments would be 
necessary to confirm this interpretation. Nevertheless, as already mentioned, the 
attractive forces between positive and negative domain of associating proteins are 
strongly influenced by the ionic strength of the solution, which in turn influences 
the charge states of exposed amino acids (99). Accordingly, we found that AGT 
aggregation is prevented by the presence of salts, which can cover and screen the 
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charged patches on the surface (Fig. 32). The electrostatic maps of the protein 
obtained at various ionic strengths between 0.05 M and 1 M reported in Fig. 34, 
predict strong screening effects of the buffer ions above 0.2 M. This is in line with 
the data obtained in solution indicating that the aggregation of AGT-Ma is 
completely prevented at ionic strength ≥ 0.2 M. It can be observed that under 
conditions mimicking a physiological ionic strength, the surface charge of AGT-
Ma should be significantly screened. This explains why no aggregates of AGT 
have been reported in liver biopsies of healthy subjects (103) and only a small 
portion of the protein is in the insoluble fraction when overexpressed in cellular 
systems (32, 55). However, even small changes of either the intracellular 
chemical/physical conditions or the protein surface as a consequence of inherited 
mutations could promote aggregation. 
 
 
Fig. 34. Potential contours (-1.0 (red) and +1.0 (blue) kT/e) aound AGT-Ma at pH 7.4, at 
37°C, at the indicated ionic strength. 
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6.3 Effects of the P11L and I340M polymorphic mutations on the 
aggregation process of AGT 
 
AGT-Mi displays an increased tendency to aggregation both in the purified form 
and in cellular systems with respect to AGT-Ma (30, 32). This effect has been 
attributed to a reduced stability of the dimeric structure, mainly caused by the 
P11L mutation that could weaken the interaction between the N-terminal arm of 
one subunit and the large domain of the neighboring subunit thus promoting the 
population of monomeric forms of the protein prone to aggregate (32). However, 
it cannot be excluded that either the P11L and/or the I340M mutation typical of 
the minor allele could also influence the electrostatically-driven aggregation of the 
protein. Moreover, it has been reported that several pathogenic mutations that lead 
to PH1 associated with the minor allele, play their effects by increasing the AGT 
aggregation propensity (32, 35).   
We analyzed the aggregation process of apo- and holoAGT-Mi as a function of 
pH by DLS under the same experimental conditions used for AGT-Ma. We found 
that the aggregation rate increased at decreasing ionic strength, thus indicating 
that the process is mediated by electrostatic forces (data not shown). The trends of 
the k1 and k2 as a function of pH of holo- and apoAGT-Mi, reported in Fig. 35, 
reveal that (i) both species show an increased aggregation propensity at acidic pH 
with estimated values of pKspec of 5.8 ± 0.3 and 5.7 ± 0.1 for k1 and 6.4 ± 0.1 and 
6.2 ± 0.3 for k2 of apo and holoAGT-Mi, respectively; (ii) at the same pH, the k1 
values of apoAGT-Mi are 7-, 10- and 15-fold higher than the corresponding of 
holoAGT-Mi from pH 5.5 to 7.0, while the k2 values are of the same order of 
magnitude, thus suggesting that PLP binding to AGT-Mi could mainly affect the 
nucleation step of the aggregation process. By comparing the aggregation rate of 
holo- and apoAGT-Mi with the corresponding forms of AGT-Ma we noticed that 
the minor allelic form shows an increased aggregation propensity. In fact, a 
visible aggregation event was present at pHs lower or equal to 7 in holoAGT-Mi, 
while holoAGT-Ma only aggregates at pH 5.5. At the latter pH value, holoAGT-
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Mi showed k1 and k2 values about 2- and 10-fold higher, respectively, as 
compared with those of holoAGT-Ma. As for the apo-form, the values of k1 and 
k2 were from 1- to 2.5-fold and from 2- to 4-fold higher than those of apoAGT-
Ma, respectively. The species populating during AGT-Mi aggregation were 
similar to those formed by AGT-Ma although aggregates of higher molecular 
weight are formed (~1000 nm). Overall, these data allow to conclude that AGT-
Mi is prone to an electrostatically-driven process of self-association similar to that 
already observed for AGT-Ma, but characterized by an higher aggregation 
tendency. This suggest that one or both of the two polymorphic mutations typical 
of the minor allele, P11L and I340M, could directly or indirectly change the 
surface of the protein and somehow influence the interaction between oppositely-
charged patches.  
 
 
 
Fig. 35. Plots of k1 and k2 values vs pH of holo and apoAGT-Mi. Plot of the k1 (black dots) and 
k2 (blue dots) rate constants (obtained using Eq. 7) as a function of pH. The lines represent the 
fitting of each set of data to Eq. 8.  Holo- (A) or apoAGT-Mi (B) were incubated in 0.1 M 
potassium phosphate buffer at different pHs and the mean count rate in DLS has been monitored.  
 
 
In order to understand the structural determinants responsible for the increased 
aggregation propensity of AGT-Mi, we expressed, purified and characterized the 
two single mutants P11L and I340M. Their absorbance and CD spectra in the 
visible region were similar to the corresponding of AGT-Ma and AGT-Mi (data 
not shown). The P11L and I340M mutations did not alter the KD(PLP) value of 
AGT as well as the kinetic parameters of the overall transamination reaction, 
except for a 30% reduction in kcat of the P11L variant (data not shown). Moreover, 
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the two mutations did not alter the quaternary structure of the protein up to 0.3 
µM (the detection limit of SEC experiments). Interestingly, we found that the 
I340M mutation increased the thermal stability of AGT, as shown by the thermal 
denaturation curves of apo and holoI340M which showed a single transition at 
70.1 ± 0.3 °C and 83.3 ± 0.3 °C, respectively. The latter values are higher than 
those of AGT-Ma, which displays apparent mid-denaturations at 61.1 ± 0.3 °C 
and 66.4 ± 0.3 °C in the apo-form and 77.5 ± 0.3 °C in the holo-form (33). On the 
other hand, previous data have shown that the P11L mutation decreases by 3 °C 
and 1 °C and 4 °C the thermal denaturation mid-point of apo- and holoAGT, 
respectively. 
 
 
Fig. 36. Time dependence of total count rate of holo (panel A) and apoI340M (panel B) as 
function of pH, I = 0.1 M, at 37°C. Panel A: time dependence of total count rate (measured as 
kilo counts per second) of holoI340M. Panel B: time dependence of total count rate (measured as 
kilo counts per second) of apoI340M. Measurements were performed at 10 µM enzyme 
concentration, 0.1 M ionic strength in potassium phosphate buffer, at 37°C. The color code is the 
following: black, pH 5.5; red, pH 6.0; green, pH 6.5; blue, pH 7.5 and cyan pH 8.0. 
 
 
We thus investigated the aggregation behavior of I340M and P11L single 
variants. The data reported in Fig. 36 panel A, show that holoI340M displayed a 
visible increase in count rate only at pH 5.5 and 6. At pH 5.5 the values of k1 and 
k2 equal to 1.5 * 10-2 ±  4.0 * 10-3 min-1 and 6.0 * 10-5  ±  1.0 * 10-6 min-1 µM-1, 
respectively. The value of k1 was similar to those of holoAGT-Ma but the k2 is 12-
fold lower than the corresponding of holoAGT-Ma. Similarly, apoI340M (Fig. 36, 
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panel B) only aggregated at pH 5.5, with a k1 value similar to that of apoAGT-Ma 
but a k2 value 14-fold lower than the corresponding one of apoAGT-Ma (k1 = 3.2 * 
10-2 ±  1.5 * 10-3 min-1, k2 = 1.9 * 10-4  ±  1.0 * 10-5 min-1 µM-1). Hence, the I340M 
mutation has a stabilizing effect on the AGT structure, in terms of both reduced 
sensitivity to thermal stress and lower aggregation propensity.  
A completely different effect is exerted by the P11L mutation, as shows by the 
pH-dependence of the k1 and k2 values of aggregation of the apo and holovariant, 
respectively (Fig. 37). An increase in count rate was detectable for both forms in 
the whole pH range, although the k1 values of apoP11L are from 5- (pH 5.5) to 
1.3-fold (pH 8.0) higher than those of holoP11L, in analogy with the data 
obtained on AGT-Ma and AGT-Mi. The aggregation increased at acidic pH with 
pKspec for k1 and k2 of 6.1 ± 0.2 and 6.4 ± 0.2 respectively, for oloP11L, and 6.1 ± 
0.4 and 6.9 ± 0.2, respectively, for apoP11L.  
 
 
 
 
Fig. 37. Plots of k1 and k2 values vs pH of holo and apoAGT-P11L. Plot of the k1 (black dots) 
and k2 (blue dots) rate constants (obtained using Eq. 7) as a function of pH. The lines represent the 
fitting of each set of data to Eq. 8. Holo- (A) or apoP11L (B) were incubated in 0.1 M potassium 
phosphate buffer at different pHs and the mean count rate in DLS has been monitored. 
 
 
These values agree quite well with those previously found for AGT-Ma and AGT-
Mi (taking into consideration the noise of the count rate signal and the consequent 
experimental error), thus suggesting that aggregation could be governed by a 
molecular mechanism similar to that already proposed for AGT-Ma and AGT-Mi 
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(). Nevertheless, P11L displays a significantly higher aggregation extent with 
respect to AGT-Ma. In fact, the signal of the dimer disappeared after ~20 minutes 
during the aggregation process, as reported in the experiment shown in Fig. 38. 
This indicates that a significant portion of the variant is present as aggregated 
species in agreement with the fact that the mixture displays a visible turbidity at 
the end of the analysis.  
 
 
Fig. 38. Time dependent changes of the apparent particle size of 10 µM apoP11L in KP 0.1 
M at pH 5.5, 37°C. Black and red dots indicate dimer and aggregates, respectively. 
 
To investigate the consequences of the aggregation process for AGT functionality, 
as well as the effect of the two polymorphic mutations, we measured the residual 
catalytic activity of AGT-Ma, AGT-Mi, P11L and I340M upon 3 h incubation in 
KP 0.1 M pH 5.5, at a protein concentration of 10 µM, 37°C. These experimental 
conditions were chosen to favour the aggregation process as revealed by DLS. 
The assays were then performed in KP 0.1 M pH 7.4 at 25°C in presence of 
saturating PLP at saturating substrates concentrations, to stop the aggregation 
process. Holo and apoAGT-Ma, holo and apoI340M and holoAGT-Mi showed a 
residual catalytic activity >90%. On the other hand, apoAGT-Mi, holo P11L and 
apoP11L displayed a residual activity of 64%, 48%, and 26%, respectively. These 
data indicate that although AGT undergoes a native-like aggregation, the process 
is associated with loss of protein functionality. Moreover, they confirm the 
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destabilizing effect of the P11L mutation as well as the protective role of the PLP 
coenzyme. 
By comparing the data obtained on AGT-Mi, the P11L, and the I340M variant, 
with those of AGT-Ma, we can conclude that while the I340M mutation exerts a 
stabilizing effect, the P11L mutation significantly increases the aggregation 
propensity of AGT. The hypothesis that the two polymorphic mutations could 
have opposite effects on AGT has been previously advanced. Mesa-Torres N et al 
(104) have reported the mutation of Ile340 as one of the consensus amino acids 
substitutions that contribute to create a form of AGT endowed with a higher 
stability in solution and in cellular systems. On the other hand, the P11L mutation 
has been claimed as the responsible for the increased sensitivity of AGT-Mi to 
chemical and thermal stress (23, 45). However, all these data have been 
interpreted by looking to the possible effects of the two substitutions on dimer 
stability (32). Our data indicate that they also play a role on the propensity of the 
protein to electrostatic aggregation.  
From a structural point of view, Pro11 is located at the monomer-monomer 
interface. The visual inspection of the structure reveal that its substitution with a 
leucine residue could increase the flexibility of the N-terminal arm of AGT, 
possibly promoting its dissociation from the neighboring subunit. In silico results 
are also confirmed by biochemical studies revealing an increased susceptibility of 
AGT variants bearing the P11L mutation to proteolytic cleavage at the N-terminus 
(92). Based on these data and considerations, we compared the electrostatic map 
of AGT-Ma with that of a truncated form of the protein deleted by the first 21 
residues mimicking the possible detachment of the N-terminal arm (Fig. 39).  
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Fig. 39. Electrostatic potential contours (-0.5 (red) and +0.5 (blue) kT/e) of full lenght AGT-
Ma (panels A and B) and that of AGT-Ma truncated of the residues 1-21 (panels C and D) at 
pH 7.4, ionic strength 0.06 M, 37°C. Blue and red arrows indicate the differences between the 
electrostatic potential map of AGT-Ma and its truncated form. 
 
 
In analogy with previous reports, we found that several negatively charged 
residues are present under the N-terminal arm of AGT, including Asp52, Glu59, 
Asp196, Glu274 and Glu281. It can be hyphotized that the increased flexibility of 
the N-terminal arm due to the P11L mutation could promote its transient 
dissociation from the neighboring subunit, thus causing the exposure of negatively 
charges residues. This in turn would increase the anisotropy of charge distribution 
on the AGT surface, thus creating more favorable conditions for the electrostatic 
interactions between dimers. This hypothesis could also explain the lower 
aggregation propensity of holoP11L in comparison with the apo-form. PLP 
binding could increase the overall rigidity of the structure in particular through an 
indirect effect on the loop 24-32 that is connected to the N-terminal arm on one 
side, and to the active site on the other side (10). A rigid positioning of the loop 
reduces the flexibility of the AGT N-terminus. As for the I340M mutation, it is 
not easy to envisage how the substitution of Ile340 with a Met residue could alter 
the electrostatic potential of the AGT surface. Ile340 is located in the apha-helix 
16 at the monomer-monomer interface and it interacts mainly with Gln23 of the 
other subunit. In silico analyses reveal that the contact remains present also after 
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Ile340-to-Met substitution. However, the predicted binding energy increase from -
1.401 kcal/mol of the Ile-Gln interaction to -2.039 kcal/mol of the Met-Gln 
interaction. The consequent predicted stabilizing effect of Met340 on the position 
of Gln23 could in turn stabilize interchain hydrogen bonds between Gln23 and 
Gly47 of the other subunit, thus increasing the overall rigidity of the N-terminal 
region of AGT.   
 
6.4 Predicted effect of pathogenic mutations on the electrostatic 
potential of the AGT surface 
 
The peculiar asymmetric distribution of charge on the AGT surface allows to 
hypothesize that point amino acid substitutions can make the protein more prone 
to aggregate under physiological condition of pH, temperature and ionic strength. 
Based on these considerations, we mapped all the missense mutations associated 
with PH1 known to date on the crystal structure of AGT and we observed that 
some of them involve residues located on the protein surface (Fig. 40). In 
particular, we focused our attention on the mutations D129H, E141D, and R289H 
associated with the major allele, and on the mutations E95K, R197Q and R289C 
associated with the minor allele.  We investigated if and how each amino acid 
substitution could impact the surface charge distribution and hence the 
aggregation propensity of the protein.  
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Fig. 40. Representation of surface residues of AGT involved in pathogenic mutations 
associated with PH1. PLP is represented as green sticks. Glu95, Asp129, Glu141, Arg197 and 
Arg289 are represented as red sticks in the red monomer. Oxygen, phosphate and nitrogen atoms 
are colored red, purple and blue, respectively. The figure was rendered using MOE 2016.08, by the 
available AGT structure (PDB 3R9A). 
 
 
Asp129 is a residue located on the connection loop between the α-helix 5 and 6 
and it is highly exposed to the solvent. The estimated exposure is 76%, expressed 
as computed by MOE.2016.08 using as reference a Gly_X_Gly triplet. The 
residue is far away from the active site and has a predicted pKa of 3.80. Molecular 
modelling analyses and in silico mutagenesis do not reveal any relevant alteration 
of orientation of residues located near Asp129 upon replacement by a His residue. 
In line with these predictions, it has been reported that the D129H-Ma mutation 
causes only a 10% reduction of activity and stability in a heterologous yeast assay 
(105). By analyzing the electrostatic potential map of the D129H variant (Fig. 41) 
we observed that the mutation determines an increased exposure to the solvent of 
Lys128 and Lys357, which in turn increases the potential of the positive patches 7 
and 8 (Fig. 29, chapter 6.1). Based on our data indicating that AGT aggregation is 
promoted by a high charge anisotropy, the increased positive potential could 
enhance the aggregation propensity of the variant under physiological conditions. 
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Fig. 41. Distribution of electrostatic potential (-0.5 (red) and +0.5 (blue) kT/e) of AGT-Ma 
and pathogenic variants D129H-Ma, R289H-Ma and E141D-Ma under physiological 
conditions (pH 7.4., I = 0.06 M, 37°C). Blue and red arrows indicate regions with differences 
between the electrostatic potential map of AGT-Ma and the variants. 
 
 
Glu141 is located on the α-helix 6 and it shows a predicted solvent exposure of 
59.67% and a predicted pKa of 4.64. Its main chain is involved in a hydrogen 
bond with Gln137 of the same helix, which should be maintained upon 
substitution by an Asp residue, as revealed by molecular modeling studies (data 
not shown). Although the E141D mutation does not eliminate or change a surface 
charge, the electrostatic potential map shows that it (i) increases the size and 
modifies the shape of the negative patches 3 and 4 (red arrows of Fig. 41) and (ii) 
decreases the exposure to the solvent of Lys234 (from 90.7 to 42.6%) thus 
changing the shape and slightly reducing the potential of the positive patch 5 and 
6 (blue arrows of Fig. 41). While this modest reduction of positive potential could 
not be enough to prevent AGT aggregation, the increased size of negative patches 
could promote the electrostatic interactions with positive regions on the surface.  
Arg289 is located at the C-terminus of α-helix 11. Having a predicted pKa of 
12.29, it contributes to the AGT surface charge, although it only shows a 41.9% 
predicted exposure to the solvent. Interestingly, the mutation of Arg289 to His or 
Cys is pathogenic on the background of the major or the minor allele, 
respectively. The electrostatic map of the R289H/C variants (identical results 
were obtained with both mutations) does not shows remarkable differences with 
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respect to AGT-Ma or AGT-Mi, except for a slight reduction of the size and 
potential of the positive patches 4 and 5 (blue arrow in Fig. 41), which is expected 
to reduce the aggregation propensity of AGT under physiological conditions by 
disfavoring the interaction with the negative patches. Nevertheless, the visual 
inspection of the AGT structure reveals that Arg289 interacts with Glu293 
through an ionic bridge that stabilizes the conformation of α-helix 11. By in silico 
mutagenesis analyses we found that the replacement of Arg289 by a His or a Cys 
residue could prevent the formation of the ionic bridge with Glu293, thus 
probably destabilizing the architecture of the region (Fig 42). On these bases, it 
can be hypothesized that the most probable defect of the R289H-Ma and R289C-
Mi variants is a structural alteration of the overall folding, rather than a change of 
the electrostatic surface promoting aggregation. 
 
 
 
Fig. 42. Ionic bridge between Arg289 and Glu293 (A) and molecular modeling of the 
mutation R289H (B). The position of Arg289 (A), Glu293 (A and B) and His289 (B) are 
indicated as sticks. The monomers of AGT are colored yellow and grey. The image was 
constructed by means of MOE 2016.08. 
 
 
 
 
 
 
 
 
!! 117!
The electrostatic potential map of the pathogenic variant E95K-Mi shows 
significant alterations of charges distribution in comparison with that of AGT-Mi 
(Fig. 43). Glu95 is located on a connection loop between α-helix 4 and 5 and it is 
involved in a hydrogen bond with the main chain of Lys234, which in turn 
interacts through a hydrogen bond with Thr235 of the same subunit. This residue 
shows a predicted solvent exposure and pKa of 12.17% and 3.01, respectively. 
The Glu-to-Lys substitution remarkably increases the potential and the size of 
positive patches 5 and 6 as shown by the blue arrows in Fig. 43, due to the 
presence of Lys95 that is more exposed to the solvent with respect the native 
Glu95 (28.35% instead of 12.17%).  
 
 
 
 
Fig. 43. Distribution of electrostatic potential (-0.5 (red) and +0.5 (blue) kT/e) of AGT-Mi 
and the pathogenic variants E95K-Mi and R197Q-Mi under physiological conditions (pH 
7.4, I = 0.06 M, 37°C). The blue arrows indicate regions with differences between the electrostatic 
potential map of AGT-Mi and the variants. 
 
Thus, the presence of Lys at position 95 not only prevents the formation of the 
hydrogen bond with Lys234 (Fig. 44), thus probably causing a conformational 
change, but also generates a wide positive patch on the AGT surface under 
physiological conditions, which would promote protein aggregation. In agreement 
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with these considerations, it has been reported that E95K-Mi shows a very low 
growth and activity in yeast assay (105).  
 
 
 
Fig. 44. Hydrogen bond between Glu95 and Lys234 (A) and molecular modeling of the 
mutation E95K (B). The position of Glu95 (A), Lys236 (A and B) and Lis95 (B) are indicated as 
sticks. The monomers of AGT are colored red and grey. The image was constructed by means of 
MOE 2016.08. 
 
 
Arg197, located in the loop between β-strands 7 and 8, shows a 65.17% solvent 
exposure and it contributes to the formation of the positive patch 7 (Fig. 29). The 
side chain of Arg197 forms a hydrogen bond with the main chain of Lys5 of the 
neighboring subunit, which is expected to stabilize the dimeric structure of AGT 
by forcing the positioning and orientation of the N-terminal arm (106). The 
presence of a Gln residue at position 197 should interrupt this interaction (Fig. 
45). In the R197Q-Mi variant, the consequent increased flexibility of the N-
terminal arm could worsen the effects of the P11L mutation and strongly increase 
the aggregation propensity of AGT. The electrostatic map of the variant only 
reveals a slight alteration of the charge distribution consisting in a local reduction 
of the positive potential (blue arrows of Fig. 43), which is not expected to 
influence the aggregation propensity of AGT per se.  
 
 
 
Lys234
Lys234
Lys95
Glu95
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Fig. 45. Hydrogen bond between Arg197 and lys5 (A) and molecular modeling of the 
mutation R197Q (B). The position of Arg197 (A), Lys5 (A and B) and Gln197 (B) are indicated 
as sticks. The monomers of AGT are colored yellow and grey. The image was constructed by 
means of MOE 2016.08. 
 
 
Overall, the in silico analyses reported above allow to formulate hypotheses on 
the possible molecular effects of pathogenic mutations of AGT involving residues 
exposed to the solvent, taking into account not only the local conformational 
change caused by each mutation, but also the possible alterations of the 
electrostatic surface, which could change the aggregation propensity of the protein 
(Table 9).  
 
Table 1. Predicted effects of pathogenic missense mutations of AGT involving surface 
residues 
 
Mutation Allelic 
background 
Surface charge 
alteration 
Folding defect 
D129H Major Yes No 
E141D Major Yes No 
R289H Major No Yes 
E95K Minor Yes Yes 
R197Q Minor Yes Yes 
R289C Minor No Yes 
 
 
!! 120!
However, site-directed mutagenesis experiments followed by studies at molecular 
and cellular level will be necessary to better clarify the defect of each variant.  
 
CONCLUSION 
 
We combined in silico and in vitro study to analyse the aggregative behaviour of 
AGT and to shed light on the possible influence of polymorphic and pathogenic 
mutations. The results obtained indicate that: (i) the major allelic form of AGT 
shows a high surface charge anisotropy that makes it susceptible to an aggregation 
mediated by electrostatic forces; (ii) PLP binding strongly reduces the aggregation 
of the protein, thus suggesting that the coenzyme could have a more wide 
chaperone role than previously known (54); (iii) the P11L mutation enhances the 
aggregation propensity of AGT, while the I340M mutation has a stabilizing 
effect; (iv) missense mutations associated with PH1 could play their effects by 
promoting electrostatic aggregation. These findings, by increasing the knowledge 
of the biochemical properties of AGT and of the consequences of polymorphic 
and pathogenic mutations, constitute the base to design new strategies able to 
improve the stability of the protein as a possible premise for the development of 
innovative therapeutic strategies for PH1.  
!
!
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The molecular pathogenesis of PH1 is extremely heterogeneous, as diverse 
enzymatic phenotypes can result in AGT deficiency. A destabilization of the 
dimeric structure or an increased propensity to aggregation are two of the most 
frequent defects that characterize disease-causing variants. During my PhD, I 
analyzed at molecular level both the dimerization and the aggregation processes 
of AGT. Moreover, I investigated how these phenomena are affected by 
polymorphic and pathogenic mutations leading to PH1. Altogether, the data 
obtained allow to: 
1) identify the interfacial residues Arg118, Phe238, and Phe240, as dimerization 
hot-spot and engineer a mutated form of AGT stable in solution as a folded 
monomer; 
2) demonstrate that the acquisition of the quaternary structure is essential for 
catalytic activity, study the kinetics of the dimerization process, and provide 
evidence that monomeric AGT is able to bind PLP and that the coenzyme 
promotes dimer formation; 
3) unravel the possible structural basis of the functional synergism between the 
mutations I244T or F152I and the mutation P11L responsible for the aberrant 
targeting to mitochondria of the variants I244T-Mi and F152I-Mi associated with 
PH1; 
4) elucidate the molecular and cellular consequences of pathogenic mutations 
involving residues located at the dimer interface and suggest a possible inverse 
correlation between the degree of structural alteration of a variant and its in vitro 
responsiveness to the treatment with Vitamin B6; 
5) provide some insights into the AGT folding mechanism, by suggesting that 
PLP binding and dimerization should be late events of the pathway; 
6) define that AGT is prone to an electrostatically-driven aggregation process and 
show that the polymorphic mutations P11L and I340M have opposite effects on 
the aggregation propensity of the protein.  
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Overall, these results will contribute to better understand PH1 pathogenesis, by 
unravelling the molecular defect of several AGT variants, to predict the major 
determinants of the response of the patients to the available therapy with Vitamin 
B6, as well as to pave the way for the development of new therapeutic strategies.  
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ADDENDUM 
 
 
 
 
 
 
 
 
 
!! 125!
During my PhD course I have been involved in other projects related to 1) the 
pathogenesis of AADC deficiency, a neurometabolic disorder due to the deficit of 
human Dopa decarboxylase, and 2) the analysis of the pathogenesis of Primary 
Hyperoxaluria Type I and the development of a new therapeutic strategy based on 
the use of substrate analogs acting as pharmacological chaperones. A brief 
summary of the results obtained is reported below. 
 
 
MOLECULAR PATHOGENESIS OF AADC DEFICIENCY 
 
 
Aromatic amino acid decarboxylase (AADC) deficiency is a rare neurometabolic 
disorder caused by the absence of functional Dopa decarboxylase (DDC). More 
than 50 patients with DDC deficiency have been tabulated on the BIOMDB 
database (http://www.biopku.org/biomdb/biomdb_start.asp), and 23 missense 
pathogenic mutations have been identified, half of which in homozygous patients. 
DDC is a PLP-dependent enzyme responsible for the production of the 
neurotransmitters dopamine and serotonin. Although the clinical phenotype 
associated with the disease has been widely investigated, the molecular effect(s) 
that each mutation induces on DDC are almost unknown. Nonsense and 
frameshifts mutations lead to the complete loss of the gene product, while 
missense point mutations cause the synthesis of an aberrant gene product which 
can be characterized by defects of enzymatic activity, PLP binding, protein 
stability and/or folding, protein half-life, etc. Current treatments for AADC 
deficiency include the administration of pyridoxine or PLP to increase the residual 
DDC activity, monoamine oxidase inhibitors to minimize dopamine degradation, 
or dopamine agonists to mime the action of the neurotransmitter. The response to 
these therapies is variable, but the overall outcome is poor, probably reflecting the 
allelic heterogeneity. Moreover, since drugs are almost always given in 
combination, response is hardly ascribable to a single drug. In diseases related to 
protein malfunction it is diagnostically and therapeutically essential to understand 
the multiple mechanisms that relate the specific mutants with the pathology. 
Therefore, the knowledge of the structural and/or functional effect(s) that each 
amino acid substitution produces on DDC would be highly desirable. 
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1. A comprehensive picture of the mutations associated with aromatic amino 
acid decarboxylase deficiency: from molecular mechanism to therapy 
implications. 
 
During my PhD, I contributed to explore the molecular basis of the pathogenesis 
of AADC deficiency. We studied the structural and functional effects caused by 18 
pathogenic mutations present in homozygous patients by applying an integrated 
strategy which uses bioinformatic, spectroscopic and kinetic analyses. These 
measurements constitute the first comprehensive functional view of AADC 
deficiency mutants. The first point deriving from our study is that all variants 
either concerning residues located at/near the active site or far from the active site 
are characterized by a reduced catalytic activity and a different microenvironment 
of the external aldimines with respect to the wild-type enzyme. Moreover, for all 
but one (R347Q) we observed a perturbation of the topography of the active site 
(see below). The second finding is that the majority of the variants show (i) an 
alteration of the tertiary structure of holoDDC that linearly correlates with an 
enhanced exposure of hydrophobic sites, (ii) an impairment of the proper apo-holo 
transition, known to be a conversion from an open to a closed active 
conformation, and (iii) a decrease of decarboxylase activity. This structure–
function relationship allows us to identify the residues which play the most 
relevant role in the apo-holo conversion (i.e. His70, His72, Tyr79, Phe80 and 
Pro81 mapping to loop 1 as well as Arg462 and Arg447 directly interacting with 
loop 1) and suggest that the absence of a proper apo-holo conversion might be 
sufficient to induce pathogenicity. A different mechanism must be envisaged to 
explain DDC malfunction for other mutations. R347Q is a catalytic mutation 
since, albeit no conformational alteration was observed for this variant, it is 
characterized by a severe loss of decarboxylase activity. On the other hand, 
replacement of Ala by Gln at position 110 or of Leu by Pro at position 38 appears 
to have an impact on decarboxylase activity more pronounced than that on the 
structural integrity of the enzyme. On the basis of the comparative MD study of 
the putative structure of wild-type, A110Q and L38P, it can be speculated that the 
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decrease in catalytic activity could be due to the rearrangements occurring around 
the mutated residue transmitted to the active site, in particular to Phe103 and 
Ile101 mapping to loop 2. Finally, the finding that, among all the mutations, 
several of them affect the expression level and solubility of DDC in the E. coli 
expression system suggests folding defects of the variants harboring these 
mutations. Altogether, our results indicate for the first time that a large percentage 
of the variants associated with AADC deficiency arising from point mutations 
show conformational changes that, at various degrees, do not allow a proper apo-
holo transition and a full catalytic activity. This suggests that mutations occurring 
in distinct regions of a molecule can cause similar conformational changes with 
similar biological consequences. These events could not be predicted simply 
based on gene sequences. On the other hand, L38P, A110Q and R347Q result to 
be mainly or only catalytic mutations, for which additional kinetic features must 
be identified and understood to explain the kinetic reason(s) underlying their 
pathogenicity. Overall, these data allow us to acquire a complete knowledge of the 
enzymatic phenotype associated with each pathogenic mutation and to group 
patients with AADC deficiency into different therapeutic categories. This general 
picture of structural and/or functional effects of each mutation linked to AADC 
deficiency mutations will be a help to guide therapeutic decision and prevent 
inappropriate use of treatment regiments. 
2. The novel R347G pathogenic mutation of aromatic amino acid 
decarboxylase provides additional molecular insights into enzyme catalysis 
and deficiency. 
This study started from a clinical case of a patient bearing a novel mutation in 
DDC, R347G, associated with severe enzyme activity deficit. We found that the 
R347G mutant appears to be affected by a catalytic rather than a folding defect. 
Thus, we investigated the reason(s) underlying the dramatic loss of decarboxylase 
activity caused by the substitution of Arg347 with either Gly (~ 475-fold) or Gln 
(~ 87-fold). The in silico modelling of the missing loop 328–339 on the DDC 
structure predicted interactions of Arg347 with Asp345 and Leu333. Structural 
and functional features of the new designed mutants, D345A and R347K in 
!! 128!
recombinant DDC strongly suggested that residues Arg347, Asp345, and Leu333, 
as well as their mutual interaction, are structural elements relevant for a proper 
location/orientation of the substrate and/or of the catalytic groups at or near the 
active site. Altogether, our data highlight the molecular defects caused by the 
mutations of Arg347, and allow us to propose a therapeutic approach suitable for 
patients bearing the mutation R347G. In particular, the low kcat value of the 
purified recombinant R347G strongly suggests that a dopamine agonist together 
with folinate could be the best way of assessing a good clinical response of 
patients bearing the R347G mutation. In fact, while the therapy with dopamine 
agonists could mime the dopamine effects, the one with folinic acid could not 
allow its depletion due to the conversion of accumulated l-Dopa into 3-O-
methylDopa. The same therapy strategy could be applied to patients harbouring 
the R347Q variant. However, in the case of mutation R347G, which, unlike 
R347Q, has a 4-fold KD(PLP) value higher than that of the wild-type, the 
supplementation of pyridoxine could also be useful.  
 
 
 
ANALYSIS OF THE PATHOGENESIS OF PRIMARY 
HYPEROXALURIA TYPE I AND DEVELOPMENT OF A NEW 
THERAPEUTIC STRATEGY BASED ON THE USE OF 
PHARMACOLOGICAL CHAPERONES 
 
 
1. Misfolding caused by the pathogenic mutation G47R on the minor allele of 
alanine:glyoxylate aminotransferase and chaperoning activity of pyridoxine 
 
Gly47 is a highly conserved residue whose mutation to Arg is associate to PH1. 
We studied the molecular bases of the AGT deficit caused by Gly47 mutation by 
expression studies in a mammalian cellular system paired with biochemical 
analyses on the purified recombinant protein evaluating its responsiveness upon 
PN treatment. 
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Recombinant purified G47R-Mi variant exhibits only a 2.5-fold reduction of its 
kcat, and its apo-form displays a remarkably decreased PLP binding affinity, 
increased dimer–monomer equilibrium dissociation constant value, susceptibility 
to thermal denaturation and to N-terminal region proteolytic cleavage, and 
aggregation propensity. When stably expressed in a mammalian cell line, we 
found ~ 95% of the intact form of the variant in the insoluble fraction, and 
proteolyzed (within the N-terminal region) and aggregated forms both in the 
soluble and insoluble fractions. Moreover, the intact and nicked forms have a 
peroxisomal and a mitochondrial localization, respectively. Unlike what already 
seen for G41R-Mi, exposure of G47R-Mi expressing cells to pyridoxine (PN) 
remarkably increases the expression level and the specific activity in a dose-
dependent manner, reroutes all the protein to peroxisomes, and rescues its 
functionality. Although the mechanism of the different effect of PN on the 
variants G47R-Mi and G41R-Mi remains elusive, the chaperoning activity of PN 
may be of value in the therapy of patients bearing the G47R mutation.  
  
2. The Chaperoning Activity of Amino-oxyacetic Acid on Folding-Defective 
Variants of Human Alanine:Glyoxylate Aminotransferase Causing primary 
Hyperoxaluria Type I 
 
Pharmacological chaperone (PC) therapy is a newly developed approach for 
misfolding diseases based on the use of small molecule ligands able to promote 
the correct folding of a mutant enzyme. We described the interaction of amino-
oxyacetic acid (AOA) with the recombinant purified form of the two polymorphic 
species of AGT, AGT-Ma and AGT-Mi, and with three pathogenic variants 
bearing previously identified folding defects: G41R-Ma, G170R-Mi and I244T-
Mi. We found that for all these enzymes AOA (i) forms an oxime at the active 
site, (ii) behaves as a slow, tight-binding inhibitor with KI values in the nanomolar 
range, and (iii) increases the thermal stability. Furthermore, experiments 
performed in mammalian cells revealed that AOA act as PC by partly preventing 
the intracellular aggregation of G41R-Ma and by promoting the correct 
peroxisomal import of G170R-Mi and I244T-Mi. Based on these data, we carried 
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out a small-scale screening campaign. We identified four AOA analogues acting 
as AGT inhibitor, even if only one was found to act as PC. The possible 
relationship between the structure and the PC activity of these compounds is 
discussed. Altogether, these results provide the proof-of-principle for the 
feasibility of a therapy with PCs for PH1-causing variants bearing folding defects 
and provide the scaffold for the identification of more specific ligands. 
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Dopa decarboxylase (DDC), or aromatic amino acid decarboxylase (AADC), is a pyridoxal 5′-phosphate enzyme
responsible for the production of the neurotransmitters dopamine and serotonin. Deficit of this enzyme causes
AADC deficiency, an inherited neurometabolic disorder. To date, 18 missense homozygous mutations have
been identified through genetic screening in ∼80 patients. However, little is known about the mechanism(s)
bywhichmutationscausedisease.Herewe investigated the impactof thesepathogenicmutationsandofanarti-
ficial one on the conformation and the activity of wild-typeDDCby a combined approach of bioinformatic, spec-
troscopic and kinetic analyses. All mutations reduce the kcat value, and, except the mutation R347Q, alter the
tertiary structure, as revealedby an increasedhydrophobic surface and adecreasednear-UVcircular dichroism
signal. The integrated analysis of the structural and functional consequences of each mutation strongly sug-
gests that the reason underlying the pathogenicity of themajority of disease-causingmutations is the incorrect
apo-holo conversion. In fact, the most remarkable effects are seen upon mutation of residues His70, His72,
Tyr79, Phe80, Pro81, Arg462 and Arg447 mapping to or directly interacting with loop1, a structural key element
involved in theapo-holoswitch. Instead,differentmechanismsare responsible for thepathogenicityofR347Q,a
mere catalyticmutation, andof L38P andA110Qmutations causing structural-functional defects. These are due
to local perturbation transmitted to the active site, as predicted by molecular dynamic analyses. Overall, the
results not only give comprehensivemolecular insights intoAADCdeficiency, but alsoprovide an experimental
framework to suggest appropriate therapeutic treatments.
INTRODUCTION
Dopa decarboxylase (DDC) (EC 4.1.1.28) is a homodimeric
stereospecifica-decarboxylase that utilizes pyridoxal 5′-phosphate
(PLP) as coenzyme. The enzyme is found in neural and peripheral
tissues, notably liver and kidney.DDC is responsible for the con-
version of L-Dopa and L-5-hydroxytryptophan (L-5HTP) to
dopamine and serotonin, respectively, which are two of the
major neurotransmitters of the mammalian nervous system.
However, since the enzyme, at least in vitro, displays a much
broader substrate specificity, it is also named aromatic amino
aciddecarboxylase (AADC).Naturally occurring and recombin-
ant pig kidney and rat liver enzymes aswell as humanDDC in the
recombinant form have been purified and characterized (1–3).
Many structural and functional data were obtained from pig
kidney, and, recently, from human DDC enzymes (4). They
consist in the definition of the steady-state kinetic parameters
for L-Dopa and L-5-HTP (5,6), the absorbance and dichroic fea-
tures of the enzyme in the internal and external aldimine forms
(5,6), and in the identification of structural elements functionally
relevant for catalysis, like a loop susceptible to proteases and
some residues at or near the active site (7–10).
Burkhard et al. (11) obtained the crystal structure of ligand-
free pig kidney DDC and its complex with the anti-Parkinson
drug carbidopa. Several features of DDC were evident in these
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structures.Theoverall structureof theprotein isa tightlyassociated
dimer in which eachmonomer consists of a large domain contain-
ing the PLP-binding site, a C-terminal small domain, and a
N-terminal domain packing on the top of the large domain. In
both these structures a short stretch of 11 amino acids (residues
328–339), invisible in the electron density map, represents a
mobile loop important for the catalytic mechanism (7,10). The
resolved structures also revealed theway inwhichPLP is anchored
to the enzyme,which amino acid residuesmight be involved in the
catalytic activity of the enzyme, and, importantly, how carbidopa,
a substrate analog, binds DDC. The inhibitor forms a hydrazone
linkage with PLP, its carboxylate moiety is nearly orthogonal to
the PLP ring and its 3′ and 4′ catechol hydroxyl groups are hydro-
gen bonded to the hydroxyl group of the phosphate of the coen-
zyme and to Thr82, respectively. The resolution of the crystal
structure of the apo form of human DDC is a recent achievement
(12). Unexpectedly, this structure is an open conformation in
which the active site becomes solvent exposed and the dimer inter-
face is reducedtoonly theN-domains.Thecomparisonof this struc-
ture with that of the holoenzyme from pig kidney allowed us to
establish that a remarkablechangeof loop1 (residues66–84) trans-
mitted to loops 2 (residues 100–110) and 3 (residues 323–357)
of the adjacent subunit occurs in the transition from the apo to the
holo form of DDC.
The enzyme is of medical interest because it is the target of
drugs used in the therapy of Parkinson’s disease (13,14) and
because its deficit leads to AADC deficiency (OMIM#608643),
a human autosomal recessive disorder. This inherited disease
is caused by mutations in the AADC gene on chromosome
12p123-p12.1 leading to the loss of function ofDDC.The clinical
phenotypeof thepathologyvaries extensivelyamongpatients,but
common manifestations include vegetative symptoms, oculogy-
ric crises, dystonia and severe neurologic dysfunction, usually
beginning in infancy or childhood (15). A mild form of the
disease has also been reported (16). Diagnosis of AADC defi-
ciency may be made by a finding of reduced levels of
5-hydroxindolacetic acid andhomovanillic acid in cerebrospinal
fluid in conjunction with elevated levels of 3-O-methyldopa,
L-Dopa and L-5HTP in cerebrospinal fluid, plasma and urine
(17–19). Definitive diagnosis may be obtained by the measure-
ment of DDC activity in plasma. Genotyping of .80 AADC
deficiency homozygous and compound heterozygous patients
identified 28 missense mutations, 18 of which in homozygous
patients. The distribution of mutants among patients is quite
homogeneous (with a mean value of two patients per mutation
except for S250F that is present in about five cases). Clinical
data for AADC deficiency-causing mutations are limited to a
small number of individuals, and, thus the genotype-phenotype
correlation is almost completely unknown. The chemical man-
agement of AADC deficiency, usually involving vitamin B6,
dopamine agonists and monoamine oxidase (MAO) inhibitors,
is aimed at correcting the neurotransmitters abnormalities.
Moreover, gene therapy appears to be a better prospect for the
future treatment of AADC deficiency (20–22). However, up to
date treatment options are limited, and in many cases response
to the current treatments is disappointing.
Since an inheritedmutation can alter protein function inmany
differentways (change in the kinetic parameters and/or in the co-
enzyme binding, reduced protein expression level, protein mis-
folding or instability), it is essential to understand the molecular
mechanism(s) of the effects of each disease-causing mutation.
Characterization of some variants linked to AADC deficiency
has begun to provide invaluable insights into their molecular
defects, thus allowing to foresee the proper therapeutic treat-
ments for patients bearing the examined mutations (3,23).
However, a thorough study of the pathogenic effects of a signifi-
cant number of missense pathogenic mutations is still lacking.
In the present study we have employed bioinformatic, kinetic
and spectroscopic analyses to characterize all the AADC defi-
ciency associated point mutations identified in homozygous
patients. The already studied pathogenic variants (G102S,
F309L and S250F) were included in this study for a more
in-depth and complete molecular insights into the pathogenesis
of AADC deficiency. In addition, the artificial variant F80Awas
also taken in consideration since Phe80, a key residue of loop 1,
is involved in the switch between the apo and holo forms of the
enzyme (12). All variants in the recombinant purified formwere
analyzed to determine their PLP binding mode and affinity,
secondary and tertiary structure, surface hydrophobicity, and
kinetic parameters. The results allowed us to highlight a linear
correlation between the structural and functional effects of a
large number of mutations, and to suggest that the affected resi-
dues are involved, even if at a different degree, into the conver-
sion from the open apo conformation to the closed active holo
form. This set of mutations does not include the catalytic muta-
tion R347Q or themutations L38P andA110Q, for which a cata-
lytic effect predominant over a structural one has been observed.
Bioinformatic andmolecular dynamic (MD) analyses help to en-
visage the possible role of the residues Arg347, Leu38 and
Ala110 affected by pathogenic mutations on the structure–
function relationship of DDC.
RESULTS AND DISCUSSION
Location of pathogenic mutations in the crystal structure of
human DDC
In the past few decades, a number of rare inborn errors due to the
loss of function of enzymes requiring PLP to functionwere iden-
tified (24,25).Thegenetic defects aremost frequentlydue tomis-
sense mutations. Among these inherited diseases, we focused
our attention on homocystinuria, gyrate atrophy, primary hyper-
oxaluria type1 andAADCdeficiency.These are caused, respect-
ively, by deficit of cystathionine-b-synthase (CBS), ornithine
aminotransferase (OAT), alanine glyoxylate aminotransferase
(AGT) and DDC. The reasons for such focusing are the follow-
ing. First, a remarkable number (ranging from8 to 150) of patho-
genicmutations havebeen identified for these disorders. Second,
the crystal structure of humanCBS (26),OAT(27) andAGT(28)
aswell as that of pig kidneyDDC (11) (" 90%sequence identity
with human DDC) has been solved. The inspection of these
structures reveals that while the pathogenic mutations of CBS,
OAT, and AGT are spread out over the entire structure (Supple-
mentaryMaterial, Fig. S1), thoseofDDCare essentially grouped
in a central region of each enzyme monomer. This region com-
prises a large portion of the large domain, two b-strands and
an a-helix of the C-terminal domain as well as a limited
portion of the N-terminal domain. The majority of the residues
affected by mutations map to highly or moderately conserved
residues among a-decarboxylases of distantly related species.
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This indicates that they are essential for enzyme structure and
function (Fig. 1).
Eight mutations are located at loop 1 (T69M, H70T, H72Y,
Y79C, P81L), 2 (G102S, A110Q) and 3 (R347Q), which have
a leading role in the conversion from the apo to the holo form
of DDC. Even if not affected by a pathogenic mutation, the
residue Phe80 mapping to loop 1 deserves note since, together
with Tyr79, it represents a key residue in the loop 1 rearrange-
ment (12). The other mutations that affect residues not directly
involved in the apo-holo transition comprise two mutations
(L38P and P47H) of residues belonging to the N-terminus,
four mutations (L408I, R412W, R447H and R462P) of residues
lying on the C-terminal domain and four mutations (G123R,
S250F, R285W, F309L) of residues mapping to the large
domain, but outside the loops (Fig. 2A).
Functional and conformational impact of amino acid
replacement on 3D networks of side-chain interactions in
human DDC
The position and the possible structural effects of each mutation
were analyzed by the inspection of the crystal structures of pig
kidney holoDDC (pdb file 1js6) and human apoDDC (pdb file
3rbf), and by in silico mutational analysis. On the basis of the
position of the mutated residue, the examined mutations can
be grouped in four clusters. The first cluster comprisesmutations
of residues belonging to loops 1, 2 or 3 of DDC (Fig. 2B). The
side chain of Thr69 and His70 points far from the active site,
whereas His72 side chain faces the active site and contributes
to generate the hydrophobic cleft that accommodates the sub-
strate.Mutational analysis predicted thatwhile theT69Msubsti-
tution does not produce significant steric clashes with the
neighboring residues, H70T and H72Y substitution could affect
both the loop 1 conformation and the active site microenviron-
ment, and might alter the position of Trp71, a residue involved
in the substrate binding (13). Tyr79 and Phe80 are located
in the center of loop 1 and, as already reported, upon PLP
binding both residues undergo an inversion of position with
respect to the loop 1 backbone (12). In fact, in the holoDDC
structure Tyr79 interacts with the N11 of Arg447 and the side
chain of Phe103 by, respectively, a hydrogen bond and a s-p
hydrophobic interaction. The phenyl ring of Phe80 engages
Arg447 and Tyr274 with a cation-p and a p–p interaction, re-
spectively, while in the apoDDC structure the hydroxyl group
of Tyr79 is hydrogen bonded to the Nd1 of His302, and Phe80
phenyl ring interacts with the Trp71 side chain. Moreover,
Tyr79 is involved in the binding of the substrate (13). On this
basis, it is reasonable to say that the Y79C and F80A substitu-
tions could cause the loss of important anchoring points that sta-
bilize the loop 1 conformation both in the holo and in the apo
form.Pro81 is located in the center of loop1 anddoes not interact
with any of the neighboring residues neither in the holo- nor in
the apoDDC form. Its presence reduces the flexibility of the
backbone, thus possibly affecting the torsion movement of
loop 1 during the apo-holo transition. It is reasonable to infer
that the Pro-to-Leu substitution could alter either the conform-
ation and/or the movement of loop 1. Gly102 and Ala110 are
located in proximity of the N- and C-terminal ends of loop 2, re-
spectively. In silico analyses, together with previously reported
molecular modeling studies (3), indicate that the G102S substi-
tution could introduce a minimal steric hindrance in the cleft
between loop 2 and loop 3 and indirectly alter the position of
Phe103, a residue that plays a role in substrate binding (11).
TheA110Q substitution generates a remarkable steric hindrance
between thea-helix 8 and the N-terminala-helix 4 (55–65) that
could induce a repositioning of the two helices and a local alter-
ation of loop 2 conformation.Arg347 adopts a central position in
loop 3 at the entrance of the active site cavity. It is noteworthy
that Arg347 is close to the loop 328–339, a mobile segment
invisible in the electron density map that is essential for the
decarboxylase activity (7,10,11). Nevertheless, in silico ana-
lyses predict that R347Q substitution does not generate substan-
tial local structural alterations.
The second cluster comprises the L408I, R412W, R462P and
R447Hmutations that affect residues belonging to theC-terminal
domain of the protein (Fig. 2C). Arg447 and Arg462 are directly
interactingwith loop 1. In fact, in the holoDDC structure, the side
chain of Arg447 interacts with the phenyl ring of the Phe80
through an hydrophobic s-p linkage and, in the apoDDC struc-
ture, the N11 of the side chain of Arg462 is hydrogen bonded
with the side chainhydroxyl groupofTyr75.Thus, it is reasonable
thatR447HandR462Psubstitutionscouldperturb thecorrectpos-
itionof loop1and/or theconformational changeof the loopduring
the apo-holo transition. Leu408 is located in the N-terminal end
of the b-strand 9 in proximity of Arg447 and contributes in gen-
erating the hydrophobic compartment that hosts Phe80 in the
holoDDC. The L408I substitution does not change the polarity
of the region but could determine a moderate steric hindrance
that possibly disturbs the correct position of the side chain of
Phe80. Arg412 is a surface residue located far from the active
site at the C-terminal end of the b-strand 9 and does not interact
with loops 1, 2 and 3. The drastic substitutionR412W is predicted
to generate a remarkable steric hindrance between b-strand 9 and
the a-helix 25, which could impair the correct folding of the
overall C-terminal domain conformation.
The third cluster comprises the N-terminal domain mutations
L38P and P47H (Fig. 2D). Leu38 belongs to the 3/10 helix 3 and
faces the Ala110 side chain, while Pro47 is positioned in the
Figure 1.Amino acids conservation and pathogenicmutation sitesmap ofDDC.
Ribbon representation of the dimeric structure of pig kidney holoDDC (pdb file
1js6) colored on the basis of the conservation degree as light gray, dark gray and
black for low (up to 25%),medium (from25 to 75%) and high (from75 to 100%)
conservation level, respectively, in the selected subset of DDC homologous se-
quence (see Material and Methods). The pathogenic mutation sites and the
PLP molecules are represented as yellow and green sticks, respectively.
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middle of the unstructured loop 42–52. TheLeu38!Pro substi-
tution alters the backbone flexibility of the short helix 3 and
could impair the hydrophobic contact with Ala110, while the
Pro47!His substitution could affect the conformation of loop
42–52. Considering the distance of the mutation sites from the
active site, the possible functional effects of both substitutions
are expected to be only indirect and hard to predict.
The fourth cluster comprises the G123R, S250F, R285W and
F309L mutations that affect residues belonging to the large
domain of DDC that do not directly interact with loops 1, 2
and 3 (Fig 2E). Gly123 and Arg285 are located far from the
active site on thea-helix 8 and 16, respectively. The bulky argin-
ine side chain introduced by the G123R substitution generates a
considerable hindrance between the surface helix 8 and the
b-barrel structure that wraps up the active site on the re face of
PLP. Moreover the R285W substitution impairs the Arg285
side chain interactions with the Gln127 and Asn289, and intro-
duces a bulky hydrophobic side chain in a surface region.
Ser250 is located on loop 243–252. As already reported (23),
the S250F substitution impairs the H-bond between the Ser250
and Thr245 side chains, and could locally change the surface
hydrophobicity and destabilize the conformation of loop 243–
252. Considering the distance from the active site and the chem-
ical changes introduced by the G123R, S250F and R285W sub-
stitutions, it is reasonable to suggest that these mutations
probably cause structural and/or folding alterationswith only in-
direct functional effects. Differently from the other residues
belonging to the third cluster that are located far from the coen-
zyme, Phe309 is placed in proximity of the PLPphosphate group
in loop 304–311. As previously reported (3), the reduced
hindrance of Leu309 in the F309Lmutant might be less efficient
in delimiting the apolar cavity of the substrate binding cleft.
Expression and purification of the variants
All mutations under study were inserted in the DDC cDNA by
site-directed mutagenesis, and the variants were expressed in
Escherichia coli and purified. The purified variants were homo-
geneous as indicated by a single band on SDS–PAGE electro-
phoresis with a mobility identical to that of the wild-type.
Yields of the mutant enzymes after standard purification were
quite variable, ranging from5 to90%with respect to that ofwild-
type. In comparison with wild-type DDC, the total expression
level of each variant inE. coliwas (i) equal, within experimental
error, for the L38P, T69M, R347Q and L408I variants, (ii)
≥75% for the H70T, H72Y, Y79C, F80A, G102S, A110Q,
G123R and F309L variants (iii) between 50 and 75% for the
P47H, P81L, S250F, R285W, R412W, R447H and R462P var-
iants. Moreover, the soluble fraction of the lysate contained
#50% of the total protein for all the enzymatic species except
the P47H, R285W, R412W and R447H variants, for which this
percentage dropped to #20%. The effects of each amino acid
substitution were analyzed by means of bioinformatic, spectro-
scopic and kinetic analyses of the variants.
PLP binding of variants: mode and affinity
Titration analysis of the apomutantswith PLPfitted to the appro-
priate equation yielded the equilibrium dissociation constant for
PLP (KD(PLP)) values reported in the first column of Table 1. All
Figure 2. Tridimensional representation of the mutation sites. Ribbons representation of the crystal structure of pig kidney holoDDC. The large domains of bothmono-
mers are coloredwhite except for loops 1, 2 and 3 that are colored yellow, cyan and blue, respectively. TheC-terminal and theN-terminal domains are colored in red and
magenta, respectively. The described color code has been used for all the panels. (A) The overall dimeric structure of holoDDCwith all themutation sites represented as
white sticks. (B,C,D andE) The residues subjected topathogenicmutations (orange stick) and theirmain contact residues (white sticks) belonging to loops 1, 2 and3 (B),
the C-terminal domain (C), the N-terminal domain (D), and the remaining portion of large domain (E). The PLP molecules are represented as green sticks.
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variants examined, except P47H, T69M, G102S, G123R,
R347Q,R412W,L408I andS250F, showed, even if to a different
extent, an increased value of the KD(PLP), ranging from 2- to at
least 43-fold that of wild-type DDC (Table 1). In most cases,
these data are in line with the in silico analyses. For the variants
L38P andA110Qwe could not explain the effect of themutation
on thecoenzymebindingaffinityby in silicomutagenesis, butwe
referred to MD analyses (see below). Human DDC displays ab-
sorbance maxima at 420 and 335 nm (ratio A335nm/A420nm ≈ 2)
associated with positive dichroic bands centered at the same
wavelengths, and emits fluorescence at 384 and504 nmuponex-
citation at 335 nmand at 504 nmwhen excited at 420 nm.On the
basis of these spectral features and of their dependence on pH,
the absorbance bands at 420 and 335 nm have been attributed
to the ketoenamine and the enolimine tautomers of the internal
aldimine (5). The absorbance and dichroic properties of all var-
iants examined were generally similar to those of the wild-type.
However, with respect to the wild-type, the following differ-
ences were observed: (i) the absorbance maxima at 420 nm is
1–14 nm blue shifted for all variants but F309L and R347Q
(Supplementary Material, Fig. S2), (ii) the ratio between the ab-
sorbance and dichroic bands of the enolimine and the corre-
sponding ones of the ketoenamine is lower for all variants but
R347Qand (iii) theoptical activity (mdeg/absorbanceunit)mea-
sured at the maximum absorbance of the ketoenamine changes
for all variants, with the exception of T69M, G102S, G123R,
S250F, R347Q and L408I. Altogether, these data indicate that
the chiral environment of the PLP-binding site of the majority
of the examined variants is altered, at varying degree.
Structural features of the variants
We first investigated whether the examined mutations affect the
secondary structure composition of DDC.Wemeasured the cir-
cular dichroism (CD) signal of each variant in the far-UV region
and compared it to that of the wild-type. The overall shape of the
CD spectrum of the variants in the region 190–260 nm was es-
sentially identical to that of the wild-type indicating that the
mutations do not affect the secondary structure of the protein.
To examine whether the mutations previously investigated and
under study here affect the tertiary structure of holoDDC, the
near-UV CD spectra and the 1-anilino naphthalene sulfonic
acid (ANS) emission spectra were acquired for all variants in
the holo form and compared with the corresponding ones of
the wild-type. As previously reported (3,12), the holo DDC dis-
plays a positive dichroic band in the 280 nm region, and binding
of ANS to the holoenzyme results in an "4-fold increase in its
fluorescence emission intensity accompanied by a 27-nm blue
shift consistent with ANS binding to hydrophobic sites of the
enzyme. In fact, it is well known that binding of ANS to the
exposed hydrophobic clusters of a protein results in both an
increased intensity of the emission of the dye and a blue shift
in its maximum emission fluorescence. For all variants but one
(R347Q)we observed a reduction, at varying degree, of themag-
nitude of the CD signal in comparison with that of the wild-type
(Supplementary Material, Fig. S3). Moreover, upon addition of
ANS to each of the holo variants we saw in comparison with the
wild-type (i) no significant changes in the ANS emission spec-
trum of R347Q and (ii) an enhanced emission fluorescence
intensity, even if at a different extent (from 7- to 35-fold) and
a blue shift (in the range 14–34 nm) for all other variants
(Fig. 3). When we plotted the magnitude of the near-UV CD
signal versus the ANS emission intensity, we noticed for all
the variants, except L38P and P47H (both bearing mutations of
residues located on the N-terminal domain), a linear relation
between the variables whose values span over a wide range
with R347Q having equivalent values to those of wild-type
(Fig. 4A). From this plot it can be derived that (i) the mutation
of Arg347 does not significantly affect the tertiary structure of
holoDDC and (ii) the H70T, H72Y, Y79C, F80A, P81L,
Table 1. Equilibrium dissociation constants for PLP (KD(PLP)) and steady-state kinetic parameters for L-dopa of wild-type DDC and variants
Enzyme Location of mutated residue KD(PLP) (nM) kcat (s
21) Km (mM) kcat/Km (mM s
21)
Wild type 43+12 7.6+0.1 0.11+0.01 70.6+8.4
T69M LOOP 1 100+13 3.5+0.2 0.46+0.07 7.6 + 1.2
H70T 510+90 0.34+0.02 0.69+0.09 0.49+0.07
H72Y 2145+409 0.20+0.01 1.38+0.23 0.14+0.02
Y79C 487+110 0.32+0.01 3.98+0.37 0.080+0.007
F80A 1520+280 0.24+0.01 1.03+0.06 0.23+0.04
P81L 390+63 0.50+0.01 0.19+0.02 2.6+0.5
G102Sa LOOP 2 61.7+9.2 1.2+0.1 1.2+0.1 1.0+0.1
A110Q 829+60 0.015+0.01 3.6+0.4 0.004+0.002
R347Q LOOP 3 54+10 0.087+0.005 0.49+0.08 0.16+0.06
L38P N-Terminal domain 460+58 n.d. n.d. n.d.
P47H 100+24 1.70+0.06 0.60+0.05 2.8+0.2
L408I C-Terminal domain 105+33 0.78+0.06 1.78+0.26 0.44+0.07
R412W 84+23 1.45+0.05 0.27+0.03 5.37+0.61
R447H 1010+160 0.38+0.02 0.79+0.13 0.41+0.07
R462P 544+50 0.40+0.01 0.25+0.03 1.60+0.19
G123R Large domain (outside loops) 101+13 3.30+0.14 0.74+0.07 4.46+0.45
S250Fb 62+24 2.1+0.1 0.22+0.04 9.3+1.7
R285W 335+39 2.08+0.08 0.16+0.03 13.0+2.5
F309La 225+26 0.47+0.03 4.8+0.6 0.097+0.013
n.d., not determined.
aFrom reference (3).
bFrom reference (23).
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A110Q, R447H and R462P mutations cause a structural alter-
ation more pronounced than that due to the T69M, G102S,
G123R, F309L, S250F, R285W, L408I and R412W mutations.
In order to verify if the alteration of the structural integrity is
only limited to theholoforms, thenear-UVCDspectra of the var-
iants in the apo form were acquired. The data obtained indicate
that (i) the variants T69M, H70T, H72Y, P81L and R447H
display a positive dichroic signal whose magnitude is remark-
ably reduced (≤50%) in comparison with that of the wild-type,
(ii) the variants L38P and R412W show a slightly negative band
and (iii) the remaining variants donot exhibit significant changes
in their dichroic spectra, or, as is the case for R347Q, any change
at all (Supplementary Material, Fig. S3). The finding that the
positive dichroic band of the apo wild-type is "2.8-fold lower
than that of the holo is consistent with the conformational
change accompanying the transition from the apo-open form
to the holo-closed one of DDC (12). Thus, the extent of the dif-
ference between the dichroic bands of the holo and the apo forms
could represent an indication of the impact of a mutation on the
apo-holo conversion. When we plotted the difference of the
near-UV CD signal between the holo and the apo form against
the ANS emission intensity of each variant (Fig. 4B), a linear
relation similar to that of Figure 4A could be observed. Thus,
it seems reasonable to suggest that in the apo-holo transition
(i) the mutations H70T, H72Y, Y79C, F80A, P81L, A110Q,
R447H andR462P havemoremarked impact than themutations
T69M, G102S, G123R, F309L, S250F, R285W, L408I and
R412W, (ii) the R347Q mutation does not have any effect, and
the mutations L38P and P47H appear not to be involved. This
could imply that 16 residues affected by mutations are, yet at
varying degree, structural elements involved in the achievement
of the correct conformation of holoDDC.
Catalytic features of the variants
In order to understand if all mutations taken in consideration in
this study affect the decarboxylase activity, the steady-state
kinetic parameters of the variants were measured (Table 1).
All variants exhibited a decrease in the kcat/Km value spanning
from "6-fold to "17 000-fold. Reduced kcat values were
found for variants T69M (46%), G123R (43%), S250F and
R285W (27%), P47H (22%), and G102S (16%). The remaining
variants showed amore remarkable reduction in kcat value (0.2–
10%). For most variants, the Km value was slightly increased
(from1.5- to 16-fold). OnlyY79C,A110QandF309L showa re-
markably decreased L-Dopa affinity with an "35-fold increase
inKm in comparisonwith that of thewild-type. The in silico ana-
lysis predicted a decrease of the substrate binding affinity for the
substitution of Tyr79 and Phe309 by Cys and Leu, respectively,
but did not explain the high Km value of A110Q. The kinetic
parameters of the L38P variant for L-Dopa were difficult to
obtain because of the very slow reaction rate. In fact, when
10 mMvariantwas allowed to reactwith 2 mML-Dopa in thepres-
ence of 50 mM PLP, we found that dopamine was linearly pro-
duced with time, reaching after 40 min a value of 13 nmol,
which corresponds to an initial rate of 2.1 × 10–3 s21. Assum-
ing that this value is close to the kcat value of decarboxylation,
the rate of this reaction in L38P is "3800-fold lower than the
Figure 3.ANS emission fluorescence spectra of wild-type DDC and variants in
theholo form.Fluorescence emission spectra of 1 mMwild-typeand the indicated
variants in the presence of 20 mM PLP incubated with 1 mM ANS at 258C for 1 h
and registered upon excitation at 365 nm. All measurements were made in
100 mM potassium phosphate buffer, pH 7.4.
Figure 4. Correlation between the ANS emission fluorescence intensity and the
magnitude of the near-UVofwild-type and 19 variants. TheANSemissionfluor-
escence intensity of the holoforms is plotted (A) versus the magnitude of their
near-UV CD signal or (B) versus the difference between the magnitude of the
near-UV CD signal of the holoenzyme and the corresponding apoenzyme. The
diagonal lines correspond to a linear fit, with R2 values of 0.86 and 0.76, for
(A) and (B), respectively.
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corresponding reaction in wild-type. Taken together, these
results indicate that none of the examined mutations involves
residues essential for the catalytic activity of DDC. However,
they open the question if the loss of decarboxylase activity is
related or not to the incorrect apo-holo transition. In attempting
to clarify this point, we plotted the ratio kcat(wild-type)/kcat(variant)
value as a function of the ratio ANSemission fluorescence intensity
(variant)/ANSemission fluorescence intensity (wild-type) (or the difference
of the near-UV CD dichroic signal between the holo and apo
form) of the enzymatic species, which fit the linear correlation
shown in Figure 4A and B. With the exception of A110Q and
R347H, a linear relation statistically significant could be
observed for 15 variants (Fig. 5). This implies that for these var-
iants the following relationship holds: high extent of conform-
ational change ! increase of the exposure of hydrophobic
clusters ! decrease of decarboxylase activity. Thus, on the
basis of all our data, the mutations can be arranged in two cat-
egories with a different degree of structural and functional
effects within each category. One group comprises the holo
forms of the variants H70T, H72Y,Y79C, F80A, P81L concern-
ing residues mapping to loop 1, and those of R462P and R447H
relative to residues mapping to the C-terminal domain. These
variants showed a near-UV CD signal similar or close to that
of the corresponding apo form, the highest increase in the add-
itional hydrophobic regions, a relevant change in the PLP
bindingmode and affinity, and a remarkably decreased catalytic
activity (from 15- to 38-fold) in comparison with the wild-type.
This is in line with the in silico prediction showing that except
T69M, all mutations of residues belonging to loop 1 or residues
(Arg462 andArg447) directly interactingwith loop 1 could have
a remarkable impact on the architecture of the active site. The
other group includes the holo forms of T69M, G102S, G123R,
S250F, R285W, F309L, L408I andR412Wwhich are character-
ized by a near-UV-CD signal higher than that of the correspond-
ing apo forms, a mild increase in the accessible hydrophobic
surface areas, a modest change in the PLP binding mode and af-
finity, and a slightly decreased catalytic activity (from 2- to
9-fold) with respect to the wild-type. Consistent with these
data, mutations of residues Thr69 and Gly102 located on the
N-terminal end of loops 1 and 2, respectively, are predicted to
induce a mild local perturbation at the active site microenviron-
ment.Moreover, mutations of residues Gly123, Ser250, Arg285
and Phe309 located on the large domain as well as mutations of
residues Leu408 and Arg412 located on the C-terminal domain
are predicted not to directly affect both the active site and loops
residues.
Besides the variants of these twogroups, twovariants (A110Q
and R347Q) have different characteristics. In fact, the R347Q
variant mapping to loop 3 exhibited a severely reduced catalytic
activity despite its conformation being comparable to that of
wild-type, while the A110Q variant mapping to loop 2 disclosed
signs of loss of catalytic activity more pronounced than signs of
impairment of structural integrity of its holo form. While the
catalytic effect of the R347Q mutation should be related to the
proximity of Arg347 to the flexible catalytic loop 328–339,
that of A110Q is hard to explain. Amore deep kinetic character-
ization should be required to identify the step(s) along the cata-
lytic pathway of decarboxylation altered in each of these
variants. Finally, it was surprising to find a different impact of
the mutations L38P and P47H of residues located on the
N-terminal domain and far from the active site. Indeed, both
the variants showed similar extents of alteration of their tertiary
structure (Fig. 4A).However,while theP47Hvariant displayed a
modestly reduced catalytic activity, the L38P variant unexpect-
edly exhibited an extremely lowdecarboxylase activity such that
the kinetic parameters values could not be determined.
MD
To gain insights into the functional effect of L38P and A110Q
pathogenic mutations, MD simulations were run on DDC for
wild-type, L38P and A110Q mutants. A structural analysis of
the wild-type protein reveals that Leu38 and Ala110, located
on two opposite alpha helices that run parallel to each other,
form a hydrophobic interaction (Fig. 2D).
Three MD simulations of 50 ns were performed, totalizing
150 ns of total simulation time. We have first calculated the
root mean square deviation (RMSD) on the backbone atoms of
the three simulations in order to assess the stability of the three
systems. Indeed, it can be appreciated (SupplementaryMaterial,
Fig. S4) that all systems became equilibrated after the first 10 ns
ofMD simulations. The simulated time spanwas long enough to
relax and equilibrate the molecules, as indicated by the leveling
of the RMSD from the initial conformations to values of
"0.3 nm (Supplementary Material, Fig. S4). Moreover, since
no significant differences could be observed between the
mutants and the wild-type forms, we can assume that the muta-
tions do not destabilize the folding of the enzyme in an extensive
manner, in agreement with results obtained with purified pro-
teins (see above).
We then calculated the rootmean square fluctuations (RMSF)
on theC-alpha atoms of the three systems in order to characterize
the flexibility of the three simulated systems and to assess puta-
tive differences at the backbone level due to the mutations.
Indeed, RMSF represents the standard deviation of atomic posi-
tions in the trajectory after fitting to a reference frame. Important
Figure5.Correlationbetween thedecreaseof thekcat and the increaseof theANS
emission fluorescence intensity of 17 variants with respect to wild-type. The de-
crease in the kcat valuewith respect towild-typewas plotted versus the increase in
the ANS emission fluorescence intensity. The diagonal line corresponds to a
linear fit with a R2 value of 0.72.
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differences on the backbone flexibility only localized in the
neighborhoods of the mutated residues could be appreciated
(Supplementary Material, Fig. S5). We thus concentrated in
analyzing differences in the active site. With this aim, we have
analyzed the c/F angle variation of residues involved in PLP-
carbidopa binding during the MD simulation. In particular, we
considered residues located on the three loops near the active
sites, i.e. loops 1, 2 and 3. While in loops 1 and 3 there were
not clear differences in the distribution of the angle values
between the three simulations (data not shown), a significant dif-
ference could be appreciated for residues belonging to loop
2. Indeed, it can be clearly seen that Ile101 (Fig. 6A) and
Phe103 (Fig. 6B) explore different regions of theRamachandran
plot uponmutations comparedwith thewild-type. In this regard,
it can be observed that (i) the L38Pmutant showed themost rele-
vant variation with respect to the wild-type, and (ii) the A110Q
mutant showed disperse values that localize in the middle
between the values obtained for the wild-type and for the L38P
mutant. It is interesting to note that Ile101 and Phe103 were
already identified as involved in substrate binding (11,13).
In summary, the MD simulations revealed that, although the
L38P and the A110Qmutations do not change the conformation
of DDC structure in amacroscopic way, they create local pertur-
bations at the backbone level extending, through loop 2, towards
the active site. Moreover, differences in the dynamic properties
of the A110Q mutant compared with the wild-type were less
evident than those of the L38P mutant. Although these predic-
tions are of course not an experimental evidence of the structural
effects caused by these mutations, they are consistent with the
finding that L38P mutation has an impact on the catalysis
higher than that of A110Q.
Catalytic intermediates of variants
In order to ascribe the catalytic consequence of the amino acid
substitutions under study to a particular reaction step, the effects
of each mutation on the formation of the external aldimine were
investigated bymeans ofCDanalyses. The CD features of the ex-
ternal aldimine of DDC wild-type with L-Dopa cannot be moni-
tored because the kcat value is 7.6 s
21. This implies that, at 6 mM
enzyme concentration, the DDC wild-type-L-Dopa complex
remains close to saturation for only !45 s, a time too short to
register a CD spectrum. Since the kcat value of the wild-type for
L-5HTP is 1.0+0.1 s21 (Km ¼ 0.05+0.01 mM), we used this
substrate to perform these measurements. As reported previously
for wild-type human DDC (3), the binding of L-5HTP to the
enzyme leads to the inversionof the420 nmCDsignal, i.e. thedis-
appearance of the original positive CD band and its replacement
by a negative CD band shifted to 440 nm and the increase of the
positive 335 nm dichroic band. In contrast, when L-5HTP was
added to each of the variants examined, the CD spectrum imme-
diately registered was characterized by positive dichroic bands
at 420 and 335 nm, the latter with a magnitude unaltered with
respect to that of the corresponding holoenzyme. The only excep-
tions were relative to the R285W and R412W variants, for which
the addition of L-5HTPcaused a slightly negative dichroic band at
!420 nm and did not change the 335-nm positive dichroic band
(Fig. 7). Taken together, these data indicate that the binding of
L-5HTP to each of the variants causes changes in the orientation
of the coenzyme, with respect to the neighboring residues,
different from that of the wild-type. It is of interest to note that
this occurs in the case of mutated residues at the active site or
interacting with the active site as well as in the case of residues
located away from the active site. This suggests that the effect
of each of these mutations is possibly communicated throughout
the protein by disruption of functionally crucial network of amino
acid interactions.
Therapeutic implications
The current clinical management of AADC deficiency is aimed
at potentiating monoaminergic transmission, and usually
includes the administration of: (i) L-Dopa and pyridoxine to
increase the DDC activity; (ii) MAO inhibitors to slow down
the dopamine degradation; and (iii) dopamine agonists to mimic
the dopamine effect (29,30). Because of the scarcity of informa-
tion about the molecular defects associated to each pathogenic
mutation causing the AADC deficiency, the aforementioned
drugs are almost always administered in combination, and in the
Figure 6. Distribution of the c/F dihedral angles values along the molecular
dynamic trajectories. Dihedrals angle distributions for residues Ile101 (A) and
Phe103 (B) in the wild-type form (black squares), the A110Q mutant (green
squares) and theL38Pmutant (red squares).The corresponding3Dgraphic repre-
sentations are squared in black for the wild-type, in green for the A110Qmutant
and in red for the L38P mutant.
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absence of specific treatment guidelines. The presented results
correlate each patient genotype with a specific enzymatic pheno-
type and allow us to group the DDCmutations on the basis of the
possible responsiveness to the available pharmacological therap-
ies. All mutants display at least one of the following functional
defects: (i) highKD(PLP), (ii) highKm and (iii) low kcat. In particu-
lar, among the variantswith amodest reduction of kcat (≤10-fold)
the P47H, T69M, G102S, G123R, S250F, L408I and R412W
mutations only cause a decrease of the substrate binding affinity,
while the F309L andR285Wmutations induce an increase inboth
the KD(PLP) and the Km values. The patients carrying the former
group of mutations could be responsive to therapy with L-Dopa,
whereas the patients harboring the second group of mutations
could be responsive to the combined administration of pyridoxine
and L-Dopa.Anyway,MAOinhibitors couldbe auseful treatment
for patients bearing each of these eightmutations. It could be also
envisaged, on the basis of our data on the expression level in E.
coli, that pyridoxine administration to patients with R285W and
R412W mutations could result in a chaperoning effect, as
already demonstrated for S250F (23).
The mutations L38P, P47H, H70T, H72Y, Y79C, P81L,
A110Q, R347Q, R447H andR462P cause a consistent reduction
of the kcat value (from15 to"3600-fold)with respect to thewild-
typeDDC. Therefore, although some of them have a remarkable
impact on theKD(PLP) and/or theKmvalues, the administration of
L-Dopa and pyridoxine to patients carrying these mutationsmay
be useless. On the other hand, the administration of dopamine
agonists and/or MAO inhibitors could be the most reasonable
therapy, except for the patients carrying the mutations L38P
andA110Q that cause an extreme reduction of theDDCcatalytic
activity (500- and 3600-fold). For these patients the only suitable
therapeutic management appears to be the administration of
dopamine agonists since MAO inhibitors may be ineffective.
Unfortunately, considering the limited number of patients with
AADC deficiency and the low frequency of each pathogenic
mutation, the available data concerning clinical symptoms,
disease course and family history are, at present, not sufficient
to propose a correlation between the mutational impact on
DDC functionality and the clinical severity of the disease, i.e.
an enzymatic-clinical phenotype relationship.
CONCLUSIONS
To explore themolecular basis of the pathogenesis ofAADCde-
ficiency we studied the structural and functional effects caused
by all themutations linked toAADCdeficiency applying an inte-
grated strategy which uses bioinformatic, spectroscopic and
kinetic analyses. To our knowledge, thesemeasurements consti-
tute the first comprehensive functional view of AADC defi-
ciency mutants. The first point deriving from our study is that
all variants either concerning residues located at/near the
active site or far from the active site are characterized by a
reduced catalytic activity, even if at a different degree, and a dif-
ferent microenvironment of the external aldimines with respect
to thewild-type.Moreover, for all but one (R347Q)we observed
a perturbation of the topography of the active site. The second
finding is that the majority of the variants show, to varying
extents, an alteration of the tertiary structure of the holoDDC lin-
early related to an enhanced exposure of hydrophobic sites, to an
impairment of the proper apo-holo transition, known to be a con-
version froman open to a closed active conformation (12), and to
a decrease of the decarboxylase activity. This structure–
function relationship allows us to identify the residues which
play the most relevant role in the apo-holo conversion, i.e.
His70, His72, Tyr79, Phe80 and Pro81 mapping to loop 1 as
well as Arg462 and Arg447 directly interacting with loop 1. The
data on F80A, an artificial variant, substantiate the essential role
of loop1 in this process. Following this view, it can be suggested
that residues Pro47, Thr69, Gly102, Gly123, Ser250, Arg285,
Phe309, Leu408 and Arg412 are involved, even if to a less
extent, in the achievement of the catalytic active holoform of
DDC. Thus, the hindrance of a proper apo-holo conversion
might be sufficient to induce pathogenicity. A different mechan-
ismmust be envisaged to explain the DDCmalfunction for muta-
tions that do not fit in this set of mutations. R347Q is a catalytic
mutation since, albeit no conformational alteration was observed
for this variant, it is characterized by a severe loss of decarboxyl-
ase activity. On the other hand, replacement of Ala by Gln at pos-
ition 110 or ofLeu by Pro at position 38 appears to have an impact
ondecarboxylase activitymore pronounced than that on the struc-
tural integrity of the enzyme. On the basis of the comparativeMD
study of the putative structure of wild-type, A110Q and L38P, it
can be speculated that the decrease in catalytic activity could be
due to the rearrangements occurring around the mutated residue
transmitted to the active site, in particular to Phe103 and Ile101
mapping to loop 2.
Finally, the finding that, among all the mutations, several of
them affect the expression level and solubility of DDC in the
E. coli expression system suggests folding defects of the variants
harboring these mutations. However, the elucidation of possible
folding defects (aggregation and/or cellular degradation)
requires, as already done for S250F (23), more detailed and la-
borious expression studies using mammalian cellular systems,
which more closely reflect the true situation.
In conclusion, our results for the first time indicate that a large
percentage of the variants associated with AADC deficiency
Figure 7.CD spectra of wild-type DDC and variants in the presence of L-5HTP.
CD spectra of wild-type DDC and the indicated variants at a concentration of
9 mM in 100 mMpotassiumphosphate buffer, pH7.4, in the presence of saturating
concentration of PLP, registered immediately after the addition of L-5HTP to a
final concentration of 5 mM.
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arising from point mutations shares, irrespective of their loca-
tion, conformational changes that, at various degrees, do not
allow a proper apo-holo transition and a full catalytic activity.
This suggests that mutations occurring in distinct regions of a
molecule can cause similar conformational changes with
similar biological consequences. These events could not be pre-
dicted simplybasedongene sequences.On theother hand,L38P,
A110Q and R347Q result to be mainly or only catalytic muta-
tions, for which additional kinetic features must be identified
and understood to explain the kinetic reason(s) underlying
their pathogenicity. Overall, these data allow us to acquire a
complete knowledge of the enzymatic phenotype associated
with each pathogenic mutation and to group patients with
AADC deficiency into different therapeutic categories. This
general picture of structural and/or functional effects of each
mutation linked to AADC deficiency mutations will be a help
to guide therapeutic decision and prevent inappropriate use of
treatment regiments, thus improving the clinical outcome of
this disease.
MATERIALS AND METHODS
Materials
PLP, L-Dopa, L-5HTP, 2,4,6-trinitrobenzene-1-sulfonic acid,
isopropyl-b-d-thiogalactopyranoside, protease inhibitor cock-
tail were purchased from Sigma. ANS was purchased from
Molecular Probes. All other chemicals were of the highest
purity available.
Site-directed mutagenesis
The pDDChis plasmid, expressing the wild-type human DDC
equippedwith aC-terminal hexahistidine tag, and the expression
vectors of theG102S, F309LandS250FDDCvariants havebeen
previously obtained (3,23). The expression vectors of the 16
DDC variants listed in Supplementary Material, Table S1 have
been constructed using the Quick-Change II site-directed muta-
genesis kit (Agilent Technologies) using the pDDChis plasmid
as template and the oligonucleotides reported in Supplementary
Material, Table S1. Successful mutagenesis was verified by
DNA sequencing of the entire open reading frame.
Enzyme purification and assay
Purification of his-tagged wild-type DDC and of the variants
was performed following the procedure previously described
(3). Protein concentration was determined using the eM ¼
142 000 M21 cm21 at 280 nm. The PLP content of the variants
was determined by releasing the coenzyme in 0.1 M NaOH and
by using eM ¼ 6600 M21 cm21 at 388 nm. The decarboxylase
activity toward L-Dopa of wild-type DDC and the variants in
the purified form was measured by the spectrophotometric
assay described by Sherald et al. (31), andmodified byCharteris
and John (32). Measurements were performed in the presence of
50 mmPLP in 100 mMpotassiumphosphate buffer, pH 7.4.Data
of enzymatic activity as a function of substrate concentration
were fitted to the Michaelis–Menten equation.
Apoenzyme preparation and determination of KD(PLP)
For the apoenzyme preparation, each variant was incubatedwith
10 mM hydroxylamine in 0.5 M potassium phosphate buffer, pH
6.9 at 258C for 3 h and the mixture was loaded on a desalting
26/10 column (GE Healthcare) pre-equilibrated with the
same buffer without hydroxylamine (33).
TheKD(PLP) value from the variants was determined bymeas-
uring the quenching of the intrinsic fluorescence of the apoen-
zyme (0.15 mM) in the presence of PLP at a concentration
range of 0.01–10 mM in 100 mM potassium phosphate buffer,
pH 7.4 and by fitting the data to the following equation:
where [E]t and [PLP]t represent the total concentrations of the
enzymeandPLP, respectively,Y refers to the intrinsic quenching
changes at a PLP concentration, [PLP], and Ymax refers to the
aforementioned changes when all enzyme molecules are com-
plexed with coenzyme.
Molecular modeling and conservation analysis
Starting from the available structure of pig kidney holoDDC
(pdb file 1JS6) (11) and human apoDDC (pdb file 3RBF) (12),
the inspection of the 3D structures and the prediction of the pos-
sible steric clashes, loosing of interactions and local structural
rearrangements causedby the analyzedmutations havebeenper-
formed using the Molecular Operating Environment (MOE)
software by Chemical Computing Group (34). The evolutionary
conservation score of each amino acid of DDC has been calcu-
lated using the ConSurf server (35,36). The closed homologous
sequences of DDC (150) have been collected from UNIREF90
using PSI-BLAST algorithm and the multiple sequence align-
ment was constructed using T-COFFEE.
MD simulations
TheMDsimulationswere performed using theGromacs program
(37), and the structure ofDDC enzyme carrying carbidopa inhibi-
tor [pdb file 1JS3 (11)]. Since in this homodimeric structure the
crystallographic coordinates between residues 328–339 are
missing, a loop modeling script of the Modeller 9.8 software
(38) was constructed. The mutations in the DDC enzyme were
prepared using VMD software (39). The carbidopa ligand was
parameterizedwithProdrg software (40).Proteinswere simulated
inexplicit aqueous solution inserted intoa tetrahedral boxofwater
Y = YMAX
[E]t + [PLP]t + KD(PLP) −
NameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMe
([E]t + [PLP]t + KD(PLP))2 − 4[E]t[PLP]t
√
2[E]t
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molecules, ensuring that the solvent shellwould extend for at least
1.0 nm around them. Gromos96 43a1 fields (41), in combination
with the explicit simple point charge (spc/e) force field, were used
for the simulation. Long-range electrostatic interactions were
treated with the particle mesh Ewald (PME) method using a
grid with a spacing of 0.12 nm (42). The time step was set to
2 fs. The cut-off radius for the Lennard–Jones interactions, as
well as for the real part of the PME calculations, was set to
1 nm. The LINCS algorithm was used to constrain all bond
lengths involving hydrogen atoms, and the time step used was
2 fs. The three systems were energy-minimized imposing har-
monic position restraints of 1000 kJ mol_1 nm_2 on solute
atoms, allowing the equilibration of the solventwithout distorting
the solution structure.After an energyminimization of the solvent
and the solutewithout harmonic restraints, the systemswere equi-
librated and temperaturewas gradually increased from0 to 300 K
in 2 ns of simulation. The system was finally simulated for 50 ns
for the analysis shown in this report. The RMSD/RMSF analysis
and the Ramachandran plot analysis were performed through
Gromacs tools. The 3D Ramachandran plots were obtained
using VMD analysis tools.
Spectral measurements
All the spectral measurements were carried out using 100 mM
potassium phosphate, pH 7.4, at 258C. Absorption spectra
were recorded with a Jasco V-550 spectrophotometer. CD mea-
surements were made with a Jasco J-710 spectropolarimeter at a
protein concentration of 6 mM. CD spectra were recorded at a
scan speed of 50 nm/minwith a bandwidth of 2 nmand averaged
automatically except where indicated. The ANS fluorescence
measurementswere takenwith aFP750 Jasco spectrofluorimeter
using 5 nm excitation and emission bandwidths at 1 mM protein
and 15 mM ANS concentration.
Statistical analysis
Data analysis was performed by linear and non-linear regression
curve fitting usingOriginw 7.03 (Origin Lab) and the errors indi-
cated result from fitting to the appropriate equation.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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Liver peroxisomal alanine:glyoxylate aminotransferase (AGT), a pyridoxal 5′-phosphate (PLP) enzyme, exists as
two polymorphic forms, the major (AGT-Ma) and the minor (AGT-Mi) haplotype. Deﬁcit of AGT causes Primary
Hyperoxaluria Type 1 (PH1), an autosomal recessive rare disease. Although ~one-third of the 79 disease-causing
missense mutations segregates on AGT-Mi, only few of them are well characterized. Here for the ﬁrst time the
molecular and cellular defects of G47R-Mi are reported. When expressed in Escherichia coli, the recombinant pu-
riﬁed G47R-Mi variant exhibits only a 2.5-fold reduction of its kcat, and its apo form displays a remarkably de-
creased PLP binding afﬁnity, increased dimer–monomer equilibrium dissociation constant value, susceptibility
to thermal denaturation and to N-terminal region proteolytic cleavage, and aggregation propensity. When stably
expressed in amammalian cell line, we found ~95% of the intact form of the variant in the insoluble fraction, and
proteolyzed (within the N-terminal region) and aggregated forms both in the soluble and insoluble fractions.
Moreover, the intact and nicked forms have a peroxisomal and a mitochondrial localization, respectively. Unlike
what already seen for G41R-Mi, exposure of G47R-Mi expressing cells to pyridoxine (PN) remarkably increases
the expression level and the speciﬁc activity in a dose-dependent manner, reroutes all the protein to peroxi-
somes, and rescues its functionality. Although the mechanism of the different effect of PN on the variants
G47R-Mi and G41R-Mi remains elusive, the chaperoning activity of PNmay be of value in the therapy of patients
bearing the G47R mutation.
© 2015 Published by Elsevier B.V.
1. Introduction
The human inborn error of metabolism Primary Hyperoxaluria Type
1 (PH1: OMIM 259900) is caused by a disfunction of liver peroxisomal
alanine:glyoxylate aminotransferase (AGT; EC 2.6.1.4.4), and is inherited
in an autosomal recessive fashion [1]. AGT is a pyridoxal 5′-phosphate
(PLP) enzyme, which catalyzes the conversion of alanine and glyoxylate
into pyruvate and glycine [2]. HumanAGT is present as two polymorphic
forms, the most frequent called the major allele (AGT-Ma) and a less
common polymorphic variant called the minor allele (AGT-Mi). The
minor allele shows two point mutations leading to single amino acid
substitutions (P11L and I340M) among other genomic changes [3].
Even though AGT-Mi is not pathogenic, it exhibits a 30% reduction of
transaminase activity with respect to AGT-Ma and 5% of mistargeting
to mitochondria [4,5]. The solved crystal structure of AGT reveals that
the enzyme belongs to the Fold Type I family of PLP-enzymes and is a
compact homodimer, each subunit of which contains one PLP-binding
site [6]. Each protomer folds into a large N-terminal domain (residues
22–282) and a smaller C-terminal domain (283–392). Most of the
contacts within the dimer involve the large domain. Besides them, a
long unstructured N-terminal tail (residues 1–21) grabs the subunits
within the dimer. In the latter structural element, not typical of the
family to which AGT belongs, is located Pro11 whose replacement by
Leu is an important structural element since it generates a functionally
ineffective mitochondrial targeting sequence (MTS), which represents
an anchoring point for binding to the mitochondrial import receptor
TOM20 [7,8]. Among the 79 disease-associated missense mutations
identiﬁed up to date in the human AGXT gene, 36 and 26 are on the
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background of the major and the minor allele, respectively, while only 5
are on the background of either themajor or theminor allele [9]. For the
remaining mutations the allele in which are present has not yet been
identiﬁed. Expression analyses in E. coli, yeast and/or mammalian cellu-
lar systems of ~60 PH1-related variants have allowed to establish differ-
ences in their kinetic behavior and/or coenzyme binding mode and
afﬁnity, degradation and/or aggregation propensity, expression level,
thermodynamic and/or kinetic stability and subcellular localization [2,
5,10–25]. Among the variants on the background of the minor allele,
only G170R, F152I, G161S, G161C, G41R and I244T have been in depth
characterized [13–16,18,22]. The subcellular localization of these vari-
ants is different. G170R, F152I and I244T mutations cause a partial or
completemistargeting intomitochondria in patients and/or mammalian
cells [13], Gly161 variants give rise to aggregates in the cytosol
of Chinese hamster ovary (CHO) cells [18], G41R leads to a partial
mistargeting and intraperoxisomal aggregates [13]. Moreover, multiple
mechanisms of action of pyridoxine (PN) on these variants have been
observed [18,26]. In order to have a wider picture of the defects generat-
ed by mutations on the background of the minor allele, we decided to
focus our attention on the pathogenic variant G47R-Mi. Biochemical
and cellular biology experiments allowed us to establish that several
defects, similar to those of G41R [15], characterize the variant G47R-Mi.
In particular, the mutation generates a misfolded apoprotein with a
low PLP binding afﬁnity, an increased dimer–monomer equilibrium
dissociation constant value, prone to aggregation inside peroxisomes
and to proteolytic degradation inside mitochondria. However, unlike
what already observed for G41R-Mi [26], PN is found to rescue the
functionality of the variant by partially preventing aggregation and
degradation, and by redirecting all the protein to the peroxisome.
2. Materials and methods
2.1. Materials
PLP, L-alanine, sodium glyoxylate, rabbit muscle L-lactic dehydroge-
nase, PN, betaine, 4-phenylbutyric acid (4-PBA), tauroursodeoxycholic
acid (TUDCA), phenylmethylsulfonyl ﬂuoride (PMSF), dithiothreitol
(DTT), and glycolate were purchased from Sigma. Aniline-1-
naphthalenesulphonic acid (ANS) was purchased from Molecular
Probes. Ham's F12 Glutamax medium, zeocin, geneticin and Alexa
Fluor antibodies were purchased from Life-technologies. All other
chemicals were of the highest purity available. Chinese hamster ovary
(CHO)-glycolate oxidase (GO) cells, CHO-GO cells expressing AGT-Mi
(CHO-GO-AGT-Mi), the rabbit polyclonal antihuman AGT, the rabbit
polyclonal anti-AGTLeu11 and the guinea-pig anti-peroxisomal protein
antibodies were kindly provided by Prof. C.J. Danpure of the University
College London (UK). The anti-rabbit HRP antibodywas purchased from
GE Healthcare. Oligonucleotides for site directed mutagenesis were
purchased from MWG Biotech AG (Anzinger, Germany).
2.2. Site directed mutagenesis
Site-directedmutagenesis was performed by the QuikChange II site-
directed mutagenesis kit (Stratagene) using pAGThis-Mi [16] and
pcDNA3.1AGT-Mi [18], as templates. On each vector, the pathogenic
G47R mutation was introduced by using the primer 5′-GCTGCAGATG
ATCCGGTCCATGAGCAAGG-3′ and its complement (the mutated codon
is underlined). The mutation was conﬁrmed by entire DNA sequence
analysis.
2.3. Enzyme expression and puriﬁcation
AGT-Mi and G47R-Mi in their His-tagged form were expressed and
puriﬁed as already described [2]. The apo forms of both variants were
prepared as previously reported [2]. The protein concentration in
the AGT samples was determined by absorbance spectroscopy using
an extinction coefﬁcient of 9.4 × 104 M−1 cm−1 at 280 nm.
2.4. Spectroscopic measurements
Absorption measurements were made with a Jasco V-550 spectro-
photometer with 1 cm path length quartz cuvettes at a protein concen-
tration of 1–10 μM. Circular dichroism (CD) spectra were made with a
Jasco-J710 spectropolarimeter by using 0.1 or 1 cmpath-length cuvettes
for the near UV and far UV measurements, respectively, at 1–5 μM
enzyme concentration.
ANS ﬂuorescence measurements were taken with a FP750 Jasco
spectroﬂuorimeter using 5 nm excitation and emission bandwidths at
1 μM protein and 15 μM ANS concentration. All the absorbance, CD
and ﬂuorescence measurements were performed at 25 °C in 100 mM
potassium phosphate (KP) buffer, pH 7.4. Dynamic light scattering
(DLS) measurements were performed on a Zetasizer Nano S device
(Malvern Instruments) equipped with a Peltier temperature controller
by using disposable 12.5 × 45-mm cells with stopper. The aggregation
kinetics were studied by incubating the enzymes in KP buffer, pH
7.4 at different ionic strengths at 37 °C. The buffer was ﬁltered immedi-
ately before use to eliminate any impurities.
2.5. Binding afﬁnity for PLP
The equilibrium dissociation constant for PLP (KD(PLP)) of G47R-Mi
was determined by CD spectrophotometric titration at 420 nm of the
apo form (5 μM) in the presence of PLP at concentrations ranging
from 1 to 100 μM. The experimentwas carried out in 100mMKP buffer,
pH 7.4. The KD(PLP) value was obtained using the following equation:
Y ¼ YMAX
E½ #t þ PLP½ #t þ KD PLPð Þ−
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
E½ #t þ PLP½ #t þ KD PLPð Þ
" #2−4 E½ #t PLP½ #tq
2 E½ #t
where [E]t and [PLP]t represent the total concentrations of the G47R-Mi
and PLP, respectively, Y refers to the 420 nmdichroic signal changes at a
PLP concentration [PLP]t, and Ymax refers to the maximum intensity of
the 420 nm dichroic signal when all enzyme molecules are complexed
with coenzyme.
2.6. Thermostability
The thermostability studies on puriﬁed G47R-Mi in the holo- (in the
presence of saturating PLP) or the apo-form were performed at 10 μM
enzyme concentration in 100 mM KP buffer, pH 7.4, by monitoring the
CD signal at 222 nm from 25 to 90 °C at a heating rate of 1.5 °C/min
[17]. Calculation of the melting temperatures (Tm) was carried out by
ﬁtting the data using the Origin Pro7 software according to the method
of Pace [27].
2.7. Limited proteolysis
Holo and apoG47R-Mi at 10 μM enzyme concentration were treated
with proteinase K at a protease/enzyme ratio of 1/10 (w/w) in 100mM
KPbuffer, pH 7.4, at 25 °C. At various times, 15 μl-aliquotswere removed
for electrophoresis or western-blot analysis. The protease reaction was
stopped by the addition of 2 mM PMSF. After staining with Coomassie
blue the band intensities were visualized and analyzed using the ImageJ
software (Rasband, WS).
2.8. Cell culture and selection
CHO-GO cells were cultured at 37 °C under O2/CO2 (19:1) in
Ham's F12 Glutamax medium, containing 0.3 μM PN hydrochloride
(Invitrogen), supplemented with fetal bovine serum (10% v/v),
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penicillin (100units/ml), streptomycin (100 μg/ml) and zeocin (0.4mg/
ml). Cells were transfected with the pcDNA3.1G47R-Mi construct by
using the Turbofect™ Transfection Reagent (Thermo-Fisher) according
to manufacturer instructions. After 24 h, G-418 (1.25 mg/ml) was
added as selective agent and cellswere left to grow for 48 h. To generate
a monoclonal stably transformed cell line (CHO-GO-G47R-Mi), the
antibiotic-resistant cells were seeded at limiting dilution of 10 cells/ml
in 96-well plates in selective medium and incubated until single
colonies started growing. Clones (at least 12) were then grown and
screened for exogenous gene expression by western-blot and immuno-
ﬂuorescence analysis.
Where indicated, CHO-GO-G47R-Mi cells were treated with PN
(0.3, 1, 3, 10, 30, 100 and 300 μM), betaine (15 mM), β-alanine
(5 mM), 4-PBA (1 mM) and TUDCA (0.5 mM) for three days. Prelimi-
nary experiments demonstrated that three days is a time sufﬁcient to
allow that all the protein is synthesized in the presence of the selected
compound.
2.9. Cell lysis and western-blot analyses
Cells were harvested after 24 h and lysed in phosphate saline buffer
(PBS), pH 7.2, plus protease inhibitor cocktail (Complete Mini, Roche),
by ﬁve freeze/thaw cycles followed by addition of DNAse (100 units/ml)
at room temperature for 45 min. The whole cell extract was separated
by centrifugation (29,200 g, 10 min, 4 °C) to obtain the soluble fraction.
Pelletswere then resuspended in an equal volume of denaturing gel load-
ing buffer to obtain the insoluble fraction. The protein concentration in
the soluble fraction was measured using the Bradford protein assay, as
previously described [18].
Two micrograms of AGT-Mi cell lysate and 10 μg of G47R-Mi cell
lysate were loaded per lane on a Mini Protean TGXTM pre-cast gel
(10%, Biorad) along with the Precision plus protein KaleidoscopeTM
(Bio-Rad) molecular mass markers. Following transfer on a nitrocellu-
lose membrane by the iBlot device (Invitrogen) the membrane was
blocked with 5% milk in TBST (50 mM Tris–HCl pH 7.5, 150 mM NaCl,
0.1% Tween 20) for 1 h at 37 °C. For AGT detection the membrane was
incubated with polyclonal rabbit anti-AGT serum (dilution 1:6000) or
with polyclonal rabbit anti-AGT Leu11 serum (1:2000), washed three
times in TBST and then incubated with peroxidase-conjugated anti
rabbit IgG (dilution 1:1000). Blotted proteins were detected with
ECL® (Millipore), using the ChemiDoc XRS Imaging System (Bio-Rad,
Hercules, CA). For densitometry analysis of western-blots, the band
volume (intensity ×mm2) was quantiﬁed using the software Quantity
One 4.6.3. Resultswere expressed relative to the densitometry of AGT-Mi.
2.10. Enzymatic assays
90 μg of cell lysate were incubated with 0.5 M L-alanine and 10 mM
glyoxylate at 25 °C in 100mMKP buffer, pH 7.4 in the presence or in the
absence of 200 μMPLP. In order to obtain a detectable signal of pyruvate
in the linear phase of the kinetics, the reaction timewas set to 20min for
cells expressing AGT-Mi, and to 120 min for cells expressing G47R-Mi.
The kinetic parameters for the overall transamination of the pair L-
alanine/glyoxylate of G47R-Miwere determined by incubating the puri-
ﬁed protein (0.1 μM) in the presence of 200 μMPLP in 100mMKPbuffer
at 25 °C and by varying the substrate concentration at a ﬁxed
cosubstrate concentration. Data were ﬁtted to the Michaelis–Menten
equation. For the activity assay on both the puriﬁed protein and the
cell lysate the reactions were stopped by adding TCA 10% (v/v) and py-
ruvate production was measured using a spectrophotometric assay
coupled with lactate dehydrogenase as previously described [2].
2.11. Glycolate toxicity assay
CHO-GO cells expressing AGT-Mi and G47R-Mi were grown for
three days in the absence or in the presence of 3 μMPN. After treatment
cells were seeded at 8000 cells/well in a 96-well plate and incubated
24 h before inducing glyoxylate production by adding Hepes buffered
glycolate pH 7.0 at a ﬁnal concentration of 500 μM. Cell viability was
evaluated after further 24 h incubation using the crystal violet staining
(Sigma Aldrich) as previously described [19]. Eight replicates were per-
formed for each assay condition. Statistical analysis was done with
GraphPad Prism Version 5.0 (GraphPad software, San Diego, CA, USA).
2.12. Size exclusion chromatography (SEC)
SEC analyses were performed on an Akta FPLC system (GE
Healthcare) using the Unicorn 5.01 (GE Healthcare) software and a
Sephacryl S-300 10/600 column at 25 °C. The injection volume was
100 μl with detection at 280 nm, and the ﬂow rate was 0.4 ml/min. To
determine the dimer–monomer equilibrium dissociation constant,
Kdim–mon, the AGT-Mi or G47R-Mi either in the apo or holo forms was
incubated at different enzyme concentrations (from 3 to 12 μM) in
100 mM KP buffer, pH 7.4, for 1 h at 25 °C (a sufﬁcient time to reach
the equilibrium between monomer and dimer), and then subjected to
SEC. The elution volume and the peak areas were measured using the
software Unicorn 5.01 (Amersham Biosciences). The rapid equilibrium
dissociation process observed for the G47R-Mi variant in the apo
form was analyzed according to the method of Manning et al. [28]. If
the maximum amount of AGT dimer is [E] and the concentrations of
monomeric and dimeric species are [M] and [D], respectively, so that
%D = 100 [D] / [E], it follows that
Kdim−mon ¼ M½ #2= D½ # ¼ 4 E½ #− D½ #ð Þ2= D½ # ¼ 100−%Dð Þ2 E½ #= 25%Dð Þ
h i
¼ 0:04 100−%Dð Þ E½ #=%D
hence,
Log Kdim−monð Þ ¼ log E½ #− log %D= 0:04 100−%Dð Þ2
! "! "
:
Thus, a plot of log[%D / (0.04(100 − %D)2)] to log[E] results
in a straight line of slope 1. When (%D / (0.04(100− %D)2) = 1, Kdim–
mon = [E].
SEC analyses of lysates of CHO-GO cellswere performed according to
the method of Siekierska A. et al. [29]. Four 10 cm diameter dishes of
conﬂuent CHO-GO-G47R-Mi cells were grown in the absence or in the
presence of PN (3 μM), harvested and lysed in 500 μl of PBS as previous-
ly described. Total lysateswere then loaded into a Superdex 200 H10/30
column (GE Healthcare), equilibrated in PBS plus 1 mM EDTA, 1 mM
EGTA and 1 mM DTT, using an AKTA FPLC system (Amersham Biosci-
ences). The absorbance signal of the eluate at 280 nm, representing
the total protein content, was registered. TCA 20% (v/v) was added to
each eluted fraction and the samples were incubated overnight at
4 °C. After centrifugation at 16,000 g for 30min, the precipitated protein
was washed twice in PBS and resuspended in 40 μl of denaturing gel
loading buffer. 15 μl of each sample were separated by SDS-PAGE and
immunoblotted against anti-AGT or anti-Leu11 as previously described
[18].
2.13. Immunoﬂuorescence microscopy (IFM)
CHO-GO cells expressing AGT-Mi and G47R-Mi were grown for
three days in the absence or in the presence of 3 μM PN. Approximately
3 × 105 cells were seeded into each well of a 24-well plate, containing a
13-mm glass coverslip, and grown for 24 h in complete Ham's F12 me-
dium at 37 °C under O2/CO2 (19:1). Mitochondria were vitally stained
prior to ﬁxation by incubating the cells for 30 min with MitoTracker
(Red CMXRos version;Molecular Probes, Life technologies) in complete
Ham's F12 medium following the manufacturer's instructions. Cells
were ﬁxed in 4% (w/v) paraformaldehyde permeabilized with 0.3%
Triton X-100 in PBS and then blocked in 3% bovine serum albumin
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(BSA) in PBS. For the immunolabeling, rabbit polyclonal anti-human
AGT rabbit polyclonal anti-human Leu11, and anti-peroxisomal protein
from guinea-pig were used as primary antibodies, and Alexa Fluor
conjugated antibodies (AF488 and AF555, Life technologies) were used
as secondary antibodies. Nucleiwere stainedwithDAPI and the coverslips
were mounted over slides in AF1medium (Dako). Images were captured
using a confocal laser-scanning ﬂuorescence microscope Leica SP5 (Leica
Microsystem, Manheim, Germany) at 63× magniﬁcation. For ﬁgure
preparation images were processed using Adobe Photoshop.
3. Results
3.1. Impact of the G47R mutation on the speciﬁc activity and the expression
level of AGT-Mi in E. coli and in CHO cells stably expressing GO
As aﬁrst assessment of structural and/or functional consequence(s) of
the G47Rmutation segregating on the minor allele of AGT, we expressed
the variant in E. coli and in CHO-GO cells [30]. The catalytic activity,
expressed as speciﬁc activity, and the expression level in the soluble
crude cellular extracts of cells expressing G47R-Mi were measured and
compared with the corresponding ones of cells expressing AGT-Mi. In
E. coli the speciﬁc activity and the immunoreactivity of the G47R-Mi
variant were both about 30% of the corresponding ones of AGT-Mi. On
the other hand, in CHO-GO cells the speciﬁc activity was not measurable
since no transaminase activity could be detected and the intensity of the
speciﬁc band of immunoreactive AGT was about 0.6% that of AGT-Mi.
Furthermore, when we compared the soluble and insoluble fractions of
lysates of CHO-GO cells expressing AGT-Mi and G47R-Mi by means of
western-blot, we observed that, while about 80% of AGT-Mi was present
in the soluble fraction, more than 95% of G47R-Mi in its intact form was
present in the insoluble fraction. Moreover, a proteolyzed form of G47R-
Mi was found in deﬁnitely higher amount with respect to the intact one
in the soluble fraction. In contrast, the undigested form highly prevailed
in the insoluble fraction. Nonetheless, aggregated forms of the variant
were detected in either the soluble and the insoluble fractions (Fig. 1).
All together, these data provide a ﬁrst evidence that the loss of catalytic
activity and the reduction of the expression level, possibly due to proteo-
lytic degradation and formation of aggregates, underlie the pathogenicity
of G47R-Mi. Thus, we decided to explore in detail the structural and func-
tional properties of the variant by combining biochemical analyses on the
puriﬁed recombinant protein with expression studies in mammalian
cells, and to compare them with the corresponding ones of AGT-Mi.
3.2. Impact of the G47R mutation on the spectroscopic and kinetic features
of AGT-Mi
The equilibrium dissociation constant value for PLP, KD(PLP), of the
G47R-Mi variant was equal to 10 μM, i.e. 38-fold higher than that of
AGT-Mi (Table 1). The visible CD spectrumof the variant in the presence
of a saturating PLP concentration showed a positive dichroic band at
420 nm whose magnitude was slightly lower than that of AGT-Mi.
Furthermore, the substitution of Gly by Arg at position 47 mainly alters
the tertiary structure of the apo form, as indicated by a consistent
change in the magnitude of the dichroic bands in the near-UV region
with respect to those of AGT-Mi (Fig. 2A). This is consistent with the
ﬁnding that the apo form of the variant showed a ~1.5-fold reduction
of the intrinsic ﬂuorescence emission intensity and amaximum intensi-
ty 2 nm red-shifted with respect to apo AGT-Mi (Fig. 2B). On the other
hand, as compared with AGT-Mi, both the holo and the apo forms of
the variant exhibited a ~5-fold increase in ANS ﬂuorescence emission
intensity as well as 6-nm blue shift of the emission maximum (inset
of Fig. 2B). Taken together, these data reveal that, although the G47R
mutation causes a similar increase in the surface hydrophobicity of
both the holo and the apo forms of the variant, it generates an altered
asymmetry of certain aromatic amino acid residues, most probably
those associated with the active site, more pronounced for the apo
than for the holo. However, the mutation does not affect the overall
secondary structure of the enzyme since the CD spectra in the range
190–240 nm of the mutant and AGT-Mi enzymes appear to be almost
indistinguishable (data not shown).
To understand if the structural changes caused by the G47R
mutation have consequences on the catalysis of AGT, the steady-state
kinetic parameters for the pair alanine–glyoxylate for AGT-Mi and
G47R-Mi were compared (Table 1). The kcat/Km value of the variant is
reduced only about 5-fold as comparedwith that of AGT-Mi. This reduc-
tion is due to approximately equalmagnitude changes in the kcat andKm
values. Considering that the kcat value of the variant is ~2.5-fold lower
than that of AGT-Mi, it can be established that the not measurable
speciﬁc activity of the G47R-Mi variant in CHO-GO cells is mainly due
to a low expression level of the intact protein.
3.3. Impact of the G47R mutation on the dimer–monomer dissociation,
thermal stability and propensity to aggregation and degradation of AGT-Mi
The conformational changes induced by the replacement of Gly47 by
arginine lead to further consequences on the dimeric structure of the
enzyme. Theﬁrst concerns theKdim–mon value of the enzyme. SEC exper-
iments performed on holo and apo AGT-Mi from 5 to 0.1 μM enzyme
concentrations (the latter value being the detection limit) previously
demonstrated that the enzyme eluted as a single peak with a retention
volume corresponding to a dimer [15]. Since an identical behavior was
observed for the variant G47R-Mi in the holo form, we can claim that
the Kdim–mon value of these species is≪0.1 μM. Therefore, the possible
effect of the mutation G47R-Mi on the Kdim–mon of the holoenzyme is
not measurable. On the other hand, we observed that the apo form of
the variant under study eluted as a single peak whose position shifts
from that of the dimeric to that of the monomeric form as the enzyme
concentration decreased from 1 to 0.17 μM. This indicates a rapid equi-
libriumprocess. A plot of the percent dimer as a function of apoG47R-Mi
concentration gives a hyperbolic curve, whose linear transformation
yields a Kdim–mon value of 0.73 ± 0.3 μM (Supplementary Fig. 1).
These data clearly indicate that the G47R mutation causes an at least
~7-fold increase of the Kdim–mon value of apoAGT-Mi.
A second aspect taken in consideration is the effect of the mutation
G47R on the thermal stability of AGT-Mi. Thermal protein denaturation
was studied bymonitoring thedecrease of the dichroic signal at 222 nm,
indicative of the loss of the protein secondary structure. Like holoAGT-
Mi, the holo form of G47R-Mi displayed a single thermal transition,
but the transition from the native to the unfolded state occurred at a
Fig. 1. Analyses of the AGT expression in CHO-GO cells expressing AGT-Mi and G47R-Mi
variant. The soluble and insoluble fractions of CHO-GO (10 μg), CHO-GO-AGT-Mi (2 μg)
and CHO-GO-G47R-Mi (10 μg) cellular lysates were subjected to SDS-PAGE and
immunoblotted with anti-AGT (1:6000). Immunoblot lanes are coded as follows:
(1) CHO-GO-AGT-Mi, (2) CHO-GO-G47R-Mi and (3) CHO-GO.
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temperature 12 °C lower than that of holoAGT-Mi. On the other hand, un-
like apoAGT-Mi showing two unfolding phases with mid-denaturations
at 53 °C and 66 °C [17], apoG47R-Mi exhibited a single thermal denatur-
ation transitionwith amid-point at about 48 °C (Table 1). Thus, the G47R
mutation leads to a reduction in the thermal stability of both the holo and
the apo forms of AGT-Mi.
Then, we decided to establish if other effects, like protein degrada-
tion and/or aggregation, could be induced by the mutation on both
the apo and holo forms of the variant G47R-Mi.
Limited proteolysis is used for probing protein conformation. It can
provide important information on local unfolding and the equilibrium
between the native state of an oligomeric protein and its folding inter-
mediates, since misfolded proteins are more susceptible to degradation
by proteases [31]. Therefore, the variant G47R-Mi was probed with
proteinase K, because its proteolysis is not limited to sequence speciﬁcity
but is also linked to stereochemistry and ﬂexibility of the protein sub-
strate. Unlike AGT-Mi [15], when the holo or the apo forms of G47R-Mi
were subjected to limited proteolysis by proteinase K under experimen-
tal conditions identical to those of AGT-Mi (protease:substrate ratio =
1:500 at 25 °C), the gradual disappearance of the 37 kDa band (corre-
sponding to the undigested enzyme) and the concomitant appearance
of a 35 kDa band (corresponding to the major proteolytic fragment)
could be seen. The proteolytic cleavage proceeded for the apo at a rate
higher than for the holo form of the variant. In particular, apo and holo
showed a half-life of 12 min and higher than 60 min, respectively, with
residual protein amounts of 10 and 60% after 60 min of reaction
(Fig. 3A). Moreover, the ﬁnding that only the 37 kDa band of the apo
variant stained with an antibody raised against AGTLeu11, as revealed
by western blot analysis, indicates that the cleavage occurs within the
N-terminal region (Fig. 3B). This is consistent with the ﬁnding that
when the soluble fraction of CHO-GO cells stably expressing AGT-Ma,
AGT-Mi or G47R-Mi was incubated with antibody against AGTLeu11 an
immunoreactive band appeared only for AGT-Mi (Fig. 3C). Thus,
Table 1
Kinetic parameters, KD(PLP) and Tm values of AGT-Mi and G47R-Mi.
Enzyme KD(PLP) (μM) Km(L-Ala) (mM) kcat (s-1) kcat/Km (M-1s-1) Tm holo (°C) Tm apo (°C)
AGT-Mi 0.26 ± 0.02a 28 ± 2a 37 ± 5a 1.32 ± 0.2a 73.6 ± 0.3b 53.1 ± 0.3b
66.0 ± 0.3b
G47R-Mi 10.1 ± 0.7 61 ± 3 14 ± 1 0.23 ± 0.02 61.4 ± 0.1 48.6 ± 0.1
a Ref. [16].
b Ref. [17].
Fig. 2. Comparative spectroscopic analysis of AGT-Mi andG47R-Mi. (A) Dichroic spectra of
apo AGT-Mi (\\\\), holo AGT-Mi (- - -), apo G47R-Mi (∙∙∙∙∙) and holo G47R-Mi (∙-∙-∙) at 5 μM
enzyme concentration; (B) intrinsic ﬂuorescence emission spectra of apo AGT-Mi and apo
G47R-Mi at 1 μMenzyme concentration; inset of panel B: ANSﬂuorescence emission spec-
tra of AGT-Mi and G47R-Mi in both apo and holo forms at 1 μM enzyme concentration
after the incubation with 15 μM ANS. Symbols are the same in each panel. All the spectra
were registered in 100 mM KP buffer, pH 7.4.
Fig. 3. Proteolytic cleavage of the G47R-Mi variant. (A) Kinetics of proteolysis of apo and
holo G47R-Mi 10 μM incubated at 25 °C in 100 mM KP buffer, pH 7.4, at a 500:1 (w/w)
mutant:proteinase K ratio. At times indicated, aliquots were removed, treated with
2 mM PMSF and subjected to 12% SDS-PAGE. The band intensities were analyzed using
the ImageJ software (Rasband,WS) and the rate of proteolysiswas determined by plotting
the percentage of native apo (■) and holo (●) enzyme vs time and ﬁtting to a ﬁrst-order
equation (B) SDS-PAGE (1) and western blot (2) analysis of the native (0′) and digested
(60′) apoG47R-Mi with proteinase K. (C) The soluble fraction of CHO-GO-AGT-Ma
(2 μg), CHO-GO-AGT-Mi (2 μg) and CHO-GO-G47R-Mi (10 μg) cellular lysates was subjected
to SDS-PAGE and immunoblotted with anti-AGTLeu11 (1:6000). Immunoblot lanes are
coded as follows: (1) CHO-GO-AGT-Mi, (2) CHO-GO-AGT-Ma and (3) CHO-GO-G47R-Mi.
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increased susceptibility to proteases occurswithin the N-terminal region
as a consequence of structural changes due to mutation G47R. It could
have been of interest to measure the extent of the susceptibility of the
variant to proteasomal degradation in CHO-GO cells. Unfortunately, con-
sidering the low amount of the immunoreactive band corresponding to
the intact protein, it was not possible tomeasure the half-life of the path-
ogenic variant.
As mentioned above, about 95% of the variant G47R-Mi stably
expressed in CHO-GO cells is present in the insoluble fraction. This ob-
servation strongly suggests the propensity of the variant to aggregation.
Indeed, when the crude extract of CHO-GO cells stably expressing the
G47R-Mi variant was fractionated by SEC, the immunoreactive protein
was detected both in fractions with an elution volume corresponding
to proteic species with apparent molecular weight ranging from ~350
to more than 1000 kDa, and in fractions with an elution volume corre-
sponding to that of the active dimeric form of AGT. While the intact
form was more populated in the aggregated fraction, the contrary was
true in the second peak, which indeed mainly contained the nicked
form. Thus, the aggregates are primarily formed by the intact form of
the variant (Fig. 4).
To further examine the self-association process, DLS experiments of
the recombinant puriﬁed variant both in the holo and apo forms were
performed under physiological conditions (37°C, 150 mM ionic
strength, pH 7.4) and the results were compared with those of AGT-
Mi. As already known [15], the count rate as a function of time increases
in a slowmanner for apo and holo AGT-Mi, and their dimer signal is al-
ways present over the incubation time examined, even if small aggre-
gates appear at about 10 min. Since in DLS experiments the effective
weight of the oligomers on the photon correlation signal is modest
due to the 1/d6 scaling of scattered light intensity, we concluded that
the dimer is the species most relevant in solution. On the contrary, fol-
lowing the incubation of the holo or apo forms of G47R-Mi under the
same experimental conditions, the total count rate plotted as a function
of time shows typical aggregation curves more fast for the apo than for
the holo form, and leveling off after about 50 and 100 min for apo and
holo, respectively (Fig. 5A). Moreover, the time dependence of the
apparent particle size of both the holo and apo forms of the variant
indicates (i) the disappearance of the dimeric species of the holo and
apo variant at about 84 min and 20 min, respectively, (ii) the presence
of two populations, a dimeric form with a hydrodynamic diameter of
10 nm, and high order oligomers of both apo and holo forms with a
hydrodynamic diameter of 200–600 nm appearing after about 40 min,
and (iii) the appearance of an additional and distinct population of
higher order oligomers of apovariant (~5000 nm) at about 25 min
(Fig. 5B and C). This aggregation phenomenon was also analyzed
under different ionic strengths (from 0.15 to 1.5 mM) or enzyme con-
centrations (from 1 to 20 μM). The results indicate that the aggregation
extent increases as the ionic strength decreases and as the protein con-
centration increases, thus suggesting the involvement of dimer–dimer
electrostatic interactions in the formation of aggregates of the variant
Fig. 4. Gel ﬁltration analyses of CHO-GO cells expressing the G47R-Mi variant. CHO-GO-
G47R-Mi cells grown in the absence or in the presence of 3 μM PN were harvested, lysed
and the total lysate was loaded on a Superdex 200 H10/30 SEC column run in PBS contain-
ing 1 mM EDTA, 1 mM EGTA and 1 mM DTT. The picture shows the elution proﬁle of the
total lysate of CHO-GO-G47R-Mi grown in the absence (solid line) or in the presence
(dashed line) of PN. Insets show the western blot analyses of the selected SEC fractions.
Fig. 5. Time dependent aggregation of G47R-Mi variant. (A) The total count rate
(measured as kilo counts per second) of apoG47R-Mi (solid line) and holoG47R-Mi
(dotted line) variants is plotted as a function of time. The diameter of the species present
in solution is reported as function of time for (B) holoG47R-Mi and (C) apoG47R-Mi. Color
code: black, dimer; light gray, aggregates; dark gray, high-molecular weight aggregates.
All measurements have been performed at 1 μM enzyme concentration, 37 °C, in 60 mM
KP buffer, pH 7.4.
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G47R-Mi. Taken together, all these data provide evidence that the
mutation causes an altered folding equilibrium shifted towards folding
intermediates and destabilization due to local protein unfolding leading
to protein degradation and aggregation. These effects appear in the re-
combinant puriﬁed variant more pronounced for the apo than for the
holo one. Considering that the apo variant displays a ~38-fold increase
in KD(PLP) value aswell as an increase of the Kdim–mon value with respect
to AGT-Mi, it can be inferred that the apo form of the G47R-Mi variant
could be the form mainly present in CHO-GO cells where it undergoes
dimer–monomer dissociation, aggregation and/or degradation.
3.4. Impact of the G47R mutation on the subcellular localization of AGT-Mi
As shown in Fig. 6A, IFM experiments indicated that the variant
G47R-Mi exhibits a double subcellular localization: peroxisomal and
mitochondrial. To investigate the subcellular localization of the
intact and the nicked form of G47R-Mi we stained CHO-GO-AGT-Ma,
CHO-GO-AGT-Mi and CHO-GO-G47R-Mi cells with an anti-AGTLeu11,
an antibody that speciﬁcally recognized Leu11. As expected, while no
immunoreactive AGT signal is visible in cells expressing AGT-Ma, a
signal that co-localized with peroxisomes is visible in cells expressing
AGT-Mi (Supplementary Fig. 2). Interestingly, in cells expressing
G47R-Mi the stainingwith anti-AGTLeu11gives a signal that completely
co-localizes with that of peroxisomes, but does not show any co-
localization with mitochondria (Fig. 6B). These data indicate that the
intact species of G47R-Mi is exclusively peroxisomalwhereas thenicked
one, or at least the majority of it, is mitochondrial. On the basis of
the Kdim–mon value of the recombinant variant (higher than that of
AGT-Mi) and on the observed subcellular localization of G47R-Mi, it is
reasonable to suggest that a fraction of the monomeric apo form
(unfolded or partly unfolded) of the variant, once imported into mito-
chondria is subjected to proteolysis giving rise to species lacking the
N-terminal region, and that another fraction of the unproteolyzed
apodimer is imported into peroxisomes, where in large amounts possi-
bly undergoes self-association. However, it cannot be excluded that
events of degradation and aggregation could occur, at least in part, in
the cytosol.
3.5. Effects of PN on the speciﬁc activity, the expression level, the susceptibility
to protease, the propensity to aggregation and the subcellular localization of
the G47R-Mi variant
Following all the above data on the impact of the G47Rmutation,we
investigated the effect of compounds, known to act as chaperones, on
the expression level of the G47R-Mi variant in the soluble fraction of
lysates of CHO cells. No one of the tested compounds, except 4-PBA
and PN, affects the expression level of the variant. 4-PBA increases the
expression level of only about 2-fold (Supplementary Fig. 3). Thus,
considered its small effect, the compound was not further explored in
subsequent experiments. Instead, the remarkable effect of PN along
with its current use in clinical cases to treat PH1 patients [32], urged
us to investigate in detail its action. In the presence of PN (from 0.3 to
300 μM) in the culture medium the expression level of the G47R-Mi
variant in the soluble fraction raises. At 3 μM PN the improvement is
about 30-fold with respect to the untreated cells (Fig. 7A and B). Indeed
the protein level of the variant reaches ~26% that of AGT-Mi. Moreover,
at this PN concentration the amount of the immunoreactive band corre-
sponding to the proteolyzed variant appears to be remarkably reduced
in comparison with that detected in the soluble fraction of the variant
grown in the basalmedium. On the other hand, the analysis of the insol-
uble fraction of CHO-GO cells expressing G47R-Mi provides a rough ev-
idence for the different amounts of insoluble G47R-Mi in the absence or
presence of 3 μM PN. However, if the total amount of the expressed
AGT-Mi and G47R-Mi is normalized to 100%, it can be observed that
upon addition of 3 μM PN to the culture medium the relative amounts
of soluble and insoluble fractions of AGT-Mi remain unchanged, while
Fig. 6. Subcellular localization of AGT in CHO-GO cells expressing the G47R-Mi variants. Cells grown in the absence or in the presence of 3 μM PN have been ﬁxed and stained as follows:
(A) anti-AGT (green), anti-peroxisomal protein (red),MitoTracker® (red); (B) anti-AGTLeu11 (green), anti-peroxisomal protein (red),MitoTracker® (red). Nucleiwere stainedwith Dapi
(blue). Merge and single channel images come from a single z-plane. Scale bar: 10 μm.
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the amount of the insoluble fraction decreases of about 3-fold, reaching
a value about 2-fold that of AGT-Mi (Fig. 8). The dose–response for the
speciﬁc activity of the soluble fraction is similar to that observed for
the expression level, even if, as already seen [18,26], it decreases at PN
concentrations higher than 3 μM (Fig. 7C). It was previously suggested
that PN at high concentrations could exert an inhibitory action against
PLP binding to the apoenzyme, possibly due to the formation of an inac-
tive complex at the active site of the enzyme [26]. We also found that
when the lysate of cells expressing G47R-Mi in the presence of 3 μM
PN was subjected to SEC, the immunoreactive protein was found both
in fractions corresponding to aggregates and in fractions corresponding
to the dimer, as already seen in the absence of PN. However, in this case,
both fractionsmainly contain undigested protein (Fig. 4), thus suggesting
that PN limits the proteolytic cleavagewithout completely preventing its
aggregation. In order to establish if PN rescues the intracellular level of
the apo and/or holo form of the variant, wemeasured the catalytic activ-
ity of the soluble fraction of lysates of CHO-GO cells expressing G47R-Mi
in the presence of 3 μM PN. The measurements, performed in the
presence or absence of added PLP in the assay mixture, allowed us to
distinguish between the total amount of active AGT, i.e. holo plus apo,
and the active holoAGT. Although we are aware that a comparison with
our data on the variant grown in the basal medium is not possible since
the amount of the holo and apo forms is not detectable, it is of interest
to point out that when 3 μM PN was present in the culture medium,
the amount of holo and apo forms of the variant represents the 80 and
20%, respectively, of the total amount of the enzyme. A less relevant effect
was seen for AGT-Mi under the same experimental conditions, i.e. an in-
crease from 75 to 95% for the holo and a decrease from 25 to 5% for the
apo. Thus, PN mainly increases the intracellular level of the active holo
form of the variant. The impact of PN on the subcellular localization of
G47R-Miwas also investigated. IFM analyses revealed that upon addition
of PN to the culture medium of the G47R-Mi variant the protein is only
present in the peroxisomes in its intact form (as revealed by staining
with the anti-AGTLeu11 antibody). Accordingly, assays aimed atmeasur-
ing the ability of the variant to detoxify glyoxylate by using CHO-GO cells
treated with glycolate showed that PN causes a 4-fold increase in the
functionality reaching a value of relative viability of the cells equal to
about 40% that of untreated AGT-Mi (data not shown). Altogether, the
results indicate that PN acts as a chaperone on the G47R-Mi variant. In
particular, it was demonstrated that the action of PN consists in increas-
ing the proper folding, in partly rescuing the catalytic activity, and in
preventing proteolytic degradation and aggregation of the variant. More-
over, PN is able to redirect all the protein to peroxisomes, thus restoring
the ability to detoxify glyoxylate. A partial reroute to peroxisomes was
previously reported for the variants G170R-Mi and F152I-Mi upon PN
supplementation to the culture medium [26].
4. Discussion
This paper reports biochemical studies on the puriﬁed recombinant
G47R-Mi in combination with expression experiments in CHO-GO cells
aimed at identifying the consequences of the mutation G47R on the
structural and/or functional features of AGT-Mi. The role of PN in rescu-
ing the intracellular functionality of this variant was also investigated.
The variant G47R-Mi was ﬁrst expressed in E. coli, puriﬁed, and the
spectroscopic and kinetic properties analyzed. Our results show that
the mutation causes only a 5.7-fold reduction of the catalytic efﬁciency.
This result, consistent with the modest change in the visible CD spec-
trum of the variant with respect to AGT-Mi, indicates that the residue
at position 47 does not play a critical role in the catalysis and does not
provide any indication for the pathogenicity of the variant. Neverthe-
less, we noticed that the Gly47 mutation causes consistent changes
mainly to the apo form with respect to the apo form of AGT-Mi. They
consist in remarkable changes in the dichroic signals in the near-UV
region and in the intrinsic emission ﬂuorescence, a signiﬁcant increase
of the KD(PLP) and Kdim–mon values, a considerable propensity to proteol-
ysis occurring within its N-terminal region, and ameaningful propensity
to form high order aggregates resulting from dimer–dimer electrostatic
interactions. Several relevant observations could be also made by exam-
ining CHO-GO cells stably expressing G47R-Mi: (i) while AGT-Mi
remains in the supernatant, more than 95% of the variant comes down
Fig. 7. Effect of PN treatment on AGT expression level and speciﬁc activity in CHO-GO cells
expressing G47R-Mi variant. CHO-GO-G47R-Mi cells were grown at the reported PN
concentrations. After three days cells were harvested lysed and assayed for the AGT immu-
noreactivity and transaminase activity. (A) The soluble and insoluble fractions of lysate
(10 μg) of CHO-GO-G47R-Mi grown at different PN concentration were subjected to SDS-
PAGE and immunoblotted with anti-AGT (1:6000). (B) Immunoblot band quantiﬁcation
performed by the software Quantity One 4.6.3. Histogram bars are colored as follows:
white, insoluble fraction; gray, soluble fraction. (C) Histogram representative of the AGT
speciﬁc activity. In all cases 100 μg of soluble lysate were incubated with 0.5 M L-alanine,
10mMglyoxylate and 200 μMPLP at 25 °C in 100mMKP buffer, pH 7.4 for 120′. Bar graphs
represent the mean ± SEM. Data come from the mean of three different experiments.
Fig. 8. Effect of PN on the soluble/insoluble protein ratios of AGT-Mi and G47R-Mi
expressed in CHO-GO cells. Histogram bars represent the percentage of soluble (gray)
and insoluble (white) amount of AGT for the analyzed enzymatic species in the reported
conditions. Bar graphs represent the mean ± SEM. Data come from the mean of three
different experiments.
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in the pellet, (ii) the transaminase activity could not be detected in the
soluble fraction neither in the absence nor in the presence of added
PLP in the assay mixture, (iii) only a low amount of undigested variant
is detected in the soluble fraction where we also noticed the presence
of the variant proteolyzed within the N-terminal region as well as of ag-
gregates of high molecular weight, and (iv) the nicked protein was
localized into mitochondria, while the intact protein was found in the
peroxisomes, where it possibly undergoes aggregation. Taken together,
these data indicate that (i) the G47R mutation cannot be considered a
catalytic mutation, rather a folding mutation, and (ii) altered subcellular
localization, aggregation and proteolytic degradation represent critical
issues in the pathogenicity of G47R-Mi (Scheme 1). The aberrant intra-
cellular trafﬁcking is shared with other mutants on the background of
the minor allele characterized by a low kinetic stability of their apo
forms, like F152I-Mi, I244T-Mi, G170R-Mi and G41R-Mi [14–16], even
if is the ﬁrst time that a nicked form of a pathogenic variant was found
localized into mitochondria in a cellular model. It has been already sug-
gested that a distribution between mitochondria and peroxisomes
could be due to mutations of residues causing a kinetic interference
with the dimerization process of the enzyme [33]. Besides the
mistargeting, it should be noted that both variants G47R-Mi and G41R-
Mi are characterized by a remarkable propensity to proteolytic degrada-
tion and aggregation [15]. This is not unexpected considering that both
the residues (i) belong to the N-terminal region and are located at the
dimer interface (Supplementary Fig. 4) and (ii) are replaced by a bulky
polar side chain lying between the N-terminal regions of two subunits.
As already predicted by in silico analysis on the G41R-Mi [15],
the Gly47 to Arg substitution is expected to weaken the interactions be-
tween the twomonomers and promote the ﬂuctuation of theN-terminal
arm. The latter event could cause the exposure of negatively charged res-
idues leading to the electrostatically-driven aggregation of the protein,
and a susceptibility of the N-terminal region to proteolytic attack. On
the basis of all these considerations, it can be advanced the view that a
different partitioning between protein mitochondrial mistargeting,
aggregation and degradation of variants on the background of the
minor allele might depend on the location of the mutated residue in
the structure of AGT-Mi.
Besides all these data and considerations, the most relevant ﬁnding
is that PN appears to facilitate appropriate folding of the variant G47R-
Mi, by increasing the intracellular concentration of PLP, which possibly
acts as a nucleation site. This is consistent with the following data:
(i) a remarkable increase of the expression level and the speciﬁc activity
of the variant, (ii) a decreased extent of proteolytic degradation and
aggregation, (iii) a redirection of all the protein into peroxisomes, and
(iv) an increased ability to detoxify glyoxylate. Basing on these data,
the fate of the variant in the presence of PN is depicted in Scheme 1. It
is of interest to note that, although there is no report of PN responsive-
ness in patients with G47R or G41R mutations, PN has been found to
have little or no effect on speciﬁc activity, expression level and subcellu-
lar localization of the G41R-Mi variant in the same cellular system we
used [26]. Thus, the most striking difference between the variants
G47R-Mi and G41R-Mi is the response to PN. These data imply that PN
plays a role in the folding and/or dimerization of G47R-Mi, while it
has amodest impact, if any, on G41R-Mi. This effect is surprising consid-
ering that the twomutated residues are near to each other in the prima-
ry structure of AGT even if they have a different location in the crystal
structure. Gly41 lies in an α-helix, whereas Gly47 in a mobile loop. It
can be speculated that these residues may have a distinct role in the
folding and/or dimerization process of AGT. However, since the folding
pathway and the possible role of the coenzyme are unknown, no valid
conclusions can be drawn on this issue.
5. Conclusions
Overall, the combinedmolecular and cellular analyses of the effects of
the G47R mutation on AGT-Mi allow us to conclude that the G47R-Mi
variant exhibits a folding defect resulting in (i) an altered dimerization
process of the apo-form, which leads to mitochondrial mistargeting,
and (ii) an increased ﬂexibility of the N-terminus, which causes a
remarkable propensity to proteolytic cleavage inside mitochondria and
aggregation inside peroxisomes. Although G47R-Mi shares many of
these features with Gly41 variants, it differs because it responds to PN,
whose main effect is to prevent the mitochondrial mistargeting and the
proteolytic degradation. Therefore, a conﬁdent prediction of PN respon-
siveness of PH1-causing mutations based only on the structural context
of the mutated residues is unfortunately not possible. The same is also
true for tetrahydrobiopterin responsive mutations associated with
phenylketonuria [34].
Nevertheless, whatever themechanism of action of PN could be, the
signiﬁcant functional rescue of the variant might be clinically relevant,
and, therefore, it might be a great promise for the use of PN in the treat-
ment of PH1 patients bearing the G47R mutation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbapap.2015.07.002.
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ABSTRACT: The rare disease Primary Hyperoxaluria Type I (PH1)
results from the deﬁcit of liver peroxisomal alanine:glyoxylate
aminotransferase (AGT), as a consequence of inherited mutations on
the AGXT gene frequently leading to protein misfolding. Pharmaco-
logical chaperone (PC) therapy is a newly developed approach for
misfolding diseases based on the use of small molecule ligands able to
promote the correct folding of a mutant enzyme. In this report, we
describe the interaction of amino-oxyacetic acid (AOA) with the
recombinant puriﬁed form of two polymorphic species of AGT, AGT-
Ma and AGT-Mi, and with three pathogenic variants bearing previously
identiﬁed folding defects: G41R-Ma, G170R-Mi, and I244T-Mi. We
found that for all these enzyme AOA (i) forms an oxime at the active
site, (ii) behaves as a slow, tight-binding inhibitor with KI values in the nanomolar range, and (iii) increases the thermal stability.
Furthermore, experiments performed in mammalian cells revealed that AOA acts as a PC by partly preventing the intracellular
aggregation of G41R-Ma and by promoting the correct peroxisomal import of G170R-Mi and I244T-Mi. Based on these data, we
carried out a small-scale screening campaign. We identiﬁed four AOA analogues acting as AGT inhibitors, even if only one was
found to act as a PC. The possible relationship between the structure and the PC activity of these compounds is discussed.
Altogether, these results provide the proof-of-principle for the feasibility of a therapy with PCs for PH1-causing variants bearing
folding defects and provide the scaﬀold for the identiﬁcation of more speciﬁc ligands.
Primary Hyperoxaluria Type I (PH1, OMIM 259900) is arare metabolic recessive disorder whose principal hallmark
is the formation of calcium oxalate stones at ﬁrst in the kidneys
and then in the whole body.1 Although renal dysfunctions are
the ﬁrst clinical manifestations of the disease, the cause is the
functional deﬁcit of liver peroxisomal alanine:glyoxylate amino-
transferase (AGT).2 AGT is a pyridoxal 5′-phosphate (PLP)-
dependent enzyme, which catalyzes the conversion of L-alanine
and glyoxylate into pyruvate and glycine. In the absence of
functional AGT, glyoxylate accumulates and is oxidized to
oxalate, an end product of metabolism that undergoes renal
excretion, leading to the formation and deposition of calcium
oxalate crystals (CaOx).3
AGT is homodimeric and belongs to the aspartate amino-
transferase family of PLP-dependent enzymes.4 The protein is
highly speciﬁc for the glyoxylate-to-glycine conversion, in line
with its physiological role in glyoxylate detoxiﬁcation.5 Like in
all PLP enzymes, the coenzyme is bound through a Schiﬀ base
linkage with a lysine residue that in AGT is Lys209. This
complex, called internal aldimine, gives rise to two absorbance
bands at 423 and 330 nm, attributed to the ketoenamine and
enolimine tautomer of the internal aldimine, respectively.5
The AGXT gene encoding AGT is present in humans as two
polymorphic forms named “major allele,” coding for AGT-Ma,
and “minor allele,” coding for AGT-Mi. The minor allele has a
frequency of 20% in European and North American
populations and diﬀers from the major allele by a 74 bp-
duplication in intron 1 and by two point mutations leading to
the P11L and I340M amino acid substitutions.6 Biochemical
and cell biology studies performed in the past few years have
highlighted that many mutations associated with PH1 (among
the 150 identiﬁed so far) cause folding defects in AGT that
result in (i) an increased aggregation propensity, either in the
cell cytosol or in the peroxisomes; (ii) a reduced stability of the
dimeric structure of the protein, usually in the apo-form; (iii)
an increased susceptibility to proteolytic degradation; and/or
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(iv) a mislocalization of the protein to mitochondria.7 Thus,
PH1 can be also referred to as a misfolding disease.
Only two curative treatments are currently available for PH1:
the administration of pyridoxine, a precursor of the PLP
coenzyme eﬀective only in a minority (25−35%) of the
patients,8 and liver transplantation, a very invasive procedure
often carried out in combination with kidney transplantation.9
Thus, the development of new speciﬁc and noninvasive
treatments would be highly desirable. Among the strategies
under investigation to treat misfolding diseases there is the use
of pharmacological chaperones (PCs), small molecules that
bind a target protein and enable its proper folding and
traﬃcking.10 In the case of diseases due to enzymatic deﬁcits,
molecules acting as PCs are usually competitive inhibitors of
the enzyme involved.10 On these bases, it can be hypothesized
that molecules acting as competitive inhibitors of AGT could
represent useful PCs for pathogenic variants bearing folding
defects. Aminooxyacetic acid (AOA) is a well-known inhibitor
that binds the AGT active site by mimicking the position of the
substrate L-alanine and is supposed to form an oxime with the
carbonylic group of PLP, similarly to what happens in other
PLP-dependent enzymes.11−13 It has been reported that AOA
increases the thermal stability of both AGT-Ma and AGT-Mi14
and decreases the sensitivity to trypsin digestion of some AGT
variants.15 However, neither the interaction of AOA with AGT
nor its possible eﬀect as a PC for PH1-causing variants has been
extensively investigated.
In this study, we analyzed the interaction of AOA with AGT-
Ma, AGT-Mi, and three pathogenic variants known to be
aﬀected by folding defects: G41R-Ma, characterized by a less
stable dimeric structure in the apo-form and by an increased
susceptibility to aggregation and proteolytic degradation;
G170R-Mi, which shows an aberrant targeting to mitochon-
dria;16 and I244T-Mi, which is prone to aggregation and
proteolytic degradation and is partly mistargeted to mitochon-
dria.16−18 We found that AOA (i) acts as a slow, tight-binding
competitive inhibitor of the examined species in the puriﬁed
recombinant form and (ii) behaves as a PC by reducing the
aggregation propensity of G41R-Ma and promoting the correct
localization of G170R-Mi and I244T-Mi. Moreover, to look for
novel AGT ligands, we carried out a small-scale screening
campaign of AOA analogues that were tested both for their
ability to inhibit recombinant puriﬁed AGT and for their
activity as a PC. The possible implications of the results for the
pharmacological treatment of PH1 are discussed.
■ RESULTS AND DISCUSSION
AOA Forms an Oxime at the Active Site of AGT-Ma,
AGT-Mi, and Pathogenic Variants. The binding of AOA to
recombinant puriﬁed AGT-Ma and AGT-Mi was monitored by
absorbance and CD spectroscopy. The absorbance spectrum of
AGT-Ma and AGT-Mi presents a visible band at 423 nm
associated with a positive CD band at 429 nm and a minor
shoulder at 330 nm associated with a negative dichroic band at
340 nm. These bands have been already attributed to the
ketoenamine and the enolimine tautomer of the internal
aldimine, respectively.5 The addition of 20 μM AOA caused the
immediate disappearance of the absorbance and dichroic bands
at 423 and 330 nm and the concomitant appearance of an
absorbance band at 350 nm associated with a positive dichroic
signal (Figure 1 and inset). Moreover, AOA binding caused a
remarkable change in the near-UV region consisting in an
increase of the magnitude of the dichroic bands at 280 and 260
nm (inset of Figure 1). Upon excitation at 350 nm, the AGT-
Ma−AOA and the AGT-Mi−AOA complexes showed a
ﬂuorescence emission spectrum with a maximum at 450 nm,
typical of the oxime PLP−AOA.11,12 The spectral features of
G170R-Mi, I244T-Mi, and G41R-Ma in complex with AOA
appeared to be similar to those of the AGT-Ma−AOA and
AGT-Mi−AOA complexes (data not shown). These data
indicate that the interaction of AOA with the enzymatic species
under study involves the formation of an oxime with PLP at the
active site, consistently with what was already observed for
other PLP enzymes.13 Moreover, CD spectral changes in the
near-UV suggest that oxime formation is accompanied by a
conformational change of aromatic amino acid residues,
possibly located at or near the active site. However, it cannot
be excluded that the optically active band at 260 nm is a signal
due to the PLP−AOA complex itself. Notably, the crystal
structure of the AGT−AOA complex does not reveal the
presence of a Schiﬀ base linkage between the inhibitor and PLP.
In fact, although the carboxyl moiety of AOA is hydrogen-
bonded to Arg360, thus mimicking the position of the amino
donor L-alanine, the PLP cofactor appears to be in the internal
aldimine form.4 It can be speculated that the rigid conformation
of the protein in the crystalline state does not allow the
displacement of Lys209 by the amino group of AOA.
AOA Is a Slow, Tight-Binding Inhibitor of AGT-Ma,
AGT-Mi, and Pathogenic Variants. The preincubation of 5
μM AGT-Ma or AGT-Mi with 10 μM AOA for 30′ at 25 °C
caused a complete loss of enzymatic activity, in line with what
was previously found by Horvath et al., who reported that AOA
at 50 μM concentration is able to completely inhibit AGT-Ma
activity in liver homogenates.19 The recovery of the trans-
aminase activity was not observed even after extensive dialysis
of the mixture against 100 mM potassium phosphate (KP)
buﬀer at pH 7.4. However, when the AGT-Ma−AOA or the
AGT-Mi−AOA complex was incubated at 25 °C in the
presence of 500 mM L-alanine, a slow recovery of up to 75% of
the enzymatic activity was observed in 24 h. These data
strongly suggest that AOA acts as a slow, tight-binding
inhibitor. A similar behavior has been also reported for
aspartate aminotransferase from pig heart, whose reaction
with AOA can only be reversed in the presence of the substrate
analogue cysteine sulphinic acid.13
Figure 1. Absorbance and dichroic spectra of AGT-Ma in complex
with AOA. Absorbance and CD (inset) spectra of 6 μM AGT-Ma in
the absence (solid line) and in the presence (dotted line) of 20 μM
AOA. Spectra were recorded in 100 mM KP, pH 7.4, at 25 °C. The
absorbance and CD spectral properties of AGT-Mi under the same
experimental conditions are identical to those of AGT-Ma.
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Further evidence for slow, tight-binding inhibition was
obtained by measuring pyruvate production at diﬀerent times
after the addition of AGT-Ma or AGT-Mi in the presence of
saturating PLP to assay mixtures containing L-alanine (250
mM), glyoxylate (10 mM), and AOA at concentrations ranging
from 100 to 700 nM. The resulting progression curves (Figure
2A and B) revealed that the initial velocities (v0) were
independent of inhibitor concentration, and that the reaction
rate gradually decreased with time reaching a steady-state value
(vs). Similar progression curves were obtained for G41R-Ma,
G170R-Mi, and I244T-Mi. Data for AGT-Ma, AGT-Mi, and
the pathogenic variants were ﬁtted to eq 1, using the estimated
v0 and vs values to determine the kobs for each AOA
concentration. The kobs were then plotted against AOA
concentration, and a linear relationship was observed (inset
of Figure 2). Both features indicate that AOA is a slow, tight-
binding inhibitor for all the examined enzymatic species
according to a mechanism reﬂecting the direct formation of a
slowly dissociating E-AOA complex without the initial
formation of a rapidly reversible E-AOA complex. The data
were ﬁtted to eqs 2 and 3, and k−1, k1, and KI were determined.
As reported in Table 1, the KI value for AOA of G41R-Ma is
∼17 fold higher than that of AGT-Ma, while the KI values of
G170R-Mi and I244T-Mi are ∼2- and ∼5-fold higher,
respectively, than that of AGT-Mi. These increases are due to
approximately equal magnitude changes in k1 and k−1. The
decrease in the AOA binding aﬃnity of the pathogenic variants
could be a consequence of the subtle active site alterations
induced by each mutation, as revealed by the slight diﬀerences
observed in the spectral and kinetic properties of the variants
with respect to AGT-Ma and AGT-Mi20−22 (Supporting
Information Figure 1 and Supporting Information Table 1).
AOA Increases the Thermal Stability of AGT-Ma, AGT-
Mi, and Pathogenic Variants. It is well-known that the
binding of low-molecular weight ligands can increase the
thermal stability of proteins, an eﬀect that has many important
implications for the evaluation of the inhibitor potency and
eﬃcacy in a cellular environment.23 Thus, we investigated if
AOA binding could aﬀect the thermal stability of AGT-Ma,
AGT-Mi, G41R-Ma, G170R-Mi, and I244T-Mi by determining
the melting curve in the absence and in the presence of the
inhibitor at a saturating concentration (Table 1). As previously
shown by both circular dichroism and calorimetry studies,22,24
all the species display a two-state unfolding pathway. AGT-Mi
has a lower thermal stability with respect to AGT-Ma. In
agreement with previous data,20,22 the G170R and I244T
mutations do not signiﬁcantly aﬀect the Tm of AGT-Mi in the
holo-form, while the G41R mutation signiﬁcantly reduces the
thermal stability of AGT-Ma.21 The binding of AOA has a
global stabilizing eﬀect, as indicated by the shift of 5−10 °C of
the melting temperature. The lowest eﬀect observed for G41R-
Ma and I244T-Mi could be understood considering the
reduced aﬃnity of these variants for AOA and the correlation
existing between the thermal stabilization exerted by a ligand
on a protein and its binding aﬃnity.25 Since the ability of a
ligand to prevent the heat-induced unfolding of an enzyme
could indicate a possible stabilizing eﬀect of the ligand,26 these
data suggest that AOA could behave as a PC for AGT.
AOA Variably Aﬀects the Speciﬁc Activity and the
Expression Level of AGT-Ma, AGT-Mi, and Pathogenic
Variants. We wonder if AOA could be able to partly
counteract three pathogenic mutations that do not signiﬁcantly
aﬀect the AGT catalytic activity but cause a folding defect, by
forcing the variants to assume the proper conformation. To this
aim, we studied the interaction between AOA and AGT in a
well-known cellular model of PH1 made of Chinese Hamster
Ovary (CHO) cells stably expressing glycolate oxidase (GO).27
In particular, we used the previously characterized clones of
Figure 2. Kinetic analysis of the slow, tight-binding inhibition of AGT-
Ma and AGT-Mi by AOA. Progression curves of pyruvate production
during the reaction of 50 nM AGT-Ma (A) or AGT-Mi (B) in the
presence of 10 mM glyoxylate, 250 mM L-alanine, and AOA at the
indicated concentrations. The reactions were performed in 100 mM
KP, pH 7.4, at 25 °C. Kinetic data were ﬁtted to eq 1. Insets show the
linear ﬁts of the obtained kobs values as a function of the inhibitor
concentration.
Table 1. AOA: Kinetic Constants of Inhibition and Eﬀect on Thermal Stability
Enzymatic k1 k−1 KI (k−1/k1) Tm‑holo Tm‑holo+AOA
species (nM−1 min−1) (min−1) (nM) (°C) (°C)
AGT-Ma 44·10−4 ± 2·10−4 0.038 ± 0.012 9 ± 3 81.91 ± 0.04 >90 °C
AGT-Mi 36·10−4 ± 3·10−4 0.056 ± 0.015 15.5 ± 4.4 73.73 ± 0.06 83.91 ± 0.03
G41R-Ma 8.3·10−4 ± 1.7·10−4 0.125 ± 0.009 149.7 ± 29.9 60.03 ± 0.02 65.09 ± 0.03
G170R-Mi 25·10−4 ± 3·10−4 0.093 ± 0.008 37.2 ± 5.6 73.83 ± 0.09 84.40 ± 0.04
I244T-Mi 32·10−4 ± 7·10−4 0.269 ± 0.041 83.5 ± 19 73.42 ± 0.02 80.80 ± 0.03
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CHO-GO cells stably expressing AGT-Ma (CHO-GO-AGT-
Ma), AGT-Mi (CHO-GO-AGT-Mi), G170R-Mi (CHO-GO-
G170R-Mi), and I244T-Mi (CHO-GO-I244T-Mi),16 and we
selected a clone of CHO-GO cells expressing the G41R-Ma
variant (CHO-GO-G41R-Ma). We ﬁrst measured the AGT
speciﬁc activity (Figure 3) and the expression level (Figure 4A
and B) in the soluble fraction of the lysates of each clone. In
line with previous data,16 the speciﬁc activity of G170R-Mi and
I244T-Mi in CHO-GO cells was about 80% and 25%,
respectively, and their expression level was about 83% and
70%, respectively, as compared with the corresponding values
of AGT-Mi. Moreover, here we found that the speciﬁc activity
and expression level of CHO-GO-G41R-Ma cells were 4% and
18%, respectively, as compared with those of CHO-GO-AGT-
Ma. Since, under our experimental conditions, both I244T and
G41R mutations slightly reduce the enzymatic activity of AGT-
Mi and AGT-Ma, respectively (Supporting Information Table
1), the decreased speciﬁc activity of the I244T-Mi and G41R-
Ma variants in CHO-GO cells can be ascribed partly to the
reduced activity and partly to the reduced expression level.
To investigate whether AOA could act as a PC, CHO-GO-
AGT-Ma, CHO-GO-AGT-Mi, CHO-GO-G41R-Ma, CHO-
GO-G170R-Mi, and CHO-GO-I244T-Mi cells were grown in
the presence of AOA in the culture medium. AGT-Ma and
AGT-Mi have a half-life of 29 and 27 h, respectively;28 thus we
chose an incubation time of 7 days to allow the majority of
AGT to be synthesized in the presence of AOA. Moreover,
considering that the predicted partition coeﬃcient of AOA
(LogP) is equal to −0.978,29 which indicates a very low
membrane passive permeability, we treated the cells with ligand
concentrations (8 μM, 20 μM, and 50 μM) much higher than
the KI of the analyzed species (Table 1). We checked that,
under our experimental conditions, the presence of AOA in the
culture medium up to 50 μM does not interfere with cell
growth and does not adversely aﬀect the cellular ﬁne structure
(data not shown). Upon incubation, we determined the AGT
speciﬁc activity (Figure 3) and expression level (Figure 4) in
the soluble fraction of the cellular lysates. Since AOA is a slow,
tight-binding inhibitor of each species in the recombinant
puriﬁed form, thus implying that the dissociation from the
enzyme occurs only in the presence of the substrate, we
measured the speciﬁc activity under three diﬀerent conditions:
(i) immediately after cell lysis (Figure 3A), (ii) after incubation
of the lysate for 24 h at 4 °C (Figure 3B), and (iii) after
incubation of the lysate for 24 h at 4 °C in the presence of
excess substrate (0.5 M L-alanine; Figure 3C). From the data
obtained at increasing AOA concentrations, we could make the
following observations. First, the expression level of cells
expressing AGT-Ma, AGT-Mi, and G170R-Mi did not change,
but their speciﬁc activity decreased, reaching a value equal to
42%, 36%, and 43%, respectively, that of untreated cells. Similar
results were observed upon incubation at 4 °C in the absence of
the substrate, while the speciﬁc activity was completely restored
after prolonged incubation of the lysate with saturating
amounts of substrate. These data indicate that, in the stable
clones of CHO-GO cells, AOA behaves as a tight-binding
inhibitor of AGT-Ma, AGT-Mi, and G170R-Mi. It should be
noted that although we treated cells with AOA concentrations
much higher than the KI of the analyzed species, we did not
observe a 100% inhibition of the enzymatic activity, as expected
if AOA was totally internalized. We speculate that this could be
due to (i) the low permeability of AOA, leading to an
intracellular concentration of the inhibitor much lower than the
extracellular one, and (ii) the highly reactive aminic group of
AOA, able to interact with many molecules endowed with
reactive carbonyl groups, thus lowering the eﬀective amount of
inhibitor available for AGT. Second, the speciﬁc activity of
CHO-GO-I244T-Mi cells does not change under the three
diﬀerent assay conditions (Figure 3), and the expression level
remains unaltered (Figure 4A and B), in agreement with
previous results.17 These data appear to indicate that AOA does
not act as a tight-binding inhibitor of I244T-Mi. However, we
cannot exclude that under our experimental conditions AOA
could dissociate from I244T-Mi considering that this variant
has values of KI and k−1 higher than those of AGT-Ma, AGT-
Mi, and G170R-Mi. Third, the speciﬁc activity of CHO-GO-
G41R-Ma cells increased, reaching a value ∼7-fold higher than
that of untreated cells under the three assay conditions, and
their expression level increased by 1.7 fold, reaching a value of
33% as compared to CHO-GO-AGT-Ma cells. These data
suggest that at the actual intracellular concentration AOA does
not exert a detectable inhibitory eﬀect on G41R-Ma for reasons
similar to what was already proposed for I244T-Mi (see above).
Notably, AOA is able to partly rescue for the eﬀect of the G41R
mutation by possibly acting as a PC. Since the puriﬁed G41R-
Ma variant has a strong propensity to aggregate under
physiological conditions,21 we determined the amount of
Figure 3. Eﬀect of AOA treatment on AGT speciﬁc activity. The AGT
speciﬁc activity in the cellular lysate was determined under three
diﬀerent conditions: (A) immediately after lysis, (B) after 24 h
incubation at 4 °C and (C) after 24 h incubation at 4 °C with 0.5 M L-
alanine. In all cases 100 μg of lysate were incubated with 0.5 M L-
alanine, 10 mM glyoxylate and 200 μM PLP at 25 °C in 100 mM KP,
pH 7.4. Bars are colored as follow: CHO-GO-AGT-Ma (black), CHO-
GO-G41R-Ma (white), CHO-GO-AGT-Mi (dark gray), CHO-GO-
G170R-Mi (light gray) and CHO-GO-I244T-Mi (stripe). Data are
representative of three independent experiments. Bar graphs represent
the mean ± SEM. The statistical signiﬁcance of the increment in
speciﬁc activity in the presence of diﬀerent AOA concentrations with
respect to the value in absence of AOA is shown: *P < 0.05, ** P <
0.005.
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protein present in the soluble and insoluble fraction of the
lysate of CHO-GO-G41R-Ma cells grown for 7 days in the
absence and in the presence of AOA at 8 μM, 20 μM, and 50
μM concentrations. We did not see any change of the total
expression level of the variant, but we noticed a progressive
decrease of the protein present in the insoluble fraction and a
concomitant increase of the protein present in the soluble
fraction of the lysate. These data reinforce the view that G41R-
Ma has a signiﬁcant aggregation propensity inside the cell and
led us to conclude that the treatment with AOA could partially
counteract this eﬀect. It has been demonstrated that the
aggregation of G41R-Ma is a consequence of the increased
ﬂexibility of the N-terminal arms of the variant in the dimeric
form leading to the exposure of negatively charged residues,
which interact with the positively charged surface of
neighboring protein dimers.21 It can be hypothesized that the
formation of the oxime AOA-PLP could counteract the
perturbation caused by Gly41 mutation by promoting the
correct positioning of the loop 24−32. This in turn would
decrease the ﬂexibility of the N-terminal arm thus reducing the
aggregation extent.
In order to have a solid conﬁrmation of the PC role of AOA,
we also investigated its eﬀects on the speciﬁc activity and the
expression level of each species transiently expressed in CHO-
GO or COS7 cells in the absence or in the presence of 50 μM
AOA (Supporting Information Figure 2). The results are
consistent with those obtained in stable clones of CHO-GO
cells. However, in transient transfection experiments, AOA was
found to behave as a tight-binding inhibitor for both G41R-Ma
and I244T-Mi, as shown by the increase in the speciﬁc activity
observed upon incubation with excess L-alanine. This could be
due to the higher intracellular concentration of the variants in
transiently transfected cells as compared with stable clones,
which would possibly favor the formation of the enzyme−AOA
complexes.
AOA Promotes the Peroxisomal Localization of
G170R-Mi and I244T-Mi. Investigations performed in stably
transformed CHO-GO cells have demonstrated that both
G170R-Mi and I244T-Mi, the two most common variants
associated with PH1 present in European patients, are
mistargeted to mitochondria.16,30,31 Thus, we investigated if
AOA could aﬀect the subcellular localization of the variants by
determining the AGT intracellular compartmentalization in
CHO-GO-AGT-Mi, CHO-GO-G170R-Mi, and CHO-GO-
I244T-Mi cells before and after a 7-day treatment with 50
μM AOA. We performed both a qualitative inspection of the
images and a quantitative analysis, by determining the Pearson’s
coeﬃcient for the colocalization of the AGT/peroxisomes and
the AGT/mitochondria signals. As expected, the distribution of
AGT-Mi was entirely peroxisomal (Figure 5A), and no
colocalization with the mitochondrial marker was detected
(Supporting Information Figure 3A). In agreement with
previous results,16 G170R-Mi was entirely mitochondrial
while I244T-Mi was equally distributed between peroxisomes
and mitochondria (Figure 5A and Supporting Information
Figure 3A). No change of AGT-Mi localization was seen upon
treatment with AOA, while an increased amount of peroxisomal
AGT (and a decreased amount of mitochondrial AGT) was
observed in cells expressing G170R-Mi and I244T-Mi (Figure
5B and Supporting Information Figure 3B). In fact, upon AOA
treatment, the Pearson’s coeﬃcient for the colocalization AGT/
peroxisomes increased from 0.15 to 0.51 and from 0.53 to 0.76,
respectively, while the Pearson’s coeﬃcient for the colocaliza-
tion AGT/mitochondria decreased from 0.81 to 0.68 and from
Figure 4. Eﬀect of AOA treatment on AGT expression. (A) 2 μg of lysate of CHO-GO cells expressing the analyzed species grown in the absence or
in the presence of AOA at diﬀerent concentrations were subjected to SDS/PAGE, immunoblotted with anti-AGT from rabbit (1:6000), and then
detected by chemiluminescence. (B) Histogram showing the band volume of the immunoblot in A. Bars are colored as follows: CHO-GO-AGT-Ma
(black), CHO-GO-G41R-Ma (white), CHO-GO-AGT-Mi (dark gray), CHO-GO-G170R-Mi (light gray), and CHO-GO-I244T-Mi (stripe). (C) 2
μg of the soluble and insoluble fractions of lysate of CHO-GO-G41R-Ma cells grown in the absence or in the presence of AOA at diﬀerent
concentrations were subjected to SDS/PAGE, immunoblotted with anti-AGT from rabbit (1:6000), and then detected by a chemiluminescent
substrate. (D) Histograms representative of the percentage of protein in the soluble (black) and insoluble (white) fractions of the lysate. Data are
representative of three independent experiments. Bar graphs represent the mean + SEM. The statistical signiﬁcance of the increment in protein
expression level in the presence of diﬀerent AOA concentrations with respect to the value in the absence of AOA is shown: *P < 0.05.
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0.51 to 0.26 for G170R-Mi and I244T-Mi, respectively. These
data indicate that the treatment with AOA signiﬁcantly favors
the peroxisomal import of the two variants. In particular, for
I244T-Mi, this eﬀect is so strong that its colocalization with the
mitochondrial marker becomes nonsigniﬁcant. An analogous
trend can be also observed in CHO-GO or COS7 cells
transiently expressing G170R-Mi or I244T-Mi. As shown in
Supporting Information Figure 2C and F, upon treatment with
50 μM AOA, both variants display an increased peroxisomal
localization. It should be noted that, as previously found,17 the
I244T-Mi variant transiently expressed in COS7 cells does not
show a mitochondrial localization, but it is almost equally
distributed between peroxisomes and cytosol, probably as a
consequence of the diﬀerent expression of cellular components
involved in protein folding and traﬃcking in the two cell types.
Both Gly170 and Ile244 are located at the AGT subunit
interface.4 It has been widely claimed that the erroneous
localization of G170R-Mi and I244T-Mi is due to the
occurrence of two necessary conditions: (i) a putative
mitochondrial targeting sequence (MTS) produced by the
P11L polymorphic mutation16,32,33 and (ii) a folding defect
caused by the pathogenic mutation, allowing the population of
partly folded monomeric intermediates able to interact with the
mitochondrial import machinery.16,20,34 On these bases, the
most plausible explanation for the peroxisomal import induced
by AOA is that its binding to the AGT active site could
promote the attainment or the maintenance of the dimeric
structure, thus preventing the mitochondrial import and
allowing the interaction with the peroxisomal import machinery
that acts on fully folded dimeric proteins.35 Since residues of
both subunits form the AGT active site, the presence of a ligand
mimicking the substrate such as AOA is expected to force the
positioning of the active site residues in the conformation
typical of the native enzyme and shift the equilibrium toward a
dimeric structure. A similar eﬀect has been already documented
for a monomeric variant of T. denticola cystalysin.36
AOA Increases the Glyoxylate Detoxiﬁcation Ability
of G41R-Ma, G170R-Mi, and I244T-Mi. When CHO-GO
cells are treated with glycolate, they produce glyoxylate inside
peroxisomes through GO. Since glyoxylate induces cell death,
the viability of the cells in the presence of glycolate represents a
measure of the amount of functional AGT.27 After 7 days of
culture either in the presence or in the absence of 50 μM AOA,
CHO-GO cells stably expressing all the analyzed species were
treated with 1 mM glycolate for 24 h to allow the formation of
peroxisomal glyoxylate. As shown in Figure 6, the viability of
cells treated with glycolate with respect to untreated cells was
around 13% for CHO-GO cells, while it increased up to 60−
70% for cells expressing AGT-Ma and AGT-Mi and drastically
dropped to 17%, 20%, and 21% for cells expressing G41R-Ma,
G170R-Mi, and I244T-Mi, respectively. The growth in the
presence of AOA did not aﬀect the viability of cells expressing
AGT-Ma and AGT-Mi, while it increased 1.6-, 1.5-, and 1.9-fold
the viability of cells expressing G41R-Ma, G170R-Mi, and
I244T-Mi, respectively. Thus, the treatment with AOA is able
to signiﬁcantly increase the amount of functional AGT in cells
Figure 5. Eﬀect of AOA treatment on the subcellular localization of AGT-Mi, G170R-Mi, and I244T-Mi. After 7 days of culture in the absence (A)
or in the presence (B) of 50 μM AOA, cells were ﬁxed and colored as follows: anti-AGT (green) and antiperoxisomal proteins (red). Nuclei were
stained with Dapi (blue). Merge and single-channel images come from a single z-plane. Scale bar: 10 μm. (C) Pearson’s coeﬃcients for the
subcellular distribution of the analyzed clones grown for 7 days in the absence (black) or in the presence (gray) of 50 μM AOA. Full and empty bars
represent the Pearson’s coeﬃcient calculated for the colocalization of AGT and mitochondria or AGT and peroxisomes, respectively. The results are
given as means (+SEM) of several images; at least 30 individual cells were analyzed for each sample.
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expressing the G41R-Ma, G170R-Mi, and I244T-Mi variants
reaching values of about 50% with respect to those of AGT-Ma
or AGT-Mi. The increased glyoxylate detoxiﬁcation ability of
cells treated with AOA probably derives from the increased
amount of active soluble AGT, in the case of CHO-GO-G41R-
Ma cells, and from the increased peroxisomal localization of
AGT, in the case of CHO-GO-G170R-Mi and CHO-GO-
I244T-Mi cells.
Small-Size Screening Campaign. To select AOA
analogues, a substructure search was carried out along with a
virtual screening of the available “drug-like” chemical space. We
tested the 426 compounds retrieved for their ability to inhibit
AGT-Ma by automated enzymatic assays, and we identiﬁed
eight primary hits. We then performed hit conﬁrmation by
concentration−response curves, to obtain a preliminary SAR.
Under the experimental conditions used, an IC50 of 0.15 μM
was found for AOA. This value agrees well with that predicted
from the KI value of the inhibitor that is equal to 0.118 μM.
37
We identiﬁed four inhibitors with IC50 ranging from 0.3 to 16.7
μM (Table 2). Interestingly, replacement of the carboxylic
moiety by an aromatic moiety such as a phenyl ring is tolerated,
as demonstrated by compound 3. On the contrary, replacement
by a hydroxyl group (compound 2) exerts a detrimental eﬀect
on the inhibitory activity. The elongation of the carbon chain
length by two and three methylene units allows maintaining
activity (compounds 4 and 5), while a complete loss of activity
is recorded in the absence of the oxygen atom of the amino-oxy
group (compounds 6, 7, and 8). The ramiﬁcation of the carbon
chain seems to be permitted, as shown by compound 9 where a
benzyl substituent on the methylene unit of AOA still gives a
moderate activity. All the identiﬁed molecules are able to bind
the AGT active site, as indicated by the conversion of the 423
nm absorbance band into a band at 365−375 nm (data not
shown). This corroborates the hypothesis that their binding
mode is similar to that of AOA.
We then performed preliminary experiments to investigate if
the AOA analogues active as AGT inhibitors could also play a
PC role. We grew CHO-GO-AGT-Ma, CHO-GO-AGT-Mi,
CHO-GO-G41R-Ma, CHO-GO-G170R-Mi, and CHO-GO-
I244T-Mi cells for 7 days in the absence or in the presence of
compound 3, 4, 5, or 9 at 50 μM concentration. None of the
compounds was found to aﬀect cell viability or morphology.
Compounds 3, 4, and 5 do not signiﬁcantly aﬀect the speciﬁc
activity, the expression level, and the subcellular localization of
all the analyzed enzymatic species (data not shown). On the
other hand, compound 9 (i) does not change the expression
level of AGT-Ma but causes a ∼30% reduction of its speciﬁc
activity (Supporting Information Figure 4A−C), which is
recovered upon incubation of the lysate with excess L-alanine
(Supporting Information Figure 4D), thus suggesting a tight-
binding behavior; (ii) causes a ∼2-fold increase of the G41R-
Ma expression level and a similar increase in speciﬁc activity
only evident upon incubation of the lysate with excess L-alanine
(Supporting Information Figure 4A−D), thus suggesting a
partial inhibition; (iii) does not aﬀect the speciﬁc activity and
the expression level of G170R-Mi and I244T-Mi but promotes
their peroxisomal import (Supporting Information Figure 4E).
Overall, these data indicate that only compound 9 appears to
behave as a PC for the three folding-defective AGT variants
stably expressed in CHO-GO cells. The diﬀerent behavior of
the tested compounds can be interpreted considering that,
while compounds 4 and 5 have a negative logP (−0.89 and
−0.44, respectively), compound 9 has a positive logP value
(0.50) that suggests a higher membrane permeability with
respect to AOA and thus an increased intracellular concen-
tration. More diﬃcult is to understand the behavior of
compound 3, which has a positive logP value (1.13) and a
lower IC50 with respect to compound 9, but does not appear to
play any PC role. It can only be speculated that the presence of
Figure 6. Eﬀect of AOA treatment on AGT functionality. Glycolate-
toxicity assay of CHO-GO cells expressing the analyzed AGT variants
after growing in the absence or presence of 50 μM AOA. The
histogram represents cell viability expressed as a percentage of the
untreated control. Bars are colored as follows: CHO-GO (square),
CHO-GO-AGT-Ma (black), CHO-GO-G41R-Ma (white), CHO-GO-
AGT-Mi (dark gray), CHO-GO-G170R-Mi (light gray), and CHO-
GO-I244T-Mi (stripe). Bar graphs represent the mean + SEM. The
statistical signiﬁcance of the increment in relative cellular viability in
the presence of diﬀerent AOA concentrations with respect to the value
in the absence of AOA is shown: *P < 0.05, **P < 0.005.
Table 2. In Vitro Activity Data of AOA Analogues
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the carboxyl moiety could be important for the chaperone
activity. However, no solid conclusions can be drawn about the
relationship between the structure and the PC activity in the
absence of detailed analyses of the actual membrane
permeability of each compound and of the kinetic parameters
of their interaction with all enzymatic species. Studies to this
aim are in progress.
Conclusions. In PH1, the majority of disease-causing
missense mutations result in the biosynthesis of AGT variants
that are catalytically competent but display folding defects
making them more susceptible to aggregation, intracellular
degradation, or mistargeting.7 Each of these eﬀects reduces the
amount of functional AGT present inside peroxisomes and,
therefore, generates the enzymatic deﬁcit found in PH1
patients. Small molecules acting as PCs on misfolded but
catalytically active variants oﬀer a convenient and cost-eﬀective
therapeutic strategy for loss-of-function diseases. They have
been developed for a number of rare diseases, and some are
already in the market.38
Although the possibility of a new therapy for PH1 addressing
the homeostasis defects of AGT has been widely claimed, no
investigations on molecules acting as PCs have been reported
until now. In PH1, it has been already documented that the
coenzyme PLP enhances the thermodynamic and kinetic
stability of pathogenic variants of AGT and, in some cases,
improves their folding eﬃciency in the cytosolic milieu.7,39,40
These results prompted the designation of PLP as a natural PC
in PH1 and explained the responsiveness of some patients
bearing folding mutations to pyridoxine, a PLP precursor.41
However, only about 30% of PH1 patients are pyridoxine-
responsive, even if they do not show complete remission of the
disease symptoms.41 Here, we provide the ﬁrst evidence that
AOA (i) is a slow, tight-binding competitive inhibitor of the
analyzed species in the puriﬁed form and (ii) is able to act as a
PC for three pathogenic variants showing folding defects,
including the two most common. Thus, we provided the proof-
of-principle that a therapy with PCs is feasible for conforma-
tionally defective pathogenic variants associated with PH1. In
this regard, a weak eﬀect of AOA has been also documented for
pathogenic forms of human cystathionine-β-synthase.42 Nota-
bly, some missense mutations associated with PH1 aﬀect the
stability and/or the folding of AGT in the apo-form. We can
speculate that in the latter cases a useful therapeutic strategy
could be a combination of pyridoxine and AOA, which could
act as PCs for the apoenzymatic and the holoenzymatic form of
each variant, respectively, thus possibly producing a synergic
eﬀect.
We are aware that although AOA is eﬀective as a PC, it lacks
of speciﬁcity because it interacts with many PLP enzymes and
free PLP, thanks to the highly reactive aminic group.13
Therefore, alongside the characterization of AOA activity as
AGT inhibitor and PC, we carried out a small screening
campaign. We identiﬁed four compounds structurally related to
AOA endowed with inhibitory activity against AGT-Ma in the
micromolar range. Moreover, we found that one of these
compounds is eﬀective as a PC. These data allowed (i) the
identiﬁcation of the molecular structural moieties that are
thought to contribute to AOA activity and (ii) the establish-
ment of a framework that, by increasing the number of
compounds screened, should lead to the identiﬁcation of more
speciﬁc AGT ligands possibly lacking the tight-binding behavior
and endowed with an increased PC activity, thus representing a
valuable starting point for drug discovery.
■ MATERIALS AND METHODS
Materials. PLP, L-alanine, sodium glyoxylate, rabbit muscle L-lactic
dehydrogenase, isopropyl-β-D-thiogalactoside, EDTA, AOA, glycolate,
and imidazole were purchased from Sigma. Ham’s F12 Glutamax
medium was purchased from Invitrogen. CHO-GO, CHO-GO-AGT-
Ma, CHO-GO-AGT-Mi, CHO-GO-G170R-Mi, CHO-GO-I244T-Mi,
the rabbit polyclonal anti-AGT human, and the guinea-pig
antiperoxisomal protein antibodies were kindly provided by Prof.
C.J. Danpure (University College London). The antirabbit HRP
antibody was purchased from GE Healthcare. Oligonucleotides for site
directed mutagenesis were purchased from MWG Biotech AG
(Anzinger, Germany). All other chemicals were of the highest purity
available.
Site-directed Mutagenesis. The G41R mutation on the cDNA of
AGT cloned into a pcDNA3.1/V5-His-TOPO vector and the I244T
mutation on the pAGThis-Mi vector were introduced using the
QuikChange II kit (Agilent Technologies). We used the oligonucleo-
tides GCAGCCCGCGGGCTGCAGATGATCGG and its comple-
ment and the oligonucleotide CCTTCTACCTGGACACCA-
AGTGGCTGGCC and its complement for the G41R and the
I244T mutation, respectively. The mutations were conﬁrmed by
sequencing.
Protein Expression and Puriﬁcation. Wild type and mutant
enzymes in their histidine-tagged form were expressed in E. coli and
puriﬁed by the procedure already described.5 The apoform of the
I244T-Mi variant was prepared as previously described.5 The protein
concentration of AGT-Ma, AGT-Mi, and the variants was determined
by absorbance spectroscopy using an extinction coeﬃcient of 9.54 ×
104 M−1 cm−1 at 280 nm.5
Cell Culture and Lysis. CHO-GO cells and COS7 cells were
cultured as described in the SI. To study the eﬀect of AOA on protein
expression and activity, stable clones of CHO-GO cells were seeded at
a density of 7.2 × 105 cell/10 cm dish and grown for 7 days in the
absence or in the presence of diﬀerent AOA concentrations (8 μM, 20
μM, and 50 μM) in the culture medium. Transient transfection
experiments were performed as described in the SI. Cells were
harvested and lysed in PBS, pH 7.2, plus protease inhibitor cocktail
(Complete Mini, Roche), by ﬁve freeze/thaw cycles followed by
treatment with DNase (10 units) at RT for 45 min. The whole cell
extract was separated by centrifugation (29 200g, 10 min, 4 °C) to
obtain the soluble fraction. The pellets were then resuspended in an
equal volume of denaturing gel loading buﬀer to obtain the insoluble
fraction. The protein concentration in the soluble fraction was
measured using the Bradford protein assay.
Enzymatic Activity Assays. The transaminase activity of the
puriﬁed enzymes and of the cellular lysates was assayed as previously
described.5
Slow, Tight-binding Kinetic Determination. Slow, tight
binding kinetics of AOA with AGT-Ma, AGT-Mi, and pathogenic
variants were evaluated by the progression curve approach described
by Chou et al.43 A series of inhibition progression curves for each
enzymatic species at diﬀerent concentrations of AOA were generated.
A total of 0.05 μM of each enzyme in the presence of saturating PLP
was added to separate reaction mixtures containing AOA (up to 700−
900 nM), L-alanine (250 mM), and glyoxylate (10 mM). Data for each
progression curve were ﬁtted to the integrated rate equation for slow-
binding inhibitors:
= + + − −v t v v k k[P] ( )(1 exp( )/ )s 0 s obs obs (1)
where [P] is the concentration of pyruvate produced at the time t, v0
and vs are the initial and steady state rates of transamination,
respectively, and kobs is the apparent ﬁrst order kinetic constant
obtained by the best ﬁt to the data. The individual rate (k−1 and k1)
and inhibition constants (KI) were determined from plots of kobs
against the inhibitors’ concentration by ﬁtting the data to the following
equations:
= + +−k k k K[I]/(1 [S]/ )obs 1 1 m (2)
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= −K k k/I 1 1 (3)
Spectrophotometric Measurements. Spectroscopic measure-
ments and thermal stability studies were performed as described in the
SI.
Western-blot Analysis. A total of 2 μg of cell lysate was loaded
per lane on a Mini Protean TGX precast gel (Biorad) along with the
Precision plus protein Kaleidoscope (Bio-Rad) molecular mass
markers. Following transfer on a nitrocellulose membrane by the
iBlot device (Invitrogen), the membrane was blocked in 5% milk
solution in TBST (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1%
Tween 20) for 1 h at 37 °C. For AGT detection. the membrane was
incubated with polyclonal rabbit anti-AGT serum (dilution 1:6000),
washed three times in TBST and then incubated with peroxidase-
conjugated anti-rabbit IgG (dilution 1:10 000). Blotted proteins were
detected and quantiﬁed with ECL (Millipore), using the ChemiDoc
XRS Imaging System (Bio-Rad, Hercules, CA).
Immunoﬂuorescence Microscopy (IFM). Cell ﬁxation and
staining were performed as described in ref 44. Details are given in
the SI.
Glycolate Toxicity Assay. Cells cultured 7 days in the absence or
in the presence of 50 μM AOA were harvested and plated at a density
of 8000 cells/well in a 96-well plate. After 24 h, glyoxylate production
was induced by the addition of Hepes buﬀered glycolate at pH 7.0 at a
ﬁnal concentration of 1 mM. Cell viability was evaluated after 24 h of
incubation by crystal violet staining as previously reported.45
Virtual Screening. A virtual screening approach was applied aimed
at selecting a library of molecules to be tested as potential AGT
inhibitors. Details are given in the SI.
Screening of AGT Ligands. The AGT transaminase activity assay
was initially adapted for a screening at higher throughput and used to
analyze the inhibitory activity of the compounds selected by virtual
screening. Compounds active as AGT inhibitors were then tested in
stable clones of CHO-GO cells. Details are given in the SI.
Statistical Analysis. Experiments were performed at least in
triplicate. Statistic analysis was performed with Origin 7.03 (Origin
Lab) or GraphPad Prism version 5.0 (GraphPad software, San Diego,
CA, USA).
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Abstract: The functional deficit of alanine:glyoxylate aminotransferase (AGT) in human hepatocytes 
leads to a rare recessive disorder named primary hyperoxaluria type I (PH1). PH1 is characterized by 
the progressive accumulation and deposition of calcium oxalate stones in the kidneys and urinary tract, 
leading to a life-threatening and potentially fatal condition. In the last decades, substantial progress in 
the clarification of the molecular pathogenesis of the disease have been made. They resulted in the un-
derstanding that many mutations cause AGT deficiency by affecting the folding pathway of the protein 
leading to a reduced expression level, an increased aggregation propensity, and/or an aberrant mito-
chondrial localization. Thus, PH1 can be considered a misfolding disease and possibly treated by approaches aimed at 
counteracting the conformational defects of the variants. In this review, we summarize recent advances in the develop-
ment of new strategies to identify molecules able to rescue AGT folding and trafficking either by acting as pharmacologi-
cal chaperones or by preventing the mistargeting of the protein. 
Keywords: Primary hyperoxaluria type I, alanine: glyoxylate aminotransferase, misfolding disease, pyridoxal 5’-phosphate, 
pathogenic variants, pharmacological chaperones. 
1. INTRODUCTION 
Since the first introduction of the concept of “molecular 
disease” in 1949 [1], the field of molecular medicine has 
greatly expanded and many efforts have been devoted to the 
identification of the molecular mechanisms underlying ge-
netic diseases as well as to develop effective treatment 
strategies. In the field of diseases caused by enzymatic defi-
cits, it is becoming increasingly clear that the inability of the 
mutated protein to acquire its functional conformation is one 
of the main pathogenetic mechanisms. In fact, most muta-
tions do not interfere with the enzyme catalytic activity, but 
reduce the efficiency of the folding pathway by stabilizing 
folding intermediates prone to aggregation, degradation, or 
aberrant interactions with other cellular components such as 
protein targeting systems [2]. This has pointed the attention 
of the scientific community to the identification of molecules 
that could rescue for the conformational defects of disease-
causing variants, thus paving the way for the development of 
new treatment strategies. In this scenario, the present review 
focuses on recent advances made on the understanding of the 
pathogenetic mechanisms underlying primary hyperoxaluria 
type I (PH1) and on the development of new treatment ap-
proaches. 
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2. PRIMARY HYPEROXALURIA TYPE I 
Primary hyperoxaluria (PH) refers to diseases of genetic 
origin characterized by an abnormal production of endoge-
nous oxalate in the liver. Since oxalate is an end-product of 
human metabolism that is excreted by urine, this condition 
results into an excessive urinary oxalate concentration, 
which in turn causes the deposition of insoluble calcium ox-
alate (CaOx) crystals in the urinary tract manifesting as uro-
lithiasis and/or nephrocalcinosis [3, 4]. In the most severe 
forms renal failure occurs at early stages. The consequent 
increased plasmatic oxalate concentration leads to systemic 
oxalosis with CaOx deposition in various organs, including 
mainly bones and vessels, but also skin and retina [5, 6]. The 
clinical spectrum of PH is heterogeneous and varies from 
infantile nephrocalcinosis and renal failure to less aggressive 
forms manifesting as recurrent kidney stones formation in 
adulthood. The genetic background of the patient is one of 
the factors that contribute to the clinical heterogeneity of the 
disease, along with environmental factors (i.e. the daily fluid 
intake) and modifier genes [7]. 
Three forms of PH are known that are transmitted as 
autosomal recessive disorders. PH1 (OMIM 256600) is the 
most common, accounting for approximately 80% of PH 
patients. It has an estimated prevalence of 1-3 per million 
population and an incidence around 1:120000 live births per 
year in Europe [8, 9]. However, the incidence is higher in 
countries with a high level of consanguinity and in histori-
cally isolated populations such as in the Canary Islands [10]. 
PH1 is caused by the deficit of alanine:glyoxylate 
aminotransferase (AGT), an enzyme specifically present in 
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liver peroxisomes that converts L-alanine and glyoxylate to 
pyruvate and glycine, respectively [11]. This reaction repre-
sents a glyoxylate detoxification reaction. In fact, in the ab-
sence of AGT glyoxylate builds up and is converted to ox-
alate by L-lactate dehydrogenase in the hepatocyte cytosol 
(Fig. 1) [12]. The resulting increased urinary oxalate concen-
tration is the primary cause of CaOx stones formation in PH1 
patients. 
From a clinical point of view, an increased concentration 
of urinary oxalate and recurrent urolithiasis with rapid pro-
gression to renal failure are signs indicative of PH1. Al-
though the first symptoms usually appear during the first 
decade of life, the diagnosis is often delayed and many pa-
tients are recognized only upon recurrent CaOx stones for-
mation after kidney transplantation. The definitive diagnosis 
of the disease is made by genetic tests indicating the pres-
ence of mutations on the AGXT gene on chromosome 2q37.3 
that encodes AGT [13].  
The currently available treatment strategies for PH1 
comprise both conservative and curative measures. A high 
fluid intake, the administration of crystallization inhibitors 
and a low-oxalate diet are the most used conservative treat-
ments along with dialysis under selected clinical conditions 
[13]. These approaches can efficiently slow down the disease 
progression and in some patients they can prevent kidney 
failure. The administration of vitamin B6 in form of pyridox-
ine (PN), a precursor of the AGT coenzyme, is helpful in a 
minority of PH1 patients (25-35%) but the biochemical 
mechanisms underlying responsiveness have not been com-
pletely clarified [14, 15]. The only curative treatment avail-
able to date is liver transplantation. It replaces the organ re-
sponsible for excessive oxalate production, but it is a very 
invasive and risky procedure that comes with important side-
effects and long-term complications. Indeed, combined liver-
kidney transplantation is the present choice only for PH1 
patients presenting end-stage renal disease [10, 16-18].  
3. AGT FUNCTIONAL AND STRUCTURAL PROP-
ERTIES 
AGT is a pyridoxal 5’-phosphate (PLP)-dependent per-
oxisomal enzyme specifically expressed in human liver and 
it is involved in the metabolism of glyoxylate. The physio-
logical reaction catalyzed by AGT, the conversion of L-
alanine and glyoxylate to pyruvate and glycine, occurs by a 
ping-pong mechanism typical of PLP-dependent aminotrans-
ferases [11]. In the first half-reaction, L-alanine reacts with 
the PLP form of the enzyme (AGT–PLP) producing pyruvate 
and the pyridoxamine 5’-phosphate form of the enzyme 
(AGT–PMP). In the second half-reaction, glyoxylate reacts 
with AGT–PMP to form AGT–PLP and glycine. The equi-
librium constant of the overall transamination is ~ 9500 and 
the kcat of the direct reaction (L-alanine + glyoxylate  py-
ruvate + glycine) is about 100-fold higher than that of the 
reverse reaction, thus providing the experimental evidence 
that the physiological function of the enzyme is glyoxylate 
detoxification [11]. Besides the transaminase activity, AGT 
also shows an eliminase activity toward -chloro-L-alanine 
and an eliminase activity accompanied by a half-
transaminase activity toward L-cysteine, whose physiologi-
cal significance has not been demonstrated yet [19].  
Structural studies reveal that AGT is a compact homodi-
mer and belongs the Fold Type I class of the PLP-enzymes 
family [20]. Each monomer contains a PLP-binding site and 
consists of an N-terminal domain (residues 1-21) that grasps 
the surface of the other monomer, a large domain (residues 
22-282) that includes the dimerization interface and the ac-
tive site, and a smaller C-terminal domain (residues 283-392) 
comprising an atypical KKL peroxisomal targeting sequence 
(PTS1) (Fig. 2A). The PLP cofactor is covalently bound to 
the protein by a Schiff base linkage with Lys209, a base 
stacking hydrophobic  interaction involving Trp108 and the 
pyridine ring, a salt bridge between the side chain of Asp183 
and the N1 nitrogen of PLP, a hydrogen bond between the 
side chain of Ser158 and the 3-hydroxyl group of PLP, and 
 
Fig. (1). Metabolic consequences of AGT deficiency. Sites and mechanisms of oxalate formation are shown. LDH, lactic dehydrogenase. 
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hydrogen bonds between residues belonging to both subunits 
(Ser81, Gly82, His83, Tyr260* and Thr263*) and the phos-
phate group of the cofactor [20]. The enzyme in the AGT-
PLP form shows an absorption maximum at 423 nm associ-
ated with a positive dichroic band at 429 nm, attributed to 
the ketoenamine tautomer of the internal aldimine, and a 
shoulder at 340 nm associated with a negative dichroic signal 
at the same wavelength, attributed to the enolimine tautomer 
[11]. 
The AGXT gene is present in humans as two polymorphic 
forms: the most common major allele encoding AGT-Ma, 
and the less common minor allele encoding AGT-Mi. The 
latter, which has a frequency around 20% in Caucasian 
population, differs from the major allele for the presence of a 
74-bp duplication in intron 1 and of two polymorphisms 
leading to the Pro11-to-Leu and Ile340-to-Met amino acid 
substitutions (Fig. 2A) [21-23]. It has been demonstrated that 
the P11L polymorphism causes an ~ 30% reduction of the 
AGT catalytic activity, destabilizes the dimeric structure, and 
promotes the aggregation and the degradation of the protein 
[24]. Moreover, while AGT-Ma is 100% peroxisomal, AGT-
Mi is about 95% peroxisomal and 5% mitochondrial [21]. 
Evidence has been provided that the P11L polymorphism 
generates a weak putative mitochondrial targeting sequence 
(MTS), an important structural element acting as anchoring 
point for the mitochondrial import receptor TOM20. How-
ever, the rapid dimerization of AGT-Mi in the cell cytosol 
makes it incompatible with the mitochondrial import ma-
chinery that only operates on partly-folded or unfolded 
monomeric species. This explains why the vast majority of 
AGT is correctly located into peroxisomes even in the pres-
ence of the polymorphism and why the minor allele is not 
pathogenic per se [25]. 
Like most peroxisomal proteins bearing a PTS1 targeting 
sequence, AGT is imported into the peroxisomal matrix upon 
interaction with the Pex5p carrier [26]. This interaction is 
quite weak, being mediated by a non-canonical PTS1 se-
quence (KKL) at the C-terminus and by an “extended PTS1” 
formed by residues 381–388 and 327–330 [27] (Fig. 2B). 
The knowledge of the import mechanisms is still scarce, but 
it has been clarified that peroxisomes import their matrix 
proteins in a folded and even oligomerized manner, probably 
through the formation of a transient translocation pore in the 
membrane [28]. Thus, Pex5p is proposed to bind the folded 
AGT dimer and the complex then translocates into the perox-
isomal matrix. This implies that AGT should achieve its final 
dimeric structure in the cell cytosol before the import and 
that the efficiency of the enzyme folding and dimerization 
pathway dictates how much of the newly synthetized AGT 
molecules reach their active conformation and final subcellu-
lar localization. Many groups have investigated the AGT 
folding and dimerization pathways in vitro, as a prerequisite 
to dissect the molecular effect(s) of pathogenic mutations 
leading to structural rather than functional defects. Studies 
performed by means of either chemical and/or thermal de-
naturation methods [24, 29-33] have revealed that (i) AGT-
Ma is an extremely stable protein, whose denaturation fol-
lows a two-state process in the holo-form and a two- or 
three-state process in the apo-form; (ii) the coenzyme PLP 
exerts a remarkable stabilizing effect, by either maintaining 
the integrity of the dimeric structure and/or by increasing the 
denaturation free energy of each subunit (see below); (ii) the 
unfolding pathway of both holo- and apoAGT involves the 
formation of aggregation-prone intermediates able to interact 
with molecular chaperones [30]. This has been also demon-
strated by the resolution of the structure of a folding inter-
mediate of a pathogenic AGT variant in complex with 
GroEL by cryoelectron microscopy [34]; (iii) AGT-Mi dis-
plays a lower stability with respect to AGT-Ma, mainly as a 
consequence of the P11L polymorphism, which increases the 
flexibility of the N-terminal arm [35, 36] and reduces the 
stability of the dimeric structure. Unfortunately, the very low 
refolding efficiency of AGT upon denaturation did not allow 
researchers to draw thermodynamic conclusions about the 
equilibrium refolding pathway. Nevertheless, the data ob-
tained have provided a solid base to rationalize the effects of 
several PH1-associated mutations, as well as to design and 
test therapeutic approaches able to overcome folding-
defective variants [37, 38]. 
 
 
Fig. (2). Structural representation of AGT and of the AGT-
Pex5p complex. (A) Ribbons representation of the AGT dimeric 
structure. The N-terminal domain, the large domain and the C-
terminal domain of one monomer are coloured cyan, dark, grey, and 
white, respectively. The neighbouring monomer is coloured purple. 
Pro11 and Ile340 residues are represented as yellow sticks and the 
PLP molecules are shown as green sticks. (B) Ribbons representa-
tion of the C-terminal domain of AGT (white) interacting with the 
Pex5p carrier (orange). Residues forming the PTS1 are represented 
as magenta sticks, while residues 381-388 and 327-330, originating 
the “extended PST1”, are coloured green and red, respectively. 
Structures were generated starting from the coordinate files of AGT 
(pdb file 1H0C) and of the AGT-Pex5p complex (pdb file 3R9A). 
The images were rendered using the MOE 2013 software (CCG 
group). 
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4. FOLDING DEFECTS LEADING TO AGT DEFI-
CIENCY IN PH1 
Over 150 mutations on the AGXT gene have been identi-
fied until now as being associated with PH1. About half of 
these are point mutations leading to single amino acid substi-
tutions on the enzyme sequence. Missense mutations identi-
fied so far are spread over the protein structure, thus suggest-
ing that different enzymatic phenotypes could lead to AGT 
deficiency, and many of them co-segregate and functionally 
synergize with the minor allele [25].  
It is well known that the substitution of just one residue 
of a protein can have a dramatic effect on the macromolecu-
lar structure itself, the binding of ligands, the ability to inter-
act with protein partners, and the cellular localization. Stud-
ies on both purified proteins and cellular model systems have 
been used to determine the impact of missense mutations on 
AGT, in order to shed light on the pathogenetic mechanisms 
underlying PH1 [4, 37, 38]. The results obtained have indi-
cated that all mutations cause a remarkable reduction of the 
amounts of active peroxisomal AGT. In many cases this is 
not due to a reduced catalytic efficiency of the enzyme itself, 
as a consequence for example of the mutation of residues 
involved in catalysis or in PLP binding. Rather, most muta-
tions mainly affect the structural properties and decrease the 
amount of correctly folded AGT present inside peroxisomes. 
In all these conditions PH1 is caused by a proteostasis im-
pairment, as a result of alterations of the AGT fold-
ing/misfolding thermodynamics or kinetics, and/or of the 
inability of the polypeptide chain to interact with the proteo-
stasis network components that facilitate protein folding [24, 
30, 32, 33, 39-47]. Moreover, a mutation can impact the be-
haviour of AGT in the cellular microenvironment in a much 
more complex way than predicted by the simple description 
of the effects at a structural level. Three main effects can be 
outlined (Fig. 3) with more than one effect possibly co-
existing in a variant: 
1) The mutation strongly reduces the AGT expression level 
and specific activity. When expressed in a cellular system 
many AGT variants are characterized by a very low or even 
undetectable specific activity and expression level [48], thus 
indicating that they are affected by a structural defect that 
reduces the amount of protein reaching the folded and active 
conformation. This condition can be produced by mutations 
that strongly reduce the AGT folding efficiency, as revealed 
by the enhanced interaction with molecular chaperones, thus 
suggesting the trapping in partly-folded states [30]. The latter 
effect has been observed for the G170R, A295T and P319L 
mutations [30, 32]. Alternatively, the pathogenic mutation 
can reduce the half-life of AGT by making the protein prone 
to degradation in the cell cytosol, as demonstrated for the 
Gly161 mutation. In fact, pulse-chase experiments per-
formed in a cellular disease model have shown that the half-
life of the G161R-Ma, G161S-Mi and G161C-Mi variants is 
reduced from 2- to more than 7-fold as compared with that of 
AGT-Ma or AGT-Mi [43]. Analogous results have been ob-
tained for the G41R-Mi, W108R-Mi, G156R-Ma, C173Y-
Ma, S187F-Ma and S205P-Ma variants expressed in cell-free 
systems [46]. A reduced intracellular stability has been also 
postulated as the defect of some variants on the basis of lim-
ited proteolysis experiments [46], starting from the idea that 
an increased sensitivity to proteolytic cleavage indicates an 
increased local flexibility of the polypeptide chain, which in 
turn suggests the population of high-energy folding interme-
diates prone to degradation. Interestingly, a decreased resis-
tance to thermal or chemical stress often accompanies the 
reduced expression level of pathogenic variants of AGT in 
the recombinant purified form. Studies performed by means 
of spectroscopy and calorimetry techniques [24, 29, 30, 32, 
33, 39, 47] have revealed that PH1-causing mutations affect 
the thermodynamic and/or the kinetic stability of AGT. In 
many cases the structural defect is only or mainly evident on 
the apo-form of the variants and is rescued by the binding of 
the coenzyme PLP, which probably exerts a chaperone role 
(see section 5). Moreover, the effect of many mutations is 
enhanced by the presence of the P11L amino acid substitu-
tion, in agreement with the finding that they are pathogenic 
only when inherited on the background of the minor allele 
[24, 25, 31, 39].  
 
Fig. (3). Folding defects of AGT variants leading to PH1. U: unfolded monomer, M*: partially folded monomer, M: folded monomer, D*: 
partly folded apodimer, D: apodimer, DPLP: PLP-bound dimer, Agg: aggregates. 
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2) The mutation increases the aggregation propensity of 
AGT. The formation of protein aggregates, with either a or-
dered (i.e. in form of amyloid fibrils) or a disordered struc-
ture, is common to most misfolding diseases [49]. In the case 
of PH1, the presence of a large amount of AGT in form of 
high-molecular weight aggregates has been initially observed 
in cells expressing the I244T-Mi variant, which is mainly 
present in the insoluble fraction of the lysate [45]. More re-
cently, the mutation of residues Gly41, Gly47 or Gly161 was 
also found to make AGT prone to aggregation both inside 
the cell and in the purified form [42-44, 47]. Investigations 
on the molecular and cellular properties of the aggregates 
have revealed that they are stabilized by electrostatic interac-
tions, do not show any ordered conformation, and are not 
toxic for the cell, in agreement with PH1 having a loss-of-
function pathogenesis [37]. While aggregates of Gly41 and 
Gly47 variants are deposited inside peroxisomes, those 
formed by Gly161 variants accumulate in the cell cytosol. 
This is probably linked to the relationship between the two 
kinetics of aggregation and peroxisomal import of each vari-
ant.  
3) The mutation causes the aberrant targeting of AGT to 
mitochondria. When inherited on the background of the mi-
nor allele, pathogenic mutations that interfere with the fold-
ing pathway of AGT can make the population of monomeric 
intermediates susceptible to import by the mitochondrial 
import machinery, thanks to the presence of the putative 
MTS generated by the P11L polymorphism [22]. Mitochon-
drial AGT is still catalytically active, but is metabolically 
ineffective because it is not able to convert peroxisomal 
glyoxylate to glycine. This is the case of the G170R-Mi vari-
ant, the most common in PH1. The G170R mutation does not 
affect neither the spectroscopic nor the kinetic properties of 
AGT, but favours the mitochondrial import of the protein, as 
shown both in patient tissues and in cellular models [44, 50, 
51]. On purified AGT, the substitution of Gly170 by an Arg 
residue reduces the resistance to chemical denaturation and 
the kinetic stability of the protein in the apo-form [24, 30], 
thus promoting the formation of monomeric partly-folded 
intermediates that can be imported into mitochondria. 
Moreover, the G170R-Mi variant displays an enhanced in-
teraction with the molecular chaperones Hsp70, Hsp90 and 
Hsp60, which can present the protein to mitochondrial recep-
tors [30]. A similar behaviour has been found in other vari-
ants such as F152I-Mi, I244T-Mi, G41R-Mi and G47R-Mi 
[42, 44, 52] and it has been speculated that the mitochondrial 
mistargeting could be a common effect of all mutations that 
are pathogenic on the background of the minor allele [44]. 
Recently, a comprehensive analysis of the effect of sev-
eral naturally-occurring and consensus-based mutations on 
the energetics of the AGT stability has been carried out [33]. 
These studies support the view that while AGT-Ma repre-
sents the state endowed with the optimal conformational 
stability to fold and be targeted efficiently in a cell, AGT-Mi 
represents the lower limit of AGT foldability leading to a 
minimum glyoxylate detoxification ability. Following this 
view, a model has been proposed in which most mutations 
favour AGT misfolding by reducing the thermodynamic sta-
bility below the threshold of AGT-Mi and natural or unnatu-
ral AGT ligands rescue for the effect of the mutations by 
increasing the stability of pathogenic variants above the 
threshold. 
5. USE OF B6 VITAMERS FOR THE PHARMACOL-
OGICAL TREATMENT OF PH1 
Almost all inborn errors of metabolism caused by muta-
tions in a gene encoding a PLP-dependent enzyme, including 
PH1, are treated by the administration of vitamin B6 in form 
of PN [53]. The first evidence that PN treatment was able to 
reduce urine oxalate (Uox) levels in PH1 patients was pro-
vided in 1961 [54]. However, only after the discovery that 
mutations on the AGXT gene are the cause of the disease [12] 
PN is used as therapeutic standard. A three month-treatment 
with 5 to 20 mg/kg/day of PN is recommended to all patients 
[55], especially to those bearing missense mutations [4, 13]. 
However, only 25-35% of PH1 patients are reported to be 
responsive. Although in 2014 a prospective trial with vitamin 
B6 in form of PN has reported an efficacy of the treatment in 
about 50% of the patients examined, no complete reduction 
of the Uox levels to normal values has been observed [56]. 
In addition, since the number of disease cases is very low 
and the determination of Uox levels to establish PN respon-
siveness has some limitations [56, 57], it is not possible to 
predict the effectiveness of the treatment on the basis of the 
patient genotype. 
Despite the long-time use of PN and the well-known 
mechanisms of absorption in the intestine and conversion to 
PLP in the liver [58], the molecular bases of the positive 
effects on responsive PH1 patients are still under investiga-
tion. PLP would be expected to play essentially a prostethic 
role for pathogenic variants with a low coenzyme binding 
affinity or an altered coenzyme binding mode [59]. How-
ever, the available clinical data demonstrate that responsive 
patients bear mutations of residues located far from the ac-
tive site of the protein (such as F152I, G170R and I244T 
associated with the minor allele) that lead to the accumula-
tion of folding intermediates causing protein aggregation, 
degradation and/or mitochondrial mistargeting (Fig. 3) [56, 
57, 60]. In order to shed light on the molecular mechanism 
underling PN administration, the effects of vitamin B6 have 
been widely investigated in the last few years. The results 
obtained have revealed that PLP exerts a stabilizing effect on 
purified recombinant AGT by: (i) increasing the resistance to 
chemical and thermal unfolding [24, 29, 31], (ii) enhancing 
the kinetic stability of 4-5 orders of magnitude [30, 32] and 
(iii) reducing the aggregation propensity [39, 47] and the 
proteolytic cleavage susceptibility [39, 47]. Since the respon-
sive F152I-Mi, G170R-Mi and I244T-Mi variants display a 
reduced stability in the apo-form with respect to AGT-Mi 
[24, 30, 32, 33, 39], it has been proposed that PLP might 
influence the folding pathway of the variants by shifting the 
equilibrium from the unstable apo-form to the more stable 
holo-form (Fig. 4A). However, it remains to be established if 
the coenzyme binds partly-folded intermediates or the 
apoenzyme once folded. Recent studies focused on the be-
havior of PN-responsive variants in a cellular model of PH1, 
specifically Chinese Hamster Ovary (CHO) cells stably ex-
pressing glycolate oxidase (GO)[61], have revealed that the 
coenzyme exerts a chaperone role [62, 63]. In fact, the pres-
ence of PN in the culture media of CHO-GO cells expressing 
F152I-Mi, G170R-Mi or I244T-Mi variants not only im-
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proves the specific activity, but also increases the total ex-
pression level of the variants and promotes their correct sub-
cellular localization, thus enhancing the capability to detox-
ify glyoxylate. These data suggest that PLP increases the 
productive folding of the proteins and prevents their aggre-
gation and degradation, leading to higher amounts of active 
dimers imported inside peroxisomes (Fig. 4A) [62, 63]. In-
terestingly, the increase of PN concentration up to 250 μM 
reduces by about 50% the specific activity and the glyoxylate 
detoxification capability of cells expressing AGT-Ma and 
AGT-Mi [62, 63]. This effect, in the absence of reduced pro-
tein expression levels, has been attributed to the finding that 
the supplementation with PN leads not only to the intracellu-
lar accumulation of PLP, but also of pyridoxine 5’-phosphate 
(PNP) and PN [62, 63]. PNP, but not PN, is able to interact 
with AGT-Ma, AGT-Mi, F152I-Mi and G170R-Mi variants 
in the purified form and to compete with PLP for apoenzyme 
binding giving rise to an inactive AGT-PNP complex (Fig. 
4A) [63]. Thus, the global positive effect seen upon PN ad-
ministration is probably a balance between the chaperone 
effect exerted by PLP and the inhibitory effect exerted by 
PNP (Fig. 4A) [63]. Following this idea, the B6-
responsiveness measured upon PN administration could be 
underestimated. Even if no clinical data have been published 
that support this thesis, it is worth noting that most patients 
respond to low PN doses (< 10 mg/kg/day) [58, 64] and that 
Uox levels are not correlated with serum B6 levels [56].  
Expanding upon the inhibitory effects of PN administra-
tion, other B6 vitamers were investigated for their effects 
[63]. In fact, although only PN has been used for the treat-
ment of PH1, two other un-phosphorylated B6 vitamers are 
absorbed by the intestine and then converted to PLP by the 
liver salvage pathway [65]: pyridoxamine (PM) and pyri-
doxal (PL). In 2005 Chetyrkin et al. [66, 67] reported that 
the administration of PM reduced Uox and kidney crystals in 
hyperoxaluric untreated animals but the mechanism of action 
was not investigated. Recently, our group [63] could show 
that PM and PL are more effective than PN in rescuing the 
two PN-responsive variants F152I-Mi and G170R-Mi when 
expressed in a cellular model of PH1. Indeed, PM or PL sup-
plementation causes the intracellular accumulation of PLP 
and PMP, the two active forms of the coenzyme exerting 
both a chaperone and a prosthetic role, without any accumu-
lation of PNP (Fig. 4B) [63]. These results support the poten-
tial use of PM and PL as a novel coenzyme administration 
therapy for patients bearing PH1-causing mutations that af-
fect protein folding. In this regard, it is of note that the ad-
ministration of PM and PL to mice does not result in the sub-
 
Fig. (4). Proposed molecular effect of PN (A) and of PM or PL (B) treatment on AGT variants bearing folding defects. U: unfolded 
monomer, M*: partially folded monomer, M: folded monomer, MPLP: PLP-bound monomer, MPNP: PNP-bound monomer, MPMP: PMP-
bound monomer D*: partly folded apodimer, D: apodimer, DPLP: PLP-bound dimer, DPNP: PNP-bound dimer, DPMP: PMP-bound dimer, Agg: 
aggregates. PLP, PNP and PMP are represented as yellow, red or blue circles, respectively. Dashed arrows indicate minor routes. 
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tle neurological effects seen with high PN doses, and that 
PM is actually under phase II clinical trial for diabetes type I 
and type II (Pyridorin
TM
) and does not appear to be toxic for 
humans even at high doses [68, 69]. 
6. INNOVATIVE TREATMENT STRATEGIES BASED 
ON THE USE OF UNNATURAL COMPOUNDS 
Upon the discovery that the majority of PH1-causing 
missense mutations negatively influence AGT folding, nu-
merous efforts have been dedicated to the identification of 
small molecules able to promote the achievement of the na-
tive structure. In particular, the effect of compounds possibly 
acting as chemical chaperones (CCs) or pharmacological 
chaperones (PCs) for AGT has been tested on folding-
defective variants in the purified form and/or expressed in 
cellular models. CCs are usually low molecular weight com-
pounds that nonselectively stabilize proteins and assist the 
folding process. CCs require high concentrations to rescue in 
vivo misfolded proteins, making them unsuitable for therapy. 
On the other hand, PCs are site-specific compounds that usu-
ally resemble natural ligands of the target protein and facili-
tate the correct folding by acting on protein thermodynamic 
and/or kinetic stability, leading to improved folding and traf-
ficking in cells. The higher specificity permits them to be 
effective at very low concentrations [70]. Glycerol, betaine, 
phenylbutyric acid (PBA), and trimethylamine N-oxide 
(TMAO) are potential CCs tested on AGT variants [31, 45, 
46, 71] (Table 1). Glycerol has been found to prevent the 
mistargeting to mitochondria of the G170R-Mi variant and to 
redirect the enzyme to peroxisomes in COS7 cells [71]. It 
has been suggested that glycerol could stabilize the protein, 
enabling it to adopt a more compact dimeric form that is 
incompatible with the mitochondrial import machinery. Be-
taine is able to increase the solubility of the I244T-Mi vari-
ant expressed in COS7 cells by reducing the amount of pro-
tein present as insoluble aggregates [45]. Moreover, it also 
exerts a stabilizing effect, by decreasing the sensitivity of the 
G41R-Ma and G41V-Ma variants to tryptic digestion in vitro 
[46]. None or minimal effects on protein solubility, stability 
or protease sensitivity have been observed upon treatment of 
AGT variants with PBA or TMAO [45, 46].  
Compounds acting as PCs for diseases caused by an en-
zymatic deficit are usually competitive inhibitors of the en-
zyme involved, because they show high binding affinity and 
specificity [70]. A compound known to act as an AGT in-
hibitor is aminooxyacetic acid (AOA) (Table 1), which binds 
the active site mimicking the position of the substrate L-
alanine [52]. Although AOA displays a low specificity, be-
cause it binds and inhibits many PLP-dependent enzymes 
[72-74], the possible action of this molecule as PC for fold-
ing-defective AGT variants has been tested by various 
groups and in different experimental conditions [31, 45, 46, 
52]. The first evidence of the stabilizing effect of AOA on 
AGT was provided by a mass spectrometry-based technique 
and by differential scanning fluorimetry (DSF). These analy-
ses revealed that the binding of AOA increases the thermal 
Table 1. Unnatural compounds able to rescue AGT misfolding or mistargeting. 
Compound Structure Action References 
Betaine 
 
Chemical chaperone [45, 46] 
Glycerol 
 
Chemical chaperone [71] 
Amiooxyacetic acid 
(AOA) 
 
Pharmacological chaperone [46, 52] 
2-aminooxy 3-
phenylpropionic acid 
 
Pharmacological chaperone [52] 
Dequalinium chloride 
(DECA) 
 
Inhibitor of the mitochon-
drial  protein import 
[76] 
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stability of both AGT-Ma and AGT-Mi [31]. AOA was also 
reported to reduce the trypsin sensitivity of several AGT 
pathogenic variants (G41R-Ma, G41R-Mi, G41V-Ma, 
S218L, G156R, V336D-Mi) by presumably promoting their 
correct folding and reducing the exposure of flexible loops 
susceptible to proteolytic cleavage [75]. An in–depth study 
elucidating the mode of action of AOA as AGT inhibitor and 
its effectiveness as PC for three pathogenic variants has been 
recently published [52]. By kinetic analyses on purified pro-
teins, AOA was found to act as a slow, tight-binding com-
petitive inhibitor of AGT with a KI value in the low nanomo-
lar range. The presence of AOA in the culture medium in-
creases the amount of functional AGT of cells expressing 
conformational variants. In particular, it improves the folding 
of G41R-Ma, a variant mainly characterized by an increased 
susceptibility to aggregation and proteolytic degradation, and 
promotes the peroxisomal localization of G170R-Mi and 
I244T-Mi, two variants aberrantly targeted to mitochondria. 
These findings have confirmed that AOA works as a PC for 
AGT, even though the slow, tight-binding behaviour and the 
low specificity make it unsuitable for use in therapy. None-
theless, based on the idea that AOA could represent the 
chemical scaffold for the development of more specific 
ligands, a preliminary screening campaign on several AOA 
derivates was carried out [52]. Among the compounds show-
ing AGT inhibitory activity, 2-aminooxy-3-phenylpropionic 
acid (Table 1) was found to work as PC for folding-defective 
variants. This finding represents the proof-of-principle that a 
therapy with PCs for PH1 is feasible and it is a first step to-
ward the identification of more effective compounds.  
In the search of a new pharmacological non-invasive 
therapeutic for the treatment of PH1, a different approach 
was used by Miyata et al. [76], who restored the trafficking 
of the G170R-Mi variant from mitochondria to peroxisomes 
by using an inhibitor of the mitochondrial protein import. 
Since the G170R substitution on the minor allele generates 
an enzyme that is catalytically active but erroneously local-
ized, any molecule that prevents the aberrant targeting 
should allow the variant to acquire its correct dimeric struc-
ture and be imported into peroxisomes in the active form [25, 
44]. A small-scale genetic screening has been applied to 
identify FDA-approved molecules able to inhibit protein 
translocation to mitochondria. The most promising inhibitor 
identified is dequalinium chloride (DECA). Upon treatment 
of cells expressing G170R-Mi with DECA, the variant is 
correctly imported into peroxisomes and the glyoxylate de-
toxification ability of the cells is partly restored. It has been 
also shown that DECA inhibits the import of the variant to 
mitochondria. The mechanism of action is independent of 
uncoupling and maintains the protein in a conformation 
competent for the import into peroxisomes. This accounts for 
the low toxicity of the compound with respect to traditional 
uncouplers that block the import of all mitochondrial pro-
teins by a non-selective mechanism. In addition, the effect of 
DECA seems to be additive with that of PN treatment, which 
raises the intracellular PLP concentration and promotes the 
correct folding of the protein [53]. Since the AGT mitochon-
drial mistargeting is induced by mutations that affect the 
folding of the protein it can be suggested that the combina-
tion of a treatment able to rescue protein folding with a mito-
chondrial transport blocker could increase the responsiveness 
of the patients.  
Overall, the data obtained provide the base for the use of 
mitochondrial import inhibitors as models for the study of 
AGT intracellular trafficking, as well as for the development 
of new therapeutics. In this regard, it should be noticed how-
ever that although DECA has been approved by FDA, with 
the specific indication of treating vaginal infections by topi-
cal application, it has been proved to be toxic upon par-
enteral administration to murine models [77]. On these 
bases, safety assessment should be carefully evaluated when 
designing therapeutic approaches for PH1 based on the use 
of mitochondrial import inhibitors. 
7. CONCLUSIONS 
In the last few years, many progresses have been made 
on the elucidation of the molecular pathogenesis of PH1 by 
performing analyses on cellular model systems and purified 
proteins. The picture emerging from these studies depicts 
PH1 as a disease mainly caused by conformational defects, 
thus driving the current research activity of many groups in 
the field towards the development of therapeutic strategies 
able to rescue misfolded variants. The approaches currently 
under investigation ranges from the testing of more effective 
B6 vitamers to the identification of synthetic molecules act-
ing as pharmacological chaperones or mitochondrial import 
inhibitors. The growing body of evidence will form the basis 
for future projects aimed at the design of more specific and 
more effective compounds, with the not-so-distant horizon of 
a personalized treatment of this life-threatening and poten-
tially fatal disease. 
LIST OF ABBREVIATIONS 
PLP = Pyridoxal 5’-phosphate 
AGT = Alanine: glyoxylate aminotransferase 
PH1 = Primary hyperoxaluria type I 
PTS1 = Peroxisomal targeting sequence type 1 
MTS = Mitochondrial targeting sequence 
PN = Pyridoxine 
PNP = Pyridoxine 5’-phospate 
PM = Pyridoxamine 
PL = Pyridoxal 
PMP = Pyridoxamine 5’-phosphate 
CHO = Chinese hamster ovary 
GO = Glycolate oxidase 
AOA = Aminooxyacetic acid 
PC = Pharmacological chaperone 
CC = Chemical chaperone 
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We report here a clinical case of a patient with a novel mutation (Arg347→ Gly) in the gene encoding aromatic
amino acid decarboxylase (AADC) that is associated with AADC deﬁciency. The variant R347G in the puriﬁed re-
combinant form exhibits, similarly to the pathogenic mutation R347Q previously studied, a 475-fold drop of kcat
compared to the wild-type enzyme. In attempting to unravel the reason(s) for this catalytic defect, we have car-
ried out bioinformatics analyses of the crystal structure of AADC-carbidopa complex with the modelled catalytic
loop (residues 328–339). Arg347 appears to interact with Phe103, as well as with both Leu333 and Asp345. We
have then prepared and characterized the artiﬁcial F103L, R347K and D345A mutants. F103L, D345A and R347K
exhibit about 13-, 97-, and 345-fold kcat decrease compared to thewild-type AADC, respectively. However, unlike
F103L, the R347G, R347K and R347Qmutants as well as the D345A variant appear to be more defective in catal-
ysis than in protein folding. Moreover, the latter mutants, unlike the wild-type protein and the F103L variant,
share a peculiar binding mode of dopa methyl ester consisting of formation of a quinonoid intermediate. This
ﬁnding strongly suggests that their catalytic defects are mainly due to a misplacement of the substrate at the ac-
tive site. Taken together, our results highlight the importance of the Arg347-Leu333-Asp345 hydrogen-bonds
network in the catalysis of AADC and reveal the molecular basis for the pathogenicity of the variants R347. Fol-
lowing the above results, a therapeutic treatment for patients bearing the mutation R347G is proposed.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
Aromatic amino acid decarboxylase (AADC) deﬁciency is a rare auto-
somal recessive disorder (OMIM #608643) caused by the deﬁcit of Dopa
or aromatic amino acid decarboxylase (AADC), a pyridoxal 5′-phosphate
(PLP) enzyme, which catalyses the conversion of L-Dopa and L-5-
hydroxytryptophan to dopamine and serotonin, respectively. The main
structural and functional properties of AADChave been recently reviewed
[1]. In AADC deﬁciency, impaired enzyme activity is mainly due to point
mutations in the AADC gene that lead to the synthesis of pathogenic var-
iants. The most commonly reported symptoms of AADC deﬁciency in-
clude hypotonia, neurodevelopmental delay, oculogyric crises and
complexmovement disorderwith autonomic features [2,3]. Studies of ce-
rebrospinal ﬂuid are key to diagnosis, showing reduced levels of 5-
hydroxyindoleacetic acid and homovanillic acid together with elevated
concentrations of L-Dopa, L-5-hydroxytryptophan and 3-O-methylDopa
[4–6]. Diagnosis is conﬁrmed by quantiﬁcation of plasma AADC enzyme
activity andAADC gene sequencing. To date, around 100 patientswith ho-
mozygous or compound heterozygous mutations have been genotyped.
Among them, 26 missense mutations have been identiﬁed, 18 of which
are homozygous in the affected patients (http://www.biopku.org/home/
jake.asp). Biochemical characterizations of the latter variants in the puri-
ﬁed recombinant form of the enzyme, together with bioinformatics anal-
yses, revealed that most of the examined variants displayed kcat values
linearly related to the magnitude of the near-UV CD signals and the ANS
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emission ﬂuorescence intensities [7]. These variants concernmutations of
residues mapping to or interacting with loops 1 (aa 66–84), 2 (aa 100–
110) and 3 (aa 323–357). Since the comparison of the crystal structure
of the apo and holo forms of AADChighlights the relevance of these struc-
tural elements for the transition from the apo open form to the holo
closed form [8], it was proposed that the pathogenicity of thesemutations
is due to incorrect apo-to-holo conversion [7]. The only exception is rep-
resented by the mutation R347Q which, although presenting no confor-
mational alteration and maintaining a PLP binding afﬁnity similar to
that of the wild-type, exhibits severely decreased kcat value [7]. To date,
the reasons(s) for the loss of decarboxylase activity of this variant are un-
known. Here we report a clinical case of a patient with a novel homozy-
gous mutation, R347G, associated with AADC deﬁciency. This ﬁnding,
together with the fact that the point mutation of Arg347 (to Gln or Gly)
represents one of the most frequent pathogenic mutation and is present
both in homozygous and in compound heterozygous states, urged us to
undertake a detailed investigation on the molecular effects caused by
the mutations of Arg347. The biochemical characterization of the variant
R347G in the puriﬁed recombinant form reveals that it sharesmany struc-
tural and functional features with the variant R347Q. Thereafter we have
explored by bioinformatics analyses the possible interactions of Arg347 in
the crystal structure of the carbidopa-AADC complex inwhich the confor-
mation of the mobile loop (residues 328–339), invisible in this structure,
is modelled using the homologous region of histidine decarboxylase
(HDC) as a template [9]. These studies, together with the biochemical
characterization of the artiﬁcial mutants F103L, D345A, and R347K,
allow us not only to identify the Arg347-Leu333-Asp345 triad as an im-
portant hydrogen bonds network for efﬁcient catalysis of human AADC
but also to unravel the molecular basis of the pathogenicity of the R347
mutations. Thus, our data provide potentially clinically translatable infor-
mation for the therapy of patients harbouring pathogenic mutations at
Arg347.
2. Materials and methods
2.1. Ascertainment of clinical case
Patient Awas referred to a Tertiary Paediatric Neurology Centrewith
expertise in neurotransmitter disorders. Investigations and treatment
strategies were investigated as part of routine clinical care.
2.2. Materials
PLP, L-Dopa, L-Dopa methyl ester (DME), 2,4,6-trinitrobenzene-1-
sulfonic acid (TNB) and isopropyl-β-D-thiogalactopyranosidewere pur-
chased from Sigma-Aldrich. Protease inhibitor cocktail were purchased
from Roche. The 1,8-anilinonaphtalene sulfonic acid (ANS) was pur-
chased fromMolecular Probes. The other chemicals were of the highest
purity available.
2.3. Construction, expression and puriﬁcation of the variants R347G, R347K,
F103L and D345A
The R347G, R347K, F103L and D345A variants of AADC were con-
structed starting from the pDDChis construct that contains the complete
open reading frame of the human AADC including a C-terminal 6xhis-
tag and cloned into a pTrcHis2A expression vector [10]. Mutations
were introduced by the QuikChange site-directed mutagenesis kit
(Agilent Technologies) using the oligonucleotides 5′-CTGCATCG
GCTTATCCTGGGCGGCAAG-3′ and its complement, 5′-GCTTATCACTGA
CTACGGGCATTGGCAG-3′ and its complement, 5′-GGGCTTATCACTGA
CTACAAGCATTGGCAG-3′ and its complement, 5′-GGCTTATC
ACTGCCTACCGGCATTGG-3′ and its complement for F103L, R347G,
R347K and D345A, respectively (the mutated codons are underlined).
All the mutations were conﬁrmed by the entire DNA sequence analysis.
Expression plasmids of wild-type AADC [10], R347Q [7], F103L, R347G,
R347K and D345A variants were used to transform Escherichia coli
JM109 cells. Recombinant enzymes were expressed and puriﬁed by fol-
lowing the procedure previously described [10], and stored at−20 °C.
The mutants yield after the standard puriﬁcation was about 70% that
of the wild-type enzyme. Protein concentrations were determined
using the εM = 142,000 M−1 cm−1 at 280 nm and the PLP content of
the enzymes was determined by releasing the coenzyme in the pres-
ence of 0.1 M NaOH and by using εM 6600 M−1 cm−1 at 388 nm [11].
The puriﬁed variants were homogeneous as indicated by a single band
upon migration in SDS-PAGE with mobility identical to that of the
wild-type protein.
2.4. Spectroscopic measurements
Absorption measurements of F103L, R347G, R347Q, R347K, and
D345Awere performedusing a Jasco V-550 spectrophotometer at a pro-
tein concentration of 10 μM in the absence or in the presence of 300 μM
DME. CD measurements were made with a Jasco J-710 spectropolarim-
eter at a protein concentration of 6 μM. ANS binding spectra were re-
corded using a FP Jasco spectroﬂuorimeter setting at 5 nm excitation
and emission bandwidths, following excitation at 365 nm of 1 μM en-
zyme sample that was previously incubated in the presence of 15 μM
ANS for 1 h at 25 °C (in the dark) and in the presence of 20 μM PLP.
All the spectroscopic measurements were carried out in 100mM potas-
sium phosphate buffer, pH 7.4, at 25 °C.
2.5. Apoenzyme preparation and coenzyme binding afﬁnity
Apoenzymewas prepared as described previously [10]. The equilib-
riumdissociation constant for PLP, KD(PLP), of the variants R347G, R347K,
F103L, and D345A was determined by measuring the quenching of the
intrinsic ﬂuorescence of 0.15 μM apoenzyme in the presence of PLP at
concentrations ranging from 0.01 to 20 μM in 100mMpotassium phos-
phate buffer, pH 7.4 and by ﬁtting the data to the following equation
Y ¼ Y max
E½ #t þ PLP½ #t þ KD PLPð Þ−
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
E½ #t þ PLP½ #t þ KD PLPð Þ
" #2−4 E½ #t PLP½ #tq
2 E½ #t
where [E]t and [PLP]t represent the total concentrations of the enzyme
and PLP, respectively, Y refers to the intrinsic quenching changes at a
PLP concentration, [PLP], and Ymax refers to the ﬂuorescence changes
when all enzyme molecules are complexed with coenzyme. Curves
ﬁtting was performed using Origin® 7.03 (OriginLab).
2.6. Enzyme activity assay
The decarboxylase activity of the AADC variants was measured by a
spectrophotometric assay as previously described [12] and modiﬁed
[13]. Brieﬂy, after an appropriate incubation time (a time within
which a linear product formation is observed) of the enzyme in the
presence of 2 mM L-Dopa and 10 μM PLP in a ﬁnal volume of 250 μl,
the reaction is stopped by heating at 100 °C for 1 min. Toluene
(1.5 ml) and TNB (1 ml of a 4.3 mM solution) are then added, and the
extraction of trinitrophenyldopamine is carried out at 42 °C for 1 h
with continuous shaking. The concentration of trinitrophenyldopamine
in the toluene layer is measured by using 12,400 M−1 cm−1 as the
molar extinction coefﬁcient for trinitrophenyldopamine at 340 nm
[14]. The kinetic parameterswere determined by incubating themutant
recombinant proteins in the presence of different L-Dopa concentrations
under saturating PLP concentration in 100 mM potassium phosphate
buffer, pH 7.4. The concentrations of F103L, D345A, R347G, and R347K
were 0.3 μM, 2 μM, 3 μM, and 5 μM, respectively, while the reaction
times were 10 min for F103L and D345A, or 20 min for R347G and
R347K. Data were ﬁtted to the Michaelis–Menten equation.
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2.7. HPLC analyses
Following incubation for 3 h in the presence of 300 μM DME in
100mMpotassium phosphate buffer, pH 7.4, at 25 °C, wild-type or var-
iants AADC 10 μMwere denatured by the addition of trichloroacetic acid
to a ﬁnal concentration of 5% (v/v). The quenched solutionswere centri-
fuged to remove protein, and the supernatants were analysed by HPLC,
using a Nucleodur 100–5 C18 (250 × 4.6 mm) (Macherey-Nagel) col-
umn connected to a Jasco PU-2080 PlusHPLC control system. The eluent
was 50 mM potassium phosphate buffer, pH 2.35, at a ﬂow rate of
1 ml/min. A Jasco UV-2075 Plus detector set at 295 nm was employed.
Peaks corresponding to PLP and pyridoxamine 5′-phosphate (PMP)
were integrated using the Jasco Borwin software. Standard curves of
peak area as a function of PLP or PMP concentration were prepared.
2.8. Atomic coordinates and modelling
Atomic coordinates were taken from the Protein Data Bank (PDB):
the ID code 1JS3 was used for AADC complexed with carbidopa and ID
code 4E1O for HDC [9,15]. The visualization of structures and contacts
analyses were performed using the Molecular Operating Environment
(MOE) software. Energy minimization reﬁnement, applying the
AMBER99 force ﬁeld, and the protonation state correction were per-
formed usingMOE software. Missing or substituted atoms and loop res-
idues inAADC, either native ormutant,weremodelled usingMODELLER
9.10 [16] and the solvedHDC loop (residues 328–346) [9]. Structural su-
perimpositions were conducted using PyMol [17].
3. Results and discussion
3.1. Identiﬁcation of a new homozygous mutation of AADC causing AADC
deﬁciency
Patient A, a male infant, was referred for further investigation of
neurodevelopmental delay. Routine diagnostic testing revealed a raised
prolactin level and a vanilly lactate peak on urinary organic acids. A low
homovanillic acid, low 5-hydroxyindoleacetic acid, raised 3-
orthomethyl-dopa and 5-hydroxytryptophan were evident on cerebro-
spinal ﬂuid neurotransmitter analysis. Plasma AADC enzyme activity
was undetectable. Molecular genetic testing of AADC revealed a homo-
zygousmutation, c.1039C NG (R347G) in the proband, with appropriate
familial segregation. Pyridoxine and calcium folinate treatment were
commenced initially, with some discernible clinical improvement in
baseline tone and involuntary movements. Following this, the MAO in-
hibitor, Selegeline, was added and lead to further clinical improvement.
A latter addition of the dopamine agonist, Pramipexole, has led to ongo-
ing beneﬁts. Overall there has been reduction of the frequency and se-
verity of the oculogyric crises as well as further neurodevelopmental
gains with improvement in axial and peripheral tone.
3.2. Impact of the R347G mutation on the structure and function of AADC
The spectroscopic features of the R347G variant in the puriﬁed re-
combinant form were compared with the corresponding ones of the
wild-type AADC. No differences were observed between the far-UV CD
spectra of the mutated and the wild-type forms of the enzyme (data
not shown), suggesting that the mutation does not affect the overall
secondary structure of AADC. As shown in Fig. 1 and inset, the R347G
variant exhibited in the visible region absorbance and positive dichroic
bands at 420 and 335 nm whose intensities were similar to the corre-
sponding ones of the wild-type AADC. The R347G variant had a KD(PLP)
value ~4-fold higher than that of the wild-type enzyme (Table 1). In
order to evaluate the structural features of the mutated protein, near-
UV CD spectra and ANS ﬂuorescence spectra of this variant were moni-
tored. When ANS binds to hydrophobic surfaces of proteins, it emits a
ﬂuorescence signal whose maximum wavelength (at around 450 nm)
is red-shifted and the intensity increases. The near-UV CD spectra of
the holo and the apo forms of the R347G variant as well as the ANS
emission spectra of the holo form revealed amodest decrease in the dif-
ference of the dichroic signals between the holo- and the apo- forms as
well a slight increase of the ANS emission intensity of the holo form
(data not shown), in comparison to the wild-type enzyme. Thus, these
data ﬁt the linear relation depicted in Fig. 2A, suggesting that the
R347Gmutation has amodest impact on the apo-holo transition. To de-
termine the functional effects of replacing Arg347 by Gly, the steady-
state kinetic parameters of the R347G variant were measured and com-
pared to those of the wild-type enzyme (Table 1). The variant exhibits a
very large drop in its catalytic efﬁciency, ~2760-fold, mainly driven by
the ~475-fold decrease of its kcat value. Interestingly, the location of
the R347G variant on the curve in Fig. 2B is similar to that of the
R347Q variant, suggesting that both variants R347Q and R347G behave
similarly in sharing a sharp decrease in the kcat value (corresponding to
a residual catalytic activity of 1.1% and 0.2%, respectively), despite no or
onlymodest conformational alterations. Based on these results,we have
decided to gain further insights into the catalytic relevance of the large
and positively charged side chain of Arg347 by using bioinformatics
analyses aiming to identify the possible interaction(s) between
Arg347 and other AADC residues.
3.3. Bioinformatics analyses
The position and possible interactions of Arg347 were analysed,
starting from the coordinate ﬁle of the pig kidney AADC in complex
with carbidopa (PDB ﬁle 1JS3). Arg347 belongs to loop 3 and maps
near the active site cavity in proximity of the 328–339 loop. This is amo-
bile segment, invisible in the electron density maps, that seems to be
important for the catalytic mechanism [15,18]. Before inspecting the
structure, the protonation state of the molecule was corrected to
mimic the physiological condition, and the structure was reﬁned by
Fig. 1. Absorbance and CD spectra of wild-type AADC and variants. Absorption and CD
(inset) spectra of (—) wild-type, (\\\\\\) R347G, (-⋅⋅) R347K, (—-) F103L, and (⋅⋅⋅⋅⋅)
D345A at 10 μM enzyme concentration in 100 mM potassium phosphate buffer, pH 7.4.
Table 1
Kinetic parameters and coenzyme binding afﬁnity.
Enzyme kcat
(s−1)
Km
(mM)
kcat/Km
(s−1 mM−1)
KD(PLP)
(nM)
Wild-typea 7.6 ± 0.1 0.11 ± 0.01 69 ± 6 43 ± 12
R347Qb 0.087 ± 0.005 0.49 ± 0.08 0.18 ± 0.03 54 ± 10
R347G 0.016 ± 0.001 0.64 ± 0.13 0.025 ± 0.05 178 ± 14
R347K 0.022 ± 0.003 0.31 ± 0.01 0.071 ± 0.011 214 ± 12
F103L 0.55 ± 0.09 0.15 ± 0.01 3.67 ± 0.007 98 ± 18
D345A 0.078 ± 0.001 0.60 ± 0.03 0.13 ± 0.65 150 ± 20
a Ref. [8].
b Ref. [6].
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energy minimization. As shown in Fig. 1 of SM, the side chain of Arg347
is predicted to form a hydrogen bond with the main chain oxygen of
Phe103, an active site residue composing the hydrophobic cavity that
hosts the substrate. The π system of Phe103 appears to be involved in
the binding and orientation of the substrate as well as in stabilizing
the position of the Tyr79 side chain [15]. Moreover, the proximity of
Arg347 in the primary structure to the C-terminus of the loop (aa
328–339)missing in the structure, urged us to also explore the possible
interaction(s) of this residue with those of the loop. Thus, we modelled
the latter starting from the structure of AADC complexed with
carbidopa, using the homologous region of HDC (PDB: 4E1O; residues
328–346) as template [9]. The modelling results obtained are shown
in Figs. 3 and Fig. 2 of SM. Two main interactions are engaged by
Arg347: 1) the guanidine moiety is placed at hydrogen-bond distance
from themain-chain oxygen atom of Leu333 (~3.1 Å), the latter residue
being adjacent to Tyr332, which is involved in the decarboxylase activ-
ity [18]; 2) the second one takes place between Arg347 and Asp345
(~2.4 Å), which also interacts also with the imidazole ring of His335
(~3.1 Å; Fig. 3). Therefore, it is predicted that there is a network of inter-
actions involving residues Asp345, Arg347, His335 and Leu333, the role
of which is probably to stabilize the closed conformation of the AADC
catalytic loop. Similar interactions were also observed in the crystal
structure of the close homologous human HDC (e.g., Asp345-His337;
Fig. 2 of SM). However, in HDC the stabilization of residue Leu333 rea-
sonably involves a hydrophobic interaction between its side-chain and
Met347, which corresponds to Arg347 in human AADC. Since both
interactions of Arg347 with Leu333 and Asp345 are missing in the
R347G mutant, we have modelled the previously characterized patho-
genic variant R347Q in an attempt to analyse the interactions of
Gln347 with neighbouring residues. As shown in Fig. 4, the modelling
study reveals that (i) the interaction (i.e., a hydrogen-bond) with
Asp345 is still conserved, even if the minimum distance between the
residues Gln347 and Asp345 (̴ 3.5 Å) is greater compared to the distance
observed for the residues Arg347 and Asp345, and (ii) the interaction
with Leu333 is completely lost, presumably leading to destabilization
Fig. 2. Relationship between conformational and catalytic features of wild-type and
variants. The position of wild-type AADC and variants R347G, R347Q, R347K, D345A and
F103L are indicated. The solid symbol (■) represents positions of variants previously
studied [7]. (A) Plot of difference of the magnitude of the near-UV dichroic signal of holo
and the corresponding apo enzyme as a function of the ratio of ANS intensity of each
variant and the wild-type, and (B) plot of the decrease of kcat as a function of the
increase of ANS intensity. The diagonal lines correspond to a linear ﬁt, with R2 values of
−0.926 and 0.842 for (A) and (B), respectively.
Fig. 3.Modelledmobile loop of human AADC (residues 326–346). The position of the loop
(pink ribbons and sticks) is shown in the context of theAADCstructure (grey ribbons). The
predicted hydrogen bonds network involving Arg347, Asp345 and residues of the mobile
loop (Leu333 and His335) is shown in yellow, together the relative distances (Å).
Fig. 4.Modelled R347Q and R347Kmutants of humanAADC. The position of the loop 326–
346 (pink ribbons and sticks) is shown in the context of the dimeric AADC structure. Chain
A is represented as grey ribbons. The distance (Å) between residues Gln/Lys347 and
Asp345 is shown in yellow and orange, respectively.
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of the catalytic loop. Therefore,we could reason that theArg347-Leu333
interaction is pivotal for the proper positioning of the active site residue
Tyr332 and that the lack of such interaction would result in impaired
decarboxylase activity. We have also modelled an artiﬁcial R347K mu-
tant that, according to our assumptions, was predicted to be engaged
in a similar pattern of interactions as observed for the wild-type
AADC. Interestingly, as shown in Fig. 4, the ε-amino group of Lys347
preserves the electrostatic interaction with Asp345 ( ̴ 3.4 Å), but, as in
the case of the R347Q mutant, it loses the hydrogen-bond with the
main-chain O atom of Leu333, leading us to suppose that such amutant
would also have exhibited a sharp decrease in catalytic activity similar
to that observed for the mutants R347G and R347Q. Therefore, on the
basis of all the above observations, we have prepared and characterized
the F103L, D345A and R347K mutants.
3.4. Impact of themutations F103L, D345A and R347K on the structural and
functional properties of the wild-type AADC
The variants F103L, D345A, and R347K were expressed in E. coli and
puriﬁed to homogeneity, as described inMethods section. A comparison
of their far-UV CD spectra with that of the wild-type protein revealed
superimposable features, indicating that substitution of Phe103,
Asp345 or Arg347 for leucine, alanine or lysine, respectively, does not
alter the secondary structure of the wild-type AADC, signiﬁcantly (re-
sults not shown). The visible absorption and CD spectra of the variants
F103L, D345A and R347K were similar to the corresponding spectra of
wild-type AADC (Fig. 1 and inset). The KD(PLP) values of the variants
F103L, D345A and R347K were ~2-, ~3.5-, and 5-fold, respectively,
higher than the corresponding value of the wild-type enzyme
(Table 1). Dichroic spectra in the near-UV region of both holo and apo
form of the three variants together with the ANS ﬂuorescence emission
spectra of their holo formswere acquired and comparedwith the corre-
sponding spectra of the wild-type protein. As shown in Fig. 2A, the plot
of these data indicates that the examinedmutations ﬁt the linear corre-
lation of the differences between the dichroic signals of holo and apo
form against the ANS emission intensity of each holo mutant. The posi-
tion of the F103L and D345A mutants on the curve is indicative of the
meaningful impact of the mutations F103L and D345A on the apo-
holo transition, even if less pronounced than that of mutations of resi-
dues mapping to loop 1 (H70T, H72Y, Y79C, P81L) [8]. On the other
hand, the ﬁnding that the position of the R347K in this curve is similar
to that of the wild-type AADC, R347Q and R347G variants strongly sug-
gests that the mutation R347K does not alter the tertiary structure of
holo-AADC. In order toﬁndout if themutations under study have an im-
pact on decarboxylase activity, the steady-state kinetic parameters of
the variants were measured (Table 1). The kcat/Km of the variants
F103L, D345A, and R347K was decreased by ~19-, 530-, and 970-fold,
respectively, in comparison with the wild-type AADC value. The de-
crease in catalytic efﬁciency is mainly driven by the decrease in kcat
(~14-fold in F103L, ~97-fold in D345A, and ̴ 345-fold in the case of
R347K). When Phe103, belonging to the substrate binding pocket, and
in van der Waals contact with the catecholic ring of carbidopa (a sub-
strate analogue) [15], is substituted with a residue bearing an aliphatic
side chain, there was a little change in the Km value.
As shown in Fig. 2B, F103L ﬁts the linear relation between the struc-
tural and catalytic changes already identiﬁed for other AADC variants
[7]. This result, in linewith the fact that Phe103maps to loop 2, suggests
that mispositioning of the aromatic ring of Phe103 due to the loss of the
interaction with R347 could not explain the remarkable loss of catalytic
activity of the R347 variants (Table 1). On the other hand, it is evident
that D345A and R347K do not ﬁt the linear relation, taking in the plot
a location similar to that of the wild-type protein and the other R347
variants (Fig. 2B). In other words, the drop in catalytic activity of the
variants R347Q, R347G, R347K and D345A is deﬁnitely more consistent
than the change in their conformation. These ﬁndings are in line with
the bioinformatics analyses prediction and strongly suggest that the
hydrogen bonds between Arg347 and both Asp345 and Leu333 are rel-
evant for the catalyticmechanism of AADC. In this regard, it is of interest
to note that both Arg347 and Asp345 residues are close to the dynamic
catalytic loop (residues 328–339) of AADC, while Leu333 is in the mid-
dle of this loop. Previous spectroscopic and kinetic studies indicated that
this catalytic loop undergoes a conformational change upon substrate
binding, leading to a closure of the active site thereby achieving a con-
formational state that is productive for decarboxylation [19]. Indeed,
site-directed mutagenesis has strongly suggested that Tyr332 performs
the protonation of the Cα atom of the quinonoid intermediate which is
crucial for the decarboxylation pathway [18].
3.5. Binding mode of variants with DME
Based on the above-mentioned results and considerations, we have
decided to analyse the effects of the mutations under study on the for-
mation of the external aldimine. This is the ﬁrst intermediate that
forms upon covalent binding of the substrate to the formyl group of
the cofactor in PLP-enzymes while exchanging internal with external
Schiff base through a gem-diamine intermediate [20]. PLP reactivity
has beenwidely studied for this family of enzymes and the generally ac-
cepted hypothesis is based on Dunathan's proposal, published in 1966,
suggesting that PLP-enzymes employ stereoelectronic effects to control
their reaction speciﬁcity [21]. Dunathan's hypothesis assumes that en-
zymes place the bond to be broken of the external aldimine parallel to
the p-system. In thisway the developing p orbital is aligned formaximal
overlap with the extended p system, lowering the energy of the transi-
tion state and increasing the reaction rate. In decarboxylases, the Cα-
COO− should be found in the orthogonal position to the p-system and
its rupture allows the generation of a carboanionic quinonoid interme-
diate which is further protonated at the Cα leading to amine generation
[22].
We have selected DME, a substrate analogue that contains an ester-
iﬁed carboxyl group and, therefore, is not susceptible to decarboxyl-
ation. For this reason, the AADC-DME complex appears to be a good
model for studying the external aldimine intermediate. The absorption
spectra upon addition of DME to the wild-type AADC and the variants
under study have been registered up to 3 h, a time after which DME un-
dergoes oxidation. As shown in Fig. 5, a prominent absorbance band
centred at 398 nm, already attributed to the formation of the external
aldimine, as well as a band at 325 nm characterize the complex of the
wild-type enzyme or F103L with DME. This is similar to what was
already seen for liver and kidney AADC [23,24]. On the contrary, we
have noticed that DME added to R347G, R347Q, R347K, and D345A
caused, in addition to the absorbance bands at 398 nm and 325 nm
(the latter being more pronounced than for wild-type AADC and
F103L), an absorbance band at 500 nm, typical of a quinonoid
Fig. 5. Absorption spectra of the complex of wild-type and variants with DME. Absorption
spectra ofwild-type and variants (10 μM)after 3 h of incubationwith 300 μMDMEat 25 °C
in 100 mM potassium phosphate buffer, pH 7.4.
680 R. Montioli et al. / Biochimica et Biophysica Acta 1864 (2016) 676–682
intermediate. It was also observed that both 325 and 500 nm bands in-
creasedwith time, concomitantlywith the decrease of the 398nmband.
To determine if this reaction converts PLP into PMP or other coenzyme
forms, aliquots were withdrawn after 3 h of incubation of the wild-type
enzyme and the variants F103L, R347Q, or R347G or R347K or D345A
with 300 μMDME. These samples were then subjected to HPLC analysis
after total denaturation. Interestingly, it was found that, while the orig-
inal PLP content of thewild-type AADC and themutant F103L remained
unchanged, about 10–15% of the PLP of mutants R347Q, R347G, R347K
and D345A was converted into PMP.
These results may indicate that the reaction in mutants R347Q,
R347G, R347K and D345A does not stop at the step of external aldimine
formation. Instead, the appearance of the quinonoid species at 500 nm
and the production of PMP are consistent with the suggestion of DME
binding at the active site of the variants in a conformation orienting
the Cα–H bond perpendicular to the plane of the cofactor system. In
otherwords, such an event is indicative of amispositioning of the exter-
nal aldimine at the active site of these variants.
3.6. The structural and functional relevance of the Arg347-Leu333-Asp345
triad
Taken together, these results rule out the possibility that the lack of
the interaction of Arg347 with the main chain oxygen of Phe103 could
be responsible for decreased catalytic activity of the different R347mu-
tants. Rather, they point to a set of hydrogen bonds engaged by Arg347
with both Asp345 and Leu333 and its effect on the decarboxylase activ-
ity of the humanAADC. As predicted by bioinformatics analyses, the dis-
ruption of both hydrogen bonds occurs uponmutation of Arg347 to Gly,
while the disruption of one hydrogen bond takes place upon mutation
of Arg347 to Gln or Lys or inmutant D345A. Since remarkable decreases
in the kcat (even if to different degree) is shared by all the tested R347
mutants and the D345 mutant, it is reasonable to suggest that the
Arg347-Leu333-Asp345 hydrogen bonds network plays an important
role in the catalysis of AADC. Moreover, the signiﬁcant decrease in the
kcat values of R347G, R347Q, R347K, and D345A appears to be a conse-
quence of an incorrect location of the external aldimine at their active
site. These ﬁndings allow us to (i) indicate that Leu333, belonging to dy-
namic catalytic loop, and the Arg347 and Asp345 residues adjacent to it,
are structural elements that impose important constrains on the align-
ment of the catalytic groups at the active site of the human AADC
upon substrate binding, and (ii) offer an explanation for the molecular
basis of the pathogenicity of the R347Q and R347G variants.
3.7. Therapeutic suggestions
Up to date, speciﬁc treatments guidelines are lacking for patients
with AADC deﬁciency. Thus, a combination of pyridoxine, L-Dopa,
MAO inhibitors and dopamine agonists is often administered in order
to potentiate dopaminergic transmission. Like other diseases related
to protein malfunctioning, an inherited mutation can be a catalytic
and/or a folding mutation, thus altering protein function in different
ways. For this reason, a detailed analysis into how missense mutations
induce AADC deﬁcit may provide a useful guidance for a proper thera-
peutic choice, and thereby improve clinical outcome. Only in the last
three years studies performed using pathogenic AADC variants in the
puriﬁed recombinant form have allowed identifying, at the protein
and/or cellular level, their defects and, on these bases, stratify patients
into different therapeutic categories [7,10,25]. Following this view,
characterization of the variants R347Q and R347G provides the basis
for delineate themost appropriate pharmacological therapy for patients
bearing the pathogenic mutations of Arg347. The low kcat value of the
puriﬁed recombinant R347G strongly suggests that a dopamine agonist
together with folinate could be the best way of assessing a good clinical
response of patients bearing theR347Gmutation. In fact,while the ther-
apy with dopamine agonists could mime the dopamine effects, the one
with folinic acid could not allow its depletion due to the conversion of
accumulated L-Dopa into 3-O-methylDopa. The same therapy strategy
could be applied to patients harbouring the R347Q variant. However,
in the case of mutation R347G, which, unlike R347Q, has a 4-fold
KD(PLP) value higher than that of the wild-type, the supplementation of
pyridoxine could also be useful. All these considerations seem to be con-
sistent with the improvement observed following the treatment of pa-
tient A.
4. Conclusion
A clinical case of a patient bearing a novel mutation in AADC, R347G,
associated with severe enzyme activity deﬁciency is reported. Similarly
to the pathogenic R347Q variant previously studied [7], the R347Gmu-
tant appears to be defective in catalysis rather than protein folding. The
reason(s) for the dramatic loss of decarboxylase activity caused by the
substitution of Arg347 with either Gly (~475-fold) or Gln (~87-fold)
were investigated. The in silico modelling of the missing loop 328–339
of AADC structure predicted interactions of Arg347 with Asp345 and
Leu333. Structural and functional features of the newdesignedmutants,
D345A and R347K in recombinant AADC, strongly suggested that resi-
dues Arg347, Asp345, and Leu333, as well as their mutual interaction,
are structural elements relevant for a proper location/orientation of
the substrate and/or of the catalytic groups at or near the active site. Al-
together, our data highlight the molecular defects caused by the muta-
tions of Arg347, and allow us to suggest a therapeutic management of
patients bearing the mutation R347G.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbapap.2016.03.011.
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a b s t r a c t
In this work the dimerization process of the minor allelic form of human alanine glyoxylate amino-
transferase, a pyridoxal 50-phosphate enzyme, was investigated. Bioinformatic analyses followed by site-
directed mutagenesis, size exclusion chromatography and catalytic activity experiments allowed us to
identify Arg118, Phe238 and Phe240 as interfacial residues not essential for transaminase activity but
important for dimer-monomer dissociation. The apo and the holo forms of the triple mutant R118A-Mi/
F238S-Mi/F240S-Mi display a dimer-monomer equilibrium dissociation constant value at least ~260- and
31-fold larger, respectively, than the corresponding ones of AGT-Mi. In the presence of PLP, the apo-
monomer of the triple mutant undergoes a biphasic process: the fast phase represents the formation of
an inactive PLP-bound monomer, while the slow phase depicts the monomer-monomer association that
parallels the regain of transaminase activity. The latter events occur with a rate constant of
~0.02 mM!1min!1. In the absence of PLP, the apomonomer is also able to dimerize but with a rate
constant value ~2700-fold lower. Thereafter, the possible interference with the dimerization process of
AGT-Mi exerted by the mutated residues in the I244T-Mi and F152I-Mi variants associated with Primary
Hyperoxaluria type 1 was investigated by molecular dynamics simulations. On the basis of the present
and previous studies, a model for the dimerization process of AGT-Mi, I244T-Mi and F152I-Mi, which
outlines the structural defects responsible for the complete or partial mistargeting of the pathogenic
variants, was proposed and discussed.
© 2016 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights
reserved.
1. Introduction
Human liver peroxisomal alanine glyoxylate aminotransferase
(AGT) (EC 2.6.1.44) catalyses the transamination of L-alanine and
glyoxylate to pyruvate and glycine, respectively, by a classical
ping-pong mechanism. In the ﬁrst half-reaction the enzyme in
the pyridoxal 50-phosphate (PLP) form (AGTePLP) reacts with L-
alanine generating pyruvate and the enzyme in the pyridox-
amine 50-phosphate form (AGTePMP). Then, in the second half-
reaction, AGTePMP binds glyoxylate and converts it to glycine
regenerating AGTePLP [1]. Human AGT is a dimer and belongs to
the Fold Type I class of the PLP-enzyme family [2]. The crystal
structure reveals that each subunit is composed of an N-terminal
extension (residues 1e21) that wraps over the surface of the
other subunit, a large domain (residues 22e282) containing most
of the active site residues and of the dimerization interface, and a
small domain (residues 283e392) containing a peculiar KKL type
1 peroxisomal targeting sequence (PTS1) at the C-terminus [2]. A
deﬁcit of AGT causes Primary Hyperoxaluria Type I (PH1) (OMIM
Abbreviations: AGT-Mi, minor allele of human alanine glyoxylate aminotrans-
ferase; PH1, Primary Hyperoxaluria type I; PTS1, type 1 peroxisomal targeting
sequence; Kd(dim-mon), dimer-monomer equilibrium dissociation constant; MD,
molecular dynamics; ASA, solvent accessible area; Kd(PLP), equilibrium dissociation
constant for PLP; SEC, size exclusion cromatography; DLS, dynamic light scattering;
ANS, 8-anilino-1-naphthalenesulfonic acid; RMSD, root mean square deviation;
RMSF, root mean square ﬂuctuation; ED, essential dynamics.
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259900), a rare metabolic recessive disease due to inborn errors
affecting the metabolism of glyoxylate in liver peroxisomes [3].
The AGXT gene encoding AGT is present in humans in two
polymorphic forms: the most common major allele encoding
AGT-Ma, and the less common minor allele encoding AGT-Mi.
The latter differs from the major allele for the presence of a 74-
bp duplication in intron 1 and of two mutations leading to the
Pro11-to-Leu and Ile340-to-Met amino acid substitutions [4]. The
P11L replacement generates a structural motif of binding to the
mitochondrial import receptor TOM 20, and this could partly
explain why AGT-Ma is 100% peroxisomal, while AGT-Mi is 95%
peroxisomal and 5% mitochondrial. Moreover, as compared with
AGT-Ma, AGT-Mi has a reduced (~70%) catalytic activity and,
importantly, a reduced dimeric stability under chemical stress [5,
6]. Nevertheless, since the true value of the dimer-monomer
equilibrium dissociation constant (Kd(dim-mon)) for both AGT-Ma
and AGT-Mi is only assumed to be lower than 0.3 mM [5], it is
not possible to establish if the mutations P11L and/or I340M alter
the dimer-monomer dissociation under native conditions. The
AGT-Mi polymorphism is not pathogenic per se, but many mu-
tations are pathogenic only when they functionally synergize
with the minor allele. Some of them, like G170R, F152I, I224T,
G47R and G41R cause a complete or partial aberrant targeting of
AGT to mitochondria, thus resulting in a hampering of the
metabolic function. Fargue et al. [7] advanced the possibility that
all PH1-causing mutations segregating with the minor allele
synergize with the P11L mutation unmasking the cryptic mito-
chondrial targeting sequence, and, as a consequence, leading to
peroxisome-to-mitochondrion mistargeting. However, it should
be noted that, when transiently expressed in CHO cells, the G161
variants co-segregating with the minor allele were found as
cytosolic aggregates [8]. Again, it was reported that (i) the G41R-
Mi shows a complex picture, some mithocondrial labelling and
some peroxisomal in the shape of intraperoxisomal aggregates
[9], and (ii) G47R-Mi shows a peroxisomal and mitochondrial
localization [10]. Moreover, the structural basis of the suggested
synergic interaction of P11L with each mutation leading to mis-
targeting is far from being elucidated. Since AGT in the mono-
meric form and containing the P11L mutation is a prerequisite for
the aberrant targeting of the enzyme, we decided to study the
associative/dissociative process of AGT-Mi in the apo and holo
forms. Up to date, the self-association of the subunits of AGT
including the structural elements which contribute to dimer
formation is unknown. It was only demonstrated that the dele-
tion of the N-terminal extension does not prevent AGT dimer
formation [11], and it was suggested the involvement of the P11L
mutation in the destabilization of the dimeric structure of AGT [5,
11].
In this work, guided by bioinformatic information, a series of
single, double, and triple mutants was engineered and analyzed
for their catalytic activity, spectroscopic features, and quaternary
structure. Taken together, our studies allowed us to identify
Arg118 as a hotspot dimer interfacial residue playing a relevant
role in the dimerization process of AGT-Mi. Moreover, we noticed
that the combination of R118A mutation with F238S and F240S
mutations signiﬁcantly alter the extent of monomerization of
both apo and holoAGT-Mi. Starting from the folded apomonomer
of the triple mutant the process of dimerization was investigated.
We established that in the presence of PLP the formation of a
PLP-bound monomer precedes the generation of the holodimer,
which parallels the regain of transaminase activity. These events
occur with a rate constant of 0.020 ± 0.002 mM!1min!1. The
apomonomer, in the absence of exogenous PLP, is also able to
dimerize even if with a rate constant 2700-fold lower that of the
PLP-bound monomer. In addition, predictions by means of
molecular dynamics (MD) simulations of the structural effects
caused by the mutations F152I and I244T on the minor allele
provide a possible interpretation and explanation for their
interference with the dimerization process.
2. Materials and methods
2.1. Materials
PLP, L-alanine, NADH, rabbit muscle L-lactic dehydrogenase, and
isopropyl-b-D-thiogalactopyranoside (IPTG) were obtained from
Sigma. 8-anilino-1-naphthalenesulfonic acid (ANS) was purchased
from Molecular Probes. All other chemicals were of the highest
grade commercially available.
2.2. Bioinformatic analyses
Alanine scanning mutagenesis, analysis of the interfacial hydro-
phobic patches and inspection of the AGT structure and interface
contacts were performed by the software Molecular Operating
Environment (MOE 2015.1001) [12] of the Chemical Computing
Group using the crystal structure of humanAGT (pdbﬁle: 1H0C). The
dimeric structure of human AGT was obtained by means of the PISA
web server [13] starting from the available coordinate ﬁle of the
monomer (PDB id: 1H0C) [2]. In particular, each residue present on
the dimerization interface involved in either intrachain or interchain
contacts was subjected to alanine scanning mutagenesis using the
UnaryQuadratic Optimization (UQO)under the LowMode ensemble,
which uses the LowModeMD [14] to search the conformational
space of the mutants. The conformations that satisﬁed the required
energetic and geometric criteria were saved to the output database.
Atoms located at a distance greater than 4.5 Å from themutation site
were marked as inert, iterations were limited to 50, and conforma-
tions were limited to ten for each mutated complex. The dStability
values (kcal/mol) were calculated with MOE 2015.1001 [12].
2.3. Site-directed mutagenesis
The mutant forms of human AGT-Mi were constructed by the
QuikChangeTM II kit from Agilent Technologies using the
pTrcHis2A vector encoding AGT-Mi (pAGT-His) [1] as template and
the oligonucleotides listed in the Supplementary Table S1.
2.4. Expression and puriﬁcation of AGT-Mi and mutants
E. coli JM109 cells transformed with vectors encoding AGT-Mi or
mutated AGT-Mi were grown in 4.5 l of Luria broth at 37 "C to an
absorbance at 600 nm of 0.4e0.6. Expression was induced after 6 h
with 0.1 mM IPTG for 15 h at 30 "C. Cells were harvested and
resuspended in 20 mM sodium phosphate buffer pH 7.4, containing
0.5MNaCl, 20mM imidazole and 100 mMPLP. Lysozymewas added
to a ﬁnal concentration of 0.2 mg/ml and the culture was incubated
for 15 min at room temperature. After a freeze-thaw, leupetin
(0.5 mg/ml) and pepstatin (0.5 mg/mL) were added and the sus-
pension was centrifuged at 30,000 g for 30 min at 4 "C. The lysate
was loaded on a HisPrep FF 16/10 equilibrated with 20 mM sodium
phosphate buffer pH 7.4 containing 0.5 M NaCl and 20 mM imid-
azole. A linear gradient was then applied (0e100% in 240 ml) with
the same buffer containing 500 mM imidazole. AGT-Mi and mu-
tants elute between 200 and 300 mM imidazole. After addition of
100 mM PLP, the protein solution was concentrated; imidazole and
unbound coenzyme were removed by extensive washing with
100mM potassium phosphate buffer, pH 7.4, using Amicon Ultra 10
concentrators (Amicon). The protein concentration in the AGT-Mi
and mutants samples in the dimeric form was determined using
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an extinction coefﬁcient of 9.54! 104M"1 cm"1 at 280 nm [15]. The
molar extinction coefﬁcient for the monomeric form of AGT-Mi at
280 nm was determined as described by Pace et al. [16] and was
4.61 ! 104 M"1cm"1. The PLP content of AGT-Mi and mutant en-
zymes was determined by releasing the coenzyme in 0.1 M NaOH
and by using an ε¼ 6600M"1cm"1 at 388 nm. The apo form of AGT-
Mi and mutants were prepared as indicated by Cellini et al. [1].
2.5. Enzymatic activity assays
The kinetic parameters for the overall transamination of the L-
alanine/glyoxylate pair of AGT-Mi and mutants was measured in
presence of saturating PLP (100 mM) at an enzyme concentration
ranging from 0.1 mM to 20 mM. Each species was incubated in the
presence of various substrate concentrations at a ﬁxed co-substrate
concentration, at 25 $C in 0.1 M potassium phosphate buffer, pH 7.4.
The reactionwas stopped after 10 min by adding TCA 10% (v/v). The
produced pyruvate was measured by a spectrophotometric assay
using the coupled lactate dehydrogenase system [1].
2.6. Binding afﬁnity of apomonomer for the PLP cofactor (Kd(PLP))
Kd(PLP) of the dimeric forms of 0.3 mMAGT-Mi, R118A-Mi, F238S-
Mi and F240S-Mi and of monomeric form of 1 mMR118A-Mi/F238S-
Mi/F240S-Mi was determined by measuring changes in the ellip-
ticity at 424 nm in 50 mM potassium phosphate buffer, pH 7.4, in
the presence of PLP concentrations ranging from 1 to 10 mM for
AGT-Mi and the single mutants and from 1 to 50 mM for the triple
mutant. The Kd(PLP) value was obtained using the following
equation:
Y¼
½E&tþ½PLP&tþKdðPLPÞ"
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃh"
½E&tþ½PLP&tþK2dðPLPÞ
#
"4½E&t ½PLP&t
ir
2½E&t
(1)
where [E]t and [PLP]t represent the total concentrations of the
enzyme expressed as monomer and of PLP, respectively, Y refers to
the 424 nm dichroic signal change at the PLP concentration [PLP],
and Ymax refers to the changes when the total enzyme molecules
are complexed with the coenzyme.
2.7. Size exclusion cromatography (SEC)
It has been used to analyze the amount of monomer and dimer
present in the protein samples. Analysis was performed on an Akta
FPLC system (GE Healthcare) using the Unicorn 5.01 (GE Health-
care) software and a Superdex 200 10/300 GL column at room
temperature. The injection volume was 100 ml, the ﬂow rate 0.5 ml/
min, and the detection at 280 nm. The mobile phase was 50 mM
potassium phosphate buffer, pH 7.4, containing 100 mM PLP. To
determine the dimer-monomer equilibrium dissociation constant
(Kd(dim-mon)), a stock solution of enzyme in the apo or holo formwas
dissolved in 50 mM potassium phosphate buffer at pH 7.4 at
different concentrations, and after overnight incubation at 25 $C (a
sufﬁcient time to reach the equilibrium between monomer and
dimer) subjected to SEC. The concentration of monomer and dimer
was determined by integration the area under the curve and
expressed as percent of total area of all protein-related peaks.
According to Manning et al. [17] the Kd(dim-mon) value was
determined by the following equation:
where %D is the percentage of dimer to total enzyme, and [E]
represents the total enzyme concentration in dimer equivalents. A
plot of log½%D=0:04ð100" %DÞ2& with respect to log[E] yields a
straight line of slope 1. When log½%D=0:04ð100" %DÞ2&]¼ 1, Kd(dim-
mon) ¼ [E].
2.8. Kinetic of dimerization of triple variant
The time course of dimerization 2M/ D induced by exogenous
PLP has been ﬁtted to a simple second-order kinetics
½D& ¼ ½D&eq½E&kasst
1þ ½E&kasst (3)
where [D] and [D]eq represent the dimer concentrations at time t
and at equilibrium, respectively, [E] the enzyme concentration
expressed as dimer, and kass the association rate constant. The
equation was derived under the assumption that the reaction of
dimerization is irreversible. Although this is never true, at condi-
tions where kass is [ kdiss this assumption is valid and will not
signiﬁcantly alter the determined kass. Eq. (3) has also been used to
ﬁt the data of regain of enzyme activity and change in CD signal at
424 nm as a function of time.
On the other hand, to determine the kass of the reversible as-
sociation of the apo form, the kobs of dimerizationwas calculated at
different protein concentrations by the linear ﬁt of the decrement
of monomer concentration (1/[M]) versus time. kobs values as a
function of protein concentration were ﬁt to a line whose slope
gives the kass value.
2.9. Spectroscopic measurements
Absorption measurements were made with a Jasco V-550
spectrophotometer. Fluorescence spectra were taken with a Jasco
FP-750 spectroﬂuorometer using 5 nm excitation and emission
bandwidths. CD spectra were obtained using a Jasco J-710 spec-
tropolarimeter with a thermostatically controlled compartment at
25 $C. In the near-UV and visible spectra, the protein concentration
varied from 1 to 20 mM in a cuvette with a path length of 1 cm. Far-
UV measurements were taken at a protein concentration of 0.1 mg/
ml using a cuvettewith a path length of 0.1 cm. Secondary structure
content was calculated from far-UV CD spectra using the “CD
deconvolution” software. The thermal unfolding of AGT-Mi and
variants was monitored by CD at 222 nm at a concentration of 1 mM
in 100 mM potassium phosphate buffer, pH 7.4 with temperature
increasing of 0.5 $C/min from 25 to 90 $C. CD signals were ﬁtted
either to two or three state unfolding mode using Origin Pro7
software according to the method of Pace [18].
%D ¼
$
ð8½E& þ Kdðdim"monÞ ÞeK2dðdim"monÞ þ 16Kdðdim"monÞ E½ &
1
2
%&
0:08 E½ & (2)
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2.10. Dynamic light scattering (DLS) measurements
DLS measurements were made on a Zetasizer Nano S device
from Malvern Instruments. The temperature of sample cell was
controlled by a thermostating systemwithin ± 0.1 !C and 12.5 " 45
mm disposable cells with stopper were used. To study the aggre-
gation kinetics, an aliquot of each enzymatic species was diluted to
a ﬁnal concentration of 4 mM in potassium phosphate buffer 50 mM
pH 7.4 at 25 !C. The buffer was ﬁltered immediately before use to
eliminate any impurities.
2.11. MD simulations
All MD simulations were carried out by using the software
GROMACS 4.5.5 [19]. GROMOS 53A6 united atom force ﬁeld [20]
and the explicit simple point charge (spc/e) water model [21]
were used for the simulations. The dimeric structure of human
AGT was obtained by means of the PISA web server starting from
the available coordinate ﬁle of the monomer (PDB id: 1H0C). In the
original structure, loop residues 120-123 are missing, so the latter
were modelled by a loop modelling script of the Modeller software
[22]. We modelled AGT-Mi by introducing the P11L and I340M
mutations in the AGT protein using the Chimera software [23]. The
latter was also used to introduce the F152I and I244T mutations on
AGT-Mi. The molecular topology and atoms parameters for PLP
covalently bound to lysine 209 were taken from ATB [24, 25]. The
systems were simulated in a triclinic water box, and the minimum
distance between any atom of the protein and the box wall was set
up to 1.0 nm. The systems were neutralized by adding Naþ and Cl$
ions using the genion program of the GROMACS 4.5.5 package [19].
Each system was energy minimized in four phases. In the ﬁrst two
phases, 800 steps of steepest descent algorithm followed by 3000
steps of conjugate gradient were performed to gently relax the
water molecule around the protein, which was constrained
imposing harmonic position restraints of 1000 kJ mol$1 nm$2. In
the third and in fourth phases, the protocol was repeated without
using any constraint. Subsequently the minimizations steps, the
systems were equilibrated in four steps. In the ﬁrst stage, the sys-
tems were slowly heated up from 0 K to 300 K in 1 ns at 1 atm,
followed by two stages of equibration in isothermal-isobaric (NPT)
conditions for 600 ps, in which positional constraints were applied
on the solute atoms (force constant of 1000 J mol$1 nm$2). In the
last stage, a 400 ps unrestrained MD simulation was performed at
300 K and 1 atm to assess the stability of the systems. The tem-
perature and pressure were regulated by a Berendsen thermostat
and barostat, respectively [26]. The LINCS algorithm [27] was used
to constrain all bonds involving hydrogen atoms and the time step
was set to 2 fs Periodic boundary conditions (PBC) were applied.
The particlemesh Ewaldmethod (PME) [28] with a cut-off length of
1 nm was used to treat long-range electrostatic interactions, and
the same cut-off length was adopted for van derWaals interactions.
Finally, all monomer systems were simulated for 170 ns while
dimer systems were simulated for 200 ns. For the dimer systems,
we decided to carry out longer MD simulations (ca. 200 ns) because
the equilibrium state of the two dimer systems was reached at ca.
110 ns. To sum up, the AGT-Mi protein was simulated, in all its
mutated forms, totalizing ca. 740 ns of simulation time. For the
production runs, a Nos!e-Hoover thermostat [29, 30] at 300 K and
an Andersen-Parrinello-Rahman barostat [31, 32], at 1 atm were
used. The trajectories were analyzed using the standard GROMACS
tools. The root mean square deviations (RMSD) and the root mean
square ﬂuctuations (RMSF) were performed through GROMACS
inbuilt tools. RMSD plots for the AGT-Mi and F152I-Mi mutant were
calculated without considering 4-23 region, which it is extremely
ﬂexible in the monomeric form and introduces artifacts to RMSD
analysis. Cutoff of 4 Å between NeO atom pairs as a deﬁnition of
salt bridge formation between Arg118 and Asp243 was used [33].
All the graphical displays were generated using XMgrace program.
The molecular graphics shown in this work were created using
UCSF Chimera [23].
2.12. Essential dynamics (ED)
ED was performed for AGT-Mi and F152I-Mi MD simulations
according to principal component analysis (PCA). ED is a standard
technique able to highlight the dominant motions of the investi-
gated systems [34e37]. The principal components (PCs), also called
eigenvectors, were calculated by using ED and represent the pro-
tein's collective motions. Here, the ﬁrst eigenvector, that accounts
for ca. 50% of the total motions accomplished by the system, was
used to understand the dynamical differences between the AGT-Mi
and the F152I-Mi systems. Therefore, RMSF along the ﬁrst eigen-
vector for the AGT-Mi and F152I-Mi (Fig. S3) were calculated.
Covariance matrix was calculated using Ca atoms and the matrix
was diagonalized. The PCs were extracted from the covariance
matrix. PCA was performed in three steps: i) the covariance matrix
was calculated using the Ca atoms; ii) the matrix was diagonalized
and iii) a set of eigenvectors and eigenvalues were extracted from
the covariance matrix. The eigenvectors correspond to a direction
in the multidimensional space while the eigenvalues express the
amplitude of the motion of each eigenvectors. PCA was carried out
by using the standard GROMACS tool i.e. g_covar and g_anaeig.
3. Results
3.1. Identiﬁcation of interface hot-spots
Homodimeric AGT-Mi shows a large monomer-monomer
interface (Fig. 1A and B) in comparison with other PLP dependent
enzymes. In fact, 48% of the total solvent accessible area (ASA) of
the protein is buried upon dimerization. Such surface comprises
110 residues per subunit, many of which are directly involved in
inter-chain contacts. In particular, 15 hydrophobic patches, 40
interchain hydrogen bonds and two salt bridges contribute to the
monomer-monomer interaction.
Considering the high number and the different type of inter-
chain contacts as well as their wide distribution, the identiﬁca-
tion of possible dimerization hot spot/s could be difﬁcult. Thus, to
identify residues or clusters of residues that mainly contribute to
the binding free energy at the AGT-Mi dimerization interface, we
performed an in silico alanine-scanning mutagenesis on the inter-
facial residues [38e40] using the Molecular Operating Environ-
ment software by Chemical Computing Group [12]. In order to ﬁnd
out residues whose substitution should have a minimal impact on
the monomer stability, the analysis was carried out on both the
dimeric and monomeric AGT-Mi structure.
As shown in Fig. 2, the dStability, representing the relative
thermostability of each mutant with respect to AGT-Mi, indicates
that among the 15 residues predicted to play a role in stabilizing the
dimeric structure (black bars), only Arg118, Phe238 and Phe240 do
not signiﬁcantly change the intrinsic stability of monomeric AGT
(red bars). The crystal structure of AGT reveals that these residues
are not involved in the binding of the coenzyme and/or the sub-
strate. Such requirements are essential to avoid possible functional
effects of the residues substitution. Arg118 forms with Asp243 of
the neighbouring chain the unique salt bridge present at the AGT-
Mi interface (Fig. 3A). The in silico mutagenesis analysis suggests
that the R118A substitution could weaken the dimer interface
without substantially affecting the monomer structure. Phe238 is
engaged in hydrophobic interaction with the same residue of the
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other subunit, while Phe240 not only interacts with Trp246 of the
same subunit but also with Ile115, and possibly with His83, of the
adjacent monomer. Thus, unlike R118A and F240S, the F238S mu-
tation could result in only one change at the interface of AGT-Mi.
The role of Phe238 and Phe240 in the AGT dimerization was also
investigated by the Protein Patch Analyzer tool of MOE 2015. The
hydrophobic patches on the dimerization interface of AGT-Mi were
ordered from 1 to 15 in the output list on the basis of a decreasing
solvent-accessible surface area of the patch (Å2). Only patches
enumerated as 1,10,13 and 14 are shown in Fig. 3B because they are
involved in the formation of the main hydrophobic interactions at
the dimer interface. In particular, Phe238 (patch 13) and Phe240
(patch 1) are predicted to critically contribute to the hydrophobicity
of the interface because both residues show a high ASA value when
they become exposed to the solvent upon monomerization. Hy-
drophobic residues, in particular phenylalanine, tryptophan and
isoleucine, and the interactions in which they are involved are
critical for stabilizing the core of proteins, native oligomeric as-
semblies, and aberrant assemblies leading to aggregation [41, 42].
On the basis of these data and observations, the substitution of
Phe238 and Phe240 with serine residues could weaken the dimer
interface and also enhance the solubility of the monomer.
3.2. Effect of the mutations R118A, F238S and F240S on the
structural and functional properties of AGT-Mi
On the basis of the above computational analysis, the con-
struction, expression, puriﬁcation and characterization of the mu-
tants R118A-Mi, F238S-Mi, and F240S-Mi were ﬁrst undertaken.
Absorbance and CD spectra of the mutants in the visible region are
similar to the corresponding ones of AGT-Mi, even if a more pro-
nounced absorbance in the 340 nm region for R118A-Mi and F238S-
Mi and a 5-nm blue shift of the 424 nm dichroic band for F240S-Mi
are observed (Fig. S1). As shown in Table 1, the mutations R118A,
F238S and F240S do not signiﬁcantly alter the Kd(PLP) value of AGT-
Mi. The impact of these single mutations on the AGT-Mi dimeric
structure was also investigated by SEC at different enzyme con-
centrations. Analyses of the SEC experiments of R118A-Mi indicate
that the holo form elutes as a peak whose elution volume corre-
sponds to that of a dimer and whose total area does not change up
to 0.3 mM, while the apo form exhibits a different elution proﬁle
consisting in three peaks whose elution volumes correspond to a
dimer, a monomer and aggregates at high molecular weight. The
integrated area of the dimer decreases and concomitantly that of
the monomer and aggregates increases as the enzyme concentra-
tion decreases from 10 to 1.25 mM. These data strongly indicate that
the apomonomer form is prone to aggregation. The formation of
aggregates in this enzymatic species is supported by DLS mea-
surements. The apo form of R118A-Mi at 5 mM concentration ex-
hibits an increase in count rate, typical of a fast aggregation with
the count rate stabilizing after about 12min (data not shown). In an
attempt to increase the solubility of the apomonomer R118A-Mi,
SEC experiments were carried out in the presence of 10% glycerol.
The elution proﬁle, under these experimental conditions, shows
that the proportion of the apomonomer increases at the expense of
the dimer as the overall enzyme concentration is lowered from 18
to 1 mM. This indicates a slow equilibrium process. A plot of the
percent dimer as a function of apoR118A-Mi concentration gives a
hyperbolic curve whose linear transformation yields a Kd(dim-mon)
value of 9.3 ± 0.1 mM (Eq. (2)) (Table S2), a value at least 30-fold
higher than that of apoAGT-Mi. The ﬁnding that, like AGT-Mi,
both apo and holo forms of the mutants F238S-Mi and F240S-Mi
Fig. 1. Representation of the AGT dimer interface. Panel A: structure of AGT high-
lighting as sticks the interface residues. Panel B: surface representation of the AGT
interface residues. The two monomers are coloured red and white.
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Fig. 2. Plot of the alanine scanning mutagenesis results either on the monomer
(red bars) and dimer (black bars) of AGT expressed as dStability (kcal/mol) of each
interfacial residue. The dStability (kcal/mol) represents the relative thermostability of
each mutant with respect to AGT-Mi. Only residues with a positive value of dStability
!2 kcal/mol are shown.
M. Dindo et al. / Biochimie 131 (2016) 137e148 141
maintain the dimeric structure up to 0.3 mM indicates that it is not
possible to establish if Phe238 or Phe240 play a role in the dimer
formation of AGT-Mi. The steady-state kinetic parameters of the
three mutants were also determined (Table 1). F238S-Mi shows a
kcat value comparable to that of AGT-Mi, while R118A-Mi and
F240S-Mi display kcat values approximately half that of AGT-Mi. The
decrease in kcat of the latter variants could suggest that, although
both Arg118 and Phe240 are residues located far from the active
site, they are required for the proper conformation of the dimer
interface and, as a consequence, for catalysis. Altogether, these data
indicate that these mutations slightly affect the PLP binding mode
and afﬁnity of AGT-Mi and that the mutated residues Arg118,
Phe238, and Phe240 are not essential for the catalytic activity. On
the basis of these results and in order to promote monomerization
of AGT-Mi, double mutants were subsequently created in the
following various combinations: F238S-Mi/F240S-Mi, R118A-Mi/
F238S-Mi, and R118A-Mi/F240S-Mi. Since both apo and holo forms
of F238S-Mi/F240S-Mi still exist predominantly in the dimeric form
up to 0.3 mM it is not possible to quantify the effect of the combi-
nations of these mutations on the Kd(dim-mon) value of AGT-Mi.
Although Phe238 and Phe240 were changed to Ser to interrupt
the hydrophobicity at the dimer interface, different elution proﬁles
on SEC are obtained when each of these mutations was combined
with the R118A mutation. The double mutant R118A-Mi/F238S-Mi
in the holo form elutes from gel ﬁltration as a dimer up to
0.3 mM, while the apo form has a Kd(dim-mon) value of 7.4 ± 0.4 mM, a
value at least ~24-fold higher than that of apoAGT-Mi, but ~1.2-fold
lower than that of apoR118A-Mi (Table S2) (Eq. (2)). Conversely,
when both R118A and F240S mutations were added to AGT-Mi, the
resulting double mutant demonstrates a signiﬁcant shift from
dimer to monomer both in the apo and holo form. The Kd(dim-mon)
value of apo and holo R118A-Mi/F240S-Mi is 24 ± 1 mM and
2.4 ± 0.9 mM, respectively, which are at least ~80- and 8-fold greater
than that of the corresponding ones of AGT-Mi (Table S2) (Eq. (2)). It
should be noted that the Kd(dim-mon) values of the mutants R118A-
Mi/F238S-Mi and R118A-Mi/F240S-Mi are obtained in the
absence of glycerol, thus suggesting that the combination of the
mutations F238S and F240S with the R118A mutation prevents the
formation of aggregates observed for the R118A-Mi mutant. All
together, these data highlight that (i) interacting forces between
Arg118 and Asp243 of the other monomer may drive dimer for-
mation in apoAGT-Mi, (ii) a synergic role of the residues Arg118 and
Phe240 exist on the formation of the dimer of AGT-Mi, and (iii)
substitution of both Phe238 and Phe240 with Ser could be relevant
in preventing monomer-monomer aggregation. Therefore, we
decided to construct, express, purify, and characterize the triple
mutant R118A-Mi/F238S-Mi/F240S-Mi. SEC analyses indicate a
slow dimer-monomer equilibrium process for both the apo and
holo form of the triple mutant. The Kd(dim-mon) values of triple
mutant in the apo and holo forms (Eq. (2)) result to be 80 ± 1 mM
and 9.4 ± 0.5 mM, respectively (Table S2). Therefore, since the
combination of these three mutations stabilizes both apo and holo
forms of AGT-Mi monomer versus dimer we chose the triple
mutant as a model to investigate the dimerization process.
Fig. 3. The main interface hot spot and hydrophobic patches along the dimeriza-
tion interface. Panel A: Detail of the main interface hotspot. The labelled residues are
shown as yellow or cyan sticks on the basis of the colour of the belonging subunit. PLP
is shown as green sticks. Panel B: interfacial hydrophobic patches of an AGT monomer
shown as green areas on the grey background of AGT. The size and the energy cut-offs
of each patch are 75 Å2 and 0.25 kcal/mol, respectively.
Table 1
Steady-state kinetic parameters and Kd(PLP) of AGT-Mi and variants obtained in 50 mM potassium phosphate buffer, pH 7.4 in the presence of 100 mM PLP.
Enzyme Substrate Cosubstrate kcat (s!1) Km (mM) kcat/Km (mM!1s!1) Kd(PLP) (mM)
AGT-Mi L-alanine Glyoxylate 35 ± 1 51 ± 7 0.68 ± 0.09 0.10 ± 0.01
Glyoxylate L-alanine 39 ± 3 0.20 ± 0.05 195 ± 43
AGT R118A-Mia L-alanine Glyoxylate 21 ± 1 77 ± 10 0.27 ± 0.04 0.20 ± 0.04
Glyoxylate L-alanine 19 ± 1 0.18 ± 0.02 106 ± 12
AGT F238S-Mi L-alanine Glyoxylate 36 ± 1 46 ± 1 0.78 ± 0.03 0.25 ± 0.02
Glyoxylate L-alanine 35 ± 1 0.71 ± 0.06 49 ± 4
AGT F240S-Mi L-alanine Glyoxylate 22 ± 1 84 ± 7 0.26 ± 0.02 0.19 ± 0.03
Glyoxylate L-alanine 20 ± 1 0.28 ± 0.04 71 ± 15
a Data obtained in presence of 10% glycerol.
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3.3. Spectroscopic features of the monomeric form of the R118A-Mi/
F238S-Mi/F240S-Mi and effect of PLP on the dimerization
The far-UV CD spectrum (reﬂecting the a-helix content) of the
apo monomer is comparable with that of apoAGT-Mi in the dimeric
form, and the deconvolution reveals that the apomonomer and the
apoAGT-Mi have an identical composition of the overall secondary
structure. On the other hand, the comparison of near-UV CD spectra
and intrinsic ﬂuorescence spectra (both reﬂecting the microenvi-
ronment of the aromatic side chains) as well as ANS ﬂuorescence
spectra and thermal stability data of the apo monomer and
apoAGT-Mi provides evidence that a different conformation exists
between the two forms. In fact, as shown in Fig. 4A and B and inset
of Fig. 4B, with respect to AGT-Mi in the apo form, the apo mono-
mer exhibits (i) a consistent decrease in the dichroic signals in the
near-UV region, (ii) a ~1.3-fold reduction of the intrinsic ﬂuores-
cence emission intensity and a 4 nm red-shift of the maximum
intensity, and (iii) a ~8-fold increase in ANS emission ﬂuorescence
intensity as well as a 4 nm red shift of the emission maximum.
Similar features are also observed for the apomonomer of the
double mutant R118A-Mi/F240S-Mi. Additionally, unlike apo AGT-
Mi which displays a thermal transition curve with an apparent
mid-denaturation at 66.1 ± 0.1 !C and 53.8 ± 0.1 !C [43], the triple
mutant in the apo form unfolds in a single process with an apparent
Tm value equal to 47.5 ± 0.3 !C.
The ability of the apo monomer to bind PLP was ﬁrst monitored
by following changes in the dichroic signal at 424 nm at 2 mM
concentration of the enzyme (expressed per monomer) in the
presence of 100 mMPLP concentration as a function of time. A rapid
increase of the magnitude of the dichroic signal at 424 nm due to
the formation of the internal aldimine is observed. The kinetics of
PLP binding is monophasic and occurs with a rate constant of
2.44 ± 0.08 min"1. At the end of the reaction, the solution has been
loaded on a Superdex 200 column. The enzyme elutes as a PLP-
bound monomer, as demonstrated by the positive dichroic band
at 424 nmwhose magnitude is about half that of holoAGT-Mi (data
not shown). These data indicate that under these experimental
conditions the apo monomer is able to bind PLP remaining in a
monomeric state. Nevertheless, when this species at a concentra-
tion of 0.1 or 0.2 mMwas incubatedwith L-alanine and glyoxylate up
to 3 h, no pyruvate formation could be detected. The comparison of
the features of the holomonomer with the corresponding ones of
holoAGT-Mi in the dimeric form also reveals (i) a decrease of the
dichroic band in the near-UV region, (ii) an approximately 21-fold
increase in the ANS emission intensity with a maximum 9-nm
red shifted, and a mid-point denaturation equal to 50.1 ± 0.1 !C,
about 23-degrees lower than that of holo AGT-Mi. Moreover, as
shown in Fig. 5 the ﬂuorescence emission spectra of the NaBH4
reduced holomonomer reveal a different PLP binding mode in
comparison with that of holo dimeric form of AGT-Mi. When
excited at 325 nm, the NABH4-reduced holomonomer displays an
emission spectrum which, in comparison with that of the reduced
holo AGT-Mi, has a 6-nm red shifted maximum and an approxi-
mately 2-fold increased emission intensity. We also performed
measurements of the intrinsic ﬂuorescence of the reduced hol-
omonomer. Unlike holoAGT-Mi which ﬂuoresces at 341 nm, the
holomonomer ﬂuoresces not only at 342 nm but also at 393 nm.
This PLP emission is possibly due to the occurrence of an energy
transfer from tryptophan(s) to the reduced coenzyme.
When the apomonomer is treated with PLP concentrations
ranging from 1 to 40 mM, the maximal magnitude of the dichroic
signal values at 424 nm exhibits a hyperbolic dependence on co-
enzyme concentration, and the data ﬁtted to Eq. (1) give a Kd(PLP)
value of 4.4 ± 0.5 mM per subunit. This value is 17-fold higher than
Fig. 4. Spectroscopic features of apo monomer R118A-Mi/F238S-Mi/F240S-Mi (red line) in comparison with apo dimer AGT-Mi (black line). Panel A: near-UV CD spectra at
5 mM concentration; Panel B: intrinsic ﬂuorescence emission spectra at 1 mM concentration. Inset of panel B: ANS emission ﬂuorescence spectra at 1 mM concentration. All
measurements were obtained in 50 mM potassium phosphate buffer, pH 7.4.
Fig. 5. Fluorescence properties of NaBH4-reduced R118A-Mi/F238S-Mi/F240S-Mi
(red line) and dimeric AGT-Mi (black line). Emission ﬂuorescence spectra upon
excitation at 325 nm. The inset show the ﬂuorescence emission upon excitation at
280 nm. Spectra were registered at 1 mM concentration.
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the Kd(PLP) value of AGT-Mi [44] calculated taking into account the
monomer concentration. Taken together these data indicate that (i)
the monomer is able to bind PLP, even if with an afﬁnity lower than
holoAGT-Mi, (ii) unlike AGT-Mi, the holo and apo monomer display
a conformation, as revealed by spectroscopic properties and
apparent Tm values, similar to each other but different from the
corresponding ones of the dimeric forms of AGT-Mi, and (iii) with
respect to AGT-Mi, the PLP-bound monomer exhibits local struc-
tural alterations of the coenzyme microenvironment leading to
exposure to the solvent of the PLP binding site as well as a distur-
bance of the correct spatial geometry of the functional groups in the
PLP microenvironment.
When PLP binding has been monitored as a function of time at
5 mM apomonomer concentration we have observed that the
magnitude of the dichroic signal at 424 nm increases in a biphasic
way. The fast phase, obtained by ﬁtting the data to a single expo-
nential process, occurs with a rate constant of 2.4 ± 0.2min!1, while
the slow phase, ﬁtted to Eq. (3), takes place with a rate constant of
0.020 ± 0.002 mM!1min!1 (Fig. 6). Thereafter, aliquots were with-
drawn from the reaction mixture at various times and subjected to
SEC and activity analyses. As shown in the inset of Fig. 6, the
dimeric species increases with time at the expense of the mono-
meric one in a slow equilibrium process. The percentage of the
dimeric form as a function of time ﬁts Eq. (3), yielding a rate con-
stant value of dimerization of 0.019 ± 0.002 mM!1min!1 (Fig. 6). On
the basis of this value and that of Kd(dim-mon) of the triple mutant in
the holo form, we can estimate a kdiss value of 0.18 ± 0.04 min!1. As
shown in Fig. 6, the regain of transaminase activity as a function of
time takes place with a rate constant of 0.021 ± 0.002 mM!1min!1, a
value in excellent agreement with those of dimerization and the
slow phase of PLP binding. Thus, it can be claimed that the biphasic
process is characterized by a fast phase representing the internal
aldimine formation between the apomonomer and the coenzyme
followed by a slow phase representing dimerization associated
with regain of transaminase activity. To obtain a realistic estimation
of the catalytic activity of the triple mutant in the holodimeric form,
after incubation of the apomonomer at concentrations ranging
from 1.4 to 19 mM with 100 mM PLP, the reaction mixtures were
assayed both for transaminase activity and amount of formed
dimer. When we plotted the catalytic activity as a function of the
percentage of dimer we noticed a linear relationship between these
variables (data not shown). From this plot it can be derived that
1 nmol of the triple mutant in the holo dimeric form reacting with
L-Ala and glyoxylate produces pyruvate with an initial rate of
4.8 nmol of pyruvate per sec. Assuming that this value is close to the
kcat of the half-transamination, the rate of this reaction is about 9-
fold lower than the kcat value of AGT-Mi.
We have also investigated the kinetics of the dimerization of the
triple mutant in the apo form. The resulting value of kass is equal to
7.9 ± 0.6 " 10!6 mM!1 min!1and on the basis of the Kd(dim-mon) we
estimated a kdiss value of 6.4± 0.4" 10!4min!1. These data indicate
that the apomomer is able to dimerize even if with a rate of asso-
ciation and of dissociation about 2700- and 280-fold, respectively,
lower than the corresponding ones of the PLP-bound monomer.
3.4. Molecular dynamics simulations of F152I-Mi and I244T-Mi
variants associated with PH1 and implications in their pathogenicity
The above results indicate Arg118 as a hot-spot interfacial res-
idue playing a relevant role in the dimerization of AGT-Mi. We
hypothesized if some PH1-disease causing mutations could be
related to mutated residues near to or interacting with Arg118.
Thus, a search in this direction has been made. Taken into consid-
eration in the crystal structure of AGT an ideal sphere of 15 Å radius
whose center is the Ca of Arg118 we noticed the presence of several
residues whose mutation is associated with PH1. All of them are
located in the large domain of the enzyme. It can be speculated that
the pathogenicity of thesemutations can be caused by perturbation
of the microenvironment of Arg118 and/or Asp243. We focused our
attention on the mutations F152I and I244T which are among the
most common and the most studied in PH1. Thus, in order to
analyze the effect of F152I and I244T pathogenic mutations on AGT-
Mi, extensive MD simulations were carried out on the modeled
structures of AGT-Mi, I244T-Mi and F152I-Mi in the dimeric form
(Material and Methods section). The comparison between AGT-Mi
and the I244T-Mi mutant showed that, on the basis of RMSD
plots, the simulations reached equilibrium at ca. 110 ns (Fig. S2),
thus providing a solid base for further analysis.
By visual inspection, we found that, over 200 ns of simulation,
the salt bridge formed by Arg118 and Asp243 is maintained for
Fig. 6. Second-order kinetic plots for data of dimerization , increase of magnitude of the CD signal at 424 nm , and catalytic activity according to Eq. (3). Inset: SEC
proﬁles of the apomonomer after addition of 100 mM PLP at the indicated times.
M. Dindo et al. / Biochimie 131 (2016) 137e148144
about 87.3% of the time in AGT-Mi, while it remains stable for only
ca. 17.5% of the time in the I244T-Mi mutant. Thus, we hypothesize
that the I244T mutation could have a direct inﬂuence on the for-
mation of a key interface contact. Indeed, we observed that the
breaking of the Arg118-Asp243 salt bridge coincides with the for-
mation of a hydrogen bond between Thr244 and Asp92, which
forces a backbone conformational change (Fig. 7 Panel A and B).
This is not possible in AGT-Mi because the isoleucine at position
244, which cannot form H-bonds with neighboring residues, gua-
rantees the stability of the Arg118-Asp243 salt-bridge.
Conversely, we did not observe any signiﬁcant difference be-
tween the interface contacts of dimeric AGT-Mi and F152I-Mi
during the simulations. Thus, we conducted MD simulations for
170 ns on the monomeric structure of both AGT-Mi and F152I-Mi.
For the two systems we have calculated i) the RMSD to analyze
how the systems evolve from the initial structure and ii) the RMSF
in order to characterize how ﬂexible they are along the simulations
(see Methods section for more details). On the basis of the RMSD of
backbone atoms, it can be observed that both systems reached
equilibrium after ca.10 ns to values of about 0.25 nm (Fig. S3). RMSF
calculations on both systems showed high ﬂuctuations at the N-
terminal and C-terminal loop extremities and in loops far from the
dimer interface e.g. 252-255, 280-285 and 355-357 (Fig. S4).
However, neither these analyses nor visual inspection revealed
signiﬁcant changes on the dimer interface regions between AGT-Mi
and F152I-Mi mutant. Thus, we decided to calculate the ED on the
MD simulations. ED technique allows not only to highlight the
dominant motions of the system, which are often meaningful and
correlated with protein function, but also to reduce the complexity
of the data (see Material and Methods section). Fluctuations anal-
ysis by ED revealed that the F152I mutation could inﬂuence the
dynamics of several amino acid stretches of AGT-Mi, i.e., 95-97, 118-
121, 141-145, 171-176 and 281-290, with peaks for residues 97, 118,
143, 175 and 281. These results suggest that the latter residues have
a different behavior in terms of ﬂexibility in F152I-Mi as compared
with AGT-Mi. In particular, it can be appreciated (Fig. 8) that one of
the stretches that exhibits different behavior in themutated system
is formed by residues 118-121, located at the dimerization interface.
On these bases, we could suggest that the F152I mutation could
affect dimer formation by increasing the ﬂexibility of the region
118-121, thus possibly reducing the complementarity between the
two monomers. Moreover, approximately 70% of all cumulative
protein ﬂuctuations are comprised within the ﬁrst two principal
components (PCs), so the overall motion of the proteins in phase
space can be showed as a projection of the ﬁrst two eigenvectors
(PC1, PC2). Our results show (Fig. S5) that F152I mutant covers a
larger region of conformational space than AGT-Mi, suggesting an
overall escalation in the ﬂexibility of the mutant with respect to
AGT-Mi. The values indicating the total variance of the systems for
AGT-Mi and F152I-Mi mutant protein were 28.1565 nm2 and
52.9434 nm2 respectively, validating the hypothesis of the overall
increased ﬂexibility of F152I mutant than AGT-Mi.
4. Discussion
The majority of PLP-enzymes exists as dimers, but dimerization
was demonstrated to be critical for catalytic activity for only three
members of this family, i.e. human ornithine decarboxylase [45],
bacterial diaminopimelate decarboxylase [46] and Treponema
Fig. 7. Perturbation of the microenvironment of Arg118. Panel A: Arg118-Asp243 salt bridge, together without Asn92-Thr244 hydrogen bond interaction. Panel B: breaking of
Arg118-Asp243 salt bridge, together with Asn92-Thr244 hydrogen bond interaction; The two monomeric subunits are displayed in aquamarine and brownish. Depicted hydrogen
atoms were added within the setup of the simulations.
Fig. 8. RMSF of Ca atoms along ﬁrst eigenvector. The simulations were run on AGT-
Mi (black) and F152I mutant (red) monomer forms. In the box, we focus our attention
on the RMSF value of the residues in the dimer interface.
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denticola cystalysin [47]. Mutagenesis targeting residues at their
dimer interface followed by analyses of the catalytic activity and
the quaternary structure of the generated variants allowed to
establish that (i) a sextuple monomeric mutant of ornithine
decarboxylase as well as a triple monomeric mutant of cystalysin
do not exhibit enzymatic activity, and (ii) two single mutants of
diaminopimelate decarboxylase display a loss of decarboxylase
activity which correlates with the attenuation in dimerization.
One such example of this approach is reported for AGT-Mi in this
study. Bymeans of bioinformatic analyses, we identify Arg118, a hot
spot residue at the dimer interface interacting with Asp243 of the
opposite subunit, and two other interfacial residues, Phe238 and
Phe240, which give a great contribution to the hydrophobic con-
tacts between the twomonomers. Thus, these residues at the dimer
interface of AGT-Mi should be crucial for monomer self-association.
Indeed, the combination of the R118A mutation with both F238S
and F240Smutations yields a triple mutant characterized by Kd(dim-
mon) values of the apo and the holo forms at least ~260- and 31-fold,
larger, respectively, than the corresponding ones of AGT-Mi.
Moreover, with respect to apo and holo AGT-Mi, the apo and the
holo monomer of the triple mutant exhibit changes in the confor-
mation, as indicated by near-UV CD signal, intrinsic ﬂuorescence
and markedly low Tm values. Again, a different PLP binding mode
and afﬁnity is seen for the apo monomer in comparison with the
apo dimeric form of AGT-Mi. The effect of PLP on dimerization of
AGT-Mi consists in a fast phase leading to an inactive PLP-bound
monomer followed by dimerization paralleling regain of catalytic
activity, which reaches an initial velocity about 9-fold lower than
the kcat of AGT-Mi. Nevertheless, the apomonomer is also able to
dimerize even if with a rate constant of association lower than that
of the PLP-bound monomer.
Overall, these data indicate that, although the dimer interface
residues Arg118, Phe238 and Phe240 are not critical for trans-
aminase activity of AGT-Mi, they contribute to formation of the
dimer, and that dimerization is essential for catalytic activity. This
ﬁnding, in linewith what already reported for the abovementioned
PLP-enzymes, is strictly related to the fact that the active site res-
idues of these enzymes are contributed by adjacent subunits. It can
be also possible to envisage that dimerization optimizes protein
dynamics to support function. The unraveling of the dimerization
process of this enzymatic species is not only important to better
understand the catalytic mechanism of the enzyme but mainly for
the possible relapse in the understanding why some PH1-causing
variants encoded on the minor allele, like F152I and I244T, are
mistargeted into mitochondria. The import into peroxisomes
mainly acts on a fully-folded dimeric state of AGT [5], while that in
mitochondria requires a monomeric state of the enzyme provided
with a mitochondrial targeting sequence resulting from the P11L
polymorphism. Since most of glyoxylate is synthesized in the per-
oxisomes, only peroxisomal AGT is metabolically efﬁcient. There-
fore, the dimerization and the correct subcellular localization of
AGT are functionally essential events for this PLP-enzyme. It has
been suggested that the combined effect of some mutations with
P11L could result in a destabilization of the dimeric structure of
AGT-Mi [5]. However, up to now, the effect of these substitutions
are not understood in structural terms. Visual inspection of the
modelled structure of AGT-Mi indicates that Phe152 and Ile244 are
not dimer interfacial residues. However, it cannot be excluded that
replacement of Phe152 or Ile244 by Ile and Thr, respectively, could
indirectly attenuate the dimerization process. To test this hypoth-
esis, MD simulations were performed on AGT-Mi, F152I-Mi and
I244-Mi. The analyses predict that both mutations interfere with
the dimerization process. In particular, replacement of Thr244 with
Ile appears to cause the breakage of the ionic bond between Arg118
and Asp243 and the formation of a hydrogen bond between Arg118
and Asp92. On the other hand, in the monomer of F152I-Mi, but not
in the dimer, the stretch 118-121 appears more ﬂexible than in the
monomer of AGT-Mi. It can be speculated that (i) the buttressing of
monomer to form a dimer may prevent increased movement at the
dimer interface, and (ii) the ﬂexibility of amino acid residues 118-
121 could result in an attenuated monomer in its dimerization
process.
Some speculations could be drawn from the data and the MD
simulations here presented as well as from previous results [2, 11].
A pathway of AGT folding was already proposed. It foresees the
conversion of the unfolded monomer to a partly unfolded mono-
mer, and then to a folded monomer which dimerizes [5]. Here, we
advance the proposal that the dimerization will start by means of
core dimer interfacial interaction. The large area of the enzyme
dimerization interface along with the ﬁnding that the 21-N-ter-
minal truncated AGT is able to dimerize [11] support this view. In
this dimerization intermediate, the N-terminal extensions, con-
taining the P11L polymorphism in AGT-Mi, should be exposed and
ﬂexible, i.e. not tightly bound to the surface of the neighboring
subunit (Fig. 9). Following this view, and considering that the
dimeric structure of AGT-Mi is less stabilized than that of AGT-Ma,
AGT-Ma and AGT-Mi are 100% and 95% peroxisomal, respectively
(Fig. 9, pathway 1) Since MD simulations predict that the mutations
I244T and F152I interfere with dimerization, the formation of the
dimeric structure of the variants I244T-Mi and F152I-Mi should be
greatly impaired, while the formation of the partly unfolded and
folded monomeric forms could prevail. Thus, the partially unfolded
monomers of the variants I244T-Mi and F152-Mi containing the
P11L polymorphism, could be imported into mitochondria, possibly
with a rate higher than that of their conversion to the corre-
sponding folded monomers (Fig. 9, pathway 2). Nevertheless, here
we have demonstrate that the dimerization of the apomonomer of
the triple mutant occurs with kass and kdiss remarkably lower that
the corresponding ones of the PLP-bound monomer. These ﬁndings
indicate that high levels of PLP could shift the equilibrium from the
PLP-bound monomer of the variants F152I-Mi and I244T-Mi to the
dimeric form, thus preventing their mislocalization. This could
explain why the F152I-Mi or I244T-Mi variants have been found to
be responsive to pyridoxine administration [44, 48e50]. The pro-
posed model illustrates a putative dimerization process and gives a
tentative explanation of the molecular basis of the pathogenicity of
Peroxisomal importMitochondrial import
1
2
Fig. 9. Proposed folding and dimerization pathway of AGT-Mi (1) and of the I244T-
Mi and F152T-Mi variants (2). The green dots indicate the P11L polymorphism. The
yellow dots represent the PLP coenzyme.
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the variants F152I-Mi and I244T-Mi (Fig. 9).
To conclude, this work allow us to (i) identify interfacial resi-
dues, Arg118, Phe238, and Phe240, which are not essential for
catalytic activity of AGT-Mi but have a relevant impact on its
dimerization process, (ii) engineer and characterize a folded apo-
momoner and holomonomer, both able to dimerize (iii) demon-
strate that dimerization is critical for catalytic activity, and (iv)
outline the possible structural basis of the functional synergism
between the mutations I244T or F152I and the mutation P11L
responsible for the aberrant targeting to mitochondria of the var-
iants I244T-Mi and F152I-Mi associated with PH1.
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